ID   P53_HUMAN               Reviewed;         393 AA.
AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809;
AC   Q16810; Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4;
AC   Q3LRW5; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2;
AC   Q9NZD0; Q9UBI2; Q9UQ61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   18-JAN-2017, entry version 250.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Antigen NY-CO-13;
DE   AltName: Full=Phosphoprotein p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=4006916;
RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT   cells.";
RL   EMBO J. 4:1251-1255(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   GLY-76.
RX   PubMed=2946935; DOI=10.1128/MCB.6.5.1379;
RA   Lamb P., Crawford L.;
RT   "Characterization of the human p53 gene.";
RL   Mol. Cell. Biol. 6:1379-1385(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3894933; DOI=10.1128/MCB.5.7.1601;
RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT   "Molecular cloning and in vitro expression of a cDNA clone for human
RT   cellular tumor antigen p53.";
RL   Mol. Cell. Biol. 5:1601-1610(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3025664; DOI=10.1128/MCB.6.12.4650;
RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
RA   Rotter V.;
RT   "Molecular basis for heterogeneity of the human p53 protein.";
RL   Mol. Cell. Biol. 6:4650-4656(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
RA   Georgiev G.P.;
RT   "A variation in the structure of the protein-coding region of the
RT   human p53 gene.";
RL   Gene 70:245-252(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS.
RX   PubMed=1915267;
RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=8316628;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX.
RX   PubMed=11058590; DOI=10.1074/jbc.M007140200;
RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA   Zevotek N.;
RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT   enhances tumor necrosis factor cytotoxicity.";
RL   J. Biol. Chem. 276:3361-3370(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE
RP   SPLICING, INDUCTION, AND VARIANT ARG-72.
RC   TISSUE=Colon;
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rozemuller E.H., Tilanus M.G.J.;
RT   "P53 genomic sequence. Corrections and polymorphism.";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND
RP   ALA-366.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and
RT   M059K has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND
RP   SER-309.
RA   Azuma K., Shichijo S., Itoh K.;
RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
RT   restricted CTL.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-72.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-278.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139
RP   AND PRO-155.
RC   TISSUE=Lung carcinoma;
RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA   Varga J.L.;
RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell
RT   lung carcinoma by antagonists of growth hormone-releasing hormone and
RT   bombesin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
RX   PubMed=6396087;
RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
RA   Benchimol S.;
RT   "Isolation and characterization of a human p53 cDNA clone: expression
RT   of the human p53 gene.";
RL   EMBO J. 3:3257-3262(1984).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
RA   Pan X.L., Zhang A.H.;
RT   "Study on the effect of tumor suppressor gene p53 in arsenism
RT   patients.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282.
RC   TISSUE=Blood;
RA   Nimri L.F., Owais W., Momani E.;
RT   "Detection of P53 gene mutations and serum p53 antibodies associated
RT   with cigarette smoking.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262.
RC   TISSUE=Ovarian adenocarcinoma;
RA   Filippini G., Soldati G.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RC   TISSUE=Glial cell, and Glial tumor;
RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
RA   Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT   "Mutation detection utilizing a novel PCR approach for amplification
RT   of the p53 gene from microdissected tissue: application to archival
RT   tumor samples.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA   Lipsky P.E.;
RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
RT   "Allelic variant in intron 9 of TP53 gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [27]
RP   NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND
RP   LYS-321.
RX   PubMed=2156209;
RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT   "The p53 nuclear localisation signal is structurally linked to a
RT   p34cdc2 kinase motif.";
RL   Oncogene 5:423-426(1990).
RN   [28]
RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX   PubMed=2141171; DOI=10.1073/pnas.87.12.4766;
RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN   [29]
RP   PHOSPHORYLATION.
RX   PubMed=1705009; DOI=10.1128/MCB.11.3.1598;
RA   Samad A., Carroll R.B.;
RT   "The tumor suppressor p53 is bound to RNA by a stable covalent
RT   linkage.";
RL   Mol. Cell. Biol. 11:1598-1606(1991).
RN   [30]
RP   DEPHOSPHORYLATION BY PP2A.
RX   PubMed=1848668; DOI=10.1128/MCB.11.4.1996;
RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
RT   by protein phosphatase 2A: inhibition by small-t antigen.";
RL   Mol. Cell. Biol. 11:1996-2003(1991).
RN   [31]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8632903;
RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA   Gilbert D., Iggo R., Frebourg T.;
RT   "The human tumour suppressor gene p53 is alternatively spliced in
RT   normal cells.";
RL   Oncogene 12:813-818(1996).
RN   [32]
RP   GLYCOSYLATION.
RX   PubMed=8632915;
RA   Shaw P., Freeman J., Bovey R., Iggo R.;
RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
RT   glycosylation and charged residues at the carboxy-terminus.";
RL   Oncogene 12:921-930(1996).
RN   [33]
RP   PHOSPHORYLATION AT SER-33.
RX   PubMed=9372954; DOI=10.1128/MCB.17.12.7220;
RA   Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y.,
RA   Prives C., Pan Z.-Q.;
RT   "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent
RT   manner.";
RL   Mol. Cell. Biol. 17:7220-7229(1997).
RN   [34]
RP   FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK.
RX   PubMed=9840937; DOI=10.1038/sj.onc.1202504;
RA   Schneider E., Montenarh M., Wagner P.;
RT   "Regulation of CAK kinase activity by p53.";
RL   Oncogene 17:2733-2741(1998).
RN   [35]
RP   SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386.
RA   Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E.,
RA   Scheffner M., Del Sal G.;
RT   "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-
RT   1.";
RL   EMBO J. 18:6462-6471(1999).
RN   [36]
RP   PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1.
RX   PubMed=10606744; DOI=10.1016/S0014-5793(99)01647-6;
RA   Dumaz N., Milne D.M., Meek D.W.;
RT   "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior
RT   phosphorylation of serine 15.";
RL   FEBS Lett. 463:312-316(1999).
RN   [37]
RP   BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT
RP   ASN-305.
RX   PubMed=10551826; DOI=10.1074/jbc.274.46.32699;
RA   Liang S.H., Clarke M.F.;
RT   "A bipartite nuclear localization signal is required for p53 nuclear
RT   import regulated by a carboxyl-terminal domain.";
RL   J. Biol. Chem. 274:32699-32703(1999).
RN   [38]
RP   PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE,
RP   CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20
RP   AND 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND
RP   MDM2.
RX   PubMed=10570149; DOI=10.1073/pnas.96.24.13777;
RA   Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.;
RT   "Phosphorylation of Ser-20 mediates stabilization of human p53 in
RT   response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999).
RN   [39]
RP   UBIQUITINATION.
RX   PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself
RT   and p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [40]
RP   ACETYLATION AT LYS-373 AND LYS-382.
RX   PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
RT   "Post-translational modification of p53 protein in response to
RT   ionizing radiation analyzed by mass spectrometry.";
RL   J. Mol. Biol. 295:853-864(2000).
RN   [41]
RP   PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF
RP   LYS-382; LEU-383 AND PHE-385.
RX   PubMed=10884347; DOI=10.1006/jmbi.2000.3830;
RA   Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.;
RT   "The C-terminal regulatory domain of p53 contains a functional docking
RT   site for cyclin A.";
RL   J. Mol. Biol. 300:503-518(2000).
RN   [42]
RP   FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION.
RX   PubMed=11025664; DOI=10.1038/35036365;
RA   Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.;
RT   "The function of PML in p53-dependent apoptosis.";
RL   Nat. Cell Biol. 2:730-736(2000).
RN   [43]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [44]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
RT   18 within the mdm-2 binding site of the p53 tumour suppressor
RT   protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [45]
RP   REVIEW ON ZINC-BINDING PROPERTIES.
RX   PubMed=11554448; DOI=10.1089/15230860152542961;
RA   Hainaut P., Mann K.;
RT   "Zinc binding and redox control of p53 structure and function.";
RL   Antioxid. Redox Signal. 3:611-623(2001).
RN   [46]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [47]
RP   DEACETYLATION AT LYS-382 BY SIRT1.
RX   PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A.,
RA   Pandita T.K., Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [48]
RP   MINIMAL REPRESSION DOMAIN.
RX   PubMed=11007800; DOI=10.1074/jbc.M008231200;
RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT   "p53 amino acids 339-346 represent the minimal p53 repression
RT   domain.";
RL   J. Biol. Chem. 276:1510-1515(2001).
RN   [49]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11447225; DOI=10.1074/jbc.M104157200;
RA   Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.;
RT   "Reactive oxygen species-induced phosphorylation of p53 on serine 20
RT   is mediated in part by polo-like kinase-3.";
RL   J. Biol. Chem. 276:36194-36199(2001).
RN   [50]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11551930; DOI=10.1074/jbc.M106050200;
RA   Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C.,
RA   Stambrook P., Jhanwar-Uniyal M., Dai W.;
RT   "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis
RT   at least in part via the p53 pathway.";
RL   J. Biol. Chem. 276:43305-43312(2001).
RN   [51]
RP   SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   PHE-385; LYS-386; THR-387 AND GLU-388.
RX   PubMed=11124955; DOI=10.1074/jbc.M009476200;
RA   Rodriguez M.S., Dargemont C., Hay R.T.;
RT   "SUMO-1 conjugation in vivo requires both a consensus modification
RT   motif and nuclear targeting.";
RL   J. Biol. Chem. 276:12654-12659(2001).
RN   [52]
RP   PHOSPHORYLATION BY PRPK.
RX   PubMed=11546806; DOI=10.1074/jbc.M105669200;
RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA   Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
RT   "Cloning and characterization of a p53-related protein kinase
RT   expressed in interleukin-2-activated cytotoxic T-cells, epithelial
RT   tumor cell lines, and the testes.";
RL   J. Biol. Chem. 276:44003-44011(2001).
RN   [53]
RP   PHOSPHORYLATION AT SER-392.
RX   PubMed=11239457; DOI=10.1016/S1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H.,
RA   Goodman R., Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2,
RT   hSpt16, and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [54]
RP   INTERACTION WITH USP7.
RX   PubMed=12507430; DOI=10.1016/S0092-8674(02)01199-6;
RA   Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E.,
RA   Shi Y.;
RT   "Crystal structure of a UBP-family deubiquitinating enzyme in
RT   isolation and in complex with ubiquitin aldehyde.";
RL   Cell 111:1041-1054(2002).
RN   [55]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [56]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [57]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF
RP   SER-46 AND LYS-382.
RX   PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-
RT   interacting protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [58]
RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
RX   PubMed=11780126; DOI=10.1038/ncb714;
RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
RA   Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
RA   Fanciulli M., Appella E., Soddu S.;
RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
RT   and mediates apoptosis.";
RL   Nat. Cell Biol. 4:11-19(2002).
RN   [59]
RP   INTERACTION WITH ING4.
RX   PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
RA   Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [60]
RP   ACETYLATION AT LYS-305.
RX   PubMed=12724314; DOI=10.1074/jbc.M212574200;
RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT   "Identification and characterization of a novel p300-mediated p53
RT   acetylation site, lysine 305.";
RL   J. Biol. Chem. 278:25568-25576(2003).
RN   [61]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML,
RP   UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20.
RX   PubMed=12810724; DOI=10.1074/jbc.M301264200;
RA   Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P.,
RA   Haupt Y.;
RT   "The promyelocytic leukemia protein protects p53 from Mdm2-mediated
RT   inhibition and degradation.";
RL   J. Biol. Chem. 278:33134-33141(2003).
RN   [62]
RP   INTERACTION WITH TP53INP1.
RX   PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [63]
RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX   PubMed=12944468; DOI=10.1128/MCB.23.18.6396-6405.2003;
RA   O'Keefe K., Li H., Zhang Y.;
RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT   cytoplasmic degradation but not ubiquitination.";
RL   Mol. Cell. Biol. 23:6396-6405(2003).
RN   [64]
RP   INTERACTION WITH HIPK1.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [65]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=15109303; DOI=10.1042/BJ20040337;
RA   Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R.,
RA   Kaul S.C.;
RT   "Alternative reading frame protein (ARF)-independent function of CARF
RT   (collaborator of ARF) involves its interactions with p53: evidence for
RT   a novel p53-activation pathway and its negative feedback control.";
RL   Biochem. J. 380:605-610(2004).
RN   [66]
RP   INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in
RT   transcriptional activation by p53.";
RL   Cell 117:735-748(2004).
RN   [67]
RP   INTERACTION WITH ANKRD2.
RX   PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071;
RA   Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V.,
RA   Valle G., Faulkner G.;
RT   "The Ankrd2 protein, a link between the sarcomere and the nucleus in
RT   skeletal muscle.";
RL   J. Mol. Biol. 339:313-325(2004).
RN   [68]
RP   PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH
RP   TAF1.
RX   PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
RT   for TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [69]
RP   DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/S1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [70]
RP   ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=15340061; DOI=10.1128/MCB.24.18.7987-7997.2004;
RA   Ghosh A., Stewart D., Matlashewski G.;
RT   "Regulation of human p53 activity and cell localization by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 24:7987-7997(2004).
RN   [71]
RP   METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
RX   PubMed=15525938; DOI=10.1038/nature03117;
RA   Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S.,
RA   McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A.,
RA   Reinberg D.;
RT   "Regulation of p53 activity through lysine methylation.";
RL   Nature 432:353-360(2004).
RN   [72]
RP   INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315.
RX   PubMed=14702041; DOI=10.1038/ng1279;
RA   Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F.,
RA   Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.;
RT   "Phosphorylation by aurora kinase A induces Mdm2-mediated
RT   destabilization and inhibition of p53.";
RL   Nat. Genet. 36:55-62(2004).
RN   [73]
RP   INTERACTION WITH NOC2L.
RX   PubMed=16322561; DOI=10.1101/gad.351205;
RA   Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N.,
RA   Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A.,
RA   Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.;
RT   "NIR is a novel INHAT repressor that modulates the transcriptional
RT   activity of p53.";
RL   Genes Dev. 19:2912-2924(2005).
RN   [74]
RP   INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT
RP   SER-15.
RX   PubMed=15701641; DOI=10.1074/jbc.M413200200;
RA   Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S.,
RA   Chattopadhyay S.;
RT   "Tumor suppressor SMAR1 activates and stabilizes p53 through its
RT   arginine-serine-rich motif.";
RL   J. Biol. Chem. 280:16019-16029(2005).
RN   [75]
RP   INTERACTION WITH PTK2/FAK1.
RX   PubMed=15855171; DOI=10.1074/jbc.M414172200;
RA   Golubovskaya V.M., Finch R., Cance W.G.;
RT   "Direct interaction of the N-terminal domain of focal adhesion kinase
RT   with the N-terminal transactivation domain of p53.";
RL   J. Biol. Chem. 280:25008-25021(2005).
RN   [76]
RP   INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
RX   PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-,
RT   staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT   phosphorylated form binds and stabilizes serine 46-phosphorylated
RT   p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [77]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y.,
RA   Birnbaum M.J., Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [78]
RP   INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND
RP   SER-392.
RX   PubMed=17108107; DOI=10.1158/0008-5472.CAN-06-0999;
RA   Zeng P.Y., Berger S.L.;
RT   "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate
RT   transcriptional activation.";
RL   Cancer Res. 66:10701-10708(2006).
RN   [79]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2)
RT   isoforms determines their different effect on p53 stability in tumour
RT   cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [80]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [81]
RP   PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG.
RX   PubMed=16377624; DOI=10.1074/jbc.M512074200;
RA   Yoshida K., Liu H., Miki Y.;
RT   "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor
RT   suppressor in the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 281:5734-5740(2006).
RN   [82]
RP   METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
RX   PubMed=17108971; DOI=10.1038/nature05287;
RA   Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M.,
RA   Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
RT   "Repression of p53 activity by Smyd2-mediated methylation.";
RL   Nature 444:629-632(2006).
RN   [83]
RP   INTERACTION WITH DAXX.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [84]
RP   MOTIF, AND METHYLATION AT LYS-372.
RX   PubMed=16415881; DOI=10.1038/nsmb1045;
RA   Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
RT   "Structural basis for the methylation site specificity of SET7/9.";
RL   Nat. Struct. Mol. Biol. 13:140-146(2006).
RN   [85]
RP   PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C.,
RA   Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III,
RA   Wright P.E., Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [86]
RP   INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143;
RP   HIS-175 AND PRO-175.
RX   PubMed=17719541; DOI=10.1016/j.cell.2007.06.013;
RA   Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A.,
RA   Lee S.W.;
RT   "Hzf Determines cell survival upon genotoxic stress by modulating p53
RT   transactivation.";
RL   Cell 130:624-637(2007).
RN   [87]
RP   UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
RX   PubMed=17170702; DOI=10.1038/sj.emboj.7601490;
RA   Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y.,
RA   Yamadera T., Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K.,
RA   Yoo E., Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S.,
RA   Eguchi K., Komiya S., Maruyama I., Higashi N., Sato M., Senoo H.,
RA   Ochi T., Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A.,
RA   Nishioka K., Tanaka K., Nakajima T.;
RT   "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident
RT   ubiquitin ligase 'Synoviolin'.";
RL   EMBO J. 26:113-122(2007).
RN   [88]
RP   INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-
RT   induced dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [89]
RP   INTERACTION WITH ARMC10.
RX   PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025;
RA   Zhou X., Yang G., Huang R., Chen X., Hu G.;
RT   "SVH-B interacts directly with p53 and suppresses the transcriptional
RT   activity of p53.";
RL   FEBS Lett. 581:4943-4948(2007).
RN   [90]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [91]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P.,
RA   Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [92]
RP   INTERACTION WITH RFFL AND RNF34.
RX   PubMed=17121812; DOI=10.1074/jbc.M610793200;
RA   Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J.,
RA   Matthew E.M., Wang W., Dicker D.T., El-Deiry W.S.;
RT   "CARPs are ubiquitin ligases that promote MDM2-independent p53 and
RT   phospho-p53ser20 degradation.";
RL   J. Biol. Chem. 282:3273-3281(2007).
RN   [93]
RP   FUNCTION, AND INTERACTION WITH MAML1.
RX   PubMed=17317671; DOI=10.1074/jbc.M608974200;
RA   Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y.,
RA   Gurumurthy C.B., Germaniuk-Kurowska A., Reddi H.V., Solomon A.,
RA   Zeng M.S., Kung A., Ma H., Gao Q., Dimri G., Stanculescu A., Miele L.,
RA   Wu L., Griffin J.D., Wazer D.E., Band H., Band V.;
RT   "The notch regulator MAML1 interacts with p53 and functions as a
RT   coactivator.";
RL   J. Biol. Chem. 282:11969-11981(2007).
RN   [94]
RP   PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=17591690; DOI=10.1242/jcs.03468;
RA   Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.;
RT   "Stabilization and activation of p53 induced by Cdk5 contributes to
RT   neuronal cell death.";
RL   J. Cell Sci. 120:2259-2271(2007).
RN   [95]
RP   INTERACTION WITH MORC3.
RX   PubMed=17332504; DOI=10.1091/mbc.E06-08-0747;
RA   Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H.,
RA   Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.;
RT   "Dynamic regulation of p53 subnuclear localization and senescence by
RT   MORC3.";
RL   Mol. Biol. Cell 18:1701-1709(2007).
RN   [96]
RP   FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46.
RX   PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007;
RA   Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.;
RT   "DYRK2 is targeted to the nucleus and controls p53 via Ser46
RT   phosphorylation in the apoptotic response to DNA damage.";
RL   Mol. Cell 25:725-738(2007).
RN   [97]
RP   DEMETHYLATION BY KDM1A.
RX   PubMed=17805299; DOI=10.1038/nature06092;
RA   Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M.,
RA   Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.;
RT   "p53 is regulated by the lysine demethylase LSD1.";
RL   Nature 449:105-108(2007).
RN   [98]
RP   METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382.
RX   PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012;
RA   Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W.,
RA   Dutta S., Appella E., Gozani O.;
RT   "Modulation of p53 function by SET8-mediated methylation at lysine
RT   382.";
RL   Mol. Cell 27:636-646(2007).
RN   [99]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [100]
RP   ACETYLATION, AND DEACETYLATION BY SIRT2.
RX   PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114;
RA   Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y.,
RA   Lee K.Y.;
RT   "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the
RT   activity of p53.";
RL   Biochem. Biophys. Res. Commun. 368:690-695(2008).
RN   [101]
RP   INTERACTION WITH SETD2.
RX   PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012;
RA   Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.;
RT   "Histone methyltransferase protein SETD2 interacts with p53 and
RT   selectively regulates its downstream genes.";
RL   Cell. Signal. 20:1671-1678(2008).
RN   [102]
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031;
RA   Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K.,
RA   Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.;
RT   "Nuclear FAK promotes cell proliferation and survival through FERM-
RT   enhanced p53 degradation.";
RL   Mol. Cell 29:9-22(2008).
RN   [103]
RP   INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT
RP   SER-15 BY ATM, AND MUTAGENESIS OF SER-15.
RX   PubMed=17967874; DOI=10.1128/MCB.00983-07;
RA   Shouse G.P., Cai X., Liu X.;
RT   "Serine 15 phosphorylation of p53 directs its interaction with
RT   B56gamma and the tumor suppressor activity of B56gamma-specific
RT   protein phosphatase 2A.";
RL   Mol. Cell. Biol. 28:448-456(2008).
RN   [104]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [105]
RP   INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND
RP   UBIQUITINATION AT LYS-291 AND LYS-292 BY MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls
RT   cell cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [106]
RP   UBIQUITINATION BY TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [107]
RP   INTERACTION WITH MTA1 AND RFWD2, AND UBIQUITINATION.
RX   PubMed=19837670; DOI=10.1074/jbc.M109.056499;
RA   Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "MTA1 coregulator regulates p53 stability and function.";
RL   J. Biol. Chem. 284:34545-34552(2009).
RN   [108]
RP   INTERACTION WITH HHV-5 PROTEIN UL123.
RX   PubMed=19776115; DOI=10.1128/JVI.00304-09;
RA   Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y.,
RA   Huang E.S.;
RT   "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits
RT   p53-dependent transactivation by a mechanism different from that of
RT   IE2-86 protein.";
RL   J. Virol. 83:12388-12398(2009).
RN   [109]
RP   INTERACTION WITH FBXO42.
RX   PubMed=19509332; DOI=10.1073/pnas.0901864106;
RA   Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y.,
RA   Li R., Yao X., Yi X., Shang Y.;
RT   "JFK, a Kelch domain-containing F-box protein, links the SCF complex
RT   to p53 regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009).
RN   [110]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J.,
RA   Bergmann A., Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [111]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [112]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP10.
RX   PubMed=20096447; DOI=10.1016/j.cell.2009.12.032;
RA   Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.;
RT   "USP10 regulates p53 localization and stability by deubiquitinating
RT   p53.";
RL   Cell 140:384-396(2010).
RN   [113]
RP   FUNCTION.
RX   PubMed=20673990; DOI=10.1016/j.cell.2010.06.040;
RA   Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J.,
RA   Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M.,
RA   Attardi L.D., Regev A., Lander E.S., Jacks T., Rinn J.L.;
RT   "A large intergenic noncoding RNA induced by p53 mediates global gene
RT   repression in the p53 response.";
RL   Cell 142:409-419(2010).
RN   [114]
RP   PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1.
RX   PubMed=20041275; DOI=10.1007/s00018-009-0236-7;
RA   Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.;
RT   "Isoform specific phosphorylation of p53 by protein kinase CK1.";
RL   Cell. Mol. Life Sci. 67:1105-1118(2010).
RN   [115]
RP   INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155;
RP   HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF
RP   ARG-248.
RX   PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006;
RA   Lim S.O., Kim H., Jung G.;
RT   "p53 inhibits tumor cell invasion via the degradation of snail protein
RT   in hepatocellular carcinoma.";
RL   FEBS Lett. 584:2231-2236(2010).
RN   [116]
RP   INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19880522; DOI=10.1074/jbc.M109.064212;
RA   Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.;
RT   "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism
RT   facilitating cell proliferation and survival.";
RL   J. Biol. Chem. 285:1743-1753(2010).
RN   [117]
RP   METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373.
RX   PubMed=20118233; DOI=10.1074/jbc.M109.062588;
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RT   "G9a and Glp methylate lysine 373 in the tumor suppressor p53.";
RL   J. Biol. Chem. 285:9636-9641(2010).
RN   [118]
RP   ERRATUM.
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RL   J. Biol. Chem. 285:18122-18122(2010).
RN   [119]
RP   PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5.
RX   PubMed=20124405; DOI=10.1074/jbc.M109.094243;
RA   Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.;
RT   "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits
RT   DNA damage-induced apoptosis.";
RL   J. Biol. Chem. 285:12823-12830(2010).
RN   [120]
RP   INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382.
RX   PubMed=20228809; DOI=10.1038/ncb2038;
RA   Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H.,
RA   Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.;
RT   "BRD7 is a candidate tumour suppressor gene required for p53
RT   function.";
RL   Nat. Cell Biol. 12:380-389(2010).
RN   [121]
RP   UBIQUITINATION BY RFWD3.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J.,
RA   Jung S.Y., O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53
RT   stability in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [122]
RP   INTERACTION WITH BRD7.
RX   PubMed=20660729; DOI=10.1073/pnas.1009559107;
RA   Burrows A.E., Smogorzewska A., Elledge S.J.;
RT   "Polybromo-associated BRG1-associated factor components BRD7 and
RT   BAF180 are critical regulators of p53 required for induction of
RT   replicative senescence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010).
RN   [123]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [124]
RP   INTERACTION WITH UHRF2.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [125]
RP   FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT
RP   SER-183; SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284,
RP   MUTAGENESIS OF SER-183 AND SER-269, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20959462; DOI=10.1074/jbc.M110.174755;
RA   Wu L., Ma C.A., Zhao Y., Jain A.;
RT   "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in
RT   its DNA-binding domain and subsequent functional suppression.";
RL   J. Biol. Chem. 286:2236-2244(2011).
RN   [126]
RP   INVOLVEMENT IN BCC7.
RX   PubMed=21946351; DOI=10.1038/ng.926;
RA   Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J.,
RA   Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B.,
RA   Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A.,
RA   Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K.,
RA   Hemminki K., Corredera C., Fuentelsaz V., Grasa P., Navarrete S.,
RA   Fuertes F., Garcia-Prats M.D., Sanambrosio E., Panadero A.,
RA   De Juan A., Garcia A., Rivera F., Planelles D., Soriano V.,
RA   Requena C., Aben K.K., van Rossum M.M., Cremers R.G., van Oort I.M.,
RA   van Spronsen D.J., Schalken J.A., Peters W.H., Helfand B.T.,
RA   Donovan J.L., Hamdy F.C., Badescu D., Codreanu O., Jinga M.,
RA   Csiki I.E., Constantinescu V., Badea P., Mates I.N., Dinu D.E.,
RA   Constantin A., Mates D., Kristjansdottir S., Agnarsson B.A.,
RA   Jonsson E., Barkardottir R.B., Einarsson G.V., Sigurdsson F.,
RA   Moller P.H., Stefansson T., Valdimarsson T., Johannsson O.T.,
RA   Sigurdsson H., Jonsson T., Jonasson J.G., Tryggvadottir L., Rice T.,
RA   Hansen H.M., Xiao Y., Lachance D.H., O'Neill B.P., Kosel M.L.,
RA   Decker P.A., Thorleifsson G., Johannsdottir H., Helgadottir H.T.,
RA   Sigurdsson A., Steinthorsdottir V., Lindblom A., Sandler R.S.,
RA   Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T.,
RA   Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M.,
RA   Wiencke J., Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A.,
RA   Kumar R., Mayordomo J.I., Olafsson J.H., Kong A., Thorsteinsdottir U.,
RA   Rafnar T., Stefansson K.;
RT   "A germline variant in the TP53 polyadenylation signal confers cancer
RT   susceptibility.";
RL   Nat. Genet. 43:1098-1103(2011).
RN   [127]
RP   INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392.
RX   PubMed=21317932; DOI=10.1038/onc.2011.19;
RA   Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.;
RT   "A new role of NUAK1: directly phosphorylating p53 and regulating cell
RT   proliferation.";
RL   Oncogene 30:2933-2942(2011).
RN   [128]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S.,
RA   Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
RN   [129]
RP   INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT
RP   LYS-386.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [130]
RP   INTERACTION WITH ZNF385B.
RX   PubMed=22945289; DOI=10.1002/eji.201242530;
RA   Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S.,
RA   Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J.,
RA   Kiyokawa N.;
RT   "ZNF385B is characteristically expressed in germinal center B cells
RT   and involved in B-cell apoptosis.";
RL   Eur. J. Immunol. 42:3405-3415(2012).
RN   [131]
RP   METHYLATION AT LYS-370 AND LYS-382.
RX   PubMed=22864287; DOI=10.1038/nsmb.2353;
RA   Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F.,
RA   Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.;
RT   "PHF20 is an effector protein of p53 double lysine methylation that
RT   stabilizes and activates p53.";
RL   Nat. Struct. Mol. Biol. 19:916-924(2012).
RN   [132]
RP   FUNCTION.
RX   PubMed=24051492; DOI=10.1038/ncomms3444;
RA   Miki T., Matsumoto T., Zhao Z., Lee C.C.;
RT   "p53 regulates Period2 expression and the circadian clock.";
RL   Nat. Commun. 4:2444-2444(2013).
RN   [133]
RP   INTERACTION WITH KAT6A, AND ACETYLATION AT LYS-120 AND LYS-382.
RX   PubMed=23431171; DOI=10.1073/pnas.1300490110;
RA   Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I.,
RA   Prives C.;
RT   "MOZ increases p53 acetylation and premature senescence through its
RT   complex formation with PML.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013).
RN   [134]
RP   INTERACTION WITH HADV5 E1B-55K.
RX   PubMed=25772236; DOI=10.1038/onc.2015.63;
RA   Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E.,
RA   Hay R.T., Dobner T., Schreiner S.;
RT   "PML isoforms IV and V contribute to adenovirus-mediated oncogenic
RT   transformation by functionally inhibiting the tumor-suppressor p53.";
RL   Oncogene 35:69-82(2016).
RN   [135]
RP   STRUCTURE BY NMR OF 319-360.
RX   PubMed=8023159; DOI=10.1126/science.8023159;
RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA   Appella E., Gronenborn A.M.;
RT   "High-resolution structure of the oligomerization domain of p53 by
RT   multidimensional NMR.";
RL   Science 265:386-391(1994).
RN   [136]
RP   STRUCTURE BY NMR OF 325-355.
RX   PubMed=7773777; DOI=10.1038/nsb1294-877;
RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT   "Solution structure of the tetrameric minimum transforming domain of
RT   p53.";
RL   Nat. Struct. Biol. 1:877-890(1994).
RN   [137]
RP   STRUCTURE BY NMR OF 326-354.
RX   PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA   Halazonetis T.D.;
RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
RT   structure of the p53 oligomerization domain.";
RL   EMBO J. 16:6230-6236(1997).
RN   [138]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX   PubMed=8023157; DOI=10.1126/science.8023157;
RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT   "Crystal structure of a p53 tumor suppressor-DNA complex:
RT   understanding tumorigenic mutations.";
RL   Science 265:346-355(1994).
RN   [139]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX   PubMed=7878469; DOI=10.1126/science.7878469;
RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
RT   "Crystal structure of the tetramerization domain of the p53 tumor
RT   suppressor at 1.7 angstroms.";
RL   Science 267:1498-1502(1995).
RN   [140]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX   PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA   Levine A.J., Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [141]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX   PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
RT   domains of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [142]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS, AND SUBUNIT.
RX   PubMed=14534297; DOI=10.1074/jbc.M309732200;
RA   Joerger A.C., Allen M.D., Fersht A.R.;
RT   "Crystal structure of a superstable mutant of human p53 core domain.
RT   Insights into the mechanism of rescuing oncogenic mutations.";
RL   J. Biol. Chem. 279:1291-1296(2004).
RN   [143]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015;
RA   Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L.,
RA   Haran T.E., Shakked Z.;
RT   "Structural basis of DNA recognition by p53 tetramers.";
RL   Mol. Cell 22:741-753(2006).
RN   [144]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7,
RP   AND INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
RN   [145]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH
RP   USP7, MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION
RP   WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by
RT   HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [146]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT
RP   LYS-382, MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1.
RX   PubMed=20870725; DOI=10.1074/jbc.M110.139527;
RA   West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E.,
RA   Kutateladze T.G., Gozani O.;
RT   "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at
RT   lysine 382 to target gene repression.";
RL   J. Biol. Chem. 285:37725-37732(2010).
RN   [147]
RP   REVIEW.
RX   PubMed=8266092; DOI=10.1126/science.8266092;
RA   Harris C.C.;
RT   "p53: at the crossroads of molecular carcinogenesis and risk
RT   assessment.";
RL   Science 262:1980-1981(1993).
RN   [148]
RP   REVIEW ON VARIANTS.
RX   PubMed=1905840; DOI=10.1126/science.1905840;
RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT   "p53 mutations in human cancers.";
RL   Science 253:49-53(1991).
RN   [149]
RP   REVIEW ON VARIANTS.
RX   PubMed=8829653;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT   "Database of mutations in the p53 and APC tumor suppressor genes
RT   designed to facilitate molecular epidemiological analyses.";
RL   Hum. Mutat. 7:202-213(1996).
RN   [150]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=17015838; DOI=10.1073/pnas.0607286103;
RA   Joerger A.C., Ang H.C., Fersht A.R.;
RT   "Structural basis for understanding oncogenic p53 mutations and
RT   designing rescue drugs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006).
RN   [151]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282.
RX   PubMed=18453682; DOI=10.1107/S0907444908003338;
RA   Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.;
RT   "Impact of low-frequency hotspot mutation R282Q on the structure of
RT   p53 DNA-binding domain as revealed by crystallography at 1.54
RT   angstroms resolution.";
RL   Acta Crystallogr. D 64:471-477(2008).
RN   [152]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN
RP   COMPLEX WITH ZINC IONS AND PHIKAN083.
RX   PubMed=18650397; DOI=10.1073/pnas.0805326105;
RA   Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J.,
RA   Veprintsev D.B., Fersht A.R.;
RT   "Targeted rescue of a destabilized mutant of p53 by an in silico
RT   screened drug.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008).
RN   [153]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN
RP   COMPLEX WITH DNA.
RX   PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063;
RA   Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N.,
RA   Shimon L.J., Frolow F., Liran A., Rotter V., Shakked Z.;
RT   "Structural basis of restoring sequence-specific DNA binding and
RT   transactivation to mutant p53 by suppressor mutations.";
RL   J. Mol. Biol. 385:249-265(2009).
RN   [154]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=19515728; DOI=10.1093/protein/gzp018;
RA   Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.;
RT   "Stabilising the DNA-binding domain of p53 by rational design of its
RT   hydrophobic core.";
RL   Protein Eng. Des. Sel. 22:421-430(2009).
RN   [155]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN
RP   COMPLEX WITH ZINC IONS.
RX   PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011;
RA   Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J.,
RA   Fersht A.R.;
RT   "Toward the rational design of p53-stabilizing drugs: probing the
RT   surface of the oncogenic Y220C mutant.";
RL   Chem. Biol. 17:46-56(2010).
RN   [156]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=20364130; DOI=10.1038/nsmb.1800;
RA   Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B.,
RA   Shakked Z.;
RT   "Diversity in DNA recognition by p53 revealed by crystal structures
RT   with Hoogsteen base pairs.";
RL   Nat. Struct. Mol. Biol. 17:423-429(2010).
RN   [157]
RP   VARIANT ARG-72.
RX   PubMed=1999338; DOI=10.1007/BF00201836;
RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT   "Characterization of a frequent polymorphism in the coding sequence of
RT   the Tp53 gene in colonic cancer patients and a control population.";
RL   Hum. Genet. 86:369-370(1991).
RN   [158]
RP   VARIANT LFS THR-133.
RX   PubMed=1933902;
RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT   family.";
RL   Cancer Res. 51:6385-6387(1991).
RN   [159]
RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX   PubMed=1978757; DOI=10.1126/science.1978757;
RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
RA   Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
RA   Friend S.H.;
RT   "Germ line p53 mutations in a familial syndrome of breast cancer,
RT   sarcomas, and other neoplasms.";
RL   Science 250:1233-1238(1990).
RN   [160]
RP   VARIANT LFS ASP-245.
RX   PubMed=2259385; DOI=10.1038/348747a0;
RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family
RT   with Li-Fraumeni syndrome.";
RL   Nature 348:747-749(1990).
RN   [161]
RP   VARIANT LFS LEU-272.
RX   PubMed=1737852; DOI=10.1172/JCI115630;
RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
RA   Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
RA   Knutsen T., Minna J.D.;
RT   "Hereditary and acquired p53 gene mutations in childhood acute
RT   lymphoblastic leukemia.";
RL   J. Clin. Invest. 89:640-647(1992).
RN   [162]
RP   VARIANTS LFS HIS-273 AND VAL-325.
RX   PubMed=1565144; DOI=10.1056/NEJM199205143262002;
RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
RA   Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
RA   Strong L.C.;
RT   "Germline mutations of the p53 tumor-suppressor gene in children and
RT   young adults with second malignant neoplasms.";
RL   N. Engl. J. Med. 326:1309-1315(1992).
RN   [163]
RP   VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285.
RX   PubMed=1694291;
RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
RT   "Genetic and immunochemical analysis of mutant p53 in human breast
RT   cancer cell lines.";
RL   Oncogene 5:893-899(1990).
RN   [164]
RP   VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273.
RX   PubMed=1699228; DOI=10.1073/pnas.87.19.7555;
RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA   Gannon J.V., Lane D.P.;
RT   "p53 mutations in colorectal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN   [165]
RP   VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND
RP   SER-278.
RX   PubMed=2263646; DOI=10.1073/pnas.87.24.9958;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN   [166]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1647768; DOI=10.1016/0006-291X(91)90623-F;
RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA   Wakui A., Yamazaki T.;
RT   "Mutations of the P53 gene, including an intronic point mutation, in
RT   colorectal tumors.";
RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN   [167]
RP   VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND
RP   HIS-273.
RX   PubMed=1868473;
RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
RA   Roth J.A.;
RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL   Cancer Res. 51:4495-4499(1991).
RN   [168]
RP   VARIANTS SPORADIC CANCERS IN CHINA.
RX   PubMed=1849234; DOI=10.1038/350427a0;
RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT   "Mutational hotspot in the p53 gene in human hepatocellular
RT   carcinomas.";
RL   Nature 350:427-428(1991).
RN   [169]
RP   VARIANTS SPORADIC CANCERS IN SOUTH AFRICA.
RX   PubMed=1672732; DOI=10.1038/350429a0;
RA   Bressac B., Kew M., Wands J., Ozturk M.;
RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma
RT   from southern Africa.";
RL   Nature 350:429-431(1991).
RN   [170]
RP   VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND
RP   HIS-273.
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RN   [171]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1327751;
RA   Crook T., Vousden K.H.;
RT   "Properties of p53 mutations detected in primary and secondary
RT   cervical cancers suggest mechanisms of metastasis and involvement of
RT   environmental carcinogens.";
RL   EMBO J. 11:3935-3940(1992).
RN   [172]
RP   VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285.
RX   PubMed=1459726; DOI=10.1002/ijc.2910520606;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral
RT   squamous-cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [173]
RP   VARIANT PRO-HIS-PRO-178 INS.
RX   PubMed=1303181; DOI=10.1093/hmg/1.3.207;
RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL   Hum. Mol. Genet. 1:207-208(1992).
RN   [174]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1437144;
RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA   Appella E., May P.;
RT   "p53 mutations in Raji cells: characterization and localization
RT   relative to other Burkitt's lymphomas.";
RL   Oncogene 7:2161-2167(1992).
RN   [175]
RP   VARIANT SPORADIC CANCER THR-280.
RX   PubMed=1631151; DOI=10.1073/pnas.89.14.6516;
RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y.,
RA   Chen I.-H., Cao Y., Yao K.-T., Colburn N.H.;
RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT   carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN   [176]
RP   VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220;
RP   GLN-248; LEU-248 AND HIS-273.
RX   PubMed=7682763;
RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT   lines.";
RL   Am. J. Pathol. 142:1131-1139(1993).
RN   [177]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8402617;
RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT   "The incidence of p53 mutations increases with progression of head and
RT   neck cancer.";
RL   Cancer Res. 53:4477-4480(1993).
RN   [178]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8336944;
RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT   "Efficient screening of p53 mutations by denaturing gradient gel
RT   electrophoresis in colorectal tumors.";
RL   Oncogene 8:2213-2220(1993).
RN   [179]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8118819;
RA   Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A.,
RA   Kelsey A.M., Harris M., Jones P.H., Binchy A., Crowther D.,
RA   Craft A.W., Eden O.B., Evans D.G.R., Thompson E., Mann J.R.,
RA   Martin J., Mitchell E.L.D., Santibanez-Koref M.F.;
RT   "Prevalence and diversity of constitutional mutations in the p53 gene
RT   among 21 Li-Fraumeni families.";
RL   Cancer Res. 54:1298-1304(1994).
RN   [180]
RP   CHARACTERIZATION OF VARIANT ALA-143.
RX   PubMed=8013454;
RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT   "A temperature-sensitive mutant of human p53.";
RL   EMBO J. 13:2535-2544(1994).
RN   [181]
RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX   PubMed=7887414;
RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL   Am. J. Hum. Genet. 56:608-615(1995).
RN   [182]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8718514;
RA   Eeles R.A.;
RT   "Germline mutations in the TP53 gene.";
RL   Cancer Surv. 25:101-124(1995).
RN   [183]
RP   VARIANT LFS HIS-175.
RX   PubMed=8825920; DOI=10.1136/jmg.32.12.942;
RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
RA   Evans D.G.R.;
RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
RT   175 mutation in TP53.";
RL   J. Med. Genet. 32:942-945(1995).
RN   [184]
RP   VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND
RP   GLN-286.
RX   PubMed=8829627;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
RA   Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL   Hum. Mutat. 7:109-113(1996).
RN   [185]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=9101296;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.0.CO;2-1;
RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Single-step DGGE-based mutation scanning of the p53 gene: application
RT   to genetic diagnosis of colorectal cancer.";
RL   Hum. Mutat. 9:348-355(1997).
RN   [186]
RP   VARIANT SPORADIC CANCER ILE-157.
RX   PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT   "Drastic genetic instability of tumors and normal tissues in Turcot
RT   syndrome.";
RL   Oncogene 15:2877-2881(1997).
RN   [187]
RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
RP   AND SER-278.
RX   PubMed=9450901;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA   Raubenheimer E.J.;
RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT   black African population sample.";
RL   Hum. Mutat. 11:39-44(1998).
RN   [188]
RP   VARIANT NON-CLASSICAL LFS CYS-337.
RX   PubMed=9452042;
RA   Luca J.W., Strong L.C., Hansen M.F.;
RT   "A germline missense mutation R337C in exon 10 of the human p53
RT   gene.";
RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
RN   [189]
RP   VARIANT LFS ILE-292.
RX   PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
RT   a Li-Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [190]
RP   VARIANTS.
RX   PubMed=10549356;
RA   Hainaut P., Hollstein M.;
RT   "p53 and human cancer: the first ten thousand mutations.";
RL   Adv. Cancer Res. 77:81-137(2000).
RN   [191]
RP   VARIANT ADCC HIS-337.
RX   PubMed=11481490; DOI=10.1073/pnas.161479898;
RA   Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P.,
RA   Michalkiewicz E., Lafferty A.R., DeLacerda L., Rabin M., Cadwell C.,
RA   Sampaio G., Cat I., Stratakis C.A., Sandrini R.;
RT   "An inherited p53 mutation that contributes in a tissue-specific
RT   manner to pediatric adrenal cortical carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001).
RN   [192]
RP   INVOLVEMENT IN CPP.
RX   PubMed=12085209; DOI=10.1038/sj.bjc.6600269;
RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
RA   Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
RT   "Investigations on a clinically and functionally unusual and novel
RT   germline p53 mutation.";
RL   Br. J. Cancer 86:1592-1596(2002).
RN   [193]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175;
RP   ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248;
RP   SER-249; TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280
RP   AND HIS-281.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [194]
RP   VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195;
RP   MET-216; ALA-241; MET-249; SER-251; TYR-259 AND CYS-273.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A.,
RA   Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S.,
RA   Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by
RT   expression profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [195]
RP   VARIANTS.
RX   PubMed=17311302; DOI=10.1002/humu.20495;
RA   Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V.,
RA   Hainaut P., Olivier M.;
RT   "Impact of mutant p53 functional properties on TP53 mutation patterns
RT   and tumor phenotype: lessons from recent developments in the IARC TP53
RT   database.";
RL   Hum. Mutat. 28:622-629(2007).
RN   [196]
RP   CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION,
RP   PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2.
RX   PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066;
RA   Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S.,
RA   Kim J., Wang L., Lou Z.;
RT   "DBC1 functions as a tumor suppressor by regulating p53 stability.";
RL   Cell Rep. 10:1324-1334(2015).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Implicated in Notch signaling cross-over.
CC       Prevents CDK7 kinase activity when associated to CAK complex in
CC       response to DNA damage, thus stopping cell cycle progression.
CC       Isoform 2 enhances the transactivation activity of isoform 1 from
CC       some but not all TP53-inducible promoters. Isoform 4 suppresses
CC       transactivation activity and impairs growth suppression mediated
CC       by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
CC       Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-
CC       mediated transcriptional activation of PER2 (PubMed:24051492).
CC       {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061,
CC       ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990,
CC       ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440,
CC       ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:9840937}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- SUBUNIT: Interacts with AXIN1. Probably part of a complex
CC       consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as
CC       a homotetramer. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. In vitro, the interaction of TP53 with cancer-
CC       associated/HPV (E6) viral proteins leads to ubiquitination and
CC       degradation of TP53 giving a possible model for cell growth
CC       regulation. This complex formation requires an additional factor,
CC       E6-AP, which stably associates with TP53 in the presence of E6.
CC       Interacts (via C-terminus) with TAF1; when TAF1 is part of the
CC       TFIID complex. Interacts with ING4; this interaction may be
CC       indirect. Found in a complex with CABLES1 and TP73. Interacts with
CC       HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with
CC       HCV core protein. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and
CC       prevent transactivation activity (By similarity). Interacts with
CC       ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1.
CC       Interacts with YWHAZ; the interaction enhances TP53
CC       transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58'
CC       inhibits this interaction. Interacts (via DNA-binding domain) with
CC       MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML
CC       (via C-terminus). Interacts with MDM2; leading to ubiquitination
CC       and proteasomal degradation of TP53. Directly interacts with
CC       FBXO42; leading to ubiquitination and degradation of TP53.
CC       Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase
CC       PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent
CC       inhibition of cell proliferation. Interacts with PPP2R2A.
CC       Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when
CC       monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with
CC       isoform 2 and with isoform 4. Interacts with GRK5. Binds to the
CC       CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage.
CC       Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2
CC       and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this
CC       promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this
CC       promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts
CC       with PPIF; the association implicates preferentially tetrameric
CC       TP53, is induced by oxidative stress and is impaired by
CC       cyclosporin A (CsA). Interacts with human cytomegalovirus/HHV-5
CC       protein UL123. Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Interacts with ZNF385B; the interaction is direct. Interacts (via
CC       DNA-binding domain) with ZNF385A; the interaction is direct and
CC       enhances p53/TP53 transactivation functions on cell-cycle arrest
CC       target genes, resulting in growth arrest. Interacts with ANKRD2.
CC       Interacts with RFFL and RNF34; involved in p53/TP53
CC       ubiquitination. Interacts with MTA1 and RFWD2. Interacts with
CC       CCAR2 (via N-terminus). Interacts (via N-terminus) with human
CC       adenovirus 5 E1B-55K protein; this interaction leads to the
CC       inhibition of TP53 function and/or its degradation
CC       (PubMed:25772236). Interacts with MORC3 (PubMed:17332504).
CC       {ECO:0000250, ECO:0000269|PubMed:10570149,
CC       ECO:0000269|PubMed:10644996, ECO:0000269|PubMed:11025664,
CC       ECO:0000269|PubMed:11058590, ECO:0000269|PubMed:11706030,
CC       ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:11780126,
CC       ECO:0000269|PubMed:11925430, ECO:0000269|PubMed:12507430,
CC       ECO:0000269|PubMed:12702766, ECO:0000269|PubMed:12750254,
CC       ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404,
CC       ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041,
CC       ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303,
CC       ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:15855171,
CC       ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561,
CC       ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624,
CC       ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402,
CC       ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107,
CC       ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:17245430, ECO:0000269|PubMed:17317671,
CC       ECO:0000269|PubMed:17332504, ECO:0000269|PubMed:17591690,
CC       ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:17904127,
CC       ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004,
CC       ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18996393,
CC       ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728,
CC       ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538,
CC       ECO:0000269|PubMed:19776115, ECO:0000269|PubMed:19837670,
CC       ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20124405,
CC       ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809,
CC       ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133,
CC       ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725,
CC       ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932,
CC       ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662,
CC       ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:22945289,
CC       ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:25732823,
CC       ECO:0000269|PubMed:25772236, ECO:0000269|PubMed:8875926,
CC       ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}.
CC   -!- INTERACTION:
CC       Self; NbExp=11; IntAct=EBI-366083, EBI-366083;
CC       P03070:- (xeno); NbExp=19; IntAct=EBI-366083, EBI-617698;
CC       P26663:- (xeno); NbExp=9; IntAct=EBI-366083, EBI-6838571;
CC       Q7L7W2:-; NbExp=2; IntAct=EBI-366083, EBI-7210801;
CC       Q8QW27:- (xeno); NbExp=2; IntAct=EBI-366083, EBI-6863726;
CC       O95376:ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158;
CC       Q9UBL3:ASH2L; NbExp=5; IntAct=EBI-366083, EBI-540797;
CC       O15169:AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484;
CC       Q8N9N5:BANP; NbExp=3; IntAct=EBI-366083, EBI-744695;
CC       P10415:BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694;
CC       Q07817-1:BCL2L1; NbExp=18; IntAct=EBI-366083, EBI-287195;
CC       P11274:BCR; NbExp=2; IntAct=EBI-366083, EBI-712838;
CC       O14503:BHLHE40; NbExp=5; IntAct=EBI-366083, EBI-711810;
CC       Q9NPI1:BRD7; NbExp=8; IntAct=EBI-366083, EBI-711221;
CC       Q9BX70:BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091;
CC       Q9ESJ1:Cables1 (xeno); NbExp=3; IntAct=EBI-366083, EBI-604411;
CC       Q9BWC9:CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501;
CC       P38936:CDKN1A; NbExp=3; IntAct=EBI-366083, EBI-375077;
CC       P17676:CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696;
CC       Q92793:CREBBP; NbExp=9; IntAct=EBI-366083, EBI-81215;
CC       P45481:Crebbp (xeno); NbExp=6; IntAct=EBI-366083, EBI-296306;
CC       P55060:CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709;
CC       P68400:CSNK2A1; NbExp=2; IntAct=EBI-366083, EBI-347804;
CC       Q14999:CUL7; NbExp=5; IntAct=EBI-366083, EBI-308606;
CC       Q8IWT3:CUL9; NbExp=4; IntAct=EBI-366083, EBI-311123;
CC       Q9P0U4:CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911;
CC       Q9UER7:DAXX; NbExp=12; IntAct=EBI-366083, EBI-77321;
CC       Q92841:DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012;
CC       P17844:DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962;
CC       Q9BV47:DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519;
CC       O14641:DVL2; NbExp=4; IntAct=EBI-366083, EBI-740850;
CC       P03126:E6 (xeno); NbExp=3; IntAct=EBI-366083, EBI-1177242;
CC       P06463:E6 (xeno); NbExp=3; IntAct=EBI-366083, EBI-1186926;
CC       Q09472:EP300; NbExp=10; IntAct=EBI-366083, EBI-447295;
CC       Q86XK2:FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804;
CC       O43524:FOXO3; NbExp=2; IntAct=EBI-366083, EBI-1644164;
CC       P49841:GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586;
CC       P32780:GTF2H1; NbExp=5; IntAct=EBI-366083, EBI-715539;
CC       Q13547:HDAC1; NbExp=7; IntAct=EBI-366083, EBI-301834;
CC       Q86Z02:HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891;
CC       P61978:HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185;
CC       P61978-2:HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731;
CC       P34931:HSPA1L; NbExp=2; IntAct=EBI-366083, EBI-354912;
CC       P38646:HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932;
CC       P04792:HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682;
CC       P42858:HTT; NbExp=4; IntAct=EBI-366083, EBI-466029;
CC       Q7Z6Z7:HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934;
CC       Q16666-2:IFI16; NbExp=3; IntAct=EBI-366083, EBI-6273540;
CC       Q08619:Ifi205b (xeno); NbExp=2; IntAct=EBI-366083, EBI-8064290;
CC       Q92993:KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080;
CC       Q9H7Z6:KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414;
CC       Q8IZD2:KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959;
CC       Q16363:LAMA4; NbExp=2; IntAct=EBI-366083, EBI-711505;
CC       P43356:MAGEA2B; NbExp=6; IntAct=EBI-366083, EBI-5650739;
CC       Q9UBF1:MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487;
CC       P46821:MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611;
CC       Q15759:MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304;
CC       Q8IW41:MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460;
CC       Q00987:MDM2; NbExp=65; IntAct=EBI-366083, EBI-389668;
CC       O15151:MDM4; NbExp=14; IntAct=EBI-366083, EBI-398437;
CC       Q9UHC7:MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524;
CC       O75970:MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405;
CC       P04731:MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030;
CC       P19338:NCL; NbExp=2; IntAct=EBI-366083, EBI-346967;
CC       Q9Y618:NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830;
CC       P23511:NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739;
CC       P25208:NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728;
CC       Q9Y3T9:NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547;
CC       P06748:NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579;
CC       P06748-1:NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150;
CC       Q15466:NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729;
CC       P22736:NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550;
CC       O43847:NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631;
CC       P89055:NSP1 (xeno); NbExp=6; IntAct=EBI-366083, EBI-9522973;
CC       O60285:NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789;
CC       Q96FW1:OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491;
CC       Q8TEW0:PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968;
CC       P09874:PARP1; NbExp=3; IntAct=EBI-366083, EBI-355676;
CC       Q96KB5:PBK; NbExp=7; IntAct=EBI-366083, EBI-536853;
CC       O75925:PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434;
CC       O75928:PIAS2; NbExp=2; IntAct=EBI-366083, EBI-348555;
CC       Q8N2W9:PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160;
CC       Q13526:PIN1; NbExp=12; IntAct=EBI-366083, EBI-714158;
CC       P53350:PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768;
CC       P29590:PML; NbExp=4; IntAct=EBI-366083, EBI-295890;
CC       P30405:PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229;
CC       P36873-1:PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289;
CC       Q8WUF5:PPP1R13L; NbExp=11; IntAct=EBI-366083, EBI-5550163;
CC       P30153:PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388;
CC       Q13362:PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156;
CC       Q05655:PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279;
CC       P61289:PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546;
CC       Q05397:PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142;
CC       Q06609:RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202;
CC       Q96PM5:RCHY1; NbExp=7; IntAct=EBI-366083, EBI-947779;
CC       P23396:RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193;
CC       Q8N488:RYBP; NbExp=3; IntAct=EBI-366083, EBI-752324;
CC       P23297:S100A1; NbExp=2; IntAct=EBI-366083, EBI-743686;
CC       P29034:S100A2; NbExp=2; IntAct=EBI-366083, EBI-752230;
CC       P26447:S100A4; NbExp=7; IntAct=EBI-366083, EBI-717058;
CC       P04271:S100B; NbExp=2; IntAct=EBI-366083, EBI-458391;
CC       Q15424:SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298;
CC       Q8WTS6:SETD7; NbExp=6; IntAct=EBI-366083, EBI-1268586;
CC       P31947:SFN; NbExp=4; IntAct=EBI-366083, EBI-476295;
CC       Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
CC       Q96EB6:SIRT1; NbExp=13; IntAct=EBI-366083, EBI-1802965;
CC       Q923E4:Sirt1 (xeno); NbExp=4; IntAct=EBI-366083, EBI-1802585;
CC       Q15796:SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141;
CC       O95863:SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459;
CC       Q12772:SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059;
CC       Q96SB4:SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478;
CC       Q86TM6:SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849;
CC       P20226:TBP; NbExp=2; IntAct=EBI-366083, EBI-355371;
CC       P15884:TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224;
CC       Q96GM8:TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460;
CC       Q12888:TP53BP1; NbExp=2; IntAct=EBI-366083, EBI-396540;
CC       Q13625:TP53BP2; NbExp=5; IntAct=EBI-366083, EBI-77642;
CC       Q9H3D4:TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775;
CC       O88898:Tp63 (xeno); NbExp=2; IntAct=EBI-366083, EBI-2338025;
CC       P13693:TPT1; NbExp=5; IntAct=EBI-366083, EBI-1783169;
CC       Q15672:TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287;
CC       P26687:Twist1 (xeno); NbExp=4; IntAct=EBI-366083, EBI-6123119;
CC       P0CG48:UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054;
CC       Q05086:UBE3A; NbExp=3; IntAct=EBI-366083, EBI-954357;
CC       Q96PU4:UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304;
CC       Q9H9J4:USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638;
CC       Q9H9J4-2:USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105;
CC       Q93009:USP7; NbExp=17; IntAct=EBI-366083, EBI-302474;
CC       P11473:VDR; NbExp=6; IntAct=EBI-366083, EBI-286357;
CC       Q99986:VRK1; NbExp=9; IntAct=EBI-366083, EBI-1769146;
CC       Q14191:WRN; NbExp=5; IntAct=EBI-366083, EBI-368417;
CC       P12956:XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208;
CC       P61981:YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-366083, EBI-347088;
CC       Q8TAQ5:ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307;
CC       Q9PST7:znf585b (xeno); NbExp=3; IntAct=EBI-366083, EBI-1782562;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body.
CC       Endoplasmic reticulum. Mitochondrion matrix. Note=Interaction with
CC       BANP promotes nuclear localization. Recruited into PML bodies
CC       together with CHEK2. Translocates to mitochondria upon oxidative
CC       stress.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but localizes to the cytoplasm when
CC       expressed with isoform 4.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm.
CC       Note=Localized in the nucleus in most cells but found in the
CC       cytoplasm in some cells.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but translocates to the cytoplasm
CC       following cell stress.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 8: Nucleus. Cytoplasm.
CC       Note=Localized in both nucleus and cytoplasm in most cells. In
CC       some cells, forms foci in the nucleus that are different from
CC       nucleoli.
CC   -!- SUBCELLULAR LOCATION: Isoform 9: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=p53, p53alpha;
CC         IsoId=P04637-1; Sequence=Displayed;
CC       Name=2; Synonyms=I9RET, p53beta;
CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay.;
CC       Name=3; Synonyms=p53gamma;
CC         IsoId=P04637-3; Sequence=VSP_040560, VSP_040561;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay.;
CC       Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47;
CC         IsoId=P04637-4; Sequence=VSP_040832;
CC       Name=5; Synonyms=Del40-p53beta;
CC         IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536;
CC       Name=6; Synonyms=Del40-p53gamma;
CC         IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561;
CC       Name=7; Synonyms=Del133-p53, Del133-p53alpha;
CC         IsoId=P04637-7; Sequence=VSP_040833;
CC         Note=Produced by alternative promoter usage.;
CC       Name=8; Synonyms=Del133-p53beta;
CC         IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing.;
CC       Name=9; Synonyms=Del133-p53gamma;
CC         IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide
CC       range of normal tissues but in a tissue-dependent manner. Isoform
CC       2 is expressed in most normal tissues but is not detected in
CC       brain, lung, prostate, muscle, fetal brain, spinal cord and fetal
CC       liver. Isoform 3 is expressed in most normal tissues but is not
CC       detected in lung, spleen, testis, fetal brain, spinal cord and
CC       fetal liver. Isoform 7 is expressed in most normal tissues but is
CC       not detected in prostate, uterus, skeletal muscle and breast.
CC       Isoform 8 is detected only in colon, bone marrow, testis, fetal
CC       brain and intestine. Isoform 9 is expressed in most normal tissues
CC       but is not detected in brain, heart, lung, fetal liver, salivary
CC       gland, breast or intestine. {ECO:0000269|PubMed:16131611}.
CC   -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is
CC       not induced in tumor cells in response to stress.
CC       {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}.
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional
CC       repression domain. The TADI and TADII motifs (residues 17 to 25
CC       and 48 to 56) correspond both to 9aaTAD motifs which are
CC       transactivation domains present in a large number of yeast and
CC       animal transcription factors. {ECO:0000269|PubMed:17467953}.
CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1
CC       impairs its ability to induce proapoptotic program and modulate
CC       cell senescence. Deacetylation by SIRT2 impairs its ability to
CC       induce transcription activation in a AKT-dependent manner.
CC       {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:20228809,
CC       ECO:0000269|PubMed:23431171}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated by HIPK1 (By similarity).
CC       Phosphorylation at Ser-9 by HIPK4 increases repression activity on
CC       BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated
CC       on Ser-20 by CHEK2 in response to DNA damage, which prevents
CC       ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in
CC       response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which
CC       promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by
CC       CDK7 in a CAK complex in response to DNA damage. Phosphorylated on
CC       Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is
CC       required for acetylation by CREBBP. Phosphorylated on Ser-392
CC       following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction
CC       with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was
CC       intially thought to be mediated by STK11/LKB1 but it was later
CC       shown that it is indirect and that STK11/LKB1-dependent
CC       phosphorylation is probably mediated by downstream NUAK1
CC       (PubMed:21317932). It is unclear whether AMP directly mediates
CC       phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1
CC       and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of
CC       VRK2 results in a reduction in ubiquitination by MDM2 and an
CC       increase in acetylation by EP300. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in
CC       response to genotoxic stress. Phosphorylated at Ser-315 and Ser-
CC       392 by CDK2 in response to DNA-damage. {ECO:0000250,
CC       ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744,
CC       ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572,
CC       ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225,
CC       ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930,
CC       ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489,
CC       ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:15866171,
CC       ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16704422,
CC       ECO:0000269|PubMed:1705009, ECO:0000269|PubMed:17108107,
CC       ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874,
CC       ECO:0000269|PubMed:18022393, ECO:0000269|PubMed:20041275,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20959462,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:2141171,
CC       ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:9372954}.
CC   -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40
CC       small T antigen inhibits the dephosphorylation by the AC form of
CC       PP2A.
CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied
CC       in EB-1 cell line. {ECO:0000269|PubMed:8632915}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to its
CC       stabilization. Ubiquitinated by TRIM24, RFFL and RNF34, which
CC       leads to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilization.
CC       Isoform 4 is monoubiquitinated in an MDM2-independent manner.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2. {ECO:0000269|PubMed:17121812,
CC       ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:25732823}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Dimethylation at Lys-370 and Lys-382 diminishes p53
CC       ubiquitination, through stabilizing association with the methyl
CC       reader PHF20. Demethylation of dimethylated Lys-370 by KDM1A
CC       prevents interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.
CC       {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662,
CC       ECO:0000269|Ref.35}.
CC   -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety
CC       of transformed cells. TP53 is frequently mutated or inactivated in
CC       about 60% of cancers. TP53 defects are found in Barrett metaplasia
CC       a condition in which the normally stratified squamous epithelium
CC       of the lower esophagus is replaced by a metaplastic columnar
CC       epithelium. The condition develops as a complication in
CC       approximately 10% of patients with chronic gastroesophageal reflux
CC       disease and predisposes to the development of esophageal
CC       adenocarcinoma.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of
CC       the esophagus. The most common types are esophageal squamous cell
CC       carcinoma and adenocarcinoma. Cancer of the esophagus remains a
CC       devastating disease because it is usually not detected until it
CC       has progressed to an advanced incurable stage. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal
CC       dominant familial cancer syndrome that in its classic form is
CC       defined by the existence of a proband affected by a sarcoma before
CC       45 years with a first degree relative affected by any tumor before
CC       45 years and another first degree relative with any tumor before
CC       45 years or a sarcoma at any age. Other clinical definitions for
CC       LFS have been proposed (PubMed:8118819 and PubMed:8718514) and
CC       called Li-Fraumeni like syndrome (LFL). In these families affected
CC       relatives develop a diverse set of malignancies at unusually early
CC       ages. Four types of cancers account for 80% of tumors occurring in
CC       TP53 germline mutation carriers: breast cancers, soft tissue and
CC       bone sarcomas, brain tumors (astrocytomas) and adrenocortical
CC       carcinomas. Less frequent tumors include choroid plexus carcinoma
CC       or papilloma before the age of 15, rhabdomyosarcoma before the age
CC       of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal
CC       and gastric cancers. {ECO:0000269|PubMed:10484981,
CC       ECO:0000269|PubMed:1565144, ECO:0000269|PubMed:1737852,
CC       ECO:0000269|PubMed:1933902, ECO:0000269|PubMed:1978757,
CC       ECO:0000269|PubMed:2259385, ECO:0000269|PubMed:7887414,
CC       ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and
CC       neck. The hallmark of cutaneous SCC is malignant transformation of
CC       normal epidermal keratinocytes. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy
CC       affecting tissues of the lung. The most common form of lung cancer
CC       is non-small cell lung cancer (NSCLC) that can be divided into 3
CC       major histologic subtypes: squamous cell carcinoma,
CC       adenocarcinoma, and large cell lung cancer. NSCLC is often
CC       diagnosed at an advanced stage and has a poor prognosis. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign
CC       tumor of neuroectodermal origin that generally occurs in
CC       childhood, but has also been reported in adults. Although
CC       generally found within the ventricular system, choroid plexus
CC       papillomas can arise ectopically in the brain parenchyma or
CC       disseminate throughout the neuraxis. Patients present with signs
CC       and symptoms of increased intracranial pressure including
CC       headache, hydrocephalus, papilledema, nausea, vomiting, cranial
CC       nerve deficits, gait impairment, and seizures.
CC       {ECO:0000269|PubMed:12085209}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant
CC       neoplasm of the adrenal cortex and a rare childhood tumor. It
CC       occurs with increased frequency in patients with Beckwith-
CC       Wiedemann syndrome and Li-Fraumeni syndrome.
CC       {ECO:0000269|PubMed:11481490}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common
CC       malignant skin neoplasm that typically appears on hair-bearing
CC       skin, most commonly on sun-exposed areas. It is slow growing and
CC       rarely metastasizes, but has potentialities for local invasion and
CC       destruction. It usually develops as a flat, firm, pale area that
CC       is small, raised, pink or red, translucent, shiny, and waxy, and
CC       the area may bleed following minor injury. Tumor size can vary
CC       from a few millimeters to several centimeters in diameter.
CC       {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and
CC       germline TP53 mutations in human cancers;
CC       URL="http://p53.iarc.fr/";
CC   -!- WEB RESOURCE: Name=The TP53 mutant web site; Note=TP53 mutations
CC       and cancer;
CC       URL="http://p53.fr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/P53ID88.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry;
CC       URL="https://en.wikipedia.org/wiki/P53";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02469; CAA26306.1; -; mRNA.
DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; K03199; AAA59989.1; -; mRNA.
DR   EMBL; M14694; AAA61211.1; -; mRNA.
DR   EMBL; M14695; AAA61212.1; -; mRNA.
DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; X01405; CAA25652.1; -; mRNA.
DR   EMBL; X60011; CAA42626.1; -; mRNA.
DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
DR   EMBL; X60013; CAA42628.1; -; mRNA.
DR   EMBL; X60014; CAA42629.1; -; mRNA.
DR   EMBL; X60015; CAA42630.1; -; mRNA.
DR   EMBL; X60016; CAA42631.1; -; mRNA.
DR   EMBL; X60017; CAA42632.1; -; mRNA.
DR   EMBL; X60018; CAA42633.1; -; mRNA.
DR   EMBL; X60019; CAA42634.1; -; mRNA.
DR   EMBL; X60020; CAA42635.1; -; mRNA.
DR   EMBL; AF307851; AAG28785.1; -; mRNA.
DR   EMBL; DQ186648; ABA29753.1; -; mRNA.
DR   EMBL; DQ186649; ABA29754.1; -; mRNA.
DR   EMBL; DQ186650; ABA29755.1; -; mRNA.
DR   EMBL; DQ186651; ABA29756.1; -; mRNA.
DR   EMBL; DQ186652; ABA29757.1; -; mRNA.
DR   EMBL; DQ191317; ABB80262.1; -; mRNA.
DR   EMBL; DQ286964; ABB80266.1; -; mRNA.
DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
DR   EMBL; AB082923; BAC16799.1; -; mRNA.
DR   EMBL; AK312568; BAG35463.1; -; mRNA.
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90143.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90144.1; -; Genomic_DNA.
DR   EMBL; BC003596; AAH03596.1; -; mRNA.
DR   EMBL; AY429684; AAR10356.1; -; mRNA.
DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
DR   CCDS; CCDS11118.1; -. [P04637-1]
DR   CCDS; CCDS45605.1; -. [P04637-3]
DR   CCDS; CCDS45606.1; -. [P04637-2]
DR   CCDS; CCDS73966.1; -. [P04637-7]
DR   CCDS; CCDS73967.1; -. [P04637-9]
DR   CCDS; CCDS73968.1; -. [P04637-8]
DR   CCDS; CCDS73969.1; -. [P04637-4]
DR   CCDS; CCDS73970.1; -. [P04637-6]
DR   CCDS; CCDS73971.1; -. [P04637-5]
DR   PIR; A25224; DNHU53.
DR   RefSeq; NP_000537.3; NM_000546.5. [P04637-1]
DR   RefSeq; NP_001119584.1; NM_001126112.2. [P04637-1]
DR   RefSeq; NP_001119585.1; NM_001126113.2. [P04637-3]
DR   RefSeq; NP_001119586.1; NM_001126114.2. [P04637-2]
DR   RefSeq; NP_001119587.1; NM_001126115.1. [P04637-7]
DR   RefSeq; NP_001119588.1; NM_001126116.1. [P04637-8]
DR   RefSeq; NP_001119589.1; NM_001126117.1. [P04637-9]
DR   RefSeq; NP_001119590.1; NM_001126118.1. [P04637-4]
DR   RefSeq; NP_001263624.1; NM_001276695.1. [P04637-6]
DR   RefSeq; NP_001263625.1; NM_001276696.1. [P04637-5]
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1. [P04637-4]
DR   RefSeq; NP_001263690.1; NM_001276761.1. [P04637-4]
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   PDB; 1A1U; NMR; -; A/C=324-358.
DR   PDB; 1AIE; X-ray; 1.50 A; A=326-356.
DR   PDB; 1C26; X-ray; 1.70 A; A=325-356.
DR   PDB; 1DT7; NMR; -; X/Y=367-388.
DR   PDB; 1GZH; X-ray; 2.60 A; A/C=95-292.
DR   PDB; 1H26; X-ray; 2.24 A; E=376-386.
DR   PDB; 1HS5; NMR; -; A/B=324-357.
DR   PDB; 1JSP; NMR; -; A=367-386.
DR   PDB; 1KZY; X-ray; 2.50 A; A/B=95-289.
DR   PDB; 1MA3; X-ray; 2.00 A; B=372-389.
DR   PDB; 1OLG; NMR; -; A/B/C/D=319-360.
DR   PDB; 1OLH; NMR; -; A/B/C/D=319-360.
DR   PDB; 1PES; NMR; -; A/B/C/D=325-355.
DR   PDB; 1PET; NMR; -; A/B/C/D=325-355.
DR   PDB; 1SAE; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAF; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAL; NMR; -; A/B/C/D=319-360.
DR   PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1UOL; X-ray; 1.90 A; A/B=94-312.
DR   PDB; 1XQH; X-ray; 1.75 A; B/F=369-377.
DR   PDB; 1YC5; X-ray; 1.40 A; B=372-389.
DR   PDB; 1YCQ; X-ray; 2.30 A; B=13-29.
DR   PDB; 1YCR; X-ray; 2.60 A; B=15-29.
DR   PDB; 1YCS; X-ray; 2.20 A; A=94-292.
DR   PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 2ADY; X-ray; 2.50 A; A/B=94-293.
DR   PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293.
DR   PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293.
DR   PDB; 2B3G; X-ray; 1.60 A; B=33-60.
DR   PDB; 2BIM; X-ray; 1.98 A; A/B=94-312.
DR   PDB; 2BIN; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIO; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIP; X-ray; 1.80 A; A=94-312.
DR   PDB; 2BIQ; X-ray; 1.80 A; A=94-312.
DR   PDB; 2F1X; X-ray; 2.30 A; A/B=359-368.
DR   PDB; 2FEJ; NMR; -; A=94-297.
DR   PDB; 2FOJ; X-ray; 1.60 A; B=361-367.
DR   PDB; 2FOO; X-ray; 2.20 A; B=358-363.
DR   PDB; 2GS0; NMR; -; B=20-73.
DR   PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292.
DR   PDB; 2H2D; X-ray; 1.70 A; B=372-389.
DR   PDB; 2H2F; X-ray; 2.20 A; B=372-389.
DR   PDB; 2H4F; X-ray; 2.00 A; D=372-389.
DR   PDB; 2H4H; X-ray; 1.99 A; B=372-389.
DR   PDB; 2H4J; X-ray; 2.10 A; D=372-389.
DR   PDB; 2H59; X-ray; 1.90 A; D/E=372-389.
DR   PDB; 2J0Z; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J10; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J11; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J1W; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J1X; X-ray; 1.65 A; A/B=94-312.
DR   PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293.
DR   PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J20; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J21; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2K8F; NMR; -; B=1-39.
DR   PDB; 2L14; NMR; -; B=13-61.
DR   PDB; 2LY4; NMR; -; B=1-93.
DR   PDB; 2MEJ; NMR; -; B=96-312.
DR   PDB; 2MWO; NMR; -; B=363-377.
DR   PDB; 2MWP; NMR; -; B=376-387.
DR   PDB; 2MWY; NMR; -; B=15-29.
DR   PDB; 2MZD; NMR; -; B=35-59.
DR   PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312.
DR   PDB; 2PCX; X-ray; 1.54 A; A=94-292.
DR   PDB; 2RUK; NMR; -; A=41-62.
DR   PDB; 2VUK; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 2WGX; X-ray; 1.75 A; A/B=94-312.
DR   PDB; 2X0U; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2X0V; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2X0W; X-ray; 2.10 A; A/B=94-312.
DR   PDB; 2XWR; X-ray; 1.68 A; A/B=89-293.
DR   PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293.
DR   PDB; 2YDR; X-ray; 2.75 A; P=144-154.
DR   PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 3D05; X-ray; 1.70 A; A=94-293.
DR   PDB; 3D06; X-ray; 1.20 A; A=94-293.
DR   PDB; 3D07; X-ray; 2.20 A; A/B=94-293.
DR   PDB; 3D08; X-ray; 1.40 A; A=94-293.
DR   PDB; 3D09; X-ray; 1.90 A; A=94-293.
DR   PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29.
DR   PDB; 3DAC; X-ray; 1.80 A; B/P=17-37.
DR   PDB; 3IGK; X-ray; 1.70 A; A=94-293.
DR   PDB; 3IGL; X-ray; 1.80 A; A=94-293.
DR   PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291.
DR   PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293.
DR   PDB; 3LW1; X-ray; 1.28 A; P=385-393.
DR   PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386.
DR   PDB; 3PDH; X-ray; 1.80 A; D=372-389.
DR   PDB; 3Q01; X-ray; 2.10 A; A/B=94-356.
DR   PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356.
DR   PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354.
DR   PDB; 3SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 3TG5; X-ray; 2.30 A; B=365-375.
DR   PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356.
DR   PDB; 3ZME; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 4AGL; X-ray; 1.70 A; A/B=94-312.
DR   PDB; 4AGM; X-ray; 1.52 A; A/B=94-312.
DR   PDB; 4AGN; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 4AGO; X-ray; 1.45 A; A/B=94-312.
DR   PDB; 4AGP; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 4BUZ; X-ray; 1.90 A; P=379-386.
DR   PDB; 4BV2; X-ray; 3.30 A; E/H=376-388.
DR   PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29.
DR   PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291.
DR   PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293.
DR   PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBV; X-ray; 2.10 A; A=94-293.
DR   PDB; 4IBW; X-ray; 1.79 A; A=94-293.
DR   PDB; 4IBY; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293.
DR   PDB; 4IJT; X-ray; 1.78 A; A=94-293.
DR   PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312.
DR   PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312.
DR   PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312.
DR   PDB; 4LOF; X-ray; 2.00 A; A=94-312.
DR   PDB; 4MZI; X-ray; 1.25 A; A=94-292.
DR   PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-388.
DR   PDB; 4QO1; X-ray; 1.92 A; B=92-312.
DR   PDB; 4RP6; X-ray; 1.70 A; Z=252-258.
DR   PDB; 4RP7; X-ray; 1.58 A; Z=253-258.
DR   PDB; 4X34; X-ray; 1.80 A; C/D=377-386.
DR   PDB; 4XR8; X-ray; 2.25 A; C/D=94-292.
DR   PDB; 4ZZJ; X-ray; 2.74 A; B=379-383.
DR   PDB; 5A7B; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 5AB9; X-ray; 1.36 A; A/B=94-312.
DR   PDB; 5ABA; X-ray; 1.62 A; A/B=94-312.
DR   PDB; 5AOI; X-ray; 1.78 A; A/B=94-312.
DR   PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312.
DR   PDB; 5AOK; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5AOL; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 5AOM; X-ray; 1.74 A; A/B=94-312.
DR   PDB; 5BUA; X-ray; 1.81 A; A=94-293.
DR   PDB; 5ECG; X-ray; 3.00 A; A/B=95-312.
DR   PDB; 5G4M; X-ray; 1.38 A; A/B=94-312.
DR   PDB; 5G4N; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5G4O; X-ray; 1.48 A; A/B=94-312.
DR   PDB; 5HOU; NMR; -; A=1-61.
DR   PDB; 5HP0; NMR; -; A=37-61.
DR   PDB; 5HPD; NMR; -; A=2-61.
DR   PDB; 5LAP; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291.
DR   PDBsum; 1A1U; -.
DR   PDBsum; 1AIE; -.
DR   PDBsum; 1C26; -.
DR   PDBsum; 1DT7; -.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1H26; -.
DR   PDBsum; 1HS5; -.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1MA3; -.
DR   PDBsum; 1OLG; -.
DR   PDBsum; 1OLH; -.
DR   PDBsum; 1PES; -.
DR   PDBsum; 1PET; -.
DR   PDBsum; 1SAE; -.
DR   PDBsum; 1SAF; -.
DR   PDBsum; 1SAK; -.
DR   PDBsum; 1SAL; -.
DR   PDBsum; 1TSR; -.
DR   PDBsum; 1TUP; -.
DR   PDBsum; 1UOL; -.
DR   PDBsum; 1XQH; -.
DR   PDBsum; 1YC5; -.
DR   PDBsum; 1YCQ; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1YCS; -.
DR   PDBsum; 2AC0; -.
DR   PDBsum; 2ADY; -.
DR   PDBsum; 2AHI; -.
DR   PDBsum; 2ATA; -.
DR   PDBsum; 2B3G; -.
DR   PDBsum; 2BIM; -.
DR   PDBsum; 2BIN; -.
DR   PDBsum; 2BIO; -.
DR   PDBsum; 2BIP; -.
DR   PDBsum; 2BIQ; -.
DR   PDBsum; 2F1X; -.
DR   PDBsum; 2FEJ; -.
DR   PDBsum; 2FOJ; -.
DR   PDBsum; 2FOO; -.
DR   PDBsum; 2GS0; -.
DR   PDBsum; 2H1L; -.
DR   PDBsum; 2H2D; -.
DR   PDBsum; 2H2F; -.
DR   PDBsum; 2H4F; -.
DR   PDBsum; 2H4H; -.
DR   PDBsum; 2H4J; -.
DR   PDBsum; 2H59; -.
DR   PDBsum; 2J0Z; -.
DR   PDBsum; 2J10; -.
DR   PDBsum; 2J11; -.
DR   PDBsum; 2J1W; -.
DR   PDBsum; 2J1X; -.
DR   PDBsum; 2J1Y; -.
DR   PDBsum; 2J1Z; -.
DR   PDBsum; 2J20; -.
DR   PDBsum; 2J21; -.
DR   PDBsum; 2K8F; -.
DR   PDBsum; 2L14; -.
DR   PDBsum; 2LY4; -.
DR   PDBsum; 2MEJ; -.
DR   PDBsum; 2MWO; -.
DR   PDBsum; 2MWP; -.
DR   PDBsum; 2MWY; -.
DR   PDBsum; 2MZD; -.
DR   PDBsum; 2OCJ; -.
DR   PDBsum; 2PCX; -.
DR   PDBsum; 2RUK; -.
DR   PDBsum; 2VUK; -.
DR   PDBsum; 2WGX; -.
DR   PDBsum; 2X0U; -.
DR   PDBsum; 2X0V; -.
DR   PDBsum; 2X0W; -.
DR   PDBsum; 2XWR; -.
DR   PDBsum; 2YBG; -.
DR   PDBsum; 2YDR; -.
DR   PDBsum; 2Z5S; -.
DR   PDBsum; 2Z5T; -.
DR   PDBsum; 3D05; -.
DR   PDBsum; 3D06; -.
DR   PDBsum; 3D07; -.
DR   PDBsum; 3D08; -.
DR   PDBsum; 3D09; -.
DR   PDBsum; 3D0A; -.
DR   PDBsum; 3DAB; -.
DR   PDBsum; 3DAC; -.
DR   PDBsum; 3IGK; -.
DR   PDBsum; 3IGL; -.
DR   PDBsum; 3KMD; -.
DR   PDBsum; 3KZ8; -.
DR   PDBsum; 3LW1; -.
DR   PDBsum; 3OQ5; -.
DR   PDBsum; 3PDH; -.
DR   PDBsum; 3Q01; -.
DR   PDBsum; 3Q05; -.
DR   PDBsum; 3Q06; -.
DR   PDBsum; 3SAK; -.
DR   PDBsum; 3TG5; -.
DR   PDBsum; 3TS8; -.
DR   PDBsum; 3ZME; -.
DR   PDBsum; 4AGL; -.
DR   PDBsum; 4AGM; -.
DR   PDBsum; 4AGN; -.
DR   PDBsum; 4AGO; -.
DR   PDBsum; 4AGP; -.
DR   PDBsum; 4AGQ; -.
DR   PDBsum; 4BUZ; -.
DR   PDBsum; 4BV2; -.
DR   PDBsum; 4HFZ; -.
DR   PDBsum; 4HJE; -.
DR   PDBsum; 4IBQ; -.
DR   PDBsum; 4IBS; -.
DR   PDBsum; 4IBT; -.
DR   PDBsum; 4IBU; -.
DR   PDBsum; 4IBV; -.
DR   PDBsum; 4IBW; -.
DR   PDBsum; 4IBY; -.
DR   PDBsum; 4IBZ; -.
DR   PDBsum; 4IJT; -.
DR   PDBsum; 4KVP; -.
DR   PDBsum; 4LO9; -.
DR   PDBsum; 4LOE; -.
DR   PDBsum; 4LOF; -.
DR   PDBsum; 4MZI; -.
DR   PDBsum; 4MZR; -.
DR   PDBsum; 4QO1; -.
DR   PDBsum; 4RP6; -.
DR   PDBsum; 4RP7; -.
DR   PDBsum; 4X34; -.
DR   PDBsum; 4XR8; -.
DR   PDBsum; 4ZZJ; -.
DR   PDBsum; 5A7B; -.
DR   PDBsum; 5AB9; -.
DR   PDBsum; 5ABA; -.
DR   PDBsum; 5AOI; -.
DR   PDBsum; 5AOJ; -.
DR   PDBsum; 5AOK; -.
DR   PDBsum; 5AOL; -.
DR   PDBsum; 5AOM; -.
DR   PDBsum; 5BUA; -.
DR   PDBsum; 5ECG; -.
DR   PDBsum; 5G4M; -.
DR   PDBsum; 5G4N; -.
DR   PDBsum; 5G4O; -.
DR   PDBsum; 5HOU; -.
DR   PDBsum; 5HP0; -.
DR   PDBsum; 5HPD; -.
DR   PDBsum; 5LAP; -.
DR   PDBsum; 5LGY; -.
DR   DisProt; DP00086; -.
DR   ProteinModelPortal; P04637; -.
DR   SMR; P04637; -.
DR   BioGrid; 113010; 997.
DR   DIP; DIP-368N; -.
DR   IntAct; P04637; 416.
DR   MINT; MINT-91013; -.
DR   STRING; 9606.ENSP00000269305; -.
DR   BindingDB; P04637; -.
DR   ChEMBL; CHEMBL4096; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family.
DR   iPTMnet; P04637; -.
DR   PhosphoSitePlus; P04637; -.
DR   BioMuta; TP53; -.
DR   DMDM; 269849759; -.
DR   SWISS-2DPAGE; P04637; -.
DR   EPD; P04637; -.
DR   MaxQB; P04637; -.
DR   PaxDb; P04637; -.
DR   PeptideAtlas; P04637; -.
DR   PRIDE; P04637; -.
DR   DNASU; 7157; -.
DR   Ensembl; ENST00000269305; ENSP00000269305; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000420246; ENSP00000391127; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000445888; ENSP00000391478; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000455263; ENSP00000398846; ENSG00000141510. [P04637-3]
DR   Ensembl; ENST00000504290; ENSP00000484409; ENSG00000141510. [P04637-9]
DR   Ensembl; ENST00000504937; ENSP00000481179; ENSG00000141510. [P04637-7]
DR   Ensembl; ENST00000510385; ENSP00000478499; ENSG00000141510. [P04637-8]
DR   Ensembl; ENST00000610292; ENSP00000478219; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000610538; ENSP00000480868; ENSG00000141510. [P04637-6]
DR   Ensembl; ENST00000617185; ENSP00000482258; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000619485; ENSP00000482537; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000620739; ENSP00000481638; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000622645; ENSP00000482222; ENSG00000141510. [P04637-5]
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   UCSC; uc002gij.4; human. [P04637-1]
DR   CTD; 7157; -.
DR   DisGeNET; 7157; -.
DR   GeneCards; TP53; -.
DR   GeneReviews; TP53; -.
DR   HGNC; HGNC:11998; TP53.
DR   HPA; CAB002973; -.
DR   HPA; CAB039238; -.
DR   HPA; CAB039239; -.
DR   HPA; CAB072876; -.
DR   HPA; HPA051244; -.
DR   MalaCards; TP53; -.
DR   MIM; 133239; phenotype.
DR   MIM; 151623; phenotype.
DR   MIM; 191170; gene+phenotype.
DR   MIM; 202300; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 260500; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 614740; phenotype.
DR   neXtProt; NX_P04637; -.
DR   OpenTargets; ENSG00000141510; -.
DR   Orphanet; 1501; Adrenocortical carcinoma.
DR   Orphanet; 67038; B-cell chronic lymphocytic leukemia.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 2807; Papilloma of choroid plexus.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA36679; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P04637; -.
DR   KO; K04451; -.
DR   OMA; SFMCNSS; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   PhylomeDB; P04637; -.
DR   TreeFam; TF106101; -.
DR   BioCyc; ZFISH:ENSG00000141510-MONOMER; -.
DR   Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804754; Regulation of TP53 Expression.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69481; G2/M Checkpoints.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P04637; -.
DR   SIGNOR; P04637; -.
DR   ChiTaRS; TP53; human.
DR   EvolutionaryTrace; P04637; -.
DR   GeneWiki; P53; -.
DR   GenomeRNAi; 7157; -.
DR   PMAP-CutDB; P04637; -.
DR   PRO; PR:P04637; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; -.
DR   ExpressionAtlas; P04637; baseline and differential.
DR   Genevisible; P04637; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:BHF-UCL.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IMP:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IPI:AgBase.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding; IDA:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; TAS:UniProtKB.
DR   GO; GO:0007569; P:cell aging; IMP:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IMP:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0034613; P:cellular protein localization; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEP:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0031497; P:chromatin assembly; IDA:UniProtKB.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IMP:BHF-UCL.
DR   GO; GO:0000733; P:DNA strand renaturation; IDA:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IMP:BHF-UCL.
DR   GO; GO:0007275; P:multicellular organism development; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:CACAO.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB.
DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IMP:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0006461; P:protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0008104; P:protein localization; IDA:UniProtKB.
DR   GO; GO:0016925; P:protein sumoylation; TAS:Reactome.
DR   GO; GO:0051262; P:protein tetramerization; TAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI.
DR   GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; TAS:Reactome.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; TAS:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IMP:CACAO.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; Disease mutation; DNA-binding;
KW   Endoplasmic reticulum; Glycoprotein; Host-virus interaction;
KW   Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation;
KW   Mitochondrion; Necrosis; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185703.
FT   DNA_BIND    102    292
FT   REGION        1    320       Interaction with CCAR2.
FT                                {ECO:0000269|PubMed:25732823}.
FT   REGION        1     83       Interaction with HRMT1L2.
FT                                {ECO:0000269|PubMed:15186775}.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX.
FT   REGION      100    370       Interaction with HIPK1. {ECO:0000250}.
FT   REGION      100    300       Required for interaction with ZNF385A.
FT                                {ECO:0000269|PubMed:17719541}.
FT   REGION      113    236       Required for interaction with FBXO42.
FT                                {ECO:0000269|PubMed:19509332}.
FT   REGION      116    292       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      241    248       Interaction with the 53BP2 SH3 domain.
FT   REGION      256    294       Interaction with E4F1.
FT                                {ECO:0000269|PubMed:10644996}.
FT   REGION      273    280       Interaction with DNA.
FT   REGION      300    393       Interaction with CARM1.
FT                                {ECO:0000269|PubMed:15186775}.
FT   REGION      319    360       Interaction with HIPK2.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF        17     25       TADI.
FT   MOTIF        48     56       TADII.
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT   MOTIF       339    350       Nuclear export signal.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc.
FT   METAL       179    179       Zinc.
FT   METAL       238    238       Zinc.
FT   METAL       242    242       Zinc.
FT   SITE        120    120       Interaction with DNA.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4.
FT                                {ECO:0000269|PubMed:18022393}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000269|PubMed:10570149,
FT                                ECO:0000269|PubMed:11554766,
FT                                ECO:0000269|PubMed:15701641,
FT                                ECO:0000269|PubMed:15866171,
FT                                ECO:0000269|PubMed:17108107,
FT                                ECO:0000269|PubMed:17591690,
FT                                ECO:0000269|PubMed:17967874,
FT                                ECO:0000269|PubMed:21317932}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000269|PubMed:10606744,
FT                                ECO:0000269|PubMed:10951572,
FT                                ECO:0000269|PubMed:16704422}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000269|PubMed:10570149,
FT                                ECO:0000269|PubMed:11447225,
FT                                ECO:0000269|PubMed:11551930,
FT                                ECO:0000269|PubMed:12810724,
FT                                ECO:0000269|PubMed:20041275}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000269|PubMed:17591690,
FT                                ECO:0000269|PubMed:9372954}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000269|PubMed:17254968}.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:11780126,
FT                                ECO:0000269|PubMed:16377624,
FT                                ECO:0000269|PubMed:17349958,
FT                                ECO:0000269|PubMed:17591690}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1 and GRK5.
FT                                {ECO:0000269|PubMed:15053879,
FT                                ECO:0000269|PubMed:20124405}.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A.
FT                                {ECO:0000269|PubMed:23431171}.
FT   MOD_RES     183    183       Phosphoserine; by AURKB.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MOD_RES     269    269       Phosphoserine; by AURKB.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MOD_RES     284    284       Phosphothreonine; by AURKB.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:12724314}.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:14702041}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000269|PubMed:17108971,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000269|PubMed:17108971,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7.
FT                                {ECO:0000269|PubMed:15525938,
FT                                ECO:0000269|PubMed:16415881}.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000269|PubMed:20118233}.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:10656795}.
FT   MOD_RES     381    381       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:10656795,
FT                                ECO:0000269|PubMed:20228809,
FT                                ECO:0000269|PubMed:23431171}.
FT   MOD_RES     382    382       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11239457,
FT                                ECO:0000269|PubMed:17108107,
FT                                ECO:0000269|PubMed:21317932,
FT                                ECO:0000269|PubMed:22214662}.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:19536131}.
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:19536131}.
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:11124955,
FT                                ECO:0000269|PubMed:22214662,
FT                                ECO:0000269|Ref.35}.
FT   VAR_SEQ       1    132       Missing (in isoform 7, isoform 8 and
FT                                isoform 9).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_040833.
FT   VAR_SEQ       1     39       Missing (in isoform 4, isoform 5 and
FT                                isoform 6). {ECO:0000305}.
FT                                /FTId=VSP_040832.
FT   VAR_SEQ     332    346       IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in
FT                                isoform 3, isoform 6 and isoform 9).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_040560.
FT   VAR_SEQ     332    341       IRGRERFEMF -> DQTSFQKENC (in isoform 2,
FT                                isoform 5 and isoform 8).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_006535.
FT   VAR_SEQ     342    393       Missing (in isoform 2, isoform 5 and
FT                                isoform 8).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_006536.
FT   VAR_SEQ     347    393       Missing (in isoform 3, isoform 6 and
FT                                isoform 9).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_040561.
FT   VARIANT       5      5       Q -> H (in a sporadic cancer; somatic
FT                                mutation; abolishes strongly
FT                                phosphorylation).
FT                                /FTId=VAR_044543.
FT   VARIANT       6      6       S -> L (in a sporadic cancer; somatic
FT                                mutation; reduces interaction with
FT                                ZNF385A).
FT                                /FTId=VAR_044544.
FT   VARIANT       7      7       D -> H (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587782646).
FT                                /FTId=VAR_005851.
FT   VARIANT       8      8       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044545.
FT   VARIANT      10     10       V -> I (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs535274413).
FT                                /FTId=VAR_044546.
FT   VARIANT      11     11       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201382018).
FT                                /FTId=VAR_044547.
FT   VARIANT      11     11       E -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201382018).
FT                                /FTId=VAR_044548.
FT   VARIANT      15     15       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044549.
FT   VARIANT      16     16       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044550.
FT   VARIANT      17     17       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044551.
FT   VARIANT      24     24       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044552.
FT   VARIANT      28     28       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044553.
FT   VARIANT      29     30       NN -> KD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047158.
FT   VARIANT      31     31       V -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201753350).
FT                                /FTId=VAR_044554.
FT   VARIANT      33     33       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044555.
FT   VARIANT      34     34       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044556.
FT   VARIANT      35     35       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912661).
FT                                /FTId=VAR_005852.
FT   VARIANT      36     36       P -> L (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587781866).
FT                                /FTId=VAR_044557.
FT   VARIANT      37     37       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044558.
FT   VARIANT      37     37       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044559.
FT   VARIANT      39     39       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044560.
FT   VARIANT      39     39       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044561.
FT   VARIANT      42     42       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044562.
FT   VARIANT      43     43       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005853.
FT   VARIANT      44     44       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044563.
FT   VARIANT      44     44       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044564.
FT   VARIANT      44     44       M -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044565.
FT   VARIANT      45     45       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044566.
FT   VARIANT      46     46       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044567.
FT   VARIANT      46     46       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044568.
FT   VARIANT      47     47       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044569.
FT   VARIANT      47     47       P -> S (in dbSNP:rs1800371).
FT                                {ECO:0000269|Ref.12}.
FT                                /FTId=VAR_014632.
FT   VARIANT      48     48       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044570.
FT   VARIANT      49     49       D -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780728).
FT                                /FTId=VAR_044571.
FT   VARIANT      49     49       D -> N (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587780728).
FT                                /FTId=VAR_044572.
FT   VARIANT      49     49       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044573.
FT   VARIANT      52     52       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044574.
FT   VARIANT      53     53       W -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005854.
FT   VARIANT      53     53       W -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044575.
FT   VARIANT      54     54       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044576.
FT   VARIANT      54     54       F -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044577.
FT   VARIANT      56     56       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044578.
FT   VARIANT      56     56       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044579.
FT   VARIANT      58     58       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044580.
FT   VARIANT      58     58       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044581.
FT   VARIANT      59     59       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044582.
FT   VARIANT      59     59       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044583.
FT   VARIANT      59     59       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045783.
FT   VARIANT      60     60       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044584.
FT   VARIANT      60     60       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044585.
FT   VARIANT      60     60       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005855.
FT   VARIANT      61     61       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044586.
FT   VARIANT      61     61       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044587.
FT   VARIANT      62     62       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044588.
FT   VARIANT      63     63       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044589.
FT   VARIANT      63     63       A -> V (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs372201428).
FT                                /FTId=VAR_044590.
FT   VARIANT      65     65       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044591.
FT   VARIANT      66     66       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044592.
FT   VARIANT      66     66       M -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044593.
FT   VARIANT      67     67       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044594.
FT   VARIANT      67     67       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044595.
FT   VARIANT      67     67       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044596.
FT   VARIANT      68     68       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044597.
FT   VARIANT      68     68       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044598.
FT   VARIANT      69     69       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044599.
FT   VARIANT      69     69       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044600.
FT   VARIANT      69     69       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044601.
FT   VARIANT      69     69       A -> V (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs756233241).
FT                                /FTId=VAR_044602.
FT   VARIANT      70     70       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044603.
FT   VARIANT      71     71       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044604.
FT   VARIANT      72     72       P -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions; dbSNP:rs730882014).
FT                                /FTId=VAR_045784.
FT   VARIANT      72     72       P -> G (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045785.
FT   VARIANT      72     72       P -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs1042522).
FT                                /FTId=VAR_045786.
FT   VARIANT      72     72       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045787.
FT   VARIANT      72     72       P -> R (in dbSNP:rs1042522).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:16131611,
FT                                ECO:0000269|PubMed:1999338,
FT                                ECO:0000269|Ref.17}.
FT                                /FTId=VAR_005856.
FT   VARIANT      73     73       V -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044605.
FT   VARIANT      73     73       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044606.
FT   VARIANT      73     73       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782423).
FT                                /FTId=VAR_044607.
FT   VARIANT      74     74       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044608.
FT   VARIANT      75     75       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044609.
FT   VARIANT      75     75       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044610.
FT   VARIANT      75     75       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044611.
FT   VARIANT      76     76       A -> G (in a sporadic cancer; somatic
FT                                mutation). {ECO:0000269|PubMed:2946935}.
FT                                /FTId=VAR_044612.
FT   VARIANT      76     76       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044613.
FT   VARIANT      77     77       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044614.
FT   VARIANT      78     78       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044615.
FT   VARIANT      79     79       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044616.
FT   VARIANT      79     79       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005857.
FT   VARIANT      79     79       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044617.
FT   VARIANT      80     80       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044618.
FT   VARIANT      80     80       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044619.
FT   VARIANT      81     81       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044620.
FT   VARIANT      82     82       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs534447939).
FT                                /FTId=VAR_044621.
FT   VARIANT      82     82       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044622.
FT   VARIANT      83     83       A -> E (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs201717599).
FT                                /FTId=VAR_044623.
FT   VARIANT      83     83       A -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201717599).
FT                                /FTId=VAR_044624.
FT   VARIANT      84     84       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044625.
FT   VARIANT      84     84       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044626.
FT   VARIANT      85     85       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044627.
FT   VARIANT      85     85       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044628.
FT   VARIANT      86     86       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044629.
FT   VARIANT      87     87       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005858.
FT   VARIANT      88     88       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044630.
FT   VARIANT      88     88       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044631.
FT   VARIANT      89     89       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730881994).
FT                                /FTId=VAR_044632.
FT   VARIANT      89     89       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044633.
FT   VARIANT      90     90       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044634.
FT   VARIANT      90     90       S -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044635.
FT   VARIANT      91     91       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044636.
FT   VARIANT      92     92       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044637.
FT   VARIANT      92     92       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044638.
FT   VARIANT      92     92       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044639.
FT   VARIANT      93     93       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044640.
FT   VARIANT      93     93       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044641.
FT   VARIANT      94     94       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044642.
FT   VARIANT      94     94       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005859.
FT   VARIANT      95     95       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044643.
FT   VARIANT      95     95       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044644.
FT   VARIANT      96     96       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044645.
FT   VARIANT      96     96       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044646.
FT   VARIANT      96     96       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044647.
FT   VARIANT      97     97       V -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044648.
FT   VARIANT      97     97       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044649.
FT   VARIANT      97     97       V -> I (in familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation).
FT                                /FTId=VAR_044650.
FT   VARIANT      98     98       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044651.
FT   VARIANT      98     98       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044652.
FT   VARIANT      99     99       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044653.
FT   VARIANT      99     99       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044654.
FT   VARIANT     100    100       Q -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044655.
FT   VARIANT     101    101       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044656.
FT   VARIANT     101    101       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044657.
FT   VARIANT     102    102       T -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202717).
FT                                /FTId=VAR_044658.
FT   VARIANT     104    104       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044659.
FT   VARIANT     104    104       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044660.
FT   VARIANT     105    105       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044661.
FT   VARIANT     105    105       G -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781504).
FT                                /FTId=VAR_044662.
FT   VARIANT     105    105       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044663.
FT   VARIANT     105    105       G -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044664.
FT   VARIANT     105    105       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044665.
FT   VARIANT     106    106       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044666.
FT   VARIANT     106    106       S -> R (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044667.
FT   VARIANT     107    107       Y -> C (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587782447).
FT                                /FTId=VAR_044668.
FT   VARIANT     107    107       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044669.
FT   VARIANT     107    107       Y -> H (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs368771578).
FT                                /FTId=VAR_044670.
FT   VARIANT     108    108       G -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044671.
FT   VARIANT     108    108       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782461).
FT                                /FTId=VAR_044672.
FT   VARIANT     109    109       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044673.
FT   VARIANT     109    109       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044674.
FT   VARIANT     109    109       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044675.
FT   VARIANT     110    110       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781371).
FT                                /FTId=VAR_005860.
FT   VARIANT     110    110       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044676.
FT   VARIANT     110    110       R -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540654).
FT                                /FTId=VAR_044677.
FT   VARIANT     110    110       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation; does not
FT                                induce SNAI1 degradation;
FT                                dbSNP:rs11540654).
FT                                {ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_005861.
FT   VARIANT     110    110       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540654).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_005862.
FT   VARIANT     110    110       R -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587781371).
FT                                /FTId=VAR_044678.
FT   VARIANT     111    111       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044679.
FT   VARIANT     111    111       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044680.
FT   VARIANT     111    111       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044681.
FT   VARIANT     111    111       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044682.
FT   VARIANT     112    112       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044683.
FT   VARIANT     112    112       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044684.
FT   VARIANT     113    113       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005863.
FT   VARIANT     113    113       F -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045788.
FT   VARIANT     113    113       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044685.
FT   VARIANT     113    113       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044686.
FT   VARIANT     113    113       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044687.
FT   VARIANT     113    113       F -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781642).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033033.
FT   VARIANT     115    115       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044688.
FT   VARIANT     116    116       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044689.
FT   VARIANT     116    116       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044690.
FT   VARIANT     116    116       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044691.
FT   VARIANT     117    117       G -> E (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs755238756).
FT                                /FTId=VAR_044692.
FT   VARIANT     117    117       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044693.
FT   VARIANT     118    118       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044694.
FT   VARIANT     118    118       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044695.
FT   VARIANT     118    118       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044696.
FT   VARIANT     119    119       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044697.
FT   VARIANT     119    119       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044698.
FT   VARIANT     120    120       K -> E (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912658).
FT                                /FTId=VAR_044699.
FT   VARIANT     120    120       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044700.
FT   VARIANT     120    120       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044701.
FT   VARIANT     120    120       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044702.
FT   VARIANT     121    121       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044703.
FT   VARIANT     122    122       V -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044704.
FT   VARIANT     123    123       T -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044705.
FT   VARIANT     123    123       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044706.
FT   VARIANT     124    124       C -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044707.
FT   VARIANT     124    124       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044708.
FT   VARIANT     124    124       C -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730881997).
FT                                /FTId=VAR_044709.
FT   VARIANT     124    124       C -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044710.
FT   VARIANT     124    124       C -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044711.
FT   VARIANT     125    125       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044712.
FT   VARIANT     125    125       T -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201057).
FT                                /FTId=VAR_044713.
FT   VARIANT     125    125       T -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201057).
FT                                /FTId=VAR_005864.
FT   VARIANT     125    125       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044714.
FT   VARIANT     125    125       T -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044715.
FT   VARIANT     126    126       Y -> C (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044716.
FT   VARIANT     126    126       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005865.
FT   VARIANT     126    126       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044717.
FT   VARIANT     126    126       Y -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045789.
FT   VARIANT     126    126       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044718.
FT   VARIANT     126    126       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005866.
FT   VARIANT     126    126       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044719.
FT   VARIANT     127    127       S -> C (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs730881999).
FT                                /FTId=VAR_044720.
FT   VARIANT     127    127       S -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730881999).
FT                                /FTId=VAR_005867.
FT   VARIANT     127    127       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044721.
FT   VARIANT     127    127       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044722.
FT   VARIANT     127    127       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044723.
FT   VARIANT     128    128       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044724.
FT   VARIANT     128    128       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044725.
FT   VARIANT     128    128       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044726.
FT   VARIANT     128    128       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005868.
FT   VARIANT     129    129       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005869.
FT   VARIANT     129    129       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044727.
FT   VARIANT     129    129       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044728.
FT   VARIANT     129    129       A -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs137852792).
FT                                /FTId=VAR_044729.
FT   VARIANT     130    130       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs863224683).
FT                                /FTId=VAR_044730.
FT   VARIANT     130    130       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044731.
FT   VARIANT     130    130       L -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044732.
FT   VARIANT     130    130       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044733.
FT   VARIANT     130    130       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005870.
FT   VARIANT     130    130       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044734.
FT   VARIANT     131    131       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044735.
FT   VARIANT     131    131       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044736.
FT   VARIANT     131    131       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044737.
FT   VARIANT     131    131       N -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs769270327).
FT                                /FTId=VAR_005872.
FT   VARIANT     131    131       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005871.
FT   VARIANT     131    131       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044738.
FT   VARIANT     131    131       N -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782160).
FT                                /FTId=VAR_044739.
FT   VARIANT     132    133       KM -> NL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047159.
FT   VARIANT     132    132       K -> E (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs747342068).
FT                                /FTId=VAR_044740.
FT   VARIANT     132    132       K -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045790.
FT   VARIANT     132    132       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005873.
FT   VARIANT     132    132       K -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs866775781).
FT                                /FTId=VAR_044741.
FT   VARIANT     132    132       K -> Q (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1694291}.
FT                                /FTId=VAR_005874.
FT   VARIANT     132    132       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044742.
FT   VARIANT     132    132       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044743.
FT   VARIANT     132    132       K -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045791.
FT   VARIANT     133    133       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044744.
FT   VARIANT     133    133       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044745.
FT   VARIANT     133    133       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044746.
FT   VARIANT     133    133       M -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044747.
FT   VARIANT     133    133       M -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934873).
FT                                {ECO:0000269|PubMed:1933902}.
FT                                /FTId=VAR_005875.
FT   VARIANT     133    133       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044748.
FT   VARIANT     134    134       F -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs780442292).
FT                                /FTId=VAR_044749.
FT   VARIANT     134    134       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044750.
FT   VARIANT     134    134       F -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs267605077).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036504.
FT   VARIANT     134    134       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044751.
FT   VARIANT     134    134       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044752.
FT   VARIANT     135    135       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005877.
FT   VARIANT     135    135       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044753.
FT   VARIANT     135    135       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044754.
FT   VARIANT     135    135       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005876.
FT   VARIANT     135    135       C -> T (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045792.
FT   VARIANT     135    135       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044755.
FT   VARIANT     135    135       C -> Y (in sporadic cancers; somatic
FT                                mutation; decreased E6-mediated binding
FT                                to E6-AP; dbSNP:rs587781991).
FT                                /FTId=VAR_044756.
FT   VARIANT     136    136       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005878.
FT   VARIANT     136    136       Q -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs758781593).
FT                                /FTId=VAR_044757.
FT   VARIANT     136    136       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005879.
FT   VARIANT     136    136       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044758.
FT   VARIANT     136    136       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044759.
FT   VARIANT     137    137       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044760.
FT   VARIANT     137    137       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044761.
FT   VARIANT     137    137       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005880.
FT   VARIANT     137    137       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044762.
FT   VARIANT     138    138       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044763.
FT   VARIANT     138    138       A -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934875).
FT                                /FTId=VAR_005881.
FT   VARIANT     138    138       A -> S (in LFS; germline mutation).
FT                                /FTId=VAR_044764.
FT   VARIANT     138    138       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044765.
FT   VARIANT     138    138       A -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs750600586).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033034.
FT   VARIANT     139    139       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044766.
FT   VARIANT     139    139       K -> N (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:14660794}.
FT                                /FTId=VAR_005882.
FT   VARIANT     139    139       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044767.
FT   VARIANT     139    139       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044768.
FT   VARIANT     139    139       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044769.
FT   VARIANT     140    140       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044770.
FT   VARIANT     140    140       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044771.
FT   VARIANT     140    140       T -> N (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs786202561).
FT                                /FTId=VAR_044772.
FT   VARIANT     140    140       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044773.
FT   VARIANT     140    140       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044774.
FT   VARIANT     141    141       C -> A (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045793.
FT   VARIANT     141    141       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005885.
FT   VARIANT     141    141       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005884.
FT   VARIANT     141    141       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044775.
FT   VARIANT     141    141       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044776.
FT   VARIANT     141    141       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044777.
FT   VARIANT     141    141       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587781288).
FT                                /FTId=VAR_005886.
FT   VARIANT     142    142       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044778.
FT   VARIANT     142    142       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045794.
FT   VARIANT     142    142       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044779.
FT   VARIANT     142    142       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs779196500).
FT                                /FTId=VAR_044780.
FT   VARIANT     142    142       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044781.
FT   VARIANT     142    142       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044782.
FT   VARIANT     142    142       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044783.
FT   VARIANT     143    143       V -> A (in sporadic cancers; somatic
FT                                mutation; strong DNA binding ability at
FT                                32.5 degrees Celsius; strong reduction of
FT                                transcriptional activity at 37.5 degrees
FT                                Celsius; severely represses interaction
FT                                with ZNF385A).
FT                                {ECO:0000269|PubMed:17719541,
FT                                ECO:0000269|PubMed:8013454}.
FT                                /FTId=VAR_005887.
FT   VARIANT     143    143       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044784.
FT   VARIANT     143    143       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044785.
FT   VARIANT     143    143       V -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782620).
FT                                /FTId=VAR_044786.
FT   VARIANT     143    143       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782620).
FT                                /FTId=VAR_044787.
FT   VARIANT     144    144       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044788.
FT   VARIANT     144    144       Q -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044789.
FT   VARIANT     144    144       Q -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044790.
FT   VARIANT     144    144       Q -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203071).
FT                                /FTId=VAR_005888.
FT   VARIANT     144    144       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044791.
FT   VARIANT     145    145       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044792.
FT   VARIANT     145    145       L -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782197).
FT                                /FTId=VAR_005889.
FT   VARIANT     145    145       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005890.
FT   VARIANT     145    145       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044793.
FT   VARIANT     145    145       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044794.
FT   VARIANT     146    146       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044795.
FT   VARIANT     146    146       W -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203064).
FT                                /FTId=VAR_044796.
FT   VARIANT     146    146       W -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044797.
FT   VARIANT     146    146       W -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044798.
FT   VARIANT     146    146       W -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044799.
FT   VARIANT     147    147       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044800.
FT   VARIANT     147    147       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005891.
FT   VARIANT     147    147       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044801.
FT   VARIANT     147    147       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044802.
FT   VARIANT     147    147       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005892.
FT   VARIANT     147    147       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044803.
FT   VARIANT     148    148       D -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044804.
FT   VARIANT     148    148       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044805.
FT   VARIANT     148    148       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044806.
FT   VARIANT     148    148       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044807.
FT   VARIANT     148    148       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044808.
FT   VARIANT     148    148       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044809.
FT   VARIANT     149    149       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044810.
FT   VARIANT     149    149       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005893.
FT   VARIANT     149    149       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044811.
FT   VARIANT     150    150       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044812.
FT   VARIANT     150    150       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044813.
FT   VARIANT     150    150       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044814.
FT   VARIANT     150    150       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044815.
FT   VARIANT     150    150       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044816.
FT   VARIANT     150    150       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044817.
FT   VARIANT     151    151       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005894.
FT   VARIANT     151    151       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044818.
FT   VARIANT     151    151       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044819.
FT   VARIANT     151    151       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044820.
FT   VARIANT     151    151       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934874).
FT                                {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005895.
FT   VARIANT     151    151       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934874).
FT                                /FTId=VAR_005896.
FT   VARIANT     152    152       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044821.
FT   VARIANT     152    152       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782705).
FT                                {ECO:0000269|PubMed:1868473}.
FT                                /FTId=VAR_005897.
FT   VARIANT     152    152       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044822.
FT   VARIANT     152    152       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044823.
FT   VARIANT     152    152       P -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs767328513).
FT                                {ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005898.
FT   VARIANT     152    152       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044824.
FT   VARIANT     153    153       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044825.
FT   VARIANT     153    153       P -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045795.
FT   VARIANT     153    153       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044826.
FT   VARIANT     153    153       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044827.
FT   VARIANT     153    153       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044828.
FT   VARIANT     153    153       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044829.
FT   VARIANT     153    153       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005899.
FT   VARIANT     154    154       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044830.
FT   VARIANT     154    154       G -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044831.
FT   VARIANT     154    154       G -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs762846821).
FT                                /FTId=VAR_044832.
FT   VARIANT     154    154       G -> I (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045796.
FT   VARIANT     154    154       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs137852789).
FT                                /FTId=VAR_044833.
FT   VARIANT     154    154       G -> V (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|PubMed:2263646}.
FT                                /FTId=VAR_005900.
FT   VARIANT     155    155       T -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs772683278).
FT                                {ECO:0000269|PubMed:1868473}.
FT                                /FTId=VAR_005901.
FT   VARIANT     155    155       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044834.
FT   VARIANT     155    155       T -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044835.
FT   VARIANT     155    155       T -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044836.
FT   VARIANT     155    155       T -> P (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation).
FT                                {ECO:0000269|PubMed:14660794,
FT                                ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_044837.
FT   VARIANT     155    155       T -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202752).
FT                                /FTId=VAR_044838.
FT   VARIANT     156    156       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs563378859).
FT                                /FTId=VAR_044839.
FT   VARIANT     156    156       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044840.
FT   VARIANT     156    156       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs371524413).
FT                                /FTId=VAR_044841.
FT   VARIANT     156    156       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044842.
FT   VARIANT     156    156       R -> P (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005902.
FT   VARIANT     156    156       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044843.
FT   VARIANT     157    157       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044844.
FT   VARIANT     157    157       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005903.
FT   VARIANT     157    157       V -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912654).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_005904.
FT   VARIANT     157    157       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044845.
FT   VARIANT     157    157       V -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912654).
FT                                {ECO:0000269|PubMed:9419979}.
FT                                /FTId=VAR_012977.
FT   VARIANT     157    157       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044846.
FT   VARIANT     158    158       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780068).
FT                                /FTId=VAR_005905.
FT   VARIANT     158    158       R -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045797.
FT   VARIANT     158    158       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005906.
FT   VARIANT     158    158       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782144).
FT                                /FTId=VAR_005907.
FT   VARIANT     158    158       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044847.
FT   VARIANT     158    158       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044848.
FT   VARIANT     158    158       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044849.
FT   VARIANT     158    158       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044850.
FT   VARIANT     158    158       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045798.
FT   VARIANT     159    159       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044851.
FT   VARIANT     159    159       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions; dbSNP:rs730882022).
FT                                /FTId=VAR_045799.
FT   VARIANT     159    159       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044852.
FT   VARIANT     159    159       A -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882000).
FT                                /FTId=VAR_044853.
FT   VARIANT     159    159       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044854.
FT   VARIANT     159    159       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044855.
FT   VARIANT     159    159       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044856.
FT   VARIANT     160    161       MA -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047160.
FT   VARIANT     160    161       MA -> IS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047161.
FT   VARIANT     160    161       MA -> IT (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047162.
FT   VARIANT     160    160       M -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs772354334).
FT                                /FTId=VAR_005908.
FT   VARIANT     160    160       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044857.
FT   VARIANT     160    160       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044858.
FT   VARIANT     160    160       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044859.
FT   VARIANT     161    161       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044860.
FT   VARIANT     161    161       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045800.
FT   VARIANT     161    161       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044861.
FT   VARIANT     161    161       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044862.
FT   VARIANT     161    161       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005909.
FT   VARIANT     161    161       A -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs193920817).
FT                                /FTId=VAR_044863.
FT   VARIANT     161    161       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044864.
FT   VARIANT     162    162       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044865.
FT   VARIANT     162    162       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044866.
FT   VARIANT     162    162       I -> N (in a breast cancer with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044867.
FT   VARIANT     162    162       I -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780069).
FT                                /FTId=VAR_005910.
FT   VARIANT     162    162       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044868.
FT   VARIANT     162    162       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005911.
FT   VARIANT     163    163       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs148924904).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033035.
FT   VARIANT     163    163       Y -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203436).
FT                                /FTId=VAR_044869.
FT   VARIANT     163    163       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044870.
FT   VARIANT     163    163       Y -> H (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_005912.
FT   VARIANT     163    163       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044871.
FT   VARIANT     163    163       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044872.
FT   VARIANT     164    164       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044873.
FT   VARIANT     164    164       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044874.
FT   VARIANT     164    164       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005913.
FT   VARIANT     164    164       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005914.
FT   VARIANT     164    164       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044875.
FT   VARIANT     164    164       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044876.
FT   VARIANT     165    165       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044877.
FT   VARIANT     165    165       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044878.
FT   VARIANT     165    165       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005915.
FT   VARIANT     165    165       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044879.
FT   VARIANT     165    165       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005916.
FT   VARIANT     166    166       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044880.
FT   VARIANT     166    166       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044881.
FT   VARIANT     166    166       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005917.
FT   VARIANT     166    166       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044882.
FT   VARIANT     166    166       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044883.
FT   VARIANT     167    168       QH -> HD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047163.
FT   VARIANT     167    168       QH -> YL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047164.
FT   VARIANT     167    167       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044884.
FT   VARIANT     167    167       Q -> K (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_044885.
FT   VARIANT     167    167       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044886.
FT   VARIANT     167    167       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044887.
FT   VARIANT     168    169       HM -> LI (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047165.
FT   VARIANT     168    168       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044888.
FT   VARIANT     168    168       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044889.
FT   VARIANT     168    168       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044890.
FT   VARIANT     168    168       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044891.
FT   VARIANT     168    168       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044892.
FT   VARIANT     168    168       H -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs867114783).
FT                                /FTId=VAR_005918.
FT   VARIANT     168    168       H -> V (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045801.
FT   VARIANT     168    168       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044893.
FT   VARIANT     169    170       MT -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047166.
FT   VARIANT     169    169       M -> I (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005919.
FT   VARIANT     169    169       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044894.
FT   VARIANT     169    169       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005920.
FT   VARIANT     169    169       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044895.
FT   VARIANT     170    170       T -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780729).
FT                                /FTId=VAR_044896.
FT   VARIANT     170    170       T -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044897.
FT   VARIANT     170    170       T -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs779000871).
FT                                /FTId=VAR_005921.
FT   VARIANT     170    170       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044898.
FT   VARIANT     170    170       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005922.
FT   VARIANT     171    171       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044899.
FT   VARIANT     171    171       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044900.
FT   VARIANT     171    171       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044901.
FT   VARIANT     171    171       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781845).
FT                                /FTId=VAR_044902.
FT   VARIANT     171    171       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044903.
FT   VARIANT     171    171       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044904.
FT   VARIANT     172    172       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005923.
FT   VARIANT     172    172       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044905.
FT   VARIANT     172    172       V -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044906.
FT   VARIANT     172    172       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044907.
FT   VARIANT     172    172       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044908.
FT   VARIANT     173    173       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044909.
FT   VARIANT     173    173       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005924.
FT   VARIANT     173    173       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044910.
FT   VARIANT     173    173       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005925.
FT   VARIANT     173    173       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005926.
FT   VARIANT     173    173       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045802.
FT   VARIANT     174    174       R -> G (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation;
FT                                dbSNP:rs864622115).
FT                                /FTId=VAR_044911.
FT   VARIANT     174    174       R -> K (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005927.
FT   VARIANT     174    174       R -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044912.
FT   VARIANT     174    174       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044913.
FT   VARIANT     174    174       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044914.
FT   VARIANT     174    174       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044915.
FT   VARIANT     175    175       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs138729528).
FT                                /FTId=VAR_005928.
FT   VARIANT     175    175       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs138729528).
FT                                /FTId=VAR_005929.
FT   VARIANT     175    175       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation; does
FT                                not induce SNAI1 degradation; reduces
FT                                interaction with ZNF385A;
FT                                dbSNP:rs28934578).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17719541,
FT                                ECO:0000269|PubMed:1868473,
FT                                ECO:0000269|PubMed:20385133,
FT                                ECO:0000269|PubMed:7887414,
FT                                ECO:0000269|PubMed:8825920}.
FT                                /FTId=VAR_005932.
FT   VARIANT     175    175       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934578).
FT                                /FTId=VAR_005930.
FT   VARIANT     175    175       R -> P (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17719541}.
FT                                /FTId=VAR_005931.
FT   VARIANT     175    175       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044916.
FT   VARIANT     175    175       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044917.
FT   VARIANT     176    177       CP -> FS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047167.
FT   VARIANT     176    176       C -> F (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:1868473,
FT                                ECO:0000269|PubMed:8829627,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005933.
FT   VARIANT     176    176       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044918.
FT   VARIANT     176    176       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044919.
FT   VARIANT     176    176       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044920.
FT   VARIANT     176    176       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005934.
FT   VARIANT     176    176       C -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202962).
FT                                /FTId=VAR_044921.
FT   VARIANT     177    177       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044922.
FT   VARIANT     177    177       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045803.
FT   VARIANT     177    177       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044923.
FT   VARIANT     177    177       P -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045804.
FT   VARIANT     177    177       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005935.
FT   VARIANT     177    177       P -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs751477326).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036505.
FT   VARIANT     177    177       P -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs147002414).
FT                                /FTId=VAR_044924.
FT   VARIANT     177    177       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044925.
FT   VARIANT     178    179       HH -> QS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047168.
FT   VARIANT     178    178       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044926.
FT   VARIANT     178    178       H -> HPHP (in a Burkitt lymphoma).
FT                                {ECO:0000269|PubMed:1303181}.
FT                                /FTId=VAR_005936.
FT   VARIANT     178    178       H -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044927.
FT   VARIANT     178    178       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044928.
FT   VARIANT     178    178       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044929.
FT   VARIANT     178    178       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044930.
FT   VARIANT     178    178       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044931.
FT   VARIANT     178    178       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044932.
FT   VARIANT     179    179       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044933.
FT   VARIANT     179    179       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044934.
FT   VARIANT     179    179       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044935.
FT   VARIANT     179    179       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044936.
FT   VARIANT     179    179       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044937.
FT   VARIANT     179    179       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044938.
FT   VARIANT     179    179       H -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780070).
FT                                /FTId=VAR_044939.
FT   VARIANT     180    180       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044940.
FT   VARIANT     180    180       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044941.
FT   VARIANT     180    180       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044942.
FT   VARIANT     180    180       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044943.
FT   VARIANT     180    180       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044944.
FT   VARIANT     180    180       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044945.
FT   VARIANT     181    181       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782596).
FT                                /FTId=VAR_044946.
FT   VARIANT     181    181       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044947.
FT   VARIANT     181    181       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs397514495).
FT                                /FTId=VAR_044948.
FT   VARIANT     181    181       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs397514495).
FT                                /FTId=VAR_005937.
FT   VARIANT     181    181       R -> P (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044949.
FT   VARIANT     181    181       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044950.
FT   VARIANT     182    182       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044951.
FT   VARIANT     182    182       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005938.
FT   VARIANT     182    182       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044952.
FT   VARIANT     183    183       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044953.
FT   VARIANT     183    183       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044954.
FT   VARIANT     184    184       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044955.
FT   VARIANT     184    184       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044956.
FT   VARIANT     184    184       D -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs72661117).
FT                                /FTId=VAR_047169.
FT   VARIANT     184    184       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044957.
FT   VARIANT     184    184       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005939.
FT   VARIANT     185    185       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044958.
FT   VARIANT     185    185       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044959.
FT   VARIANT     185    185       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044960.
FT   VARIANT     185    185       S -> N (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs150607408).
FT                                /FTId=VAR_044961.
FT   VARIANT     185    185       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044962.
FT   VARIANT     185    185       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044963.
FT   VARIANT     186    186       D -> E (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs375275361).
FT                                /FTId=VAR_044964.
FT   VARIANT     186    186       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044965.
FT   VARIANT     186    186       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044966.
FT   VARIANT     186    186       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044967.
FT   VARIANT     186    186       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044968.
FT   VARIANT     186    186       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005940.
FT   VARIANT     187    187       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005941.
FT   VARIANT     187    187       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044969.
FT   VARIANT     187    187       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045805.
FT   VARIANT     187    187       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044970.
FT   VARIANT     187    187       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs776167460).
FT                                /FTId=VAR_005942.
FT   VARIANT     187    187       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044971.
FT   VARIANT     188    188       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044972.
FT   VARIANT     188    188       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044973.
FT   VARIANT     189    189       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044974.
FT   VARIANT     189    189       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044975.
FT   VARIANT     189    189       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005943.
FT   VARIANT     189    189       A -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044976.
FT   VARIANT     189    189       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044977.
FT   VARIANT     189    189       A -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs121912665).
FT                                /FTId=VAR_044978.
FT   VARIANT     190    190       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044979.
FT   VARIANT     190    190       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044980.
FT   VARIANT     190    190       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005944.
FT   VARIANT     190    190       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044981.
FT   VARIANT     190    190       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044982.
FT   VARIANT     190    190       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044983.
FT   VARIANT     191    191       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044984.
FT   VARIANT     191    191       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044985.
FT   VARIANT     191    191       P -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587778718).
FT                                /FTId=VAR_044986.
FT   VARIANT     191    191       P -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs868590738).
FT                                /FTId=VAR_044987.
FT   VARIANT     191    191       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005945.
FT   VARIANT     192    193       QH -> HN (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047170.
FT   VARIANT     192    193       QH -> HY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047171.
FT   VARIANT     192    192       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044988.
FT   VARIANT     192    192       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044989.
FT   VARIANT     192    192       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044990.
FT   VARIANT     192    192       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044991.
FT   VARIANT     192    192       Q -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882002).
FT                                /FTId=VAR_005946.
FT   VARIANT     193    193       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005947.
FT   VARIANT     193    193       H -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201838).
FT                                /FTId=VAR_044992.
FT   VARIANT     193    193       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044993.
FT   VARIANT     193    193       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044994.
FT   VARIANT     193    193       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044995.
FT   VARIANT     193    193       H -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs786201838).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:7887414}.
FT                                /FTId=VAR_005948.
FT   VARIANT     193    193       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044996.
FT   VARIANT     194    194       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780071).
FT                                /FTId=VAR_044997.
FT   VARIANT     194    194       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044998.
FT   VARIANT     194    194       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044999.
FT   VARIANT     194    194       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005949.
FT   VARIANT     194    194       L -> R (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005950.
FT   VARIANT     194    194       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045000.
FT   VARIANT     195    195       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045001.
FT   VARIANT     195    195       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047172.
FT   VARIANT     195    195       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045002.
FT   VARIANT     195    195       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045003.
FT   VARIANT     195    195       I -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs760043106).
FT                                {ECO:0000269|PubMed:17224074,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005951.
FT   VARIANT     195    195       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045004.
FT   VARIANT     195    195       I -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045806.
FT   VARIANT     196    196       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045005.
FT   VARIANT     196    196       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs483352697).
FT                                /FTId=VAR_045006.
FT   VARIANT     196    196       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045007.
FT   VARIANT     196    196       R -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs483352697).
FT                                /FTId=VAR_045008.
FT   VARIANT     196    196       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045009.
FT   VARIANT     197    197       V -> E (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045010.
FT   VARIANT     197    197       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045011.
FT   VARIANT     197    197       V -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786204041).
FT                                /FTId=VAR_045012.
FT   VARIANT     197    197       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs786204041).
FT                                /FTId=VAR_045013.
FT   VARIANT     198    198       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045014.
FT   VARIANT     198    198       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045015.
FT   VARIANT     198    198       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005952.
FT   VARIANT     198    198       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045016.
FT   VARIANT     198    198       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045017.
FT   VARIANT     199    199       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045018.
FT   VARIANT     199    199       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045019.
FT   VARIANT     199    199       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045020.
FT   VARIANT     199    199       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045021.
FT   VARIANT     200    200       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045022.
FT   VARIANT     200    200       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045023.
FT   VARIANT     200    200       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045024.
FT   VARIANT     200    200       N -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045807.
FT   VARIANT     200    200       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045025.
FT   VARIANT     200    200       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045026.
FT   VARIANT     201    202       LR -> FC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047173.
FT   VARIANT     201    201       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882024).
FT                                /FTId=VAR_045027.
FT   VARIANT     201    201       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045028.
FT   VARIANT     201    201       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045029.
FT   VARIANT     202    202       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780072).
FT                                /FTId=VAR_045030.
FT   VARIANT     202    202       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045031.
FT   VARIANT     202    202       R -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587778719).
FT                                /FTId=VAR_045032.
FT   VARIANT     202    202       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587778719).
FT                                /FTId=VAR_045033.
FT   VARIANT     202    202       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045034.
FT   VARIANT     202    202       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045035.
FT   VARIANT     203    204       VE -> LV (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047174.
FT   VARIANT     203    203       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045036.
FT   VARIANT     203    203       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045037.
FT   VARIANT     203    203       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045038.
FT   VARIANT     203    203       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882003).
FT                                /FTId=VAR_045039.
FT   VARIANT     203    203       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045808.
FT   VARIANT     204    204       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045040.
FT   VARIANT     204    204       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045041.
FT   VARIANT     204    204       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045042.
FT   VARIANT     204    204       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045043.
FT   VARIANT     204    204       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045044.
FT   VARIANT     204    204       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045045.
FT   VARIANT     205    205       Y -> C (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1459726}.
FT                                /FTId=VAR_005953.
FT   VARIANT     205    205       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005954.
FT   VARIANT     205    205       Y -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047175.
FT   VARIANT     205    205       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045046.
FT   VARIANT     205    205       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045047.
FT   VARIANT     205    205       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045048.
FT   VARIANT     206    206       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045049.
FT   VARIANT     206    206       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045050.
FT   VARIANT     207    208       DD -> EY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047176.
FT   VARIANT     207    207       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045051.
FT   VARIANT     207    207       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045052.
FT   VARIANT     207    207       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045053.
FT   VARIANT     207    207       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045054.
FT   VARIANT     207    207       D -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045055.
FT   VARIANT     207    207       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045056.
FT   VARIANT     208    208       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045057.
FT   VARIANT     208    208       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045058.
FT   VARIANT     208    208       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045059.
FT   VARIANT     208    208       D -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045809.
FT   VARIANT     208    208       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045060.
FT   VARIANT     208    208       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045061.
FT   VARIANT     208    208       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045062.
FT   VARIANT     209    209       R -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045063.
FT   VARIANT     209    209       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045064.
FT   VARIANT     209    209       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045065.
FT   VARIANT     209    209       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045066.
FT   VARIANT     210    210       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045067.
FT   VARIANT     210    210       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045068.
FT   VARIANT     210    210       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045069.
FT   VARIANT     210    210       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045070.
FT   VARIANT     210    210       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045071.
FT   VARIANT     210    210       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045072.
FT   VARIANT     210    210       N -> Y (in a familial cancer not matching
FT                                LFS; germline mutation).
FT                                /FTId=VAR_045073.
FT   VARIANT     211    211       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045074.
FT   VARIANT     211    211       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045075.
FT   VARIANT     211    211       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045076.
FT   VARIANT     211    211       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045077.
FT   VARIANT     211    211       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045078.
FT   VARIANT     212    212       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045079.
FT   VARIANT     212    212       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045080.
FT   VARIANT     212    212       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045081.
FT   VARIANT     212    212       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045082.
FT   VARIANT     212    212       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045083.
FT   VARIANT     213    213       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045084.
FT   VARIANT     213    213       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045085.
FT   VARIANT     213    213       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036506.
FT   VARIANT     213    213       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587778720).
FT                                /FTId=VAR_005955.
FT   VARIANT     213    213       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045086.
FT   VARIANT     214    214       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045087.
FT   VARIANT     214    214       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045088.
FT   VARIANT     214    214       H -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781386).
FT                                /FTId=VAR_047177.
FT   VARIANT     214    214       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045089.
FT   VARIANT     214    214       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045090.
FT   VARIANT     215    215       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045091.
FT   VARIANT     215    215       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045092.
FT   VARIANT     215    215       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045093.
FT   VARIANT     215    215       S -> K (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045810.
FT   VARIANT     215    215       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045094.
FT   VARIANT     215    215       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045095.
FT   VARIANT     215    215       S -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782177).
FT                                /FTId=VAR_045096.
FT   VARIANT     216    216       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045097.
FT   VARIANT     216    216       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045098.
FT   VARIANT     216    216       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045099.
FT   VARIANT     216    216       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045100.
FT   VARIANT     216    216       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882025).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_005956.
FT   VARIANT     216    216       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045811.
FT   VARIANT     217    217       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045101.
FT   VARIANT     217    217       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045102.
FT   VARIANT     217    217       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045103.
FT   VARIANT     217    217       V -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045104.
FT   VARIANT     217    217       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045105.
FT   VARIANT     217    217       V -> M (in dbSNP:rs35163653).
FT                                /FTId=VAR_047178.
FT   VARIANT     218    218       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045106.
FT   VARIANT     218    218       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045107.
FT   VARIANT     218    218       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045108.
FT   VARIANT     218    218       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045109.
FT   VARIANT     218    218       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045110.
FT   VARIANT     219    219       P -> C (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045812.
FT   VARIANT     219    219       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045111.
FT   VARIANT     219    219       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045112.
FT   VARIANT     219    219       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045113.
FT   VARIANT     219    219       P -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045114.
FT   VARIANT     219    219       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045115.
FT   VARIANT     220    220       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912666).
FT                                {ECO:0000269|PubMed:7682763,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005957.
FT   VARIANT     220    220       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045116.
FT   VARIANT     220    220       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045117.
FT   VARIANT     220    220       Y -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs530941076).
FT                                /FTId=VAR_005958.
FT   VARIANT     220    220       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045118.
FT   VARIANT     220    220       Y -> S (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912666).
FT                                /FTId=VAR_005959.
FT   VARIANT     221    221       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045119.
FT   VARIANT     221    221       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045120.
FT   VARIANT     221    221       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045121.
FT   VARIANT     221    221       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201592).
FT                                /FTId=VAR_045122.
FT   VARIANT     221    221       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045123.
FT   VARIANT     222    222       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045124.
FT   VARIANT     222    222       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs146340390).
FT                                /FTId=VAR_045125.
FT   VARIANT     222    222       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045126.
FT   VARIANT     222    222       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045127.
FT   VARIANT     222    222       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045128.
FT   VARIANT     222    222       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045129.
FT   VARIANT     223    223       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047179.
FT   VARIANT     223    223       P -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs138983188).
FT                                /FTId=VAR_045130.
FT   VARIANT     223    223       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045131.
FT   VARIANT     223    223       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045132.
FT   VARIANT     223    223       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045133.
FT   VARIANT     223    223       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045134.
FT   VARIANT     224    224       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045135.
FT   VARIANT     224    224       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045136.
FT   VARIANT     224    224       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045137.
FT   VARIANT     224    224       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045138.
FT   VARIANT     225    225       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045139.
FT   VARIANT     225    225       V -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045140.
FT   VARIANT     225    225       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045141.
FT   VARIANT     225    225       V -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045142.
FT   VARIANT     225    225       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045143.
FT   VARIANT     225    225       V -> L (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs746504075).
FT                                /FTId=VAR_045144.
FT   VARIANT     226    226       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045145.
FT   VARIANT     226    226       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047180.
FT   VARIANT     226    226       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045844.
FT   VARIANT     226    226       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045146.
FT   VARIANT     226    226       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045147.
FT   VARIANT     227    227       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045148.
FT   VARIANT     227    227       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045149.
FT   VARIANT     227    227       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045150.
FT   VARIANT     227    227       S -> T (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045151.
FT   VARIANT     228    228       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045152.
FT   VARIANT     228    228       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005960.
FT   VARIANT     228    228       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045153.
FT   VARIANT     228    228       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045154.
FT   VARIANT     228    228       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045155.
FT   VARIANT     228    228       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045845.
FT   VARIANT     228    228       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045156.
FT   VARIANT     228    228       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045157.
FT   VARIANT     229    229       C -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045158.
FT   VARIANT     229    229       C -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045846.
FT   VARIANT     229    229       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045159.
FT   VARIANT     229    229       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045160.
FT   VARIANT     229    229       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045161.
FT   VARIANT     230    230       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045162.
FT   VARIANT     230    230       T -> I (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005961.
FT   VARIANT     230    230       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045163.
FT   VARIANT     230    230       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045164.
FT   VARIANT     230    230       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045165.
FT   VARIANT     231    231       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045166.
FT   VARIANT     231    231       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045167.
FT   VARIANT     231    231       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045168.
FT   VARIANT     231    231       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045169.
FT   VARIANT     232    232       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045170.
FT   VARIANT     232    232       I -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045171.
FT   VARIANT     232    232       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045172.
FT   VARIANT     232    232       I -> S (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation).
FT                                {ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_045173.
FT   VARIANT     232    232       I -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781589).
FT                                /FTId=VAR_005962.
FT   VARIANT     232    232       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045174.
FT   VARIANT     233    233       H -> D (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045175.
FT   VARIANT     233    233       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045176.
FT   VARIANT     233    233       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045177.
FT   VARIANT     233    233       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045178.
FT   VARIANT     233    233       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047181.
FT   VARIANT     233    233       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045179.
FT   VARIANT     234    234       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780073).
FT                                /FTId=VAR_005963.
FT   VARIANT     234    234       Y -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs864622237).
FT                                /FTId=VAR_045180.
FT   VARIANT     234    234       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045181.
FT   VARIANT     234    234       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005964.
FT   VARIANT     234    234       Y -> K (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045847.
FT   VARIANT     234    234       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045182.
FT   VARIANT     234    234       Y -> Q (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045848.
FT   VARIANT     234    234       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045183.
FT   VARIANT     235    235       N -> D (in an adrenocortical carcinoma
FT                                with no family history; germline mutation
FT                                and in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047182.
FT   VARIANT     235    235       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045184.
FT   VARIANT     235    235       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045185.
FT   VARIANT     235    235       N -> M (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045849.
FT   VARIANT     235    235       N -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs144340710).
FT                                /FTId=VAR_045186.
FT   VARIANT     235    235       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045187.
FT   VARIANT     235    235       N -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786204145).
FT                                /FTId=VAR_045188.
FT   VARIANT     236    236       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045189.
FT   VARIANT     236    236       Y -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782289).
FT                                /FTId=VAR_045190.
FT   VARIANT     236    236       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045191.
FT   VARIANT     236    236       Y -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782289).
FT                                /FTId=VAR_045192.
FT   VARIANT     236    236       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045193.
FT   VARIANT     236    236       Y -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882026).
FT                                /FTId=VAR_045194.
FT   VARIANT     237    237       M -> I (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782664).
FT                                /FTId=VAR_005965.
FT   VARIANT     237    237       M -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs765848205).
FT                                /FTId=VAR_045195.
FT   VARIANT     237    237       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045196.
FT   VARIANT     237    237       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045197.
FT   VARIANT     237    237       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045198.
FT   VARIANT     237    237       M -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882004).
FT                                /FTId=VAR_045199.
FT   VARIANT     238    238       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005966.
FT   VARIANT     238    238       C -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045200.
FT   VARIANT     238    238       C -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045850.
FT   VARIANT     238    238       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045201.
FT   VARIANT     238    238       C -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045202.
FT   VARIANT     238    238       C -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs193920789).
FT                                /FTId=VAR_045203.
FT   VARIANT     238    238       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs730882005).
FT                                /FTId=VAR_005967.
FT   VARIANT     239    239       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045204.
FT   VARIANT     239    239       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045205.
FT   VARIANT     239    239       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045206.
FT   VARIANT     239    239       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045207.
FT   VARIANT     239    239       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045208.
FT   VARIANT     239    239       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045209.
FT   VARIANT     239    239       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045210.
FT   VARIANT     240    240       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045211.
FT   VARIANT     240    240       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045212.
FT   VARIANT     240    240       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005968.
FT   VARIANT     240    240       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045213.
FT   VARIANT     240    240       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045214.
FT   VARIANT     240    240       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045215.
FT   VARIANT     240    240       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045216.
FT   VARIANT     241    241       S -> A (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033036.
FT   VARIANT     241    241       S -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs28934573).
FT                                /FTId=VAR_045217.
FT   VARIANT     241    241       S -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934573).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:1699228}.
FT                                /FTId=VAR_005969.
FT   VARIANT     241    241       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045218.
FT   VARIANT     241    241       S -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047183.
FT   VARIANT     241    241       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045219.
FT   VARIANT     242    242       C -> F (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_005970.
FT   VARIANT     242    242       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045220.
FT   VARIANT     242    242       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045221.
FT   VARIANT     242    242       C -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912655).
FT                                /FTId=VAR_045222.
FT   VARIANT     242    242       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045223.
FT   VARIANT     242    242       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs121912655).
FT                                /FTId=VAR_045224.
FT   VARIANT     243    244       MG -> IC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047184.
FT   VARIANT     243    244       MG -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047185.
FT   VARIANT     243    243       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045225.
FT   VARIANT     243    243       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045226.
FT   VARIANT     243    243       M -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203117).
FT                                /FTId=VAR_045227.
FT   VARIANT     243    243       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045228.
FT   VARIANT     243    243       M -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882006).
FT                                /FTId=VAR_045229.
FT   VARIANT     243    243       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045230.
FT   VARIANT     244    244       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047186.
FT   VARIANT     244    244       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045231.
FT   VARIANT     244    244       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934572).
FT                                /FTId=VAR_045232.
FT   VARIANT     244    244       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045233.
FT   VARIANT     244    244       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045234.
FT   VARIANT     244    244       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045235.
FT   VARIANT     244    244       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045236.
FT   VARIANT     245    245       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005971.
FT   VARIANT     245    245       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934575).
FT                                {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:1978757}.
FT                                /FTId=VAR_005972.
FT   VARIANT     245    245       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912656).
FT                                {ECO:0000269|PubMed:2259385}.
FT                                /FTId=VAR_005973.
FT   VARIANT     245    245       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045237.
FT   VARIANT     245    245       G -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045851.
FT   VARIANT     245    245       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045852.
FT   VARIANT     245    245       G -> L (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045853.
FT   VARIANT     245    245       G -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045854.
FT   VARIANT     245    245       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045238.
FT   VARIANT     245    245       G -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934575).
FT                                {ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_005974.
FT   VARIANT     245    245       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912656).
FT                                {ECO:0000269|PubMed:2263646}.
FT                                /FTId=VAR_005975.
FT   VARIANT     246    246       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045239.
FT   VARIANT     246    246       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045240.
FT   VARIANT     246    246       M -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs483352695).
FT                                /FTId=VAR_044020.
FT   VARIANT     246    246       M -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780074).
FT                                /FTId=VAR_005976.
FT   VARIANT     246    246       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005977.
FT   VARIANT     246    246       M -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs483352695).
FT                                /FTId=VAR_005978.
FT   VARIANT     247    248       NR -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047187.
FT   VARIANT     247    248       NR -> KW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047188.
FT   VARIANT     247    247       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045241.
FT   VARIANT     247    247       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045855.
FT   VARIANT     247    247       N -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201762).
FT                                /FTId=VAR_005980.
FT   VARIANT     247    247       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045242.
FT   VARIANT     247    247       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045243.
FT   VARIANT     247    247       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047189.
FT   VARIANT     247    247       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045244.
FT   VARIANT     248    248       R -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045245.
FT   VARIANT     248    248       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005981.
FT   VARIANT     248    248       R -> L (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005982.
FT   VARIANT     248    248       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045246.
FT   VARIANT     248    248       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs11540652).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:2263646,
FT                                ECO:0000269|PubMed:7682763,
FT                                ECO:0000269|PubMed:7887414}.
FT                                /FTId=VAR_005983.
FT   VARIANT     248    248       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912651).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:1978757,
FT                                ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_005984.
FT   VARIANT     249    250       RP -> SA (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047190.
FT   VARIANT     249    250       RP -> SS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047191.
FT   VARIANT     249    249       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005985.
FT   VARIANT     249    249       R -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045247.
FT   VARIANT     249    249       R -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782329).
FT                                /FTId=VAR_045248.
FT   VARIANT     249    249       R -> M (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033037.
FT   VARIANT     249    249       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045856.
FT   VARIANT     249    249       R -> S (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation; dbSNP:rs28934571).
FT                                {ECO:0000269|PubMed:1694291,
FT                                ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_005986.
FT   VARIANT     249    249       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045249.
FT   VARIANT     249    249       R -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782082).
FT                                /FTId=VAR_045250.
FT   VARIANT     250    250       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045251.
FT   VARIANT     250    250       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045857.
FT   VARIANT     250    250       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045252.
FT   VARIANT     250    250       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047192.
FT   VARIANT     250    250       P -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045858.
FT   VARIANT     250    250       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045253.
FT   VARIANT     250    250       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045254.
FT   VARIANT     250    250       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045255.
FT   VARIANT     251    251       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045256.
FT   VARIANT     251    251       I -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882007).
FT                                /FTId=VAR_045257.
FT   VARIANT     251    251       I -> M (in LFS; germline mutation).
FT                                /FTId=VAR_045258.
FT   VARIANT     251    251       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005987.
FT   VARIANT     251    251       I -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882027).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033038.
FT   VARIANT     251    251       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045259.
FT   VARIANT     251    251       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045260.
FT   VARIANT     252    252       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045261.
FT   VARIANT     252    252       L -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045262.
FT   VARIANT     252    252       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045263.
FT   VARIANT     252    252       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912653).
FT                                {ECO:0000269|PubMed:1978757}.
FT                                /FTId=VAR_005988.
FT   VARIANT     252    252       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045264.
FT   VARIANT     253    253       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045265.
FT   VARIANT     253    253       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045266.
FT   VARIANT     253    253       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045267.
FT   VARIANT     253    253       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047193.
FT   VARIANT     253    253       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045268.
FT   VARIANT     254    254       I -> D (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045859.
FT   VARIANT     254    254       I -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045269.
FT   VARIANT     254    254       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045270.
FT   VARIANT     254    254       I -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045271.
FT   VARIANT     254    254       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017908.
FT   VARIANT     254    254       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045272.
FT   VARIANT     254    254       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017909.
FT   VARIANT     254    254       I -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs746601313).
FT                                /FTId=VAR_045273.
FT   VARIANT     255    255       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045274.
FT   VARIANT     255    255       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045275.
FT   VARIANT     255    255       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045276.
FT   VARIANT     255    255       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045277.
FT   VARIANT     255    255       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045278.
FT   VARIANT     255    255       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045279.
FT   VARIANT     256    256       T -> I (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045280.
FT   VARIANT     256    256       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045281.
FT   VARIANT     256    256       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045282.
FT   VARIANT     256    256       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045283.
FT   VARIANT     257    257       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005989.
FT   VARIANT     257    257       L -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934577).
FT                                /FTId=VAR_045284.
FT   VARIANT     257    257       L -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs28934577).
FT                                /FTId=VAR_045285.
FT   VARIANT     257    257       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045286.
FT   VARIANT     258    258       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045287.
FT   VARIANT     258    258       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005990.
FT   VARIANT     258    258       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045288.
FT   VARIANT     258    258       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912652).
FT                                {ECO:0000269|PubMed:1978757}.
FT                                /FTId=VAR_005991.
FT   VARIANT     258    258       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045860.
FT   VARIANT     258    258       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045289.
FT   VARIANT     258    258       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045290.
FT   VARIANT     259    259       D -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047194.
FT   VARIANT     259    259       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045291.
FT   VARIANT     259    259       D -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs745425759).
FT                                /FTId=VAR_045292.
FT   VARIANT     259    259       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045293.
FT   VARIANT     259    259       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045294.
FT   VARIANT     259    259       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045861.
FT   VARIANT     259    259       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045862.
FT   VARIANT     259    259       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045295.
FT   VARIANT     259    259       D -> Y (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033039.
FT   VARIANT     260    260       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045296.
FT   VARIANT     260    260       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045297.
FT   VARIANT     260    260       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045298.
FT   VARIANT     260    260       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045299.
FT   VARIANT     260    260       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045300.
FT   VARIANT     260    260       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045301.
FT   VARIANT     261    261       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045302.
FT   VARIANT     261    261       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045303.
FT   VARIANT     261    261       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045304.
FT   VARIANT     261    261       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045305.
FT   VARIANT     261    261       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045306.
FT   VARIANT     262    263       GN -> PD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047195.
FT   VARIANT     262    262       G -> C (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs200579969).
FT                                /FTId=VAR_045307.
FT   VARIANT     262    262       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047196.
FT   VARIANT     262    262       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045863.
FT   VARIANT     262    262       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs200579969).
FT                                /FTId=VAR_045308.
FT   VARIANT     262    262       G -> V (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|Ref.23}.
FT                                /FTId=VAR_045309.
FT   VARIANT     263    263       N -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs72661119).
FT                                /FTId=VAR_045310.
FT   VARIANT     263    263       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045311.
FT   VARIANT     263    263       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045312.
FT   VARIANT     263    263       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045313.
FT   VARIANT     263    263       N -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045314.
FT   VARIANT     264    264       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045315.
FT   VARIANT     264    264       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045316.
FT   VARIANT     264    264       L -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045317.
FT   VARIANT     264    264       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045318.
FT   VARIANT     264    264       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045319.
FT   VARIANT     265    265       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045320.
FT   VARIANT     265    265       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045321.
FT   VARIANT     265    265       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045322.
FT   VARIANT     265    265       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047197.
FT   VARIANT     266    266       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045323.
FT   VARIANT     266    266       G -> E (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs193920774).
FT                                /FTId=VAR_045324.
FT   VARIANT     266    266       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045325.
FT   VARIANT     266    266       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045326.
FT   VARIANT     267    267       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045327.
FT   VARIANT     267    267       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045328.
FT   VARIANT     267    267       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045329.
FT   VARIANT     267    267       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780075).
FT                                /FTId=VAR_045330.
FT   VARIANT     267    267       R -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs55832599).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036507.
FT   VARIANT     268    268       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045864.
FT   VARIANT     268    268       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045331.
FT   VARIANT     268    268       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045332.
FT   VARIANT     268    268       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045333.
FT   VARIANT     268    268       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045334.
FT   VARIANT     268    268       N -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045335.
FT   VARIANT     269    269       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045336.
FT   VARIANT     269    269       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045337.
FT   VARIANT     269    269       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047198.
FT   VARIANT     269    269       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045338.
FT   VARIANT     269    269       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045339.
FT   VARIANT     269    269       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045340.
FT   VARIANT     270    270       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045341.
FT   VARIANT     270    270       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045342.
FT   VARIANT     270    270       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045343.
FT   VARIANT     270    270       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045344.
FT   VARIANT     270    270       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045345.
FT   VARIANT     270    270       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045346.
FT   VARIANT     271    271       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045347.
FT   VARIANT     271    271       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045348.
FT   VARIANT     271    271       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045349.
FT   VARIANT     271    271       E -> K (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036508.
FT   VARIANT     271    271       E -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045865.
FT   VARIANT     271    271       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045350.
FT   VARIANT     271    271       E -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045866.
FT   VARIANT     271    271       E -> V (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047199.
FT   VARIANT     272    272       V -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045351.
FT   VARIANT     272    272       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045352.
FT   VARIANT     272    272       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045353.
FT   VARIANT     272    272       V -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912657).
FT                                {ECO:0000269|PubMed:1737852}.
FT                                /FTId=VAR_005992.
FT   VARIANT     272    272       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912657).
FT                                /FTId=VAR_045354.
FT   VARIANT     273    273       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121913343).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17224074,
FT                                ECO:0000269|PubMed:7887414,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005993.
FT   VARIANT     273    273       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005994.
FT   VARIANT     273    273       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                abolishes sequence-specific DNA binding;
FT                                does not induce SNAI1 degradation;
FT                                dbSNP:rs28934576).
FT                                {ECO:0000269|PubMed:10570149,
FT                                ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:1565144,
FT                                ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:1699228,
FT                                ECO:0000269|PubMed:1868473,
FT                                ECO:0000269|PubMed:20385133,
FT                                ECO:0000269|PubMed:7682763,
FT                                ECO:0000269|Ref.14}.
FT                                /FTId=VAR_005995.
FT   VARIANT     273    273       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934576).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036509.
FT   VARIANT     273    273       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045867.
FT   VARIANT     273    273       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045355.
FT   VARIANT     273    273       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045356.
FT   VARIANT     273    273       R -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs121913343).
FT                                /FTId=VAR_045357.
FT   VARIANT     273    273       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045868.
FT   VARIANT     274    274       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045358.
FT   VARIANT     274    274       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045359.
FT   VARIANT     274    274       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005997.
FT   VARIANT     274    274       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047200.
FT   VARIANT     274    274       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045360.
FT   VARIANT     274    274       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045361.
FT   VARIANT     275    275       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045362.
FT   VARIANT     275    275       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045363.
FT   VARIANT     275    275       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045364.
FT   VARIANT     275    275       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045365.
FT   VARIANT     275    275       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005999.
FT   VARIANT     275    275       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs863224451).
FT                                {ECO:0000269|PubMed:7887414}.
FT                                /FTId=VAR_005998.
FT   VARIANT     276    276       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045366.
FT   VARIANT     276    276       A -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202082).
FT                                /FTId=VAR_045367.
FT   VARIANT     276    276       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045368.
FT   VARIANT     276    276       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045369.
FT   VARIANT     276    276       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045370.
FT   VARIANT     276    276       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045371.
FT   VARIANT     277    277       C -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs763098116).
FT                                /FTId=VAR_045372.
FT   VARIANT     277    277       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006000.
FT   VARIANT     277    277       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045373.
FT   VARIANT     277    277       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045374.
FT   VARIANT     277    277       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047201.
FT   VARIANT     277    277       C -> Y (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs763098116).
FT                                /FTId=VAR_045375.
FT   VARIANT     278    278       P -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs17849781).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_006001.
FT   VARIANT     278    278       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045869.
FT   VARIANT     278    278       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006002.
FT   VARIANT     278    278       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|PubMed:2263646}.
FT                                /FTId=VAR_006003.
FT   VARIANT     278    278       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045376.
FT   VARIANT     278    278       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:2263646,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_006004.
FT   VARIANT     278    278       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006005.
FT   VARIANT     279    279       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006006.
FT   VARIANT     279    279       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045377.
FT   VARIANT     279    279       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045378.
FT   VARIANT     279    279       G -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045379.
FT   VARIANT     280    280       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045380.
FT   VARIANT     280    280       R -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912660).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_006008.
FT   VARIANT     280    280       R -> K (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation; no effect on
FT                                interaction with CCAR2).
FT                                {ECO:0000269|PubMed:1694291,
FT                                ECO:0000269|PubMed:25732823}.
FT                                /FTId=VAR_006007.
FT   VARIANT     280    280       R -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045381.
FT   VARIANT     280    280       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045382.
FT   VARIANT     280    280       R -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912660).
FT                                {ECO:0000269|PubMed:1631151}.
FT                                /FTId=VAR_006009.
FT   VARIANT     281    282       DR -> EW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047203.
FT   VARIANT     281    281       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006010.
FT   VARIANT     281    281       D -> E (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1459726}.
FT                                /FTId=VAR_006011.
FT   VARIANT     281    281       D -> G (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587781525).
FT                                /FTId=VAR_006012.
FT   VARIANT     281    281       D -> H (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_006013.
FT   VARIANT     281    281       D -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs764146326).
FT                                /FTId=VAR_047202.
FT   VARIANT     281    281       D -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045870.
FT   VARIANT     281    281       D -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs587781525).
FT                                /FTId=VAR_006014.
FT   VARIANT     281    281       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045383.
FT   VARIANT     282    282       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934574).
FT                                /FTId=VAR_045384.
FT   VARIANT     282    282       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045385.
FT   VARIANT     282    282       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882008).
FT                                /FTId=VAR_006015.
FT   VARIANT     282    282       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045386.
FT   VARIANT     282    282       R -> Q (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                {ECO:0000269|PubMed:18453682,
FT                                ECO:0000269|Ref.22}.
FT                                /FTId=VAR_045387.
FT   VARIANT     282    282       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation; does
FT                                not induce SNAI1 degradation;
FT                                dbSNP:rs28934574).
FT                                {ECO:0000269|PubMed:20385133,
FT                                ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_006016.
FT   VARIANT     283    283       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs149633775).
FT                                /FTId=VAR_006017.
FT   VARIANT     283    283       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006018.
FT   VARIANT     283    283       R -> H (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs371409680).
FT                                /FTId=VAR_006019.
FT   VARIANT     283    283       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045388.
FT   VARIANT     283    283       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006020.
FT   VARIANT     283    283       R -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs149633775).
FT                                /FTId=VAR_045389.
FT   VARIANT     284    284       T -> A (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:20959462}.
FT                                /FTId=VAR_006021.
FT   VARIANT     284    284       T -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs863224685).
FT                                /FTId=VAR_045390.
FT   VARIANT     284    284       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045391.
FT   VARIANT     284    284       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006022.
FT   VARIANT     285    285       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045392.
FT   VARIANT     285    285       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045393.
FT   VARIANT     285    285       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045394.
FT   VARIANT     285    285       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs112431538).
FT                                {ECO:0000269|PubMed:1459726,
FT                                ECO:0000269|PubMed:1694291}.
FT                                /FTId=VAR_006023.
FT   VARIANT     285    285       E -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006024.
FT   VARIANT     285    285       E -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912667).
FT                                /FTId=VAR_006025.
FT   VARIANT     286    286       E -> A (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006026.
FT   VARIANT     286    286       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006027.
FT   VARIANT     286    286       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006028.
FT   VARIANT     286    286       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201059).
FT                                {ECO:0000269|PubMed:11023613,
FT                                ECO:0000269|PubMed:8316628}.
FT                                /FTId=VAR_006029.
FT   VARIANT     286    286       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045871.
FT   VARIANT     286    286       E -> Q (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_006030.
FT   VARIANT     286    286       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045395.
FT   VARIANT     287    287       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047204.
FT   VARIANT     287    287       E -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs748891343).
FT                                /FTId=VAR_045396.
FT   VARIANT     287    287       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045397.
FT   VARIANT     287    287       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782006).
FT                                /FTId=VAR_045398.
FT   VARIANT     287    287       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045399.
FT   VARIANT     288    288       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045400.
FT   VARIANT     288    288       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045401.
FT   VARIANT     288    288       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045402.
FT   VARIANT     288    288       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045403.
FT   VARIANT     288    288       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045404.
FT   VARIANT     289    289       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045405.
FT   VARIANT     289    289       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045406.
FT   VARIANT     289    289       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045407.
FT   VARIANT     289    289       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045408.
FT   VARIANT     289    289       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045409.
FT   VARIANT     290    290       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs770374782).
FT                                /FTId=VAR_045410.
FT   VARIANT     290    290       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs55819519).
FT                                /FTId=VAR_045411.
FT   VARIANT     290    290       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045412.
FT   VARIANT     291    291       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045413.
FT   VARIANT     291    291       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045414.
FT   VARIANT     291    291       K -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs372613518).
FT                                /FTId=VAR_045415.
FT   VARIANT     291    291       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047205.
FT   VARIANT     291    291       K -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs781490101).
FT                                /FTId=VAR_045416.
FT   VARIANT     291    291       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045417.
FT   VARIANT     292    292       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045418.
FT   VARIANT     292    292       K -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045872.
FT   VARIANT     292    292       K -> I (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation;
FT                                dbSNP:rs121912663).
FT                                {ECO:0000269|PubMed:10484981}.
FT                                /FTId=VAR_015819.
FT   VARIANT     292    292       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045419.
FT   VARIANT     292    292       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045420.
FT   VARIANT     292    292       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045421.
FT   VARIANT     292    292       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045422.
FT   VARIANT     293    293       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045423.
FT   VARIANT     293    293       G -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780076).
FT                                /FTId=VAR_045424.
FT   VARIANT     293    293       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045425.
FT   VARIANT     293    293       G -> W (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780076).
FT                                /FTId=VAR_045426.
FT   VARIANT     294    294       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045427.
FT   VARIANT     294    294       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045428.
FT   VARIANT     294    294       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045429.
FT   VARIANT     294    294       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047206.
FT   VARIANT     294    294       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045430.
FT   VARIANT     294    294       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045431.
FT   VARIANT     295    295       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045432.
FT   VARIANT     295    295       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs751713111).
FT                                /FTId=VAR_045433.
FT   VARIANT     295    295       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045434.
FT   VARIANT     295    295       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045435.
FT   VARIANT     296    296       H -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045873.
FT   VARIANT     296    296       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045436.
FT   VARIANT     296    296       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047207.
FT   VARIANT     296    296       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045437.
FT   VARIANT     296    296       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006031.
FT   VARIANT     296    296       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045438.
FT   VARIANT     296    296       H -> R (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs483352696).
FT                                /FTId=VAR_045439.
FT   VARIANT     296    296       H -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs672601296).
FT                                /FTId=VAR_045440.
FT   VARIANT     297    297       H -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045441.
FT   VARIANT     297    297       H -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045442.
FT   VARIANT     297    297       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045443.
FT   VARIANT     297    297       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045444.
FT   VARIANT     297    297       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045445.
FT   VARIANT     298    298       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045446.
FT   VARIANT     298    298       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045447.
FT   VARIANT     298    298       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201744589).
FT                                /FTId=VAR_045448.
FT   VARIANT     298    298       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045449.
FT   VARIANT     298    298       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045450.
FT   VARIANT     299    299       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045451.
FT   VARIANT     299    299       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045452.
FT   VARIANT     299    299       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045453.
FT   VARIANT     299    299       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045454.
FT   VARIANT     300    300       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045455.
FT   VARIANT     300    300       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045456.
FT   VARIANT     300    300       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006032.
FT   VARIANT     300    300       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045457.
FT   VARIANT     301    301       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045458.
FT   VARIANT     301    301       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006033.
FT   VARIANT     301    301       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045459.
FT   VARIANT     301    301       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045460.
FT   VARIANT     301    301       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047208.
FT   VARIANT     302    302       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045461.
FT   VARIANT     302    302       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006034.
FT   VARIANT     302    302       G -> R (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs863224686).
FT                                /FTId=VAR_045462.
FT   VARIANT     302    302       G -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006035.
FT   VARIANT     303    303       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045463.
FT   VARIANT     303    303       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045464.
FT   VARIANT     303    303       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045465.
FT   VARIANT     303    303       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045466.
FT   VARIANT     304    304       T -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782654).
FT                                /FTId=VAR_045467.
FT   VARIANT     304    304       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045468.
FT   VARIANT     304    304       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045469.
FT   VARIANT     304    304       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047209.
FT   VARIANT     305    305       K -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045470.
FT   VARIANT     305    305       K -> M (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045471.
FT   VARIANT     305    305       K -> N (in sporadic cancers; somatic
FT                                mutation; loss of nuclear localization).
FT                                {ECO:0000269|PubMed:10551826}.
FT                                /FTId=VAR_045472.
FT   VARIANT     305    305       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045473.
FT   VARIANT     305    305       K -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045474.
FT   VARIANT     306    306       R -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045475.
FT   VARIANT     306    306       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006036.
FT   VARIANT     307    307       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045476.
FT   VARIANT     307    307       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045477.
FT   VARIANT     307    307       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006037.
FT   VARIANT     308    308       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045478.
FT   VARIANT     308    308       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045479.
FT   VARIANT     309    309       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045480.
FT   VARIANT     309    309       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|Ref.14}.
FT                                /FTId=VAR_006038.
FT   VARIANT     310    310       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045481.
FT   VARIANT     310    310       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045482.
FT   VARIANT     311    311       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045483.
FT   VARIANT     311    311       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045484.
FT   VARIANT     311    311       N -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs56184981).
FT                                /FTId=VAR_045485.
FT   VARIANT     311    311       N -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs56184981).
FT                                /FTId=VAR_045486.
FT   VARIANT     312    312       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045487.
FT   VARIANT     312    312       T -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs145151284).
FT                                /FTId=VAR_045488.
FT   VARIANT     313    313       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045489.
FT   VARIANT     313    313       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045490.
FT   VARIANT     313    313       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045491.
FT   VARIANT     313    313       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045492.
FT   VARIANT     314    314       S -> F (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs751440465).
FT                                /FTId=VAR_045493.
FT   VARIANT     315    315       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045494.
FT   VARIANT     315    315       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045495.
FT   VARIANT     315    315       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045496.
FT   VARIANT     316    316       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045497.
FT   VARIANT     316    316       P -> T (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs772773208).
FT                                /FTId=VAR_045498.
FT   VARIANT     317    317       Q -> H (in a kidney cancer with no family
FT                                history; germline mutation and in a
FT                                sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045499.
FT   VARIANT     317    317       Q -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs764735889).
FT                                /FTId=VAR_045500.
FT   VARIANT     317    317       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047210.
FT   VARIANT     317    317       Q -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045501.
FT   VARIANT     317    317       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045502.
FT   VARIANT     318    318       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045503.
FT   VARIANT     319    319       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045504.
FT   VARIANT     319    319       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045505.
FT   VARIANT     319    319       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045506.
FT   VARIANT     320    320       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045507.
FT   VARIANT     321    321       K -> E (in kidney cancer; germline
FT                                mutation).
FT                                /FTId=VAR_045508.
FT   VARIANT     321    321       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045509.
FT   VARIANT     322    322       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045510.
FT   VARIANT     322    322       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045511.
FT   VARIANT     323    323       L -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045874.
FT   VARIANT     323    323       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045512.
FT   VARIANT     323    323       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045513.
FT   VARIANT     323    323       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045514.
FT   VARIANT     323    323       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047211.
FT   VARIANT     324    324       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045515.
FT   VARIANT     324    324       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045875.
FT   VARIANT     324    324       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045516.
FT   VARIANT     325    325       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045517.
FT   VARIANT     325    325       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045518.
FT   VARIANT     325    325       G -> V (in LFS; germline mutation;
FT                                dbSNP:rs28934271).
FT                                {ECO:0000269|PubMed:1565144}.
FT                                /FTId=VAR_006039.
FT   VARIANT     326    326       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045519.
FT   VARIANT     327    327       Y -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045520.
FT   VARIANT     327    327       Y -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045521.
FT   VARIANT     328    328       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045522.
FT   VARIANT     328    328       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045523.
FT   VARIANT     328    328       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045524.
FT   VARIANT     329    329       T -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045525.
FT   VARIANT     329    329       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045526.
FT   VARIANT     330    330       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045527.
FT   VARIANT     330    330       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047212.
FT   VARIANT     330    330       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045528.
FT   VARIANT     331    331       Q -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11575996).
FT                                /FTId=VAR_045529.
FT   VARIANT     331    331       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045530.
FT   VARIANT     331    331       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045531.
FT   VARIANT     332    332       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045532.
FT   VARIANT     334    334       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006040.
FT   VARIANT     334    334       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045533.
FT   VARIANT     335    335       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045534.
FT   VARIANT     335    335       R -> H (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs771939956).
FT                                /FTId=VAR_045535.
FT   VARIANT     335    335       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045536.
FT   VARIANT     337    337       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782529).
FT                                {ECO:0000269|PubMed:9452042}.
FT                                /FTId=VAR_006041.
FT   VARIANT     337    337       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912664).
FT                                {ECO:0000269|PubMed:11481490}.
FT                                /FTId=VAR_035016.
FT   VARIANT     337    337       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912664).
FT                                /FTId=VAR_045537.
FT   VARIANT     337    337       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912664).
FT                                /FTId=VAR_045538.
FT   VARIANT     338    338       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045539.
FT   VARIANT     338    338       F -> L (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs150293825).
FT                                /FTId=VAR_045540.
FT   VARIANT     339    339       E -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs17882252).
FT                                {ECO:0000269|Ref.12}.
FT                                /FTId=VAR_022316.
FT   VARIANT     339    339       E -> Q (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs17882252).
FT                                /FTId=VAR_045541.
FT   VARIANT     341    341       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045542.
FT   VARIANT     342    342       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045543.
FT   VARIANT     342    342       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs375338359).
FT                                /FTId=VAR_045544.
FT   VARIANT     342    342       R -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs375338359).
FT                                /FTId=VAR_047213.
FT   VARIANT     343    343       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045545.
FT   VARIANT     344    344       L -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation;
FT                                dbSNP:rs121912662).
FT                                /FTId=VAR_045546.
FT   VARIANT     344    344       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045547.
FT   VARIANT     346    346       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045548.
FT   VARIANT     347    347       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045549.
FT   VARIANT     347    347       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045550.
FT   VARIANT     348    348       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045551.
FT   VARIANT     348    348       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045552.
FT   VARIANT     349    349       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045553.
FT   VARIANT     352    352       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045554.
FT   VARIANT     353    353       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045555.
FT   VARIANT     354    354       Q -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045556.
FT   VARIANT     354    354       Q -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs755394212).
FT                                /FTId=VAR_045557.
FT   VARIANT     354    354       Q -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs752142489).
FT                                /FTId=VAR_047214.
FT   VARIANT     356    356       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045558.
FT   VARIANT     356    356       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045559.
FT   VARIANT     358    358       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045560.
FT   VARIANT     358    358       E -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587782237).
FT                                /FTId=VAR_045561.
FT   VARIANT     360    360       G -> A (in dbSNP:rs35993958).
FT                                /FTId=VAR_045562.
FT   VARIANT     360    360       G -> V (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs35993958).
FT                                /FTId=VAR_045563.
FT   VARIANT     363    363       R -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045564.
FT   VARIANT     364    364       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045565.
FT   VARIANT     364    364       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045566.
FT   VARIANT     364    364       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045567.
FT   VARIANT     365    365       H -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047215.
FT   VARIANT     365    365       H -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation;
FT                                dbSNP:rs267605075).
FT                                /FTId=VAR_045568.
FT   VARIANT     366    366       S -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs17881470). {ECO:0000269|Ref.12}.
FT                                /FTId=VAR_022317.
FT   VARIANT     370    370       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045569.
FT   VARIANT     376    376       S -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045570.
FT   VARIANT     376    376       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045571.
FT   VARIANT     379    379       R -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045572.
FT   VARIANT     385    385       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045573.
FT   VARIANT     389    389       G -> W (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587783064).
FT                                /FTId=VAR_045574.
FT   VARIANT     392    392       S -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045575.
FT   MUTAGEN      15     15       S->A: Loss of interaction with PPP2R5C,
FT                                PPP2CA AND PPP2R1A.
FT                                {ECO:0000269|PubMed:17967874}.
FT   MUTAGEN      18     18       T->A: No effect on interaction with MDM2
FT                                and increase in protein levels after DNA
FT                                damage. {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      20     20       S->A: Abolishes phosphorylation site.
FT                                Abolishes increase in protein levels
FT                                after DNA damage.
FT                                {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      20     20       S->D: Constitutively increased TP53
FT                                protein levels.
FT                                {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      22     23       LW->QS: Loss of interaction with MDM2,
FT                                leading to constitutively increased TP53
FT                                protein levels.
FT                                {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      37     37       S->D: Abolihes phosphorylation by
FT                                MAPKAPK5. {ECO:0000269|PubMed:17254968}.
FT   MUTAGEN      46     46       S->A: Abolishes phosphorylation by DYRK2
FT                                and HIPK2 and acetylation of K-382 by
FT                                CREBBP. {ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:16219768,
FT                                ECO:0000269|PubMed:17349958}.
FT   MUTAGEN      46     46       Missing: Alters interaction with WWOX.
FT                                {ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:16219768,
FT                                ECO:0000269|PubMed:17349958}.
FT   MUTAGEN      55     55       T->A: Blocks phosphorylation by TAF1.
FT                                {ECO:0000269|PubMed:15053879}.
FT   MUTAGEN     183    183       S->A: Abolishes strongly phosphorylation.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     183    183       S->E: Inhibits slightly its
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     248    248       R->S: Does not induce SNAI1 degradation.
FT                                {ECO:0000269|PubMed:20385133}.
FT   MUTAGEN     269    269       S->A: Abolishes phosphorylation.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     269    269       S->E: Inhibits strongly its
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     284    284       T->E: Inhibits strongly its
FT                                transcriptional activity.
FT   MUTAGEN     291    292       KK->RR: Abolishes polyubiquitination by
FT                                MKRN1. {ECO:0000269|PubMed:19536131}.
FT   MUTAGEN     319    319       K->A: Loss of nuclear localization; when
FT                                associated with A-320 and A-321.
FT                                {ECO:0000269|PubMed:2156209}.
FT   MUTAGEN     320    320       K->A: Loss of nuclear localization; when
FT                                associated with A-319 and A-321.
FT                                {ECO:0000269|PubMed:2156209}.
FT   MUTAGEN     321    321       K->A: Loss of nuclear localization; when
FT                                associated with A-319 and A-320.
FT                                {ECO:0000269|PubMed:2156209}.
FT   MUTAGEN     359    359       P->D: Abolishes binding to USP7.
FT                                {ECO:0000269|PubMed:16402859}.
FT   MUTAGEN     361    361       G->E: Abolishes binding to USP7.
FT                                {ECO:0000269|PubMed:16402859}.
FT   MUTAGEN     362    362       S->A: Abolishes binding to USP7.
FT                                {ECO:0000269|PubMed:16402859}.
FT   MUTAGEN     370    370       K->R: Induces a decrease in methylation
FT                                by SMYD2. {ECO:0000269|PubMed:17108971}.
FT   MUTAGEN     372    372       K->R: Induces a decrease in protein
FT                                stabilization.
FT                                {ECO:0000269|PubMed:15525938}.
FT   MUTAGEN     373    373       K->R: Abolishes dimethylation by EHMT1
FT                                and EHMT2. {ECO:0000269|PubMed:20118233}.
FT   MUTAGEN     382    382       K->A: Abolishes acetylation by CREBBP.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725}.
FT   MUTAGEN     382    382       K->R: Abolishes monomethylation by KMT5A.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725}.
FT   MUTAGEN     383    383       L->A: Abolishes S-315 phosphorylation by
FT                                CDK2/cyclin A.
FT                                {ECO:0000269|PubMed:10884347}.
FT   MUTAGEN     385    385       F->A: Reduced SUMO1 conjugation.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11124955}.
FT   MUTAGEN     386    386       K->A: Abolishes SUMO1 conjugation, in
FT                                vitro and in vivo.
FT                                {ECO:0000269|PubMed:11124955,
FT                                ECO:0000269|Ref.35}.
FT   MUTAGEN     387    387       T->A: No effect SUMO1 conjugation.
FT                                {ECO:0000269|PubMed:11124955}.
FT   MUTAGEN     388    388       E->A: Abolishes SUMO1 conjugation.
FT                                {ECO:0000269|PubMed:11124955}.
FT   HELIX         3      6       {ECO:0000244|PDB:5HOU}.
FT   TURN          8     10       {ECO:0000244|PDB:5HOU}.
FT   HELIX        19     23       {ECO:0000244|PDB:3DAC}.
FT   STRAND       27     29       {ECO:0000244|PDB:2K8F}.
FT   STRAND       33     35       {ECO:0000244|PDB:2L14}.
FT   HELIX        36     38       {ECO:0000244|PDB:2B3G}.
FT   HELIX        41     44       {ECO:0000244|PDB:2B3G}.
FT   HELIX        47     55       {ECO:0000244|PDB:2B3G}.
FT   TURN        105    108       {ECO:0000244|PDB:3D06}.
FT   STRAND      110    112       {ECO:0000244|PDB:3D06}.
FT   STRAND      119    121       {ECO:0000244|PDB:5BUA}.
FT   STRAND      124    127       {ECO:0000244|PDB:3D06}.
FT   TURN        128    131       {ECO:0000244|PDB:3D06}.
FT   STRAND      132    135       {ECO:0000244|PDB:3D06}.
FT   STRAND      141    146       {ECO:0000244|PDB:3D06}.
FT   STRAND      156    165       {ECO:0000244|PDB:3D06}.
FT   HELIX       166    168       {ECO:0000244|PDB:3D06}.
FT   HELIX       177    180       {ECO:0000244|PDB:3D06}.
FT   STRAND      181    183       {ECO:0000244|PDB:4KVP}.
FT   STRAND      187    189       {ECO:0000244|PDB:4MZI}.
FT   STRAND      194    199       {ECO:0000244|PDB:3D06}.
FT   STRAND      204    207       {ECO:0000244|PDB:3D06}.
FT   TURN        209    211       {ECO:0000244|PDB:3D06}.
FT   STRAND      214    219       {ECO:0000244|PDB:3D06}.
FT   TURN        225    227       {ECO:0000244|PDB:2FEJ}.
FT   STRAND      228    236       {ECO:0000244|PDB:3D06}.
FT   HELIX       240    242       {ECO:0000244|PDB:3D07}.
FT   TURN        243    248       {ECO:0000244|PDB:3D06}.
FT   STRAND      251    258       {ECO:0000244|PDB:3D06}.
FT   STRAND      260    262       {ECO:0000244|PDB:2ADY}.
FT   STRAND      264    274       {ECO:0000244|PDB:3D06}.
FT   HELIX       278    287       {ECO:0000244|PDB:3D06}.
FT   HELIX       288    290       {ECO:0000244|PDB:4HJE}.
FT   HELIX       322    324       {ECO:0000244|PDB:3Q01}.
FT   STRAND      327    334       {ECO:0000244|PDB:3Q01}.
FT   HELIX       335    354       {ECO:0000244|PDB:1AIE}.
FT   HELIX       375    380       {ECO:0000244|PDB:1YC5}.
FT   HELIX       381    385       {ECO:0000244|PDB:4X34}.
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
ID   P53_MOUSE               Reviewed;         387 AA.
AC   P02340; Q9QUP3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   18-MAR-2008, sequence version 3.
DT   30-NOV-2016, entry version 212.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=Tp53; Synonyms=P53, Trp53;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6092064;
RA   Bienz B., Zakut-Houri R., Givol D., Oren M.;
RT   "Analysis of the gene coding for the murine cellular tumour antigen
RT   p53.";
RL   EMBO J. 3:2179-2183(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6646235; DOI=10.1038/306594a0;
RA   Zakut-Houri R., Oren M., Bienz B., Lavie V., Hazum S., Givol D.;
RT   "A single gene and a pseudogene for the cellular tumour antigen p53.";
RL   Nature 306:594-597(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6379601; DOI=10.1093/nar/12.14.5609;
RA   Jenkins J.R., Rudge K., Redmond S., Wade-Evans A.;
RT   "Cloning and expression analysis of full length mouse cDNA sequences
RT   encoding the transformation associated protein p53.";
RL   Nucleic Acids Res. 12:5609-5626(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (CLONES PCD53; P53-M11 AND P53-M8).
RX   PubMed=3023970; DOI=10.1128/MCB.6.9.3232;
RA   Arai N., Nomura D., Yokota K., Wolf D., Brill E., Shohat O.,
RA   Rotter V.;
RT   "Immunologically distinct p53 molecules generated by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 6:3232-3239(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-132.
RX   PubMed=3329909;
RA   Chumakov P.M.;
RT   "Primary structure of DNA complementary to mRNA of murine oncoprotein
RT   p53.";
RL   Bioorg. Khim. 13:1691-1694(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=SCID;
RA   Araki R., Fukumura R., Fujimori A., Tatsumi K., Abe M.;
RT   "Cell cycle in DNA-PKcs knock-out mice.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10403253; DOI=10.1038/21913;
RA   Jimenez G.S., Bryntesson F., Torres-Arzayus M.I., Priestley A.,
RA   Beeche M., Saito S., Sakaguchi K., Appella E., Jeggo P.A.,
RA   Taccioli G.E., Wahl G.M., Hubank M.;
RT   "DNA-dependent protein kinase is not required for the p53-dependent
RT   response to DNA damage.";
RL   Nature 400:81-83(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary carcinoma;
RA   Araki R., Fukumura R., Fujimori A., Tatsumi K., Abe M.;
RT   "Characterization of DNA-PKcs null mutant SX9.";
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=129/SvJ; TISSUE=Lung fibroblast;
RA   Fujimori A., Abe M.;
RT   "p53 in 129-SVJ mice.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 219-255.
RX   PubMed=1766680;
RA   Burns P.A., Kemp C.J., Gannon J.V., Lane D.P., Bremner R., Balmain A.;
RT   "Loss of heterozygosity and mutational alterations of the p53 gene in
RT   skin tumours of interspecific hybrid mice.";
RL   Oncogene 6:2363-2369(1991).
RN   [12]
RP   DISCOVERY OF P53.
RX   PubMed=221923; DOI=10.1073/pnas.76.5.2420;
RA   DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., Old L.J.;
RT   "Detection of a transformation-related antigen in chemically induced
RT   sarcomas and other transformed cells of the mouse.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:2420-2424(1979).
RN   [13]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [14]
RP   INTERACTION WITH HIPK1, AND PHOSPHORYLATION.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [15]
RP   INTERACTION WITH AXIN1, AND IDENTIFICATION IN A COMPLEX WITH HIPK2 AND
RP   AXIN1.
RX   PubMed=15526030; DOI=10.1038/sj.emboj.7600475;
RA   Rui Y., Xu Z., Lin S., Li Q., Rui H., Luo W., Zhou H.-M.,
RA   Cheung P.-Y., Wu Z., Ye Z., Li P., Han J., Lin S.-C.;
RT   "Axin stimulates p53 functions by activation of HIPK2 kinase through
RT   multimeric complex formation.";
RL   EMBO J. 23:4583-4594(2004).
RN   [16]
RP   PHOSPHORYLATION AT SER-309 AND SER-386, AND RNA-BINDING.
RX   PubMed=3006031; DOI=10.1073/pnas.83.4.897;
RA   Samad A., Anderson C.W., Carroll R.B.;
RT   "Mapping of phosphomonoester and apparent phosphodiester bonds of the
RT   oncogene product p53 from simian virus 40-transformed 3T3 cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:897-901(1986).
RN   [17]
RP   PHOSPHORYLATION AT SER-386.
RX   PubMed=2145148;
RA   Meek D.W., Simon S., Kikkawa U., Eckhart W.;
RT   "The p53 tumour suppressor protein is phosphorylated at serine 389 by
RT   casein kinase II.";
RL   EMBO J. 9:3253-3260(1990).
RN   [18]
RP   PUTATIVE RNA-BINDING.
RX   PubMed=1406686; DOI=10.1128/MCB.12.11.5145;
RA   Fontoura B.M., Sorokina E.A., David E., Carroll R.B.;
RT   "p53 is covalently linked to 5.8S rRNA.";
RL   Mol. Cell. Biol. 12:5145-5151(1992).
RN   [19]
RP   DEACETYLATION BY SIRT1.
RX   PubMed=11672522; DOI=10.1016/S0092-8674(01)00524-4;
RA   Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A.,
RA   Guarente L., Gu W.;
RT   "Negative control of p53 by Sir2alpha promotes cell survival under
RT   stress.";
RL   Cell 107:137-148(2001).
RN   [20]
RP   INTERACTION WITH USP7.
RX   PubMed=14719112;
RA   Lim S.-K., Shin J.-M., Kim Y.-S., Baek K.-H.;
RT   "Identification and characterization of murine mHAUSP encoding a
RT   deubiquitinating enzyme that regulates the status of p53
RT   ubiquitination.";
RL   Int. J. Oncol. 24:357-364(2004).
RN   [21]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [22]
RP   INTERACTION WITH BANP.
RX   PubMed=12494467; DOI=10.1002/ijc.10881;
RA   Kaul R., Mukherjee S., Ahmed F., Bhat M.K., Chhipa R., Galande S.,
RA   Chattopadhyay S.;
RT   "Direct interaction with and activation of p53 by SMAR1 retards cell-
RT   cycle progression at G2/M phase and delays tumor growth in mice.";
RL   Int. J. Cancer 103:606-615(2003).
RN   [23]
RP   PHOSPHORYLATION AT SER-15, LYSINE ACETYLATION, UBIQUITINATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15195100; DOI=10.1038/ncb1147;
RA   Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H.,
RA   Pandolfi P.P.;
RT   "PML regulates p53 stability by sequestering Mdm2 to the nucleolus.";
RL   Nat. Cell Biol. 6:665-672(2004).
RN   [24]
RP   PHOSPHORYLATION AT SER-34.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C.,
RA   Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III,
RA   Wright P.E., Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [25]
RP   INTERACTION WITH ZNF385A.
RX   PubMed=17719541; DOI=10.1016/j.cell.2007.06.013;
RA   Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A.,
RA   Lee S.W.;
RT   "Hzf Determines cell survival upon genotoxic stress by modulating p53
RT   transactivation.";
RL   Cell 130:624-637(2007).
RN   [26]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [27]
RP   INTERACTION WITH CHD8.
RX   PubMed=19151705; DOI=10.1038/ncb1831;
RA   Nishiyama M., Oshikawa K., Tsukada Y.I., Nakagawa T., Iemura S.,
RA   Natsume T., Fan Y., Kikuchi A., Skoultchi A.I., Nakayama K.I.;
RT   "CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment
RT   during early embryogenesis.";
RL   Nat. Cell Biol. 11:172-182(2009).
RN   [28]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J.,
RA   Bergmann A., Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [29]
RP   FUNCTION.
RX   PubMed=20673990; DOI=10.1016/j.cell.2010.06.040;
RA   Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J.,
RA   Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M.,
RA   Attardi L.D., Regev A., Lander E.S., Jacks T., Rinn J.L.;
RT   "A large intergenic noncoding RNA induced by p53 mediates global gene
RT   repression in the p53 response.";
RL   Cell 142:409-419(2010).
RN   [30]
RP   FUNCTION.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S.,
RA   Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-315, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=23806337; DOI=10.1016/j.molcel.2013.06.001;
RA   Park J., Chen Y., Tishkoff D.X., Peng C., Tan M., Dai L., Xie Z.,
RA   Zhang Y., Zwaans B.M., Skinner M.E., Lombard D.B., Zhao Y.;
RT   "SIRT5-mediated lysine desuccinylation impacts diverse metabolic
RT   pathways.";
RL   Mol. Cell 50:919-930(2013).
RN   [32]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=24051492; DOI=10.1038/ncomms3444;
RA   Miki T., Matsumoto T., Zhao Z., Lee C.C.;
RT   "p53 regulates Period2 expression and the circadian clock.";
RL   Nat. Commun. 4:2444-2444(2013).
RN   [33]
RP   UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066;
RA   Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S.,
RA   Kim J., Wang L., Lou Z.;
RT   "DBC1 functions as a tumor suppressor by regulating p53 stability.";
RL   Cell Rep. 10:1324-1334(2015).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 96-281.
RX   PubMed=11152481; DOI=10.1074/jbc.M011644200;
RA   Zhao K., Chai X., Johnston K., Clements A., Marmorstein R.;
RT   "Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A
RT   resolution.";
RL   J. Biol. Chem. 276:12120-12127(2001).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 92-289.
RX   PubMed=17139084; DOI=10.1107/S090744490603890X;
RA   Ho W.C., Luo C., Zhao K., Chai X., Fitzgerald M.X., Marmorstein R.;
RT   "High-resolution structure of the p53 core domain: implications for
RT   binding small-molecule stabilizing compounds.";
RL   Acta Crystallogr. D 62:1484-1493(2006).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 92-289 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=16717092; DOI=10.1074/jbc.M603634200;
RA   Ho W.C., Fitzgerald M.X., Marmorstein R.;
RT   "Structure of the p53 core domain dimer bound to DNA.";
RL   J. Biol. Chem. 281:20494-20502(2006).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 92-284.
RX   PubMed=17876829; DOI=10.1002/prot.21608;
RA   Kwon E., Kim D.Y., Suh S.W., Kim K.K.;
RT   "Crystal structure of the mouse p53 core domain in zinc-free state.";
RL   Proteins 70:280-283(2008).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 93-289 IN COMPLEX WITH DNA,
RP   AND SUBUNIT.
RX   PubMed=18978813; DOI=10.1038/onc.2008.400;
RA   Malecka K.A., Ho W.C., Marmorstein R.;
RT   "Crystal structure of a p53 core tetramer bound to DNA.";
RL   Oncogene 28:325-333(2009).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression (By similarity). Induces the
CC       transcription of long intergenic non-coding RNA p21 (lincRNA-p21)
CC       and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent
CC       transcriptional repression leading to apoptosis, but seems to have
CC       to effect on cell-cycle regulation. Regulates the circadian clock
CC       by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional
CC       activation of PER2 (PubMed:24051492).
CC       {ECO:0000250|UniProtKB:P04637, ECO:0000269|PubMed:19556538,
CC       ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:22726440,
CC       ECO:0000269|PubMed:24051492}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with YWHAZ; the interaction enhances TP53
CC       transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58'
CC       inhibits this interaction. Interacts with AURKB, SETD2, UHRF2 and
CC       NOC2L. Interacts with PML (via C-terminus). Interacts with MDM2;
CC       leading to ubiquitination and proteasomal degradation of TP53.
CC       Directly interacts with FBXO42; leading to ubiquitination and
CC       degradation of TP53. Interacts with DAXX. Interacts (when
CC       monomethylated at Lys-376) with L3MBTL1. Interacts with BANP,
CC       CDKN2AIP, NUAK1, STK11/LKB1 and E4F1. Interacts with CHD8, leading
CC       to recruit histone H1 and prevent transactivation activity.
CC       Interacts with AURKA, TRIM24 and BRD7. Interacts with GRK5. Binds
CC       to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA
CC       damage. Interacts with CDK5 in neurons. Phosphorylated at Ser-309
CC       and Ser-386 by CDK2 in response to DNA-damage. Interacts (via N-
CC       terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2.
CC       Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2.
CC       Interacts with PRKCG. Interacts with PPIF; the association
CC       implicates preferentially tetrameric TP53, is induced by oxidative
CC       stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion. Interacts
CC       with KAT6A. Interacts with UBC9. Forms a complex with UBC9 and
CC       PRKRA. Interacts with ZNF385B; the interaction is direct.
CC       Interacts (via DNA-binding domain) with ZNF385A; the interaction
CC       is direct and enhances p53/TP53 transactivation functions on cell-
CC       cycle arrest target genes, resulting in growth arrest. Interacts
CC       with ANKRD2. Interacts with RFFL and RNF34; involved in p53/TP53
CC       ubiquitination. Interacts with MTA1 and RFWD2. Interacts with
CC       CCAR2 (via N-terminus). Interacts with MORC3.
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=12; IntAct=EBI-474016, EBI-617698;
CC       Q07817-1:BCL2L1 (xeno); NbExp=3; IntAct=EBI-474016, EBI-287195;
CC       B2RWS6:Ep300; NbExp=2; IntAct=EBI-474016, EBI-3953360;
CC       P23804:Mdm2; NbExp=5; IntAct=EBI-474016, EBI-641788;
CC       P23804-1:Mdm2; NbExp=2; IntAct=EBI-474016, EBI-3386476;
CC       Q9QUR7:Pin1; NbExp=3; IntAct=EBI-474016, EBI-2432975;
CC       P54099:Polg; NbExp=2; IntAct=EBI-474016, EBI-863636;
CC       Q99KR7:Ppif; NbExp=2; IntAct=EBI-474016, EBI-6455001;
CC       O08586:Pten; NbExp=4; IntAct=EBI-474016, EBI-1186266;
CC       Q61466:Smarcd1; NbExp=4; IntAct=EBI-474016, EBI-371529;
CC       P09671:Sod2; NbExp=2; IntAct=EBI-474016, EBI-1635071;
CC       P62991:Ubc; NbExp=2; IntAct=EBI-474016, EBI-413074;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- INDUCTION: Expressed in a circadian manner in the suprachiasmatic
CC       nucleus (SCN) of the brain with a peak seen at ZT8.
CC       {ECO:0000269|PubMed:24051492}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on Ser-15 upon ultraviolet irradiation; which
CC       is enhanced by interaction with BANP (By similarity).
CC       Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Probably phosphorylated on by CDK7 in a CAK
CC       complex in response to DNA damage. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15 leading to accumulation of p53/TP53, particularly in the
CC       nucleus, thus inducing the transactivation of p53/TP53 target
CC       genes (By similarity). Phosphorylated on Ser-386 following UV but
CC       not gamma irradiation. Phosphorylated by HIPK1. {ECO:0000250,
CC       ECO:0000269|PubMed:12702766, ECO:0000269|PubMed:15195100,
CC       ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:18022393,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:2145148,
CC       ECO:0000269|PubMed:3006031}.
CC   -!- PTM: Deacetylation by SIRT2 impairs its ability to induce
CC       transcription activation in a AKT-dependent manner (By
CC       similarity). Acetylated. Its deacetylation by SIRT1 impairs its
CC       ability to induce proapoptotic program and modulate cell
CC       senescence. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-285 and Lys-286, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation (By
CC       similarity). Ubiquitination and subsequent proteasomal degradation
CC       is negatively regulated by CCAR2 (PubMed:25732823).
CC       {ECO:0000250|UniProtKB:P04637, ECO:0000269|PubMed:25732823}.
CC   -!- PTM: Monomethylated at Lys-366 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       364 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-366
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-364. Dimethylated at Lys-367 EHMT1 and
CC       EHMT2. Monomethylated at Lys-376 KMT5A, promoting interaction with
CC       L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-364 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-380 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X00876; CAA25420.1; -; Genomic_DNA.
DR   EMBL; X00877; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00878; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00879; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00880; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00881; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00882; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00883; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00884; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00885; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X01237; CAA25625.1; -; mRNA.
DR   EMBL; X00741; CAA25323.1; -; mRNA.
DR   EMBL; M13872; AAA39881.1; -; mRNA.
DR   EMBL; M13873; AAA39882.1; -; mRNA.
DR   EMBL; M13874; AAA39883.1; ALT_SEQ; mRNA.
DR   EMBL; AB021961; BAA82344.1; -; mRNA.
DR   EMBL; AF151353; AAD39535.1; -; mRNA.
DR   EMBL; AB017815; BAA82339.1; -; mRNA.
DR   EMBL; AB017816; BAA82340.1; -; mRNA.
DR   EMBL; AB020317; BAA82343.1; -; mRNA.
DR   EMBL; BC005448; AAH05448.1; -; mRNA.
DR   EMBL; S77930; AAB21108.2; -; Genomic_DNA.
DR   PIR; A22739; DNMS53.
DR   PIR; S38824; S38824.
DR   RefSeq; NP_001120705.1; NM_001127233.1.
DR   RefSeq; NP_035770.2; NM_011640.3.
DR   RefSeq; XP_006533220.1; XM_006533157.3.
DR   UniGene; Mm.222; -.
DR   PDB; 1HU8; X-ray; 2.70 A; A/B/C=96-281.
DR   PDB; 2GEQ; X-ray; 2.30 A; A/B=89-289.
DR   PDB; 2IOI; X-ray; 1.55 A; A=89-289.
DR   PDB; 2IOM; X-ray; 2.00 A; A=89-289.
DR   PDB; 2IOO; X-ray; 2.02 A; A=89-289.
DR   PDB; 2P52; X-ray; 1.50 A; A=89-284.
DR   PDB; 3EXJ; X-ray; 2.00 A; A/B=93-289.
DR   PDB; 3EXL; X-ray; 2.20 A; A=93-289.
DR   PDBsum; 1HU8; -.
DR   PDBsum; 2GEQ; -.
DR   PDBsum; 2IOI; -.
DR   PDBsum; 2IOM; -.
DR   PDBsum; 2IOO; -.
DR   PDBsum; 2P52; -.
DR   PDBsum; 3EXJ; -.
DR   PDBsum; 3EXL; -.
DR   ProteinModelPortal; P02340; -.
DR   SMR; P02340; -.
DR   BioGrid; 204323; 86.
DR   DIP; DIP-369N; -.
DR   IntAct; P02340; 37.
DR   MINT; MINT-120104; -.
DR   STRING; 10090.ENSMUSP00000104298; -.
DR   ChEMBL; CHEMBL4164; -.
DR   iPTMnet; P02340; -.
DR   PhosphoSitePlus; P02340; -.
DR   SwissPalm; P02340; -.
DR   EPD; P02340; -.
DR   MaxQB; P02340; -.
DR   PaxDb; P02340; -.
DR   PRIDE; P02340; -.
DR   Ensembl; ENSMUST00000005371; ENSMUSP00000005371; ENSMUSG00000059552.
DR   GeneID; 22059; -.
DR   KEGG; mmu:22059; -.
DR   UCSC; uc007jql.2; mouse.
DR   CTD; 22059; -.
DR   MGI; MGI:98834; Trp53.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P02340; -.
DR   KO; K04451; -.
DR   Reactome; R-MMU-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-MMU-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF).
DR   Reactome; R-MMU-2559585; Oncogene Induced Senescence.
DR   Reactome; R-MMU-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-MMU-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-MMU-5689880; Ub-specific processing proteases.
DR   Reactome; R-MMU-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-MMU-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-MMU-6804754; Regulation of TP53 Expression.
DR   Reactome; R-MMU-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-MMU-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-MMU-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-MMU-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-MMU-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-MMU-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-MMU-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-MMU-69481; G2/M Checkpoints.
DR   Reactome; R-MMU-69541; Stabilization of p53.
DR   Reactome; R-MMU-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-MMU-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   EvolutionaryTrace; P02340; -.
DR   PRO; PR:P02340; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   Bgee; ENSMUSG00000059552; -.
DR   CleanEx; MM_TRP53; -.
DR   ExpressionAtlas; P02340; baseline and differential.
DR   Genevisible; P02340; MM.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IDA:MGI.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; ISO:MGI.
DR   GO; GO:0016363; C:nuclear matrix; ISO:MGI.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0016605; C:PML body; ISO:MGI.
DR   GO; GO:0043234; C:protein complex; ISO:MGI.
DR   GO; GO:0005657; C:replication fork; IDA:MGI.
DR   GO; GO:0035861; C:site of double-strand break; IDA:MGI.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; ISO:MGI.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0035035; F:histone acetyltransferase binding; ISO:MGI.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IPI:BHF-UCL.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0002020; F:protease binding; ISO:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:MGI.
DR   GO; GO:0019901; F:protein kinase binding; ISO:MGI.
DR   GO; GO:0047485; F:protein N-terminus binding; ISO:MGI.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; ISO:MGI.
DR   GO; GO:0019903; F:protein phosphatase binding; ISO:MGI.
DR   GO; GO:0043621; F:protein self-association; ISO:MGI.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; ISO:MGI.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISO:MGI.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; ISO:MGI.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0008134; F:transcription factor binding; ISO:MGI.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; ISO:MGI.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:MGI.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding; ISO:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:MGI.
DR   GO; GO:0006915; P:apoptotic process; IDA:MGI.
DR   GO; GO:0002326; P:B cell lineage commitment; IMP:MGI.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IGI:MGI.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; ISO:MGI.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:MGI.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:MGI.
DR   GO; GO:0042149; P:cellular response to glucose starvation; ISO:MGI.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IGI:MGI.
DR   GO; GO:0034644; P:cellular response to UV; IGI:MGI.
DR   GO; GO:0071494; P:cellular response to UV-C; IGI:MGI.
DR   GO; GO:0007417; P:central nervous system development; IGI:MGI.
DR   GO; GO:0021549; P:cerebellum development; IDA:MGI.
DR   GO; GO:0031497; P:chromatin assembly; ISO:MGI.
DR   GO; GO:0031052; P:chromosome breakage; IGI:MGI.
DR   GO; GO:0051276; P:chromosome organization; IGI:MGI.
DR   GO; GO:0048512; P:circadian behavior; IMP:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEP:UniProtKB.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:BHF-UCL.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:MGI.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IGI:MGI.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IDA:MGI.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IMP:MGI.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; IGI:MGI.
DR   GO; GO:0048568; P:embryonic organ development; IGI:MGI.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; IMP:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; ISO:MGI.
DR   GO; GO:0007369; P:gastrulation; IGI:MGI.
DR   GO; GO:0007507; P:heart development; IGI:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IGI:MGI.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:MGI.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:BHF-UCL.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IMP:MGI.
DR   GO; GO:0043504; P:mitochondrial DNA repair; IMP:MGI.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IDA:MGI.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IMP:MGI.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0035264; P:multicellular organism growth; IGI:MGI.
DR   GO; GO:0070266; P:necroptotic process; IGI:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IDA:MGI.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:MGI.
DR   GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IMP:MGI.
DR   GO; GO:1901525; P:negative regulation of macromitophagy; IMP:MGI.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IGI:MGI.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IGI:MGI.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IMP:MGI.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IMP:MGI.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; ISO:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IMP:MGI.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:MGI.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; ISO:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IMP:MGI.
DR   GO; GO:0090343; P:positive regulation of cell aging; IMP:BHF-UCL.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; ISO:MGI.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; ISO:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:MGI.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IDA:MGI.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; ISO:MGI.
DR   GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IGI:MGI.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; ISO:MGI.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISO:MGI.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IMP:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0006461; P:protein complex assembly; ISO:MGI.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IDA:MGI.
DR   GO; GO:0008104; P:protein localization; ISO:MGI.
DR   GO; GO:0050821; P:protein stabilization; IGI:MGI.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0042981; P:regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:MGI.
DR   GO; GO:2000772; P:regulation of cellular senescence; IGI:MGI.
DR   GO; GO:2000269; P:regulation of fibroblast apoptotic process; IGI:MGI.
DR   GO; GO:0072363; P:regulation of glycolytic process by positive regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IMP:MGI.
DR   GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IGI:MGI.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IGI:MGI.
DR   GO; GO:0070243; P:regulation of thymocyte apoptotic process; IGI:MGI.
DR   GO; GO:0034103; P:regulation of tissue remodeling; IMP:MGI.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IDA:MGI.
DR   GO; GO:0090399; P:replicative senescence; ISO:MGI.
DR   GO; GO:0042493; P:response to drug; IDA:MGI.
DR   GO; GO:0010332; P:response to gamma radiation; IDA:MGI.
DR   GO; GO:0002931; P:response to ischemia; IMP:MGI.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:MGI.
DR   GO; GO:0009651; P:response to salt stress; IGI:MGI.
DR   GO; GO:0009411; P:response to UV; IDA:MGI.
DR   GO; GO:0010165; P:response to X-ray; IDA:MGI.
DR   GO; GO:0009303; P:rRNA transcription; IGI:MGI.
DR   GO; GO:0001756; P:somitogenesis; IGI:MGI.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IGI:MGI.
DR   GO; GO:0002360; P:T cell lineage commitment; IMP:MGI.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IGI:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IGI:MGI.
DR   GO; GO:0016032; P:viral process; ISO:MGI.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Apoptosis; Biological rhythms;
KW   Cell cycle; Complete proteome; Cytoplasm; Disease mutation;
KW   DNA-binding; Endoplasmic reticulum; Isopeptide bond; Metal-binding;
KW   Methylation; Mitochondrion; Necrosis; Nucleus; Phosphoprotein;
KW   Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    387       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185709.
FT   DNA_BIND     96    286       {ECO:0000250}.
FT   REGION        1    314       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     42       Transcription activation (acidic).
FT   REGION       60    104       Interaction with WWOX. {ECO:0000250}.
FT   REGION       94    364       Interaction with HIPK1.
FT                                {ECO:0000269|PubMed:12702766}.
FT   REGION       94    294       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      107    230       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      110    286       Interaction with AXIN1.
FT                                {ECO:0000269|PubMed:15526030}.
FT   REGION      253    291       Interaction with E4F1. {ECO:0000250}.
FT   REGION      267    274       Interaction with DNA.
FT   REGION      313    354       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      319    350       Oligomerization.
FT   REGION      353    357       Interaction with USP7. {ECO:0000250}.
FT   REGION      362    381       Basic (repression of DNA-binding).
FT   MOTIF       299    315       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       333    344       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       364    366       [KR]-[STA]-K motif.
FT   METAL       170    170       Zinc.
FT   METAL       173    173       Zinc.
FT   METAL       232    232       Zinc.
FT   METAL       236    236       Zinc.
FT   SITE        114    114       Interaction with DNA.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4.
FT                                {ECO:0000269|PubMed:18022393}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000269|PubMed:15195100}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      34     34       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000269|PubMed:17254968}.
FT   MOD_RES     114    114       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     177    177       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     263    263       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     278    278       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     299    299       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     309    309       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     315    315       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:23806337}.
FT   MOD_RES     364    364       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     364    364       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     366    366       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     367    367       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     367    367       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     375    375       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     376    376       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     376    376       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     376    376       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     386    386       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    285    285       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    286    286       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    380    380       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VARIANT     132    132       A -> V (can cooperate with an activated
FT                                Ras to transform fibroblasts).
FT                                {ECO:0000269|PubMed:3329909}.
FT   VARIANT     165    165       E -> G (in clone P53-M11).
FT   VARIANT     188    188       L -> R.
FT   CONFLICT     45     45       Q -> R (in Ref. 3; CAA25323).
FT                                {ECO:0000305}.
FT   CONFLICT     76     78       PVA -> QW (in Ref. 3; CAA25323).
FT                                {ECO:0000305}.
FT   HELIX        99    101       {ECO:0000244|PDB:2P52}.
FT   STRAND      104    106       {ECO:0000244|PDB:2P52}.
FT   HELIX       113    116       {ECO:0000244|PDB:3EXJ}.
FT   STRAND      117    121       {ECO:0000244|PDB:2P52}.
FT   TURN        122    125       {ECO:0000244|PDB:2P52}.
FT   STRAND      126    129       {ECO:0000244|PDB:2P52}.
FT   STRAND      134    140       {ECO:0000244|PDB:2P52}.
FT   STRAND      150    159       {ECO:0000244|PDB:2P52}.
FT   TURN        160    164       {ECO:0000244|PDB:2P52}.
FT   HELIX       171    175       {ECO:0000244|PDB:2P52}.
FT   STRAND      181    183       {ECO:0000244|PDB:2P52}.
FT   STRAND      188    193       {ECO:0000244|PDB:2P52}.
FT   STRAND      198    201       {ECO:0000244|PDB:2P52}.
FT   TURN        203    205       {ECO:0000244|PDB:2P52}.
FT   STRAND      208    213       {ECO:0000244|PDB:2P52}.
FT   STRAND      222    230       {ECO:0000244|PDB:2P52}.
FT   HELIX       235    237       {ECO:0000244|PDB:2P52}.
FT   HELIX       239    242       {ECO:0000244|PDB:2P52}.
FT   STRAND      245    252       {ECO:0000244|PDB:2P52}.
FT   STRAND      258    268       {ECO:0000244|PDB:2P52}.
FT   HELIX       272    283       {ECO:0000244|PDB:2P52}.
FT   TURN        285    287       {ECO:0000244|PDB:3EXJ}.
SQ   SEQUENCE   387 AA;  43155 MW;  B55EB7B463E1DD9D CRC64;
     MEESQSDISL ELPLSQETFS GLWKLLPPED ILPSPHCMDD LLLPQDVEEF FEGPSEALRV
     SGAPAAQDPV TETPGPVAPA PATPWPLSSF VPSQKTYQGN YGFHLGFLQS GTAKSVMCTY
     SPPLNKLFCQ LAKTCPVQLW VSATPPAGSR VRAMAIYKKS QHMTEVVRRC PHHERCSDGD
     GLAPPQHLIR VEGNLYPEYL EDRQTFRHSV VVPYEPPEAG SEYTTIHYKY MCNSSCMGGM
     NRRPILTIIT LEDSSGNLLG RDSFEVRVCA CPGRDRRTEE ENFRKKEVLC PELPPGSAKR
     ALPTCTSASP PQKKKPLDGE YFTLKIRGRK RFEMFRELNE ALELKDAHAT EESGDSRAHS
     SYLKTKKGQS TSRHKKTMVK KVGPDSD
//
ID   MDM2_HUMAN              Reviewed;         491 AA.
AC   Q00987; A6NL51; A8K2S6; Q13226; Q13297; Q13298; Q13299; Q13300;
AC   Q13301; Q53XW0; Q71TW9; Q8WYJ1; Q8WYJ2; Q9UGI3; Q9UMT8;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   18-JAN-2017, entry version 218.
DE   RecName: Full=E3 ubiquitin-protein ligase Mdm2;
DE            EC=2.3.2.27;
DE   AltName: Full=Double minute 2 protein;
DE            Short=Hdm2;
DE   AltName: Full=Oncoprotein Mdm2;
DE   AltName: Full=RING-type E3 ubiquitin transferase Mdm2 {ECO:0000305};
DE   AltName: Full=p53-binding protein Mdm2;
GN   Name=MDM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MDM2).
RC   TISSUE=Colon;
RX   PubMed=1614537; DOI=10.1038/358080a0;
RA   Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B.;
RT   "Amplification of a gene encoding a p53-associated protein in human
RT   sarcomas.";
RL   Nature 358:80-83(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS MDM2-A; MDM2-B; MDM2-C; MDM2-D
RP   AND MDM2-E).
RC   TISSUE=Ovarian carcinoma;
RX   PubMed=8705862; DOI=10.1038/nm0896-912;
RA   Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J.;
RT   "Alternatively spliced mdm2 transcripts with loss of p53 binding
RT   domain sequences: transforming ability and frequent detection in human
RT   cancer.";
RL   Nat. Med. 2:912-917(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MDM2-ALPHA).
RX   PubMed=10597303; DOI=10.1038/sj.onc.1203182;
RA   Veldhoen N., Metcalfe S., Milner J.;
RT   "A novel exon within the mdm2 gene modulates translation initiation in
RT   vitro and disrupts the p53-binding domain of mdm2 protein.";
RL   Oncogene 18:7026-7033(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS MDM2-F AND MDM2-G), AND
RP   INTERACTION WITH TP53.
RX   PubMed=11351297; DOI=10.1002/ijc.1271;
RA   Tamborini E., Della Torre G., Lavarino C., Azzarelli A.,
RA   Carpinelli P., Pierotti M.A., Pilotti S.;
RT   "Analysis of the molecular species generated by MDM2 gene
RT   amplification in liposarcomas.";
RL   Int. J. Cancer 92:790-796(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM MDM2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM MDM2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 11).
RC   TISSUE=Rhabdomyosarcoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24.
RX   PubMed=7651818; DOI=10.1093/nar/23.14.2584;
RA   Zauberman A., Flusberg D., Haupt Y., Barak Y., Oren M.;
RT   "A functional p53-responsive intronic promoter is contained within the
RT   human mdm2 gene.";
RL   Nucleic Acids Res. 23:2584-2592(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-9.
RX   PubMed=9270029;
RA   Landers J.E., Cassel S.L., George D.L.;
RT   "Translational enhancement of mdm2 oncogene expression in human tumor
RT   cells containing a stabilized wild-type p53 protein.";
RL   Cancer Res. 57:3562-3568(1997).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-491 (ISOFORM MDM2-A1).
RX   PubMed=15315825; DOI=10.1016/j.gene.2004.05.015;
RA   Liang H., Atkins H., Abdel-Fattah R., Jones S.N., Lunec J.;
RT   "Genomic organisation of the human MDM2 oncogene and relationship to
RT   its alternatively spliced mRNAs.";
RL   Gene 338:217-223(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 301-481.
RX   PubMed=11087894; DOI=10.1016/S0027-5107(00)00112-3;
RA   Taubert H., Kappler M., Meye A., Bartel F., Schlott T.,
RA   Lautenschlaeger C., Bache M., Schmidt H., Wuerl P.;
RT   "A MboII polymorphism in exon 11 of the human MDM2 gene occurring in
RT   normal blood donors and in soft tissue sarcoma patients: an indication
RT   for an increased cancer susceptibility?";
RL   Mutat. Res. 456:39-44(2000).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TP53.
RX   PubMed=7689721;
RA   Olson D.C., Marechal V., Momand J., Chen J., Romocki C., Levine A.J.;
RT   "Identification and characterization of multiple mdm-2 proteins and
RT   mdm-2-p53 protein complexes.";
RL   Oncogene 8:2353-2360(1993).
RN   [15]
RP   MUTAGENESIS OF CYS-464.
RX   PubMed=9450543; DOI=10.1016/S0014-5793(97)01480-4;
RA   Honda R., Tanaka H., Yasuda H.;
RT   "Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.";
RL   FEBS Lett. 420:25-27(1997).
RN   [16]
RP   MUTAGENESIS OF CYS-441 AND CYS-478.
RX   PubMed=10608892; DOI=10.1074/jbc.274.53.38189;
RA   Sharp D.A., Kratowicz S.A., Sank M.J., George D.L.;
RT   "Stabilization of the MDM2 oncoprotein by interaction with the
RT   structurally related MDMX protein.";
RL   J. Biol. Chem. 274:38189-38196(1999).
RN   [17]
RP   PHOSPHORYLATION BY ATM.
RX   PubMed=10611322; DOI=10.1073/pnas.96.26.14973;
RA   Khosravi R., Maya R., Gottlieb T., Oren M., Shiloh Y., Shkedy D.;
RT   "Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation
RT   in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:14973-14977(1999).
RN   [18]
RP   MUTAGENESIS.
RX   PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself
RT   and p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [19]
RP   NUCLEOLAR LOCALIZATION SIGNAL.
RX   PubMed=10707090; DOI=10.1038/35004057;
RA   Lohrum M.A.E., Ashcroft M., Kubbutat M.H.G., Vousden K.H.;
RT   "Identification of a cryptic nucleolar-localization signal in MDM2.";
RL   Nat. Cell Biol. 2:179-181(2000).
RN   [20]
RP   MUTAGENESIS OF CYS-449.
RX   PubMed=10723139; DOI=10.1038/sj.onc.1203464;
RA   Honda R., Yasuda H.;
RT   "Activity of MDM2, a ubiquitin ligase, toward p53 or itself is
RT   dependent on the RING finger domain of the ligase.";
RL   Oncogene 19:1473-1476(2000).
RN   [21]
RP   PHOSPHORYLATION AT SER-240; SER-242; SER-246; SER-260 AND SER-262.
RX   PubMed=12167711; DOI=10.1128/MCB.22.17.6170-6182.2002;
RA   Blattner C., Hay T., Meek D.W., Lane D.P.;
RT   "Hypophosphorylation of Mdm2 augments p53 stability.";
RL   Mol. Cell. Biol. 22:6170-6182(2002).
RN   [22]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=12883554; DOI=10.1038/ncb1023;
RA   Bres V., Kiernan R.E., Linares L.K., Chable-Bessia C., Plechakova O.,
RA   Treand C., Emiliani S., Peloponese J.-M., Jeang K.-T., Coux O.,
RA   Scheffner M., Benkirane M.;
RT   "A non-proteolytic role for ubiquitin in Tat-mediated transactivation
RT   of the HIV-1 promoter.";
RL   Nat. Cell Biol. 5:754-761(2003).
RN   [23]
RP   FUNCTION IN UBIQUITINATION OF IGF1R, AND INTERACTION WITH IGF1R.
RX   PubMed=12821780; DOI=10.1073/pnas.1431613100;
RA   Girnita L., Girnita A., Larsson O.;
RT   "Mdm2-dependent ubiquitination and degradation of the insulin-like
RT   growth factor 1 receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8247-8252(2003).
RN   [24]
RP   INTERACTION WITH FHIT.
RX   PubMed=15313915; DOI=10.1158/0008-5472.CAN-04-0195;
RA   Nishizaki M., Sasaki J., Fang B., Atkinson E.N., Minna J.D.,
RA   Roth J.A., Ji L.;
RT   "Synergistic tumor suppression by coexpression of FHIT and p53
RT   coincides with FHIT-mediated MDM2 inactivation and p53 stabilization
RT   in human non-small cell lung cancer cells.";
RL   Cancer Res. 64:5745-5752(2004).
RN   [25]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ACCELERATED TUMOR FORMATION.
RX   PubMed=15550242; DOI=10.1016/j.cell.2004.11.022;
RA   Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C.,
RA   Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L.,
RA   Hwang S.J., Strong L.C., Lozano G., Levine A.J.;
RT   "A single nucleotide polymorphism in the MDM2 promoter attenuates the
RT   p53 tumor suppressor pathway and accelerates tumor formation in
RT   humans.";
RL   Cell 119:591-602(2004).
RN   [26]
RP   INTERACTION WITH DAXX.
RX   PubMed=15364927; DOI=10.1074/jbc.M406743200;
RA   Zhao L.Y., Liu J., Sidhu G.S., Niu Y., Liu Y., Wang R., Liao D.;
RT   "Negative regulation of p53 functions by Daxx and the involvement of
RT   MDM2.";
RL   J. Biol. Chem. 279:50566-50579(2004).
RN   [27]
RP   FUNCTION, INTERACTION WITH USP7, AND DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/S1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [28]
RP   FUNCTION, INTERACTION WITH PML AND RPL11, AND SUBCELLULAR LOCATION.
RX   PubMed=15195100; DOI=10.1038/ncb1147;
RA   Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H.,
RA   Pandolfi P.P.;
RT   "PML regulates p53 stability by sequestering Mdm2 to the nucleolus.";
RL   Nat. Cell Biol. 6:665-672(2004).
RN   [29]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15878855; DOI=10.1074/jbc.M501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of
RT   the insulin-like growth factor-1 receptor by acting as adaptor for the
RT   MDM2 E3 ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [30]
RP   INTERACTION WITH WWOX AND TP53.
RX   PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-,
RT   staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT   phosphorylated form binds and stabilizes serine 46-phosphorylated
RT   p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH PSMA3.
RX   PubMed=16337594; DOI=10.1016/j.molcel.2005.10.017;
RA   Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R.,
RA   Allday M.J., Xiao Z.X.;
RT   "MDM2 promotes proteasome-dependent ubiquitin-independent degradation
RT   of retinoblastoma protein.";
RL   Mol. Cell 20:699-708(2005).
RN   [32]
RP   FUNCTION, INTERACTION WITH MTBP, AND MUTAGENESIS OF CYS-464.
RX   PubMed=15632057; DOI=10.1128/MCB.25.2.545-553.2005;
RA   Brady M., Vlatkovic N., Boyd M.T.;
RT   "Regulation of p53 and MDM2 activity by MTBP.";
RL   Mol. Cell. Biol. 25:545-553(2005).
RN   [33]
RP   INTERACTION WITH CDK5RAP3 AND CDKN2A/ARF.
RX   PubMed=16173922; DOI=10.1042/BJ20050960;
RA   Wang J., He X., Luo Y., Yarbrough W.G.;
RT   "A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.";
RL   Biochem. J. 393:489-501(2006).
RN   [34]
RP   UBIQUITINATION, INTERACTION WITH PYHIN1, AND MUTAGENESIS OF CYS-464.
RX   PubMed=16479015; DOI=10.1128/MCB.26.5.1979-1996.2006;
RA   Ding Y., Lee J.-F., Lu H., Lee M.-H., Yan D.-H.;
RT   "Interferon-inducible protein IFIXalpha1 functions as a negative
RT   regulator of HDM2.";
RL   Mol. Cell. Biol. 26:1979-1996(2006).
RN   [35]
RP   IDENTIFICATION IN A COMPLEX WITH DAXX AND USP7, INTERACTION WITH DAXX,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [36]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=17460193; DOI=10.1196/annals.1395.033;
RA   Kamrul H.M., Wadhwa R., Kaul S.C.;
RT   "CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-
RT   suppressor pathway.";
RL   Ann. N. Y. Acad. Sci. 1100:312-315(2007).
RN   [37]
RP   FUNCTION, INTERACTION WITH USP2, UBIQUITINATION, AND DEUBIQUITINATION
RP   BY USP2.
RX   PubMed=17290220; DOI=10.1038/sj.emboj.7601567;
RA   Stevenson L.F., Sparks A., Allende-Vega N., Xirodimas D.P., Lane D.P.,
RA   Saville M.K.;
RT   "The deubiquitinating enzyme USP2a regulates the p53 pathway by
RT   targeting Mdm2.";
RL   EMBO J. 26:976-986(2007).
RN   [38]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ACCELERATED TUMOR FORMATION AND
RP   LI-FRAUMENI SYNDROME.
RX   PubMed=17003841; DOI=10.1038/sj.ejhg.5201715;
RA   Ruijs M.W., Schmidt M.K., Nevanlinna H., Tommiska J., Aittomaki K.,
RA   Pruntel R., Verhoef S., Van't Veer L.J.;
RT   "The single-nucleotide polymorphism 309 in the MDM2 gene contributes
RT   to the Li-Fraumeni syndrome and related phenotypes.";
RL   Eur. J. Hum. Genet. 15:110-114(2007).
RN   [39]
RP   INTERACTION WITH TBRG1.
RX   PubMed=17110379; DOI=10.1074/jbc.M609612200;
RA   Tompkins V.S., Hagen J., Frazier A.A., Lushnikova T., Fitzgerald M.P.,
RA   di Tommaso A.D., Ladeveze V., Domann F.E., Eischen C.M., Quelle D.E.;
RT   "A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains
RT   chromosomal stability.";
RL   J. Biol. Chem. 282:1322-1333(2007).
RN   [40]
RP   INTERACTION WITH RBBP6.
RX   PubMed=17470788; DOI=10.1073/pnas.0701916104;
RA   Li L., Deng B., Xing G., Teng Y., Tian C., Cheng X., Yin X., Yang J.,
RA   Gao X., Zhu Y., Sun Q., Zhang L., Yang X., He F.;
RT   "PACT is a negative regulator of p53 and essential for cell growth and
RT   embryonic development.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7951-7956(2007).
RN   [41]
RP   INTERACTION WITH RFFL AND RNF34, AND AUTOUBIQUITINATION.
RX   PubMed=18382127; DOI=10.4161/cc.7.5.5701;
RA   Yang W., Dicker D.T., Chen J., El-Deiry W.S.;
RT   "CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing
RT   MDM2.";
RL   Cell Cycle 7:670-682(2008).
RN   [42]
RP   IDENTIFICATION IN A COMPLEX WITH DAXX; RASSF1 AND USP7, INTERACTION
RP   WITH RASSF1; USP7 AND DAXX, AND SUBCELLULAR LOCATION.
RX   PubMed=18566590; DOI=10.1038/emboj.2008.115;
RA   Song M.S., Song S.J., Kim S.Y., Oh H.J., Lim D.S.;
RT   "The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by
RT   disrupting the MDM2-DAXX-HAUSP complex.";
RL   EMBO J. 27:1863-1874(2008).
RN   [43]
RP   INTERACTION WITH UBXN6.
RX   PubMed=18768758; DOI=10.1091/mbc.E08-01-0067;
RA   Zweitzig D.R., Shcherbik N., Haines D.S.;
RT   "AAA ATPase p97 and adaptor UBXD1 suppress MDM2 ubiquitination and
RT   degradation and promote constitutive p53 turnover.";
RL   Mol. Biol. Cell 19:5029-5029(2008).
RN   [44]
RP   PHOSPHORYLATION AT SER-386; SER-395; SER-407; THR-419; SER-425 AND
RP   SER-429.
RX   PubMed=19816404; DOI=10.1038/emboj.2009.294;
RA   Cheng Q., Chen L., Li Z., Lane W.S., Chen J.;
RT   "ATM activates p53 by regulating MDM2 oligomerization and E3
RT   processivity.";
RL   EMBO J. 28:3857-3867(2009).
RN   [45]
RP   FUNCTION, INTERACTION WITH RYBP, AND IDENTIFICATION IN A COMPLEX WITH
RP   RYBP AND TP53.
RX   PubMed=19098711; DOI=10.1038/embor.2008.231;
RA   Chen D., Zhang J., Li M., Rayburn E.R., Wang H., Zhang R.;
RT   "RYBP stabilizes p53 by modulating MDM2.";
RL   EMBO Rep. 10:166-172(2009).
RN   [46]
RP   FUNCTION, AND INTERACTION WITH MTA1.
RX   PubMed=19837670; DOI=10.1074/jbc.M109.056499;
RA   Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "MTA1 coregulator regulates p53 stability and function.";
RL   J. Biol. Chem. 284:34545-34552(2009).
RN   [47]
RP   PHOSPHORYLATION AT SER-166 BY SGK1.
RX   PubMed=19756449; DOI=10.1007/s00109-009-0525-5;
RA   Amato R., D'Antona L., Porciatti G., Agosti V., Menniti M.,
RA   Rinaldo C., Costa N., Bellacchio E., Mattarocci S., Fuiano G.,
RA   Soddu S., Paggi M.G., Lang F., Perrotti N.;
RT   "Sgk1 activates MDM2-dependent p53 degradation and affects cell
RT   proliferation, survival, and differentiation.";
RL   J. Mol. Med. 87:1221-1239(2009).
RN   [48]
RP   INTERACTION WITH HHV-8 PROTEIN VIRF4.
RX   PubMed=19369353; DOI=10.1128/JVI.02353-08;
RA   Lee H.R., Toth Z., Shin Y.C., Lee J.S., Chang H., Gu W., Oh T.K.,
RA   Kim M.H., Jung J.U.;
RT   "Kaposi's sarcoma-associated herpesvirus viral interferon regulatory
RT   factor 4 targets MDM2 to deregulate the p53 tumor suppressor
RT   pathway.";
RL   J. Virol. 83:6739-6747(2009).
RN   [49]
RP   FUNCTION, INTERACTION WITH APEX1, AND MUTAGENESIS OF CYS-464.
RX   PubMed=19219073; DOI=10.1038/onc.2009.5;
RA   Busso C.S., Iwakuma T., Izumi T.;
RT   "Ubiquitination of mammalian AP endonuclease (APE1) regulated by the
RT   p53-MDM2 signaling pathway.";
RL   Oncogene 28:1616-1625(2009).
RN   [50]
RP   IDENTIFICATION.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-166, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [52]
RP   FUNCTION, AND INTERACTION WITH SNAI1.
RX   PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006;
RA   Lim S.O., Kim H., Jung G.;
RT   "p53 inhibits tumor cell invasion via the degradation of snail protein
RT   in hepatocellular carcinoma.";
RL   FEBS Lett. 584:2231-2236(2010).
RN   [53]
RP   FUNCTION IN DYRK2 UBIQUITINATION, AND INTERACTION WITH DYRK2.
RX   PubMed=19965871; DOI=10.1074/jbc.M109.042341;
RA   Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.;
RT   "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 285:4909-4919(2010).
RN   [54]
RP   INTERACTION WITH TRIM28 IN THE TRIM28/KAP1-ERBB4-MDM2 COMPLEX AND WITH
RP   TP53 IN THE TRIM28/KAP1-MDM2-P53/TP53 COMPLEX, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20858735; DOI=10.1158/1541-7786.MCR-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA
RT   damage response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [55]
RP   FUNCTION, INTERACTION WITH TP53 AND RFWD3, AND MUTAGENESIS OF CYS-464.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J.,
RA   Jung S.Y., O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53
RT   stability in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [56]
RP   INTERACTION WITH USP2 AND MDM4.
RX   PubMed=19838211; DOI=10.1038/onc.2009.330;
RA   Allende-Vega N., Sparks A., Lane D.P., Saville M.K.;
RT   "MdmX is a substrate for the deubiquitinating enzyme USP2a.";
RL   Oncogene 29:432-441(2010).
RN   [57]
RP   FUNCTION, AND INTERACTION WITH SNAI1 AND NOTCH1.
RX   PubMed=22128911; DOI=10.1186/1741-7007-9-83;
RA   Lim S.O., Kim H.S., Quan X., Ahn S.M., Kim H., Hsieh D., Seong J.K.,
RA   Jung G.;
RT   "Notch1 binds and induces degradation of Snail in hepatocellular
RT   carcinoma.";
RL   BMC Biol. 9:83-83(2011).
RN   [58]
RP   INTERACTION WITH TRIM13, AND UBIQUITINATION.
RX   PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001;
RA   Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H.,
RA   Kim C.S., Kim H.S., Jeong M., An S., Jin Y.W.;
RT   "Ret finger protein 2 enhances ionizing radiation-induced apoptosis
RT   via degradation of AKT and MDM2.";
RL   Eur. J. Cell Biol. 90:420-431(2011).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-166, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [60]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=22869143; DOI=10.1038/onc.2012.332;
RA   Yang Q., Liao L., Deng X., Chen R., Gray N.S., Yates J.R. III,
RA   Lee J.D.;
RT   "BMK1 is involved in the regulation of p53 through disrupting the PML-
RT   MDM2 interaction.";
RL   Oncogene 32:3156-3164(2013).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 25-109 IN COMPLEX WITH P53.
RX   PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA   Levine A.J., Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 224-232 IN COMPLEX WITH
RP   USP7, AND INTERACTION WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by
RT   HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 145-150 IN COMPLEX WITH USP7,
RP   AND INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination
CC       of p53/TP53, leading to its degradation by the proteasome.
CC       Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and
CC       apoptosis by binding its transcriptional activation domain. Also
CC       acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the
CC       nuclear export of p53/TP53. Promotes proteasome-dependent
CC       ubiquitin-independent degradation of retinoblastoma RB1 protein.
CC       Inhibits DAXX-mediated apoptosis by inducing its ubiquitination
CC       and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53
CC       complex involved in stabilizing p53/TP53. Also component of the
CC       TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA
CC       damage response pathways. Mediates ubiquitination and subsequent
CC       proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R
CC       and SNAI1 and promotes them to proteasomal degradation
CC       (PubMed:12821780, PubMed:15053880, PubMed:15195100,
CC       PubMed:15632057, PubMed:16337594, PubMed:17290220,
CC       PubMed:19098711, PubMed:19219073, PubMed:19837670,
CC       PubMed:19965871, PubMed:20173098, PubMed:20385133,
CC       PubMed:20858735, PubMed:22128911). Ubiquitinates DCX, leading to
CC       DCX degradation and reduction of the dendritic spine density of
CC       olfactory bulb granule cells (By similarity).
CC       {ECO:0000250|UniProtKB:P23804, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:15053880, ECO:0000269|PubMed:15195100,
CC       ECO:0000269|PubMed:15632057, ECO:0000269|PubMed:16337594,
CC       ECO:0000269|PubMed:17290220, ECO:0000269|PubMed:19098711,
CC       ECO:0000269|PubMed:19219073, ECO:0000269|PubMed:19837670,
CC       ECO:0000269|PubMed:19965871, ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:22128911}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- SUBUNIT: Interacts with p53/TP53, TP73/p73, RBL5 and RP11. Binds
CC       specifically to RNA. Can interact with RB1, E1A-associated protein
CC       EP300 and the E2F1 transcription factor. Forms a ternary complex
CC       with p53/TP53 and WWOX. Interacts with CDKN2AIP, RFWD3, USP7,
CC       PYHIN1, UBXN6, and RBBP6. Interacts with ARRB1 and ARRB2.
CC       Interacts with PSMA3. Found in a trimeric complex with MDM2, MDM4
CC       and USP2. Interacts with USP2 (via N-terminus and C-terminus).
CC       Interacts with MDM4. Part of a complex with MDM2, DAXX, RASSF1 and
CC       USP7. Part of a complex with DAXX, MDM2 and USP7. Interacts
CC       directly with DAXX and USP7. Interacts (via C-terminus) with
CC       RASSF1 isoform A (via N-terminus); the interaction is independent
CC       of TP53. Interacts with APEX1; leading to its ubiquitination and
CC       degradation. Interacts with RYBP; this inhibits ubiquitination of
CC       TP53. Identified in a complex with RYBP and p53/TP53. Also
CC       component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in
CC       regulating p53/TP53 stabilization and activity. Binds directly
CC       both p53/TP53 and TRIM28. Component of the TRIM28/KAP1-ERBB4-MDM2
CC       complex involved in connecting growth factor responses with DNA
CC       damage. Interacts directly with both TRIM28 and ERBB4 in the
CC       complex. Interacts with DYRK2. Interacts with IGF1R. Interacts
CC       with TRIM13; the interaction ubiquitinates MDM2 leading to its
CC       proteasomal degradation. Interacts with SNAI1; this interaction
CC       promotes SNAI1 ubiquitination. Interacts with NOTCH1 (via
CC       intracellular domain). Interacts with FHIT. Interacts with RFFL
CC       and RNF34; the interaction stabilizes MDM2. Interacts with
CC       CDK5RAP3 and CDKN2A/ARF; form a ternary complex involved in
CC       regulation of p53/TP53 (PubMed:16173922). Interacts with MTA1.
CC       Interacts with AARB2. Interacts with MTBP. Interacts with PML.
CC       Interacts with RPL11. Interacts with TBRG1. Interacts with herpes
CC       virus 8 protein v-IRF4. Interacts with and ubiquitinates HIV-1
CC       Tat. {ECO:0000269|PubMed:11351297, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:12883554, ECO:0000269|PubMed:15053880,
CC       ECO:0000269|PubMed:15195100, ECO:0000269|PubMed:15313915,
CC       ECO:0000269|PubMed:15364927, ECO:0000269|PubMed:15632057,
CC       ECO:0000269|PubMed:15878855, ECO:0000269|PubMed:16173922,
CC       ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16337594,
CC       ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402,
CC       ECO:0000269|PubMed:16479015, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:17110379, ECO:0000269|PubMed:17290220,
CC       ECO:0000269|PubMed:17460193, ECO:0000269|PubMed:17470788,
CC       ECO:0000269|PubMed:18382127, ECO:0000269|PubMed:18566590,
CC       ECO:0000269|PubMed:18768758, ECO:0000269|PubMed:19098711,
CC       ECO:0000269|PubMed:19219073, ECO:0000269|PubMed:19369353,
CC       ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19838211,
CC       ECO:0000269|PubMed:19965871, ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22128911,
CC       ECO:0000269|PubMed:22869143, ECO:0000269|PubMed:7689721,
CC       ECO:0000269|PubMed:8875929}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-389668, EBI-389668;
CC       P25098:ADRBK1; NbExp=4; IntAct=EBI-389668, EBI-3904795;
CC       P31749:AKT1; NbExp=4; IntAct=EBI-389668, EBI-296087;
CC       P10275:AR; NbExp=2; IntAct=EBI-389668, EBI-608057;
CC       Q9Y297:BTRC; NbExp=9; IntAct=EBI-389668, EBI-307461;
CC       P42574:CASP3; NbExp=2; IntAct=EBI-389668, EBI-524064;
CC       Q8N726:CDKN2A; NbExp=5; IntAct=EBI-389668, EBI-625922;
CC       P48729:CSNK1A1; NbExp=3; IntAct=EBI-389668, EBI-1383726;
CC       P48729-2:CSNK1A1; NbExp=3; IntAct=EBI-389668, EBI-2040168;
CC       P48730:CSNK1D; NbExp=6; IntAct=EBI-389668, EBI-751621;
CC       Q06486:Csnk1d (xeno); NbExp=2; IntAct=EBI-389668, EBI-2910316;
CC       P49674:CSNK1E; NbExp=3; IntAct=EBI-389668, EBI-749343;
CC       Q13616:CUL1; NbExp=3; IntAct=EBI-389668, EBI-359390;
CC       Q9UER7:DAXX; NbExp=18; IntAct=EBI-389668, EBI-77321;
CC       P78352:DLG4; NbExp=3; IntAct=EBI-389668, EBI-80389;
CC       P68104:EEF1A1; NbExp=9; IntAct=EBI-389668, EBI-352162;
CC       P03372:ESR1; NbExp=2; IntAct=EBI-389668, EBI-78473;
CC       P15311:EZR; NbExp=3; IntAct=EBI-389668, EBI-1056902;
CC       Q9UKB1:FBXW11; NbExp=4; IntAct=EBI-389668, EBI-355189;
CC       Q00688:FKBP3; NbExp=2; IntAct=EBI-389668, EBI-1044081;
CC       Q62446:Fkbp3 (xeno); NbExp=4; IntAct=EBI-389668, EBI-8313562;
CC       Q9BVP2:GNL3; NbExp=3; IntAct=EBI-389668, EBI-641642;
CC       Q9NVN8:GNL3L; NbExp=8; IntAct=EBI-389668, EBI-746682;
CC       Q5T7V8:GORAB; NbExp=6; IntAct=EBI-389668, EBI-3917143;
CC       P61978:HNRNPK; NbExp=2; IntAct=EBI-389668, EBI-304185;
CC       P08069:IGF1R; NbExp=2; IntAct=EBI-389668, EBI-475981;
CC       Q8N9B5:JMY; NbExp=2; IntAct=EBI-389668, EBI-866435;
CC       P05412:JUN; NbExp=3; IntAct=EBI-389668, EBI-852823;
CC       P17535:JUND; NbExp=3; IntAct=EBI-389668, EBI-2682803;
CC       O15151:MDM4; NbExp=8; IntAct=EBI-389668, EBI-398437;
CC       P19338:NCL; NbExp=8; IntAct=EBI-389668, EBI-346967;
CC       P06748:NPM1; NbExp=5; IntAct=EBI-389668, EBI-78579;
CC       Q61937:Npm1 (xeno); NbExp=2; IntAct=EBI-389668, EBI-626362;
CC       Q15466:NR0B2; NbExp=4; IntAct=EBI-389668, EBI-3910729;
CC       Q96FW1:OTUB1; NbExp=5; IntAct=EBI-389668, EBI-1058491;
CC       P53350:PLK1; NbExp=7; IntAct=EBI-389668, EBI-476768;
CC       P29590:PML; NbExp=6; IntAct=EBI-389668, EBI-295890;
CC       P29590-5:PML; NbExp=6; IntAct=EBI-389668, EBI-304008;
CC       O15297:PPM1D; NbExp=4; IntAct=EBI-389668, EBI-1551512;
CC       Q13362:PPP2R5C; NbExp=5; IntAct=EBI-389668, EBI-1266156;
CC       P25788:PSMA3; NbExp=2; IntAct=EBI-389668, EBI-348380;
CC       P61289:PSME3; NbExp=8; IntAct=EBI-389668, EBI-355546;
CC       Q9NS23:RASSF1; NbExp=5; IntAct=EBI-389668, EBI-367363;
CC       P06400:RB1; NbExp=4; IntAct=EBI-389668, EBI-491274;
CC       P62913:RPL11; NbExp=11; IntAct=EBI-389668, EBI-354380;
CC       P62829:RPL23; NbExp=3; IntAct=EBI-389668, EBI-353303;
CC       P46777:RPL5; NbExp=5; IntAct=EBI-389668, EBI-358018;
CC       P42677:RPS27; NbExp=5; IntAct=EBI-389668, EBI-356336;
CC       Q71UM5:RPS27L; NbExp=6; IntAct=EBI-389668, EBI-355126;
CC       P23396:RPS3; NbExp=8; IntAct=EBI-389668, EBI-351193;
CC       P62081:RPS7; NbExp=15; IntAct=EBI-389668, EBI-354360;
CC       Q8N488:RYBP; NbExp=11; IntAct=EBI-389668, EBI-752324;
CC       Q92736:RYR2; NbExp=2; IntAct=EBI-389668, EBI-1170425;
CC       P23297:S100A1; NbExp=2; IntAct=EBI-389668, EBI-743686;
CC       P29034:S100A2; NbExp=2; IntAct=EBI-389668, EBI-752230;
CC       P26447:S100A4; NbExp=3; IntAct=EBI-389668, EBI-717058;
CC       P06703:S100A6; NbExp=2; IntAct=EBI-389668, EBI-352877;
CC       P04271:S100B; NbExp=2; IntAct=EBI-389668, EBI-458391;
CC       Q01105:SET; NbExp=2; IntAct=EBI-389668, EBI-1053182;
CC       P04637:TP53; NbExp=65; IntAct=EBI-389668, EBI-366083;
CC       P0CG48:UBC; NbExp=6; IntAct=EBI-389668, EBI-3390054;
CC       O75604:USP2; NbExp=4; IntAct=EBI-389668, EBI-743272;
CC       Q93009:USP7; NbExp=18; IntAct=EBI-389668, EBI-302474;
CC       Q2HR73:vIRF-4 (xeno); NbExp=2; IntAct=EBI-389668, EBI-9001898;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm. Cytoplasm. Nucleus,
CC       nucleolus. Note=Expressed predominantly in the nucleoplasm.
CC       Interaction with ARF(P14) results in the localization of both
CC       proteins to the nucleolus. The nucleolar localization signals in
CC       both ARF(P14) and MDM2 may be necessary to allow efficient
CC       nucleolar localization of both proteins. Colocalizes with RASSF1
CC       isoform A in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC       Name=Mdm2;
CC         IsoId=Q00987-1; Sequence=Displayed;
CC       Name=Mdm2-A;
CC         IsoId=Q00987-2; Sequence=VSP_003208;
CC       Name=Mdm2-A1;
CC         IsoId=Q00987-3; Sequence=VSP_003208, VSP_003214;
CC       Name=Mdm2-B;
CC         IsoId=Q00987-4; Sequence=VSP_003209;
CC       Name=Mdm2-C;
CC         IsoId=Q00987-5; Sequence=VSP_003211;
CC       Name=Mdm2-D;
CC         IsoId=Q00987-6; Sequence=VSP_003210;
CC       Name=Mdm2-E;
CC         IsoId=Q00987-7; Sequence=VSP_003212, VSP_003213;
CC       Name=Mdm2-alpha;
CC         IsoId=Q00987-8; Sequence=VSP_003207;
CC       Name=Mdm2-F;
CC         IsoId=Q00987-9; Sequence=VSP_022578;
CC         Note=Does not interact with p53/TP53.;
CC       Name=Mdm2-G;
CC         IsoId=Q00987-10; Sequence=VSP_022579;
CC       Name=11;
CC         IsoId=Q00987-11; Sequence=VSP_037997;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoform Mdm2-A, isoform Mdm2-B,
CC       isoform Mdm2-C, isoform Mdm2-D, isoform Mdm2-E, isoform Mdm2-F and
CC       isoform Mdm2-G are observed in a range of cancers but absent in
CC       normal tissues.
CC   -!- INDUCTION: By DNA damage.
CC   -!- DOMAIN: Region I is sufficient for binding p53 and inhibiting its
CC       G1 arrest and apoptosis functions. It also binds p73 and E2F1.
CC       Region II contains most of a central acidic region required for
CC       interaction with ribosomal protein L5 and a putative C4-type zinc
CC       finger. The RING finger domain which coordinates two molecules of
CC       zinc interacts specifically with RNA whether or not zinc is
CC       present and mediates the heterooligomerization with MDM4. It is
CC       also essential for its ubiquitin ligase E3 activity toward p53 and
CC       itself.
CC   -!- PTM: Phosphorylation on Ser-166 by SGK1 activates ubiquitination
CC       of p53/TP53. Phosphorylated at multiple sites near the RING domain
CC       by ATM upon DNA damage; this prevents oligomerization and E3
CC       ligase processivity and impedes constitutive p53/TP53 degradation.
CC       {ECO:0000269|PubMed:10611322, ECO:0000269|PubMed:12167711,
CC       ECO:0000269|PubMed:18382127, ECO:0000269|PubMed:19756449,
CC       ECO:0000269|PubMed:19816404}.
CC   -!- PTM: Autoubiquitination leads to proteasomal degradation;
CC       resulting in p53/TP53 activation it may be regulated by SFN. Also
CC       ubiquitinated by TRIM13. Deubiquitinated by USP2 leads to its
CC       accumulation and increases deubiquitination and degradation of
CC       p53/TP53. Deubiquitinated by USP7 leading to its stabilization.
CC       {ECO:0000269|PubMed:18382127}.
CC   -!- POLYMORPHISM: A polymorphism in the MDM2 promoter is associated
CC       with susceptibility to accelerated tumor formation in both
CC       hereditary and sporadic cancers [MIM:614401]. It also contributes
CC       to susceptibility to Li-Fraumeni syndrome, in patients carrying a
CC       TP53 germline mutation.
CC   -!- DISEASE: Note=Seems to be amplified in certain tumors (including
CC       soft tissue sarcomas, osteosarcomas and gliomas). A higher
CC       frequency of splice variants lacking p53 binding domain sequences
CC       was found in late-stage and high-grade ovarian and bladder
CC       carcinomas. Four of the splice variants show loss of p53 binding.
CC   -!- MISCELLANEOUS: MDM2 RING finger mutations that failed to
CC       ubiquitinate p53 in vitro did not target p53 for degradation when
CC       expressed in cells.
CC   -!- SIMILARITY: Belongs to the MDM2/MDM4 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 RanBP2-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00322}.
CC   -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00175}.
CC   -!- SIMILARITY: Contains 1 SWIB domain. {ECO:0000305}.
CC   -!- CAUTION: A report observed N-glycosylation at Asn-349
CC       (PubMed:19139490). However, as the protein is not extracellular,
CC       additional evidences are required to confirm this result.
CC       {ECO:0000305|PubMed:19139490}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MDM2ID115ch12q15.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mdm2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Mdm2 entry;
CC       URL="https://en.wikipedia.org/wiki/Mdm2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M92424; AAA60568.1; -; mRNA.
DR   EMBL; Z12020; CAA78055.1; -; mRNA.
DR   EMBL; U33199; AAA75514.1; -; mRNA.
DR   EMBL; U33200; AAA75515.1; -; mRNA.
DR   EMBL; U33201; AAA75516.1; -; mRNA.
DR   EMBL; U33202; AAA75517.1; -; mRNA.
DR   EMBL; U33203; AAA75518.1; -; mRNA.
DR   EMBL; AF092844; AAL40179.1; -; mRNA.
DR   EMBL; AF092845; AAL40180.1; -; mRNA.
DR   EMBL; AK290341; BAF83030.1; -; mRNA.
DR   EMBL; BT007258; AAP35922.1; -; mRNA.
DR   EMBL; AF527840; AAM78554.1; -; Genomic_DNA.
DR   EMBL; AC025423; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009893; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U28935; AAA82237.1; -; Genomic_DNA.
DR   EMBL; U39736; AAA82061.1; -; Genomic_DNA.
DR   EMBL; AF201370; AAF42995.1; -; mRNA.
DR   EMBL; AJ251943; CAB64448.1; -; Genomic_DNA.
DR   CCDS; CCDS61189.1; -. [Q00987-5]
DR   CCDS; CCDS8986.2; -. [Q00987-11]
DR   PIR; S24354; S24354.
DR   RefSeq; NP_001138811.1; NM_001145339.2.
DR   RefSeq; NP_001265391.1; NM_001278462.1. [Q00987-5]
DR   RefSeq; NP_002383.2; NM_002392.5. [Q00987-11]
DR   RefSeq; XP_005268929.1; XM_005268872.4. [Q00987-1]
DR   RefSeq; XP_006719462.1; XM_006719399.3. [Q00987-8]
DR   UniGene; Hs.484551; -.
DR   UniGene; Hs.733536; -.
DR   PDB; 1RV1; X-ray; 2.30 A; A/B/C=25-109.
DR   PDB; 1T4E; X-ray; 2.60 A; A/B=17-111.
DR   PDB; 1T4F; X-ray; 1.90 A; M=17-125.
DR   PDB; 1YCR; X-ray; 2.60 A; A=17-125.
DR   PDB; 1Z1M; NMR; -; A=1-118.
DR   PDB; 2AXI; X-ray; 1.40 A; A=17-125.
DR   PDB; 2C6A; NMR; -; A=290-335.
DR   PDB; 2C6B; NMR; -; A=290-335.
DR   PDB; 2F1Y; X-ray; 1.70 A; A=224-232.
DR   PDB; 2FOP; X-ray; 2.10 A; B=145-150.
DR   PDB; 2GV2; X-ray; 1.80 A; A=17-125.
DR   PDB; 2HDP; NMR; -; A/B=429-491.
DR   PDB; 2LZG; NMR; -; A=1-125.
DR   PDB; 2M86; NMR; -; B=17-125.
DR   PDB; 2MPS; NMR; -; A=3-109.
DR   PDB; 2RUH; NMR; -; A=6-102.
DR   PDB; 2VJE; X-ray; 2.20 A; A/C=428-491.
DR   PDB; 2VJF; X-ray; 2.30 A; A/C=428-491.
DR   PDB; 3EQS; X-ray; 1.65 A; A=25-109.
DR   PDB; 3G03; X-ray; 1.80 A; A/C=18-125.
DR   PDB; 3IUX; X-ray; 1.65 A; A/C=25-109.
DR   PDB; 3IWY; X-ray; 1.93 A; A/C=25-109.
DR   PDB; 3JZK; X-ray; 2.10 A; A=17-111.
DR   PDB; 3JZR; X-ray; 2.10 A; A=17-125.
DR   PDB; 3JZS; X-ray; 1.78 A; A=24-109.
DR   PDB; 3LBK; X-ray; 2.30 A; A=18-111.
DR   PDB; 3LBL; X-ray; 1.60 A; A/C/E=18-111.
DR   PDB; 3LNJ; X-ray; 2.40 A; A/C/E=25-109.
DR   PDB; 3LNZ; X-ray; 1.95 A; A/C/E/G/I/K/M/O=25-109.
DR   PDB; 3MQS; X-ray; 2.40 A; D=394-403.
DR   PDB; 3TJ2; X-ray; 2.10 A; A/C=18-111.
DR   PDB; 3TPX; X-ray; 1.80 A; A/C/E=25-109.
DR   PDB; 3TU1; X-ray; 1.60 A; A=18-125.
DR   PDB; 3V3B; X-ray; 2.00 A; A/B=24-110.
DR   PDB; 3VBG; X-ray; 2.80 A; A/B/C/D=25-109.
DR   PDB; 3VZV; X-ray; 2.80 A; A/B=25-109.
DR   PDB; 3W69; X-ray; 1.90 A; A/B=25-109.
DR   PDB; 4DIJ; X-ray; 1.90 A; A/B=17-111.
DR   PDB; 4ERE; X-ray; 1.80 A; A/B=17-111.
DR   PDB; 4ERF; X-ray; 2.00 A; A/C/E=17-111.
DR   PDB; 4HBM; X-ray; 1.90 A; A/B/C/D/E/F/G/H=6-125.
DR   PDB; 4HFZ; X-ray; 2.69 A; A/C=17-125.
DR   PDB; 4HG7; X-ray; 1.60 A; A=17-108.
DR   PDB; 4JV7; X-ray; 2.20 A; A=18-111.
DR   PDB; 4JV9; X-ray; 2.50 A; A=18-111.
DR   PDB; 4JVE; X-ray; 2.30 A; A=18-111.
DR   PDB; 4JVR; X-ray; 1.70 A; A/C/E=18-111.
DR   PDB; 4JWR; X-ray; 2.35 A; A/B/C=17-111.
DR   PDB; 4MDN; X-ray; 1.90 A; A=18-110.
DR   PDB; 4MDQ; X-ray; 2.12 A; A=25-110.
DR   PDB; 4OAS; X-ray; 1.70 A; A/C/E=17-111.
DR   PDB; 4OBA; X-ray; 1.60 A; A/B/C=17-111.
DR   PDB; 4OCC; X-ray; 1.80 A; A/C/E=17-111.
DR   PDB; 4ODE; X-ray; 1.80 A; A=6-110.
DR   PDB; 4ODF; X-ray; 2.20 A; A=6-110.
DR   PDB; 4OGN; X-ray; 1.38 A; A=6-110.
DR   PDB; 4OGT; X-ray; 1.54 A; A=6-110.
DR   PDB; 4OGV; X-ray; 2.20 A; A/B/C=17-111.
DR   PDB; 4OQ3; X-ray; 2.30 A; A/B/C/D=17-111.
DR   PDB; 4QO4; X-ray; 1.70 A; A=17-111.
DR   PDB; 4QOC; X-ray; 1.70 A; A/C/E/G/I/K=17-111.
DR   PDB; 4UD7; X-ray; 1.60 A; A/B/C/D=17-125.
DR   PDB; 4UE1; X-ray; 1.45 A; A/B/C/D=17-125.
DR   PDB; 4UMN; X-ray; 1.99 A; A/B=6-125.
DR   PDB; 4WT2; X-ray; 1.42 A; A=6-110.
DR   PDB; 4XXB; X-ray; 2.40 A; B=290-437.
DR   PDB; 4ZFI; X-ray; 2.00 A; A/B/C/D=18-113.
DR   PDB; 4ZGK; X-ray; 2.00 A; A/B=18-114.
DR   PDB; 4ZYC; X-ray; 1.95 A; A/B/C=17-111.
DR   PDB; 4ZYF; X-ray; 1.80 A; A=17-111.
DR   PDB; 4ZYI; X-ray; 1.67 A; A=17-111.
DR   PDB; 5AFG; X-ray; 1.90 A; A=17-108.
DR   PDB; 5C5A; X-ray; 1.15 A; A/B=20-111.
DR   PDB; 5HMH; X-ray; 1.79 A; A/B=21-116.
DR   PDB; 5HMI; X-ray; 1.74 A; A/B=18-116.
DR   PDB; 5HMK; X-ray; 2.17 A; A/B=17-125.
DR   PDB; 5LAV; X-ray; 1.73 A; A=19-111.
DR   PDB; 5LAW; X-ray; 1.64 A; A=18-111.
DR   PDB; 5LAY; X-ray; 2.71 A; A/B/C/D/E/F=17-111.
DR   PDB; 5LAZ; X-ray; 1.66 A; A=18-111.
DR   PDB; 5LN2; X-ray; 1.58 A; A=17-111.
DR   PDB; 5TRF; X-ray; 2.10 A; A/B/C/D/E=10-118.
DR   PDBsum; 1RV1; -.
DR   PDBsum; 1T4E; -.
DR   PDBsum; 1T4F; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1Z1M; -.
DR   PDBsum; 2AXI; -.
DR   PDBsum; 2C6A; -.
DR   PDBsum; 2C6B; -.
DR   PDBsum; 2F1Y; -.
DR   PDBsum; 2FOP; -.
DR   PDBsum; 2GV2; -.
DR   PDBsum; 2HDP; -.
DR   PDBsum; 2LZG; -.
DR   PDBsum; 2M86; -.
DR   PDBsum; 2MPS; -.
DR   PDBsum; 2RUH; -.
DR   PDBsum; 2VJE; -.
DR   PDBsum; 2VJF; -.
DR   PDBsum; 3EQS; -.
DR   PDBsum; 3G03; -.
DR   PDBsum; 3IUX; -.
DR   PDBsum; 3IWY; -.
DR   PDBsum; 3JZK; -.
DR   PDBsum; 3JZR; -.
DR   PDBsum; 3JZS; -.
DR   PDBsum; 3LBK; -.
DR   PDBsum; 3LBL; -.
DR   PDBsum; 3LNJ; -.
DR   PDBsum; 3LNZ; -.
DR   PDBsum; 3MQS; -.
DR   PDBsum; 3TJ2; -.
DR   PDBsum; 3TPX; -.
DR   PDBsum; 3TU1; -.
DR   PDBsum; 3V3B; -.
DR   PDBsum; 3VBG; -.
DR   PDBsum; 3VZV; -.
DR   PDBsum; 3W69; -.
DR   PDBsum; 4DIJ; -.
DR   PDBsum; 4ERE; -.
DR   PDBsum; 4ERF; -.
DR   PDBsum; 4HBM; -.
DR   PDBsum; 4HFZ; -.
DR   PDBsum; 4HG7; -.
DR   PDBsum; 4JV7; -.
DR   PDBsum; 4JV9; -.
DR   PDBsum; 4JVE; -.
DR   PDBsum; 4JVR; -.
DR   PDBsum; 4JWR; -.
DR   PDBsum; 4MDN; -.
DR   PDBsum; 4MDQ; -.
DR   PDBsum; 4OAS; -.
DR   PDBsum; 4OBA; -.
DR   PDBsum; 4OCC; -.
DR   PDBsum; 4ODE; -.
DR   PDBsum; 4ODF; -.
DR   PDBsum; 4OGN; -.
DR   PDBsum; 4OGT; -.
DR   PDBsum; 4OGV; -.
DR   PDBsum; 4OQ3; -.
DR   PDBsum; 4QO4; -.
DR   PDBsum; 4QOC; -.
DR   PDBsum; 4UD7; -.
DR   PDBsum; 4UE1; -.
DR   PDBsum; 4UMN; -.
DR   PDBsum; 4WT2; -.
DR   PDBsum; 4XXB; -.
DR   PDBsum; 4ZFI; -.
DR   PDBsum; 4ZGK; -.
DR   PDBsum; 4ZYC; -.
DR   PDBsum; 4ZYF; -.
DR   PDBsum; 4ZYI; -.
DR   PDBsum; 5AFG; -.
DR   PDBsum; 5C5A; -.
DR   PDBsum; 5HMH; -.
DR   PDBsum; 5HMI; -.
DR   PDBsum; 5HMK; -.
DR   PDBsum; 5LAV; -.
DR   PDBsum; 5LAW; -.
DR   PDBsum; 5LAY; -.
DR   PDBsum; 5LAZ; -.
DR   PDBsum; 5LN2; -.
DR   PDBsum; 5TRF; -.
DR   DisProt; DP00334; -.
DR   ProteinModelPortal; Q00987; -.
DR   SMR; Q00987; -.
DR   BioGrid; 110358; 441.
DR   DIP; DIP-392N; -.
DR   IntAct; Q00987; 182.
DR   MINT; MINT-101583; -.
DR   STRING; 9606.ENSP00000417281; -.
DR   BindingDB; Q00987; -.
DR   ChEMBL; CHEMBL5023; -.
DR   iPTMnet; Q00987; -.
DR   PhosphoSitePlus; Q00987; -.
DR   DMDM; 266516; -.
DR   EPD; Q00987; -.
DR   MaxQB; Q00987; -.
DR   PaxDb; Q00987; -.
DR   PeptideAtlas; Q00987; -.
DR   PRIDE; Q00987; -.
DR   DNASU; 4193; -.
DR   Ensembl; ENST00000258149; ENSP00000258149; ENSG00000135679. [Q00987-11]
DR   Ensembl; ENST00000299252; ENSP00000299252; ENSG00000135679. [Q00987-5]
DR   Ensembl; ENST00000360430; ENSP00000353611; ENSG00000135679. [Q00987-2]
DR   Ensembl; ENST00000393413; ENSP00000377065; ENSG00000135679. [Q00987-4]
DR   GeneID; 4193; -.
DR   KEGG; hsa:4193; -.
DR   UCSC; uc001sui.6; human. [Q00987-1]
DR   CTD; 4193; -.
DR   DisGeNET; 4193; -.
DR   GeneCards; MDM2; -.
DR   HGNC; HGNC:6973; MDM2.
DR   HPA; CAB000086; -.
DR   HPA; CAB016303; -.
DR   MalaCards; MDM2; -.
DR   MIM; 164785; gene.
DR   MIM; 614401; phenotype.
DR   neXtProt; NX_Q00987; -.
DR   OpenTargets; ENSG00000135679; -.
DR   Orphanet; 99970; Dedifferentiated liposarcoma.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 99971; Well-differentiated liposarcoma.
DR   PharmGKB; PA30718; -.
DR   eggNOG; ENOG410IGXG; Eukaryota.
DR   eggNOG; ENOG41125MP; LUCA.
DR   GeneTree; ENSGT00530000063539; -.
DR   HOVERGEN; HBG013472; -.
DR   InParanoid; Q00987; -.
DR   KO; K06643; -.
DR   OMA; GELPCKL; -.
DR   OrthoDB; EOG091G0FYK; -.
DR   PhylomeDB; Q00987; -.
DR   TreeFam; TF105306; -.
DR   BioCyc; ZFISH:ENSG00000135679-MONOMER; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-399719; Trafficking of AMPA receptors.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   SignaLink; Q00987; -.
DR   SIGNOR; Q00987; -.
DR   ChiTaRS; MDM2; human.
DR   EvolutionaryTrace; Q00987; -.
DR   GeneWiki; Mdm2; -.
DR   GenomeRNAi; 4193; -.
DR   PMAP-CutDB; Q00987; -.
DR   PRO; PR:Q00987; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000135679; -.
DR   ExpressionAtlas; Q00987; baseline and differential.
DR   Genevisible; Q00987; HS.
DR   GO; GO:0005737; C:cytoplasm; IMP:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IMP:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:BHF-UCL.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016874; F:ligase activity; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0019789; F:SUMO transferase activity; EXP:Reactome.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IMP:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0003283; P:atrial septum development; IEA:Ensembl.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0071312; P:cellular response to alkaloid; IEA:Ensembl.
DR   GO; GO:0071236; P:cellular response to antibiotic; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl.
DR   GO; GO:0071301; P:cellular response to vitamin B1; IEA:Ensembl.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IMP:UniProtKB.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; IEA:Ensembl.
DR   GO; GO:0045184; P:establishment of protein localization; IDA:BHF-UCL.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0010955; P:negative regulation of protein processing; IEA:Ensembl.
DR   GO; GO:1901797; P:negative regulation of signal transduction by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0018205; P:peptidyl-lysine modification; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0051865; P:protein autoubiquitination; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006461; P:protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IDA:BHF-UCL.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:BHF-UCL.
DR   GO; GO:0016925; P:protein sumoylation; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0002027; P:regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0042176; P:regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0009743; P:response to carbohydrate; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045472; P:response to ether; IEA:Ensembl.
DR   GO; GO:0010039; P:response to iron ion; IEA:Ensembl.
DR   GO; GO:0032026; P:response to magnesium ion; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:1990785; P:response to water-immersion restraint stress; IEA:Ensembl.
DR   GO; GO:0036369; P:transcription factor catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007089; P:traversing start control point of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0003281; P:ventricular septum development; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.245.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR028340; Mdm2.
DR   InterPro; IPR015459; MDM2_E3_ligase.
DR   InterPro; IPR016495; p53_neg-reg_MDM_2/4.
DR   InterPro; IPR003121; SWIB_MDM2_domain.
DR   InterPro; IPR001876; Znf_RanBP2.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR13844:SF15; PTHR13844:SF15; 1.
DR   Pfam; PF02201; SWIB; 1.
DR   Pfam; PF00641; zf-RanBP; 1.
DR   PIRSF; PIRSF500700; MDM2; 1.
DR   PIRSF; PIRSF006748; p53_MDM_2/4; 1.
DR   SUPFAM; SSF47592; SSF47592; 2.
DR   SUPFAM; SSF90209; SSF90209; 1.
DR   PROSITE; PS01358; ZF_RANBP2_1; 1.
DR   PROSITE; PS50199; ZF_RANBP2_2; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Host-virus interaction; Metal-binding; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    491       E3 ubiquitin-protein ligase Mdm2.
FT                                /FTId=PRO_0000157332.
FT   DOMAIN       27    107       SWIB.
FT   ZN_FING     299    328       RanBP2-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00322}.
FT   ZN_FING     438    479       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        1    110       Necessary for interaction with USP2.
FT   REGION      150    230       Interaction with PYHIN1 and necessary for
FT                                interaction with RFFL and RNF34.
FT                                {ECO:0000269|PubMed:16479015,
FT                                ECO:0000269|PubMed:18382127}.
FT   REGION      170    306       Interaction with MTBP. {ECO:0000250}.
FT   REGION      210    304       ARF-binding.
FT   REGION      223    232       Interaction with USP7.
FT   REGION      242    331       Region II.
FT   REGION      276    491       Necessary for interaction with USP2.
FT   MOTIF       179    185       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOTIF       190    202       Nuclear export signal.
FT   MOTIF       466    473       Nucleolar localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    210    215       Poly-Ser.
FT   COMPBIAS    243    301       Asp/Glu-rich (acidic).
FT   MOD_RES     166    166       Phosphoserine; by SGK1.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:19756449}.
FT   MOD_RES     190    190       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23804}.
FT   MOD_RES     240    240       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     242    242       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     246    246       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     260    260       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     262    262       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     386    386       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     395    395       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     407    407       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     419    419       Phosphothreonine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     425    425       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     429    429       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   VAR_SEQ       1     61       Missing (in isoform Mdm2-alpha).
FT                                {ECO:0000303|PubMed:10597303}.
FT                                /FTId=VSP_003207.
FT   VAR_SEQ       1      1       M -> MVRSRQM (in isoform 11).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037997.
FT   VAR_SEQ      28    300       Missing (in isoform Mdm2-B).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003209.
FT   VAR_SEQ      28    222       Missing (in isoform Mdm2-A and isoform
FT                                Mdm2-A1). {ECO:0000303|PubMed:15315825,
FT                                ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003208.
FT   VAR_SEQ      30    388       Missing (in isoform Mdm2-D).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003210.
FT   VAR_SEQ      53    222       Missing (in isoform Mdm2-C).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003211.
FT   VAR_SEQ      53     97       Missing (in isoform Mdm2-F).
FT                                {ECO:0000303|PubMed:11351297}.
FT                                /FTId=VSP_022578.
FT   VAR_SEQ      76    102       YCSNDLLGDLFGVPSFSVKEHRKIYTM -> NDCANLFPLV
FT                                DLSIRELYISNYITLGI (in isoform Mdm2-E).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003212.
FT   VAR_SEQ     103    491       Missing (in isoform Mdm2-E).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003213.
FT   VAR_SEQ     115    169       Missing (in isoform Mdm2-G).
FT                                {ECO:0000303|PubMed:11351297}.
FT                                /FTId=VSP_022579.
FT   VAR_SEQ     275    300       Missing (in isoform Mdm2-A1).
FT                                {ECO:0000303|PubMed:15315825}.
FT                                /FTId=VSP_003214.
FT   MUTAGEN     305    305       C->S: No loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     374    374       C->T: No loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     438    438       C->L: No loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     441    441       C->G: Fails to interact with MDM4.
FT                                {ECO:0000269|PubMed:10608892}.
FT   MUTAGEN     449    449       C->A: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10723139}.
FT   MUTAGEN     449    449       C->S: No substantial decrease of
FT                                ubiquitin ligase E3 activity.
FT                                {ECO:0000269|PubMed:10723139}.
FT   MUTAGEN     452    452       H->A: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     455    455       T->A: Significant decrease of ubiquitin
FT                                ligase E3 activity.
FT                                {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     457    457       H->S: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     461    461       C->S: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     464    464       C->A: Loss of ubiquitin ligase E3
FT                                activity, enhances protein stability.
FT                                Does not inhibit interaction with APEX1,
FT                                but inhibits its ubiquitin ligase E3
FT                                activity on APEX1.
FT                                {ECO:0000269|PubMed:15632057,
FT                                ECO:0000269|PubMed:16479015,
FT                                ECO:0000269|PubMed:19219073,
FT                                ECO:0000269|PubMed:20173098,
FT                                ECO:0000269|PubMed:9450543}.
FT   MUTAGEN     475    475       C->G: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     478    478       C->R: Fails to interact with MDM4.
FT                                {ECO:0000269|PubMed:10608892}.
FT   MUTAGEN     478    478       C->S: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10608892}.
FT   CONFLICT     17     17       S -> P (in Ref. 10; AAA82237).
FT                                {ECO:0000305}.
FT   STRAND        7     10       {ECO:0000244|PDB:4WT2}.
FT   STRAND       13     15       {ECO:0000244|PDB:4WT2}.
FT   STRAND       17     19       {ECO:0000244|PDB:2LZG}.
FT   HELIX        23     25       {ECO:0000244|PDB:4OGN}.
FT   STRAND       27     30       {ECO:0000244|PDB:5C5A}.
FT   HELIX        32     41       {ECO:0000244|PDB:5C5A}.
FT   STRAND       46     49       {ECO:0000244|PDB:4OBA}.
FT   HELIX        50     64       {ECO:0000244|PDB:5C5A}.
FT   STRAND       71     76       {ECO:0000244|PDB:5C5A}.
FT   STRAND       78     80       {ECO:0000244|PDB:3LBK}.
FT   HELIX        81     86       {ECO:0000244|PDB:5C5A}.
FT   STRAND       88     92       {ECO:0000244|PDB:5C5A}.
FT   HELIX        96    104       {ECO:0000244|PDB:5C5A}.
FT   STRAND      107    109       {ECO:0000244|PDB:5C5A}.
FT   STRAND      295    297       {ECO:0000244|PDB:2C6A}.
FT   HELIX       299    301       {ECO:0000244|PDB:4XXB}.
FT   TURN        306    308       {ECO:0000244|PDB:4XXB}.
FT   STRAND      314    318       {ECO:0000244|PDB:4XXB}.
FT   TURN        320    322       {ECO:0000244|PDB:4XXB}.
FT   HELIX       433    435       {ECO:0000244|PDB:2VJE}.
FT   TURN        439    441       {ECO:0000244|PDB:2VJE}.
FT   STRAND      442    444       {ECO:0000244|PDB:2VJE}.
FT   STRAND      448    452       {ECO:0000244|PDB:2VJE}.
FT   STRAND      455    460       {ECO:0000244|PDB:2VJE}.
FT   HELIX       462    470       {ECO:0000244|PDB:2VJE}.
FT   TURN        476    478       {ECO:0000244|PDB:2VJE}.
FT   STRAND      484    489       {ECO:0000244|PDB:2VJE}.
SQ   SEQUENCE   491 AA;  55233 MW;  F37CE163876BC983 CRC64;
     MCNTNMSVPT DGAVTTSQIP ASEQETLVRP KPLLLKLLKS VGAQKDTYTM KEVLFYLGQY
     IMTKRLYDEK QQHIVYCSND LLGDLFGVPS FSVKEHRKIY TMIYRNLVVV NQQESSDSGT
     SVSENRCHLE GGSDQKDLVQ ELQEEKPSSS HLVSRPSTSS RRRAISETEE NSDELSGERQ
     RKRHKSDSIS LSFDESLALC VIREICCERS SSSESTGTPS NPDLDAGVSE HSGDWLDQDS
     VSDQFSVEFE VESLDSEDYS LSEEGQELSD EDDEVYQVTV YQAGESDTDS FEEDPEISLA
     DYWKCTSCNE MNPPLPSHCN RCWALRENWL PEDKGKDKGE ISEKAKLENS TQAEEGFDVP
     DCKKTIVNDS RESCVEENDD KITQASQSQE SEDYSQPSTS SSIIYSSQED VKEFEREETQ
     DKEESVESSL PLNAIEPCVI CQGRPKNGCI VHGKTGHLMA CFTCAKKLKK RNKPCPVCRQ
     PIQMIVLTYF P
//
ID   MED1_HUMAN              Reviewed;        1581 AA.
AC   Q15648; A2RRQ6; O43810; O75447; Q6P9H7; Q6PK58; Q9HD39;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-SEP-2007, sequence version 4.
DT   18-JAN-2017, entry version 170.
DE   RecName: Full=Mediator of RNA polymerase II transcription subunit 1;
DE   AltName: Full=Activator-recruited cofactor 205 kDa component;
DE            Short=ARC205;
DE   AltName: Full=Mediator complex subunit 1;
DE   AltName: Full=Peroxisome proliferator-activated receptor-binding protein;
DE            Short=PBP;
DE            Short=PPAR-binding protein;
DE   AltName: Full=Thyroid hormone receptor-associated protein complex 220 kDa component;
DE            Short=Trap220;
DE   AltName: Full=Thyroid receptor-interacting protein 2;
DE            Short=TR-interacting protein 2;
DE            Short=TRIP-2;
DE   AltName: Full=Vitamin D receptor-interacting protein complex component DRIP205;
DE   AltName: Full=p53 regulatory protein RB18A;
GN   Name=MED1;
GN   Synonyms=ARC205, CRSP1, CRSP200, DRIP205, DRIP230, PBP, PPARBP,
GN   PPARGBP, RB18A, TRAP220, TRIP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), DNA-BINDING, INTERACTION WITH
RP   TP53, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=9444950; DOI=10.1038/sj.onc.1201492;
RA   Drane P., Barel M., Balbo M., Frade R.;
RT   "Identification of RB18A, a 205 kDa new p53 regulatory protein which
RT   shares antigenic and functional properties with p53.";
RL   Oncogene 15:3013-3024(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 157-168;
RP   943-952 AND 1432-1442, FUNCTION, INTERACTION WITH ESR1; PPARA; PPARG;
RP   RARA; RXRA; THRA AND VDR, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=9653119; DOI=10.1073/pnas.95.14.7939;
RA   Yuan C.-X., Ito M., Fondell J.D., Fu Z.-Y., Roeder R.G.;
RT   "The TRAP220 component of a thyroid hormone receptor-associated
RT   protein (TRAP) coactivator complex interacts directly with nuclear
RT   receptors in a ligand-dependent fashion.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:7939-7944(1998).
RN   [3]
RP   ERRATUM.
RA   Yuan C.-X., Ito M., Fondell J.D., Fu Z.-Y., Roeder R.G.;
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14584-14584(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (DEC-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Colon, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-13 AND 1452-1464, AND IDENTIFICATION IN THE ARC
RP   COMPLEX.
RX   PubMed=10235267; DOI=10.1038/19789;
RA   Naeaer A.M., Beaurang P.A., Zhou S., Abraham S., Solomon W.B.,
RA   Tjian R.;
RT   "Composite co-activator ARC mediates chromatin-directed
RT   transcriptional activation.";
RL   Nature 398:828-832(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 16-1581 (ISOFORM 1), INTERACTION WITH
RP   VDR, AND MUTAGENESIS OF 607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=10733574; DOI=10.1128/MCB.20.8.2718-2726.2000;
RA   Rachez C., Gamble M., Chang C.-P.B., Atkins G.B., Lazar M.A.,
RA   Freedman L.P.;
RT   "The DRIP complex and SRC-1/p160 coactivators share similar nuclear
RT   receptor binding determinants but constitute functionally distinct
RT   complexes.";
RL   Mol. Cell. Biol. 20:2718-2726(2000).
RN   [8]
RP   PROTEIN SEQUENCE OF 307-315 AND 584-597, IDENTIFICATION IN THE DRIP
RP   COMPLEX, AND INTERACTION WITH VDR.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10235266; DOI=10.1038/19783;
RA   Rachez C., Lemon B.D., Suldan Z., Bromleigh V., Gamble M.,
RA   Naeaer A.M., Erdjument-Bromage H., Tempst P., Freedman L.P.;
RT   "Ligand-dependent transcription activation by nuclear receptors
RT   requires the DRIP complex.";
RL   Nature 398:824-828(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 622-711.
RX   PubMed=7776974; DOI=10.1210/mend.9.2.7776974;
RA   Lee J.W., Choi H.-S., Gyuris J., Brent R., Moore D.D.;
RT   "Two classes of proteins dependent on either the presence or absence
RT   of thyroid hormone for interaction with the thyroid hormone
RT   receptor.";
RL   Mol. Endocrinol. 9:243-254(1995).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE SMCC
RP   COMPLEX.
RX   PubMed=10024883; DOI=10.1016/S1097-2765(00)80178-1;
RA   Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X.,
RA   Martinez E., Qin J., Roeder R.G.;
RT   "A novel human SRB/MED-containing cofactor complex, SMCC, involved in
RT   transcription regulation.";
RL   Mol. Cell 3:97-108(1999).
RN   [11]
RP   ERRATUM.
RA   Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X.,
RA   Martinez E., Qin J., Roeder R.G.;
RL   Mol. Cell 3:541-541(1999).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH MED24; THRA; THRB AND VDR.
RX   PubMed=10406464; DOI=10.1210/mend.13.7.0295;
RA   Zhang J., Fondell J.D.;
RT   "Identification of mouse TRAP100: a transcriptional coregulatory
RT   factor for thyroid hormone and vitamin D receptors.";
RL   Mol. Endocrinol. 13:1130-1140(1999).
RN   [13]
RP   INTERACTION WITH RORA.
RX   PubMed=10478845; DOI=10.1210/mend.13.9.0343;
RA   Atkins G.B., Hu X., Guenther M.G., Rachez C., Freedman L.P.,
RA   Lazar M.A.;
RT   "Coactivators for the orphan nuclear receptor RORalpha.";
RL   Mol. Endocrinol. 13:1550-1557(1999).
RN   [14]
RP   INTERACTION WITH ESR1; ESR2 AND VDR, AND MUTAGENESIS OF
RP   607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=10770935; DOI=10.1074/jbc.M002013200;
RA   Burakov D., Wong C.-W., Rachez C., Cheskis B.J., Freedman L.P.;
RT   "Functional interactions between the estrogen receptor and DRIP205, a
RT   subunit of the heteromeric DRIP coactivator complex.";
RL   J. Biol. Chem. 275:20928-20934(2000).
RN   [15]
RP   INTERACTION WITH ESR1 AND ESR2, AND MUTAGENESIS OF 599-SER--GLY-612;
RP   LEU-604; LEU-607; LEU-645 AND LEU-648.
RX   PubMed=11303023; DOI=10.1074/jbc.M011651200;
RA   Waernmark A., Almloef T., Leers J., Gustafsson J.-A., Treuter E.;
RT   "Differential recruitment of the mammalian mediator subunit TRAP220 by
RT   estrogen receptors ERalpha and ERbeta.";
RL   J. Biol. Chem. 276:23397-23404(2001).
RN   [16]
RP   FUNCTION, INTERACTION WITH AR, AND ASSOCIATION WITH PROMOTER REGIONS.
RX   PubMed=12218053; DOI=10.1074/jbc.M206061200;
RA   Wang Q., Sharma D., Ren Y., Fondell J.D.;
RT   "A coregulatory role for the TRAP-mediator complex in androgen
RT   receptor-mediated gene expression.";
RL   J. Biol. Chem. 277:42852-42858(2002).
RN   [17]
RP   FUNCTION, AND INTERACTION OF THE MEDIATOR COMPLEX WITH PPARG.
RX   PubMed=12037571; DOI=10.1038/417563a;
RA   Ge K., Guermah M., Yuan C.-X., Ito M., Wallberg A.E., Spiegelman B.M.,
RA   Roeder R.G.;
RT   "Transcription coactivator TRAP220 is required for PPAR gamma 2-
RT   stimulated adipogenesis.";
RL   Nature 417:563-567(2002).
RN   [18]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE
RP   MEDIATOR COMPLEX, AND INTERACTION OF THE MEDIATOR COMPLEX WITH ESR1
RP   AND ESR2.
RX   PubMed=11867769; DOI=10.1073/pnas.261715899;
RA   Kang Y.K., Guermah M., Yuan C.-X., Roeder R.G.;
RT   "The TRAP/Mediator coactivator complex interacts directly with
RT   estrogen receptors alpha and beta through the TRAP220 subunit and
RT   directly enhances estrogen receptor function in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:2642-2647(2002).
RN   [19]
RP   ASSOCIATION WITH PROMOTER REGIONS.
RX   PubMed=12034878; DOI=10.1073/pnas.122004799;
RA   Sharma D., Fondell J.D.;
RT   "Ordered recruitment of histone acetyltransferases and the
RT   TRAP/Mediator complex to thyroid hormone-responsive promoters in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7934-7939(2002).
RN   [20]
RP   FUNCTION, INTERACTION WITH ESR1; PPARG; RARA; RXRA AND THRB, AND
RP   MUTAGENESIS OF 600-GLN--SER-612; 607-LEU-LEU-608; 639-THR--PRO-653 AND
RP   648-LEU-LEU-649.
RX   PubMed=12556447; DOI=10.1074/jbc.M212950200;
RA   Coulthard V.H., Matsuda S., Heery D.M.;
RT   "An extended LXXLL motif sequence determines the nuclear receptor
RT   binding specificity of TRAP220.";
RL   J. Biol. Chem. 278:10942-10951(2003).
RN   [21]
RP   FUNCTION, INTERACTION WITH PPARGC1A, AND MUTAGENESIS OF
RP   607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=14636573; DOI=10.1016/S1097-2765(03)00391-5;
RA   Wallberg A.E., Yamamura S., Malik S., Spiegelman B.M., Roeder R.G.;
RT   "Coordination of p300-mediated chromatin remodeling and TRAP/mediator
RT   function through coactivator PGC-1alpha.";
RL   Mol. Cell 12:1137-1149(2003).
RN   [22]
RP   FUNCTION, INTERACTION WITH ESR1, AND SUBCELLULAR LOCATION.
RX   PubMed=15471764; DOI=10.1074/jbc.M409778200;
RA   Wu Q., Burghardt R., Safe S.;
RT   "Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen
RT   receptor alpha (ERalpha) involves multiple domains of both proteins.";
RL   J. Biol. Chem. 279:53602-53612(2004).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE
RP   MEDIATOR COMPLEX.
RX   PubMed=15175163; DOI=10.1016/j.molcel.2004.05.006;
RA   Sato S., Tomomori-Sato C., Parmely T.J., Florens L., Zybailov B.,
RA   Swanson S.K., Banks C.A.S., Jin J., Cai Y., Washburn M.P.,
RA   Conaway J.W., Conaway R.C.;
RT   "A set of consensus mammalian mediator subunits identified by
RT   multidimensional protein identification technology.";
RL   Mol. Cell 14:685-691(2004).
RN   [24]
RP   FUNCTION, INTERACTION OF THE MEDIATOR COMPLEX WITH THRA, AND
RP   MUTAGENESIS OF 607-LEU-LEU-608 AND 648-LEU-LEU-649.
RX   PubMed=15340084; DOI=10.1128/MCB.24.18.8244-8254.2004;
RA   Malik S., Guermah M., Yuan C.-X., Wu W., Yamamura S., Roeder R.G.;
RT   "Structural and functional organization of TRAP220, the TRAP/mediator
RT   subunit that is targeted by nuclear receptors.";
RL   Mol. Cell. Biol. 24:8244-8254(2004).
RN   [25]
RP   FUNCTION, ASSOCIATION WITH PROMOTER REGIONS, INTERACTION WITH CCNC;
RP   MED6; MED10; MED11; MED12; MED13; MED14; MED15; MED16; MED17; MED18;
RP   MED19; MED20; MED21; MED23; MED24; MED25; MED26; MED28; MED29 AND
RP   MED30, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE
RP   MEDIATOR COMPLEX, AND ASSOCIATION OF THE MEDIATOR COMPLEX WITH RNA
RP   POLYMERASE II.
RX   PubMed=15989967; DOI=10.1016/j.molcel.2005.05.015;
RA   Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T.,
RA   Roeder R.G.;
RT   "MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation
RT   enriched in RNA polymerase II and is required for ER-mediated
RT   transcription.";
RL   Mol. Cell 19:89-100(2005).
RN   [26]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-1032 AND THR-1457, AND
RP   MUTAGENESIS OF THR-1032 AND THR-1457.
RX   PubMed=16314496; DOI=10.1128/MCB.25.24.10695-10710.2005;
RA   Pandey P.K., Udayakumar T.S., Lin X., Sharma D., Shapiro P.S.,
RA   Fondell J.D.;
RT   "Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by
RT   mitogen-activated protein kinase-dependent phosphorylation.";
RL   Mol. Cell. Biol. 25:10695-10710(2005).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [28]
RP   FUNCTION, INTERACTION WITH GABPA, ASSOCIATION WITH PROMOTER REGIONS,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16574658; DOI=10.1074/jbc.M600163200;
RA   Udayakumar T.S., Belakavadi M., Choi K.-H., Pandey P.K., Fondell J.D.;
RT   "Regulation of Aurora-A kinase gene expression via GABP recruitment of
RT   TRAP220/MED1.";
RL   J. Biol. Chem. 281:14691-14699(2006).
RN   [29]
RP   INTERACTION WITH CDK8.
RX   PubMed=17000779; DOI=10.1128/MCB.00443-06;
RA   Zhou H., Kim S., Ishii S., Boyer T.G.;
RT   "Mediator modulates Gli3-dependent Sonic hedgehog signaling.";
RL   Mol. Cell. Biol. 26:8667-8682(2006).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-795; THR-805 AND
RP   THR-1057, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-805; THR-1057; SER-1207
RP   AND THR-1215, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664; THR-1051; THR-1057;
RP   SER-1207; THR-1215; SER-1463; SER-1479; SER-1481 AND SER-1482, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-805 AND THR-1215, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [36]
RP   INTERACTION WITH RXRA.
RX   PubMed=19786558; DOI=10.1124/mol.109.057000;
RA   Cho Y., Noshiro M., Choi M., Morita K., Kawamoto T., Fujimoto K.,
RA   Kato Y., Makishima M.;
RT   "The basic helix-loop-helix proteins differentiated embryo chondrocyte
RT   (DEC) 1 and DEC2 function as corepressors of retinoid X receptors.";
RL   Mol. Pharmacol. 76:1360-1369(2009).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664; THR-1051; THR-1057;
RP   SER-1463; SER-1479; SER-1481 AND SER-1482, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1177 AND LYS-1529, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664; THR-805; THR-1057;
RP   SER-1207; THR-1215; SER-1347; SER-1403 AND SER-1433, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1051; SER-1156;
RP   SER-1207; THR-1215; SER-1223 AND SER-1479, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588; SER-664; THR-805;
RP   THR-1051; THR-1057; SER-1156; SER-1207; THR-1215; SER-1223; SER-1302;
RP   SER-1433; THR-1440; SER-1463; SER-1479; SER-1481 AND SER-1482, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   FUNCTION, AND INTERACTION WITH GATA1 AND CCAR1.
RX   PubMed=24245781; DOI=10.1111/gtc.12104;
RA   Mizuta S., Minami T., Fujita H., Kaminaga C., Matsui K., Ishino R.,
RA   Fujita A., Oda K., Kawai A., Hasegawa N., Urahama N., Roeder R.G.,
RA   Ito M.;
RT   "CCAR1/CoCoA pair-mediated recruitment of the Mediator defines a novel
RT   pathway for GATA1 function.";
RL   Genes Cells 19:28-51(2014).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Component of the Mediator complex, a coactivator
CC       involved in the regulated transcription of nearly all RNA
CC       polymerase II-dependent genes. Mediator functions as a bridge to
CC       convey information from gene-specific regulatory proteins to the
CC       basal RNA polymerase II transcription machinery. Mediator is
CC       recruited to promoters by direct interactions with regulatory
CC       proteins and serves as a scaffold for the assembly of a functional
CC       preinitiation complex with RNA polymerase II and the general
CC       transcription factors (PubMed:10406464, PubMed:11867769,
CC       PubMed:12037571, PubMed:12218053, PubMed:12556447,
CC       PubMed:14636573, PubMed:15340084, PubMed:15471764,
CC       PubMed:15989967, PubMed:16574658, PubMed:9653119). Acts as a
CC       coactivator for GATA1-mediated transcriptional activation during
CC       erythroid differentiation of K562 erythroleukemia cells
CC       (PubMed:24245781). {ECO:0000269|PubMed:10406464,
CC       ECO:0000269|PubMed:11867769, ECO:0000269|PubMed:12037571,
CC       ECO:0000269|PubMed:12218053, ECO:0000269|PubMed:12556447,
CC       ECO:0000269|PubMed:14636573, ECO:0000269|PubMed:15340084,
CC       ECO:0000269|PubMed:15471764, ECO:0000269|PubMed:15989967,
CC       ECO:0000269|PubMed:16574658, ECO:0000269|PubMed:24245781,
CC       ECO:0000269|PubMed:9653119}.
CC   -!- SUBUNIT: Component of the Mediator complex, which is composed of
CC       MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13,
CC       MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21,
CC       MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31,
CC       CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8
CC       subunits form a distinct module termed the CDK8 module. Mediator
CC       containing the CDK8 module is less active than Mediator lacking
CC       this module in supporting transcriptional activation. Individual
CC       preparations of the Mediator complex lacking one or more distinct
CC       subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and
CC       TRAP. This subunit specifically interacts with a number of nuclear
CC       receptors in a ligand-dependent fashion including AR, ESR1, ESR2,
CC       PPARA, PPARG, RORA, RXRA, RXRG, THRA, THRB and VDR. Interacts with
CC       CTNNB1, GABPA, GLI3, PPARGC1A and TP53. Interacts with YWHAH.
CC       Interacts with CLOCK; this interaction requires the presence of
CC       THRAP3 (By similarity). Interacts with GATA1 and CCAR1. Interacts
CC       with NR4A3 (By similarity). {ECO:0000250|UniProtKB:Q925J9,
CC       ECO:0000269|PubMed:10024883, ECO:0000269|PubMed:10235266,
CC       ECO:0000269|PubMed:10235267, ECO:0000269|PubMed:10406464,
CC       ECO:0000269|PubMed:10478845, ECO:0000269|PubMed:10733574,
CC       ECO:0000269|PubMed:10770935, ECO:0000269|PubMed:11303023,
CC       ECO:0000269|PubMed:11867769, ECO:0000269|PubMed:12037571,
CC       ECO:0000269|PubMed:12218053, ECO:0000269|PubMed:12556447,
CC       ECO:0000269|PubMed:14636573, ECO:0000269|PubMed:15175163,
CC       ECO:0000269|PubMed:15340084, ECO:0000269|PubMed:15471764,
CC       ECO:0000269|PubMed:15989967, ECO:0000269|PubMed:16574658,
CC       ECO:0000269|PubMed:17000779, ECO:0000269|PubMed:19786558,
CC       ECO:0000269|PubMed:24245781, ECO:0000269|PubMed:9444950,
CC       ECO:0000269|PubMed:9653119}.
CC   -!- INTERACTION:
CC       O43513:MED7; NbExp=4; IntAct=EBI-394459, EBI-394632;
CC       P10276:RARA; NbExp=3; IntAct=EBI-394459, EBI-413374;
CC       P10827:THRA; NbExp=5; IntAct=EBI-394459, EBI-286285;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15471764,
CC       ECO:0000269|PubMed:16314496, ECO:0000269|PubMed:16574658}. Note=A
CC       subset of the protein may enter the nucleolus subsequent to
CC       phosphorylation by MAPK1 or MAPK3.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15648-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15648-3; Sequence=VSP_027906, VSP_027907;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:9444950, ECO:0000269|PubMed:9653119}.
CC   -!- PTM: Phosphorylated by MAPK1 or MAPK3 during G2/M phase which may
CC       enhance protein stability and promote entry into the nucleolus.
CC       {ECO:0000269|PubMed:16314496}.
CC   -!- SIMILARITY: Belongs to the Mediator complex subunit 1 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC39854.1; Type=Frameshift; Positions=543, 545; Evidence={ECO:0000305};
CC       Sequence=AAH06517.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=CAA73867.1; Type=Frameshift; Positions=4; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13467; CAA73867.1; ALT_FRAME; mRNA.
DR   EMBL; AF055994; AAC39854.1; ALT_FRAME; mRNA.
DR   EMBL; CH471152; EAW60575.1; -; Genomic_DNA.
DR   EMBL; BC006517; AAH06517.1; ALT_TERM; mRNA.
DR   EMBL; BC060758; AAH60758.1; -; mRNA.
DR   EMBL; BC131783; AAI31784.1; -; mRNA.
DR   EMBL; AF283812; AAF98352.1; -; mRNA.
DR   EMBL; L40366; AAC41736.1; -; mRNA.
DR   CCDS; CCDS11336.1; -. [Q15648-1]
DR   RefSeq; NP_004765.2; NM_004774.3. [Q15648-1]
DR   UniGene; Hs.643754; -.
DR   PDB; 1RJK; X-ray; 1.99 A; C=640-652.
DR   PDB; 1RK3; X-ray; 2.20 A; C=640-652.
DR   PDB; 1RKG; X-ray; 1.90 A; C=640-652.
DR   PDB; 1RKH; X-ray; 2.28 A; C=640-652.
DR   PDB; 2O4J; X-ray; 1.74 A; C=640-652.
DR   PDB; 2O4R; X-ray; 1.98 A; C=640-652.
DR   PDB; 2ZFX; X-ray; 1.99 A; C=640-652.
DR   PDB; 3A2H; X-ray; 2.50 A; B=640-652.
DR   PDB; 3AUN; X-ray; 1.81 A; B=640-652.
DR   PDB; 3VJS; X-ray; 1.93 A; C=640-652.
DR   PDB; 3VJT; X-ray; 2.00 A; C=640-652.
DR   PDB; 3VRT; X-ray; 2.40 A; C=640-652.
DR   PDB; 3VRU; X-ray; 2.00 A; C=640-652.
DR   PDB; 3VRV; X-ray; 1.90 A; C=640-652.
DR   PDB; 3VRW; X-ray; 2.40 A; C=640-652.
DR   PDB; 3W0G; X-ray; 1.94 A; C=640-652.
DR   PDB; 3W0H; X-ray; 1.80 A; C=640-652.
DR   PDB; 3W0I; X-ray; 1.90 A; C=640-652.
DR   PDB; 3W0J; X-ray; 1.84 A; C=640-652.
DR   PDB; 3W5P; X-ray; 1.90 A; C=640-652.
DR   PDB; 3W5Q; X-ray; 1.90 A; C=640-652.
DR   PDB; 3W5R; X-ray; 2.20 A; C=640-652.
DR   PDB; 3W5T; X-ray; 2.29 A; C=640-652.
DR   PDB; 3WT5; X-ray; 1.90 A; C=640-652.
DR   PDB; 3WT6; X-ray; 2.00 A; C=640-652.
DR   PDB; 3WT7; X-ray; 2.40 A; C=640-652.
DR   PDB; 3WTQ; X-ray; 2.10 A; C=640-652.
DR   PDB; 4YNK; X-ray; 2.30 A; C=640-652.
DR   PDB; 5AWJ; X-ray; 2.20 A; C=640-652.
DR   PDB; 5AWK; X-ray; 2.90 A; C=640-652.
DR   PDB; 5B5B; X-ray; 2.00 A; C/F=640-652.
DR   PDBsum; 1RJK; -.
DR   PDBsum; 1RK3; -.
DR   PDBsum; 1RKG; -.
DR   PDBsum; 1RKH; -.
DR   PDBsum; 2O4J; -.
DR   PDBsum; 2O4R; -.
DR   PDBsum; 2ZFX; -.
DR   PDBsum; 3A2H; -.
DR   PDBsum; 3AUN; -.
DR   PDBsum; 3VJS; -.
DR   PDBsum; 3VJT; -.
DR   PDBsum; 3VRT; -.
DR   PDBsum; 3VRU; -.
DR   PDBsum; 3VRV; -.
DR   PDBsum; 3VRW; -.
DR   PDBsum; 3W0G; -.
DR   PDBsum; 3W0H; -.
DR   PDBsum; 3W0I; -.
DR   PDBsum; 3W0J; -.
DR   PDBsum; 3W5P; -.
DR   PDBsum; 3W5Q; -.
DR   PDBsum; 3W5R; -.
DR   PDBsum; 3W5T; -.
DR   PDBsum; 3WT5; -.
DR   PDBsum; 3WT6; -.
DR   PDBsum; 3WT7; -.
DR   PDBsum; 3WTQ; -.
DR   PDBsum; 4YNK; -.
DR   PDBsum; 5AWJ; -.
DR   PDBsum; 5AWK; -.
DR   PDBsum; 5B5B; -.
DR   ProteinModelPortal; Q15648; -.
DR   SMR; Q15648; -.
DR   BioGrid; 111465; 101.
DR   DIP; DIP-24212N; -.
DR   IntAct; Q15648; 40.
DR   MINT; MINT-1345780; -.
DR   STRING; 9606.ENSP00000300651; -.
DR   iPTMnet; Q15648; -.
DR   PhosphoSitePlus; Q15648; -.
DR   BioMuta; MED1; -.
DR   DMDM; 158518535; -.
DR   EPD; Q15648; -.
DR   MaxQB; Q15648; -.
DR   PaxDb; Q15648; -.
DR   PeptideAtlas; Q15648; -.
DR   PRIDE; Q15648; -.
DR   DNASU; 5469; -.
DR   Ensembl; ENST00000300651; ENSP00000300651; ENSG00000125686. [Q15648-1]
DR   Ensembl; ENST00000394287; ENSP00000377828; ENSG00000125686. [Q15648-3]
DR   GeneID; 5469; -.
DR   KEGG; hsa:5469; -.
DR   UCSC; uc002hru.3; human. [Q15648-1]
DR   CTD; 5469; -.
DR   DisGeNET; 5469; -.
DR   GeneCards; MED1; -.
DR   HGNC; HGNC:9234; MED1.
DR   HPA; CAB017696; -.
DR   HPA; HPA052818; -.
DR   MIM; 604311; gene.
DR   neXtProt; NX_Q15648; -.
DR   OpenTargets; ENSG00000125686; -.
DR   PharmGKB; PA33556; -.
DR   eggNOG; ENOG410IEFR; Eukaryota.
DR   eggNOG; ENOG410XR2E; LUCA.
DR   GeneTree; ENSGT00660000095569; -.
DR   HOVERGEN; HBG101127; -.
DR   InParanoid; Q15648; -.
DR   KO; K15144; -.
DR   OMA; HGEDFSK; -.
DR   OrthoDB; EOG091G035E; -.
DR   PhylomeDB; Q15648; -.
DR   TreeFam; TF324954; -.
DR   BioCyc; ZFISH:ENSG00000125686-MONOMER; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-212436; Generic Transcription Pathway.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SignaLink; Q15648; -.
DR   SIGNOR; Q15648; -.
DR   ChiTaRS; MED1; human.
DR   EvolutionaryTrace; Q15648; -.
DR   GeneWiki; MED1; -.
DR   GenomeRNAi; 5469; -.
DR   PRO; PR:Q15648; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000125686; -.
DR   CleanEx; HS_MED1; -.
DR   ExpressionAtlas; Q15648; baseline and differential.
DR   Genevisible; Q15648; HS.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0016592; C:mediator complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IEA:Ensembl.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IMP:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:UniProtKB.
DR   GO; GO:0050693; F:LBD domain binding; IPI:UniProtKB.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IDA:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IMP:UniProtKB.
DR   GO; GO:0036033; F:mediator complex binding; IDA:UniProtKB.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IPI:UniProtKB.
DR   GO; GO:0042975; F:peroxisome proliferator activated receptor binding; IPI:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; IDA:UniProtKB.
DR   GO; GO:0042974; F:retinoic acid receptor binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001104; F:RNA polymerase II transcription cofactor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; IDA:UniProtKB.
DR   GO; GO:0030375; F:thyroid hormone receptor coactivator activity; IMP:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003712; F:transcription cofactor activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0042809; F:vitamin D receptor binding; IPI:UniProtKB.
DR   GO; GO:0006702; P:androgen biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0000902; P:cell morphogenesis; IMP:UniProtKB.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0035050; P:embryonic heart tube development; IEA:Ensembl.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0048822; P:enucleate erythrocyte development; IEA:Ensembl.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0048821; P:erythrocyte development; ISS:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; IDA:MGI.
DR   GO; GO:0030518; P:intracellular steroid hormone receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0002088; P:lens development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0060745; P:mammary gland branching involved in pregnancy; IEA:Ensembl.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IEA:Ensembl.
DR   GO; GO:0035855; P:megakaryocyte development; ISS:UniProtKB.
DR   GO; GO:0030224; P:monocyte differentiation; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IMP:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0035357; P:peroxisome proliferator activated receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0070318; P:positive regulation of G0 to G1 transition; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:2000347; P:positive regulation of hepatocyte proliferation; IEA:Ensembl.
DR   GO; GO:0060335; P:positive regulation of interferon-gamma-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0033601; P:positive regulation of mammary gland epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IEA:Ensembl.
DR   GO; GO:2000273; P:positive regulation of receptor activity; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; NAS:UniProtKB.
DR   GO; GO:2001141; P:regulation of RNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006356; P:regulation of transcription from RNA polymerase I promoter; IDA:UniProtKB.
DR   GO; GO:0070562; P:regulation of vitamin D receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0003406; P:retinal pigment epithelium development; IEA:Ensembl.
DR   GO; GO:0006590; P:thyroid hormone generation; IEA:Ensembl.
DR   GO; GO:0002154; P:thyroid hormone mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; IEA:Ensembl.
DR   InterPro; IPR019680; Mediator_Med1.
DR   Pfam; PF10744; Med1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; DNA-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transcription; Transcription regulation.
FT   CHAIN         1   1581       Mediator of RNA polymerase II
FT                                transcription subunit 1.
FT                                /FTId=PRO_0000058552.
FT   REGION        1    670       Interaction with the Mediator complex and
FT                                THRA.
FT   REGION       16    590       Interaction with ESR1.
FT   REGION      108    212       Interaction with the Mediator complex.
FT   REGION      215    390       Interaction with the Mediator complex.
FT   REGION      405    644       Interaction with THRA.
FT   REGION      542    789       Interaction with VDR.
FT   REGION      622    701       Interaction with PPARGC1A and THRA.
FT                                {ECO:0000269|PubMed:14636573}.
FT   REGION      656   1066       Interaction with ESR1.
FT   REGION      681    715       Interaction with GATA1.
FT                                {ECO:0000269|PubMed:24245781}.
FT   REGION     1249   1421       Interaction with TP53.
FT                                {ECO:0000269|PubMed:9444950}.
FT   MOTIF       604    608       LXXLL motif 1.
FT   MOTIF       645    649       LXXLL motif 2.
FT   COMPBIAS   1078   1482       Ser-rich.
FT   COMPBIAS   1496   1529       Lys-rich.
FT   MOD_RES     588    588       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     664    664       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     795    795       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243}.
FT   MOD_RES     805    805       Phosphothreonine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     953    953       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q925J9}.
FT   MOD_RES    1032   1032       Phosphothreonine; by MAPK1 or MAPK3.
FT                                {ECO:0000269|PubMed:16314496}.
FT   MOD_RES    1051   1051       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1057   1057       Phosphothreonine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1156   1156       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1177   1177       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1207   1207       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1215   1215       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1223   1223       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1302   1302       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1347   1347       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1403   1403       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1433   1433       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1440   1440       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1457   1457       Phosphothreonine; by MAPK1 or MAPK3.
FT                                {ECO:0000269|PubMed:16314496}.
FT   MOD_RES    1463   1463       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1465   1465       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q925J9}.
FT   MOD_RES    1479   1479       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1481   1481       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1482   1482       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1529   1529       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ     548    556       YGMTTGNNP -> SKNPELGSG (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_027906.
FT   VAR_SEQ     557   1581       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_027907.
FT   VARIANT     753    753       P -> T (in dbSNP:rs1139825).
FT                                /FTId=VAR_053955.
FT   VARIANT    1240   1240       S -> G (in dbSNP:rs35668211).
FT                                /FTId=VAR_034938.
FT   MUTAGEN     599    612       SQNPILTSLLQITG->EKHKILHRLLQDSS: Enhances
FT                                interaction with ESR1.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     600    612       QNPILTSLLQITG->RHKILHRLLQEGS: Enhances
FT                                interaction with ESR1.
FT                                {ECO:0000269|PubMed:12556447}.
FT   MUTAGEN     604    604       L->A: Impairs interaction with ESR2; when
FT                                associated with A-607; A-645 and A-648.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     607    608       LL->AA: Impairs interaction with ESR1,
FT                                PPARG, RXRA and THRB. Impairs interaction
FT                                with THRA; when associated with 648-A-A-
FT                                649. {ECO:0000269|PubMed:10733574,
FT                                ECO:0000269|PubMed:10770935,
FT                                ECO:0000269|PubMed:12556447,
FT                                ECO:0000269|PubMed:14636573,
FT                                ECO:0000269|PubMed:15340084,
FT                                ECO:0000269|PubMed:9653119}.
FT   MUTAGEN     607    607       L->A: Impairs interaction with ESR2; when
FT                                associated with A-604; A-645 and A-648.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     639    653       TKNHPMLMNLLKDNP->VSRHKILHRLLQEGS:
FT                                Enhances interaction with ESR1.
FT                                {ECO:0000269|PubMed:12556447}.
FT   MUTAGEN     645    645       L->A: Impairs interaction with ESR2; when
FT                                associated with A-604; A-607 and A-648.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN     648    649       LL->AA: Impairs interaction with ESR1,
FT                                PPARG, THRB and VDR. Impairs interaction
FT                                with THRA; when associated with 607-A-A-
FT                                608. {ECO:0000269|PubMed:10733574,
FT                                ECO:0000269|PubMed:10770935,
FT                                ECO:0000269|PubMed:12556447,
FT                                ECO:0000269|PubMed:14636573,
FT                                ECO:0000269|PubMed:15340084,
FT                                ECO:0000269|PubMed:9653119}.
FT   MUTAGEN     648    648       L->A: Impairs interaction with ESR2; when
FT                                associated with A-604; A-607 and A-645.
FT                                {ECO:0000269|PubMed:11303023}.
FT   MUTAGEN    1032   1032       T->A: Enhances protein stability; when
FT                                associated with A-1457.
FT                                {ECO:0000269|PubMed:16314496}.
FT   MUTAGEN    1457   1457       T->A: Enhances protein stability; when
FT                                associated with A-1032.
FT                                {ECO:0000269|PubMed:16314496}.
FT   CONFLICT     86     86       R -> G (in Ref. 1; CAA73867).
FT                                {ECO:0000305}.
FT   CONFLICT    147    147       F -> S (in Ref. 1; CAA73867).
FT                                {ECO:0000305}.
FT   CONFLICT    471    472       DS -> GL (in Ref. 1; CAA73867).
FT                                {ECO:0000305}.
FT   CONFLICT    563    563       P -> S (in Ref. 1; CAA73867 and 7;
FT                                AAF98352). {ECO:0000305}.
FT   CONFLICT    573    573       T -> A (in Ref. 1; CAA73867 and 7;
FT                                AAF98352). {ECO:0000305}.
FT   CONFLICT    651    651       D -> N (in Ref. 5; AAH06517).
FT                                {ECO:0000305}.
FT   CONFLICT    673    673       S -> F (in Ref. 9; AAC41736).
FT                                {ECO:0000305}.
FT   CONFLICT    702    708       Missing (in Ref. 9; AAC41736).
FT                                {ECO:0000305}.
FT   CONFLICT    721    721       N -> K (in Ref. 2; AAC39854).
FT                                {ECO:0000305}.
FT   CONFLICT    728    728       M -> R (in Ref. 7; AAF98352).
FT                                {ECO:0000305}.
FT   CONFLICT    756    761       VPHPQP -> FYLTPQ (in Ref. 5; AAH06517).
FT                                {ECO:0000305}.
FT   CONFLICT   1388   1388       G -> S (in Ref. 2; AAC39854).
FT                                {ECO:0000305}.
FT   HELIX       643    649       {ECO:0000244|PDB:2O4J}.
SQ   SEQUENCE   1581 AA;  168478 MW;  FCE0FE87EF08B887 CRC64;
     MKAQGETEES EKLSKMSSLL ERLHAKFNQN RPWSETIKLV RQVMEKRVVM SSGGHQHLVS
     CLETLQKALK VTSLPAMTDR LESIARQNGL GSHLSASGTE CYITSDMFYV EVQLDPAGQL
     CDVKVAHHGE NPVSCPELVQ QLREKNFDEF SKHLKGLVNL YNLPGDNKLK TKMYLALQSL
     EQDLSKMAIM YWKATNAGPL DKILHGSVGY LTPRSGGHLM NLKYYVSPSD LLDDKTASPI
     ILHENNVSRS LGMNASVTIE GTSAVYKLPI APLIMGSHPV DNKWTPSFSS ITSANSVDLP
     ACFFLKFPQP IPVSRAFVQK LQNCTGIPLF ETQPTYAPLY ELITQFELSK DPDPIPLNHN
     MRFYAALPGQ QHCYFLNKDA PLPDGRSLQG TLVSKITFQH PGRVPLILNL IRHQVAYNTL
     IGSCVKRTIL KEDSPGLLQF EVCPLSESRF SVSFQHPVND SLVCVVMDVQ DSTHVSCKLY
     KGLSDALICT DDFIAKVVQR CMSIPVTMRA IRRKAETIQA DTPALSLIAE TVEDMVKKNL
     PPASSPGYGM TTGNNPMSGT TTPTNTFPGG PITTLFNMSM SIKDRHESVG HGEDFSKVSQ
     NPILTSLLQI TGNGGSTIGS SPTPPHHTPP PVSSMAGNTK NHPMLMNLLK DNPAQDFSTL
     YGSSPLERQN SSSGSPRMEI CSGSNKTKKK KSSRLPPEKP KHQTEDDFQR ELFSMDVDSQ
     NPIFDVNMTA DTLDTPHITP APSQCSTPPT TYPQPVPHPQ PSIQRMVRLS SSDSIGPDVT
     DILSDIAEEA SKLPSTSDDC PAIGTPLRDS SSSGHSQSTL FDSDVFQTNN NENPYTDPAD
     LIADAAGSPS SDSPTNHFFH DGVDFNPDLL NSQSQSGFGE EYFDESSQSG DNDDFKGFAS
     QALNTLGVPM LGGDNGETKF KGNNQADTVD FSIISVAGKA LAPADLMEHH SGSQGPLLTT
     GDLGKEKTQK RVKEGNGTSN STLSGPGLDS KPGKRSRTPS NDGKSKDKPP KRKKADTEGK
     SPSHSSSNRP FTPPTSTGGS KSPGSAGRSQ TPPGVATPPI PKITIQIPKG TVMVGKPSSH
     SQYTSSGSVS SSGSKSHHSH SSSSSSSAST SGKMKSSKSE GSSSSKLSSS MYSSQGSSGS
     SQSKNSSQSG GKPGSSPITK HGLSSGSSST KMKPQGKPSS LMNPSLSKPN ISPSHSRPPG
     GSDKLASPMK PVPGTPPSSK AKSPISSGSG GSHMSGTSSS SGMKSSSGLG SSGSLSQKTP
     PSSNSCTASS SSFSSSGSSM SSSQNQHGSS KGKSPSRNKK PSLTAVIDKL KHGVVTSGPG
     GEDPLDGQMG VSTNSSSHPM SSKHNMSGGE FQGKREKSDK DKSKVSTSGS SVDSSKKTSE
     SKNVGSTGVA KIIISKHDGG SPSIKAKVTL QKPGESSGEG LRPQMASSKN YGSPLISGST
     PKHERGSPSH SKSPAYTPQN LDSESESGSS IAEKSYQNSP SSDDGIRPLP EYSTEKHKKH
     KKEKKKVKDK DRDRDRDKDR DKKKSHSIKP ESWSKSPISS DQSLSMTSNT ILSADRPSRL
     SPDFMIGEED DDLMDVALIG N
//
ID   P73_HUMAN               Reviewed;         636 AA.
AC   O15350; B7Z7J4; B7Z8Z1; B7Z9C1; C9J521; O15351; Q17RN8; Q5TBV5;
AC   Q5TBV6; Q8NHW9; Q8TDY5; Q8TDY6; Q9NTK8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   18-JAN-2017, entry version 194.
DE   RecName: Full=Tumor protein p73;
DE   AltName: Full=p53-like transcription factor;
DE   AltName: Full=p53-related protein;
GN   Name=TP73; Synonyms=P73;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA).
RC   TISSUE=Colon;
RX   PubMed=9288759; DOI=10.1016/S0092-8674(00)80540-1;
RA   Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.-C., Valent A.,
RA   Minty A., Chalon P., Lelias J.-M., Dumont X., Ferrara P., McKeon F.,
RA   Caput D.;
RT   "Monoallelically expressed gene related to p53 at 1p36, a region
RT   frequently deleted in neuroblastoma and other human cancers.";
RL   Cell 90:809-819(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM ALPHA).
RX   PubMed=9721206; DOI=10.1006/geno.1998.5387;
RA   Mai M., Huang H., Reed C., Qian C., Smith J.S., Alderete B.,
RA   Jenkins R., Smith D.I., Liu W.;
RT   "Genomic organization and mutation analysis of p73 in
RT   oligodendrogliomas with chromosome 1 p-arm deletions.";
RL   Genomics 51:359-363(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GAMMA AND DELTA).
RC   TISSUE=Neuroblastoma;
RX   PubMed=9802988; DOI=10.1084/jem.188.9.1763;
RA   De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco M.,
RA   Annicchiarico-Petruzzelli M., Levrero M., Melino G.;
RT   "Two new p73 splice variants, gamma and delta, with different
RT   transcriptional activity.";
RL   J. Exp. Med. 188:1763-1768(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS EPSILON AND ZETA).
RC   TISSUE=Hepatoma, Lymphocyte, Mammary cancer, and Skin;
RX   PubMed=10381648; DOI=10.1038/sj.cdd.4400521;
RA   De Laurenzi V., Catani M.V., Terrinoni A., Corazzari M., Melino G.,
RA   Costanzo A., Levrero M., Knight R.A.;
RT   "Additional complexity in p73: induction by mitogens in lymphoid cells
RT   and identification of two new splicing variants epsilon and zeta.";
RL   Cell Death Differ. 6:389-390(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM ALPHA).
RX   PubMed=10362363; DOI=10.1038/sj.onc.1202677;
RA   Yoshikawa H., Nagashima M., Khan M.A., McMenamin M.G., Hagiwara K.,
RA   Harris C.C.;
RT   "Mutational analysis of p73 and p53 in human cancer cell lines.";
RL   Oncogene 18:3415-3421(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS DN-ALPHA; DN-BETA AND DN-GAMMA),
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11753569; DOI=10.1038/sj.cdd.4400962;
RA   Grob T.J., Novak U., Maisse C., Barcaroli D., Luthi A.U., Pirnia F.,
RA   Hugli B., Graber H.U., De Laurenzi V., Fey M.F., Melino G., Tobler A.;
RT   "Human DeltaNp73 regulates a dominant negative feedback loop for TAp73
RT   and p53.";
RL   Cell Death Differ. 8:1213-1223(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS DN-ALPHA AND DN-BETA).
RA   Nakagawa T., Takahashi M., Ozaki T., Watanabe K., Nakagawara A.;
RT   "Identification of the p73-specific target sequence present in the
RT   deltaNp73 proper promoter.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS DN-ALPHA; 10 AND 11).
RC   TISSUE=Testis, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   INTERACTION WITH ABL1, PHOSPHORYLATION AT TYR-99 BY ABL1, AND
RP   MUTAGENESIS OF TYR-99.
RX   PubMed=10391251; DOI=10.1038/21704;
RA   Yuan Z.-M., Shioya H., Ishiko T., Sun X., Gu J., Huang Y., Lu H.,
RA   Kharbanda S., Weichselbaum R., Kufe D.;
RT   "p73 is regulated by tyrosine kinase c-Abl in the apoptotic response
RT   to DNA damage.";
RL   Nature 399:814-817(1999).
RN   [13]
RP   ERRATUM.
RA   Yuan Z.-M., Shioya H., Ishiko T., Sun X., Gu J., Huang Y., Lu H.,
RA   Kharbanda S., Weichselbaum R., Kufe D.;
RL   Nature 400:792-792(1999).
RN   [14]
RP   FUNCTION.
RX   PubMed=10203277; DOI=10.1093/jnci/91.7.594;
RA   Kaelin W.G. Jr.;
RT   "The emerging p53 gene family.";
RL   J. Natl. Cancer Inst. 91:594-598(1999).
RN   [15]
RP   SUMOYLATION AT LYS-627, AND MUTAGENESIS OF LYS-627.
RX   PubMed=10961991; DOI=10.1074/jbc.M004293200;
RA   Minty A., Dumont X., Kaghad M., Caput D.;
RT   "Covalent modification of p73alpha by SUMO-1. Two-hybrid screening
RT   with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1
RT   interaction motif.";
RL   J. Biol. Chem. 275:36316-36323(2000).
RN   [16]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP53.
RX   PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [17]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [18]
RP   INTERACTION WITH HECW2.
RX   PubMed=12890487; DOI=10.1016/S0006-291X(03)01347-0;
RA   Miyazaki K., Ozaki T., Kato C., Hanamoto T., Fujita T., Irino S.,
RA   Watanabe K., Nakagawa T., Nakagawara A.;
RT   "A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and
RT   enhances its transcriptional activity.";
RL   Biochem. Biophys. Res. Commun. 308:106-113(2003).
RN   [19]
RP   INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-487.
RX   PubMed=15070730; DOI=10.1073/pnas.0400805101;
RA   Aqeilan R.I., Pekarsky Y., Herrero J.J., Palamarchuk A., Letofsky J.,
RA   Druck T., Trapasso F., Han S.-Y., Melino G., Huebner K., Croce C.M.;
RT   "Functional association between Wwox tumor suppressor protein and p73,
RT   a p53 homolog.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4401-4406(2004).
RN   [20]
RP   INTERACTION WITH RANBP9, AND SUBCELLULAR LOCATION.
RX   PubMed=15558019; DOI=10.1038/sj.onc.1208257;
RA   Kramer S., Ozaki T., Miyazaki K., Kato C., Hanamoto T., Nakagawara A.;
RT   "Protein stability and function of p73 are modulated by a physical
RT   interaction with RanBPM in mammalian cultured cells.";
RL   Oncogene 24:938-944(2005).
RN   [21]
RP   PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=16461361; DOI=10.1083/jcb.200509132;
RA   Hoshino M., Qi M.-L., Yoshimura N., Tagawa K., Wada Y.-I., Enokido Y.,
RA   Marubuchi S., Harjes P., Arai N., Oyanagi K., Blandino G., Sudol M.,
RA   Rich T., Kanazawa I., Wanker E.E., Saitoe M., Okazawa H.;
RT   "Transcriptional repression induces a slowly progressive atypical
RT   neuronal death associated with changes of YAP isoforms and p73.";
RL   J. Cell Biol. 172:589-604(2006).
RN   [22]
RP   PHOSPHORYLATION AT THR-27.
RX   PubMed=18418051; DOI=10.4161/cc.7.9.5777;
RA   Soond S.M., Barry S.P., Melino G., Knight R.A., Latchman D.S.,
RA   Stephanou A.;
RT   "p73-mediated transcriptional activity is negatively regulated by
RT   polo-like kinase 1.";
RL   Cell Cycle 7:1214-1223(2008).
RN   [23]
RP   FUNCTION, PHOSPHORYLATION AT THR-27, AND MUTAGENESIS OF THR-27.
RX   PubMed=18174154; DOI=10.1074/jbc.M710608200;
RA   Koida N., Ozaki T., Yamamoto H., Ono S., Koda T., Ando K., Okoshi R.,
RA   Kamijo T., Omura K., Nakagawara A.;
RT   "Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis
RT   through physical interaction and phosphorylation.";
RL   J. Biol. Chem. 283:8555-8563(2008).
RN   [24]
RP   PHOSPHORYLATION AT TYR-28, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   HCK.
RX   PubMed=17535448; DOI=10.1186/1471-2199-8-45;
RA   Paliwal P., Radha V., Swarup G.;
RT   "Regulation of p73 by Hck through kinase-dependent and independent
RT   mechanisms.";
RL   BMC Mol. Biol. 8:45-45(2007).
RN   [25]
RP   INTERACTION WITH YAP1.
RX   PubMed=18280240; DOI=10.1016/j.molcel.2007.12.022;
RA   Levy D., Adamovich Y., Reuven N., Shaul Y.;
RT   "Yap1 phosphorylation by c-Abl is a critical step in selective
RT   activation of proapoptotic genes in response to DNA damage.";
RL   Mol. Cell 29:350-361(2008).
RN   [26]
RP   PHOSPHORYLATION BY PLK3.
RX   PubMed=19490146; DOI=10.1111/j.1365-2443.2009.01309.x;
RA   Sang M., Ando K., Okoshi R., Koida N., Li Y., Zhu Y., Shimozato O.,
RA   Geng C., Shan B., Nakagawara A., Ozaki T.;
RT   "Plk3 inhibits pro-apoptotic activity of p73 through physical
RT   interaction and phosphorylation.";
RL   Genes Cells 14:775-788(2009).
RN   [27]
RP   INTERACTION WITH FBXO45, AND UBIQUITINATION.
RX   PubMed=19581926; DOI=10.1038/onc.2009.177;
RA   Peschiaroli A., Scialpi F., Bernassola F., Pagano M., Melino G.;
RT   "The F-box protein FBXO45 promotes the proteasome-dependent
RT   degradation of p73.";
RL   Oncogene 28:3157-3166(2009).
RN   [28]
RP   UBIQUITINATION BY RCHY1/PIRH2.
RX   PubMed=21994467; DOI=10.1158/1541-7786.MCR-11-0157;
RA   Wu H., Zeinab R.A., Flores E.R., Leng R.P.;
RT   "Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity
RT   by promoting its ubiquitination.";
RL   Mol. Cancer Res. 9:1780-1790(2011).
RN   [29]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS PROTEIN EBNA6, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=24314664; DOI=10.1016/j.virol.2013.10.023;
RA   Sahu S.K., Mohanty S., Kumar A., Kundu C.N., Verma S.C., Choudhuri T.;
RT   "Epstein-Barr virus nuclear antigen 3C interact with p73: Interplay
RT   between a viral oncoprotein and cellular tumor suppressor.";
RL   Virology 448:333-343(2014).
RN   [30]
RP   STRUCTURE BY NMR OF 487-554.
RX   PubMed=10449409; DOI=10.1093/emboj/18.16.4438;
RA   Chi S.W., Ayed A., Arrowsmith C.H.;
RT   "Solution structure of a conserved C-terminal domain of p73 with
RT   structural homology to the SAM domain.";
RL   EMBO J. 18:4438-4445(1999).
CC   -!- FUNCTION: Participates in the apoptotic response to DNA damage.
CC       Isoforms containing the transactivation domain are pro-apoptotic,
CC       isoforms lacking the domain are anti-apoptotic and block the
CC       function of p53 and transactivating p73 isoforms. May be a tumor
CC       suppressor protein. {ECO:0000269|PubMed:10203277,
CC       ECO:0000269|PubMed:11753569, ECO:0000269|PubMed:18174154}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Found in a complex with p53/TP53 and CABLES1. The C-
CC       terminal oligomerization domain binds to the ABL1 tyrosine kinase
CC       SH3 domain. Interacts with HECW2. Isoform Beta interacts
CC       homotypically and with p53/TP53, whereas isoform Alpha does not.
CC       Isoform Gamma interacts homotypically and with all p73 isoforms.
CC       Isoform Delta interacts with isoform Gamma, isoform Alpha, and
CC       homotypically. Isoforms Alpha and Beta interact with HIPK2.
CC       Isoform Alpha interacts with RANBP9. Isoform Beta interacts with
CC       WWOX. Interacts (via SAM domain) with FBXO45 (via B30.2/SPRY
CC       domain). Interacts with YAP1 (phosphorylated form). Interacts with
CC       HCK (via SH3 domain); this inhibits TP73 activity and degradation.
CC       Interacts with Epstein-Barr virus protein EBNA6; this interaction
CC       inhibits TP73-mediated apoptotic pathway.
CC       {ECO:0000269|PubMed:10391251, ECO:0000269|PubMed:11706030,
CC       ECO:0000269|PubMed:11925430, ECO:0000269|PubMed:12890487,
CC       ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:15558019,
CC       ECO:0000269|PubMed:17535448, ECO:0000269|PubMed:18280240,
CC       ECO:0000269|PubMed:19581926, ECO:0000269|PubMed:24314664}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-389606, EBI-389606;
CC       O14965:AURKA; NbExp=11; IntAct=EBI-389606, EBI-448680;
CC       Q9ESJ1:Cables1 (xeno); NbExp=3; IntAct=EBI-389606, EBI-604411;
CC       Q9UKL3:CASP8AP2; NbExp=2; IntAct=EBI-389619, EBI-2339650;
CC       P03126:E6 (xeno); NbExp=2; IntAct=EBI-389619, EBI-1177242;
CC       P38646:HSPA9; NbExp=11; IntAct=EBI-389606, EBI-354932;
CC       Q96J02:ITCH; NbExp=5; IntAct=EBI-389619, EBI-1564678;
CC       Q13950:RUNX2; NbExp=3; IntAct=EBI-389606, EBI-976402;
CC       Q96EB6:SIRT1; NbExp=4; IntAct=EBI-389606, EBI-1802965;
CC       P46937:YAP1; NbExp=7; IntAct=EBI-389619, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24314664}.
CC       Cytoplasm. Note=Accumulates in the nucleus in response to DNA
CC       damage.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=12;
CC       Name=Alpha;
CC         IsoId=O15350-1; Sequence=Displayed;
CC       Name=Beta;
CC         IsoId=O15350-2; Sequence=VSP_006539;
CC         Note=Produced by alternative splicing of isoform Alpha.;
CC       Name=Gamma;
CC         IsoId=O15350-3; Sequence=VSP_006540, VSP_006541;
CC         Note=Produced by alternative splicing of isoform Alpha. The
CC         splicing of exon 11 results in a frameshift from the original
CC         reading frame.;
CC       Name=Delta;
CC         IsoId=O15350-4; Sequence=VSP_006542, VSP_006543;
CC         Note=Produced by alternative splicing of isoform Alpha.;
CC       Name=Epsilon;
CC         IsoId=O15350-5; Sequence=VSP_006544, VSP_006545;
CC         Note=Produced by alternative splicing of isoform Alpha. The
CC         splicing of exon 11 results in a frameshift from the original
CC         reading frame. The splicing of exon 13 reverts the reading frame
CC         to the sequence of isoform Alpha.;
CC       Name=Zeta;
CC         IsoId=O15350-6; Sequence=VSP_006546;
CC         Note=Produced by alternative splicing of isoform Alpha.;
CC       Name=dN-Alpha;
CC         IsoId=O15350-8; Sequence=VSP_014368;
CC         Note=Produced by alternative promoter usage.;
CC       Name=dN-Beta;
CC         IsoId=O15350-9; Sequence=VSP_014368, VSP_006539;
CC         Note=Produced by alternative splicing of isoform dN-Alpha.;
CC       Name=dN-Gamma;
CC         IsoId=O15350-10; Sequence=VSP_014368, VSP_006540, VSP_006541;
CC         Note=Produced by alternative splicing of isoform dN-Alpha.;
CC       Name=10;
CC         IsoId=O15350-11; Sequence=VSP_045082;
CC         Note=No experimental confirmation available.;
CC       Name=11;
CC         IsoId=O15350-12; Sequence=VSP_014368, VSP_053809;
CC       Name=12;
CC         IsoId=O15350-13; Sequence=VSP_053810;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in striatal neurons of patients with
CC       Huntington disease (at protein level). Brain, kidney, placenta,
CC       colon, heart, liver, spleen, skeletal muscle, prostate, thymus and
CC       pancreas. Highly expressed in fetal tissue.
CC       {ECO:0000269|PubMed:11753569, ECO:0000269|PubMed:16461361}.
CC   -!- INDUCTION: Not induced by DNA damage. Isoforms lacking the
CC       transactivation domain block gene induction.
CC       {ECO:0000269|PubMed:11753569}.
CC   -!- DOMAIN: Possesses an acidic transactivation domain, a central DNA
CC       binding domain and a C-terminal oligomerization domain that binds
CC       to the ABL1 tyrosine kinase SH3 domain.
CC       {ECO:0000269|PubMed:15070730}.
CC   -!- DOMAIN: The WW-binding motif mediates interaction with WWOX.
CC       {ECO:0000269|PubMed:15070730}.
CC   -!- PTM: Isoform alpha (but not isoform beta) is sumoylated on Lys-
CC       627, which potentiates proteasomal degradation but does not affect
CC       transcriptional activity. Phosphorylation by PLK1 and PLK3
CC       inhibits the transcription regulator activity and pro-apoptotic
CC       function. {ECO:0000269|PubMed:10961991}.
CC   -!- PTM: Higher levels of phosphorylation seen in the brain from
CC       patients with Huntington disease.
CC   -!- PTM: Polyubiquitinated by RCHY1/PIRH2; leading to its degradation
CC       by the proteasome. {ECO:0000269|PubMed:19581926,
CC       ECO:0000269|PubMed:21994467}.
CC   -!- MISCELLANEOUS: Maps to a chromosome region frequently mutated in
CC       diverse cell lines of human cancer. Appears not to be frequently
CC       mutated in human cancers, in contrast to p53/TP53. Hemizygosity is
CC       observed in neuroblastoma and oligodendroglioma.
CC   -!- MISCELLANEOUS: Activated and stabilized by interaction with
CC       RANBP9.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 SAM (sterile alpha motif) domain.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y11416; CAA72220.1; -; mRNA.
DR   EMBL; Y11416; CAA72221.1; -; mRNA.
DR   EMBL; Y11416; CAA72219.1; -; mRNA.
DR   EMBL; AF079094; AAD39696.1; -; Genomic_DNA.
DR   EMBL; AF079082; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079083; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079084; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079085; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079086; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079087; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079088; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079089; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079090; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079091; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079092; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF079093; AAD39696.1; JOINED; Genomic_DNA.
DR   EMBL; AF077628; AAC61887.1; -; Genomic_DNA.
DR   EMBL; AF077616; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077617; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077618; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077619; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077620; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077621; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077624; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077625; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077626; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AF077627; AAC61887.1; JOINED; Genomic_DNA.
DR   EMBL; AY040827; AAK81884.1; -; mRNA.
DR   EMBL; AY040828; AAK81885.1; -; mRNA.
DR   EMBL; AY040829; AAK81886.1; -; mRNA.
DR   EMBL; AB055065; BAB87244.1; -; mRNA.
DR   EMBL; AB055066; BAB87245.1; -; mRNA.
DR   EMBL; AK302118; BAH13630.1; -; mRNA.
DR   EMBL; AK304177; BAH14127.1; -; mRNA.
DR   EMBL; AK304784; BAH14257.1; -; mRNA.
DR   EMBL; AL136528; CAI19123.1; -; Genomic_DNA.
DR   EMBL; AL136528; CAI19124.1; -; Genomic_DNA.
DR   EMBL; AL136528; CAI19125.1; -; Genomic_DNA.
DR   EMBL; AL136528; CAI19126.1; -; Genomic_DNA.
DR   EMBL; AL136528; CAI19127.1; -; Genomic_DNA.
DR   EMBL; CH471130; EAW71464.1; -; Genomic_DNA.
DR   EMBL; BC117251; AAI17252.1; -; mRNA.
DR   EMBL; BC117253; AAI17254.1; -; mRNA.
DR   CCDS; CCDS44049.1; -. [O15350-8]
DR   CCDS; CCDS44050.1; -. [O15350-9]
DR   CCDS; CCDS49.1; -. [O15350-1]
DR   CCDS; CCDS55566.1; -. [O15350-2]
DR   CCDS; CCDS55567.1; -. [O15350-13]
DR   CCDS; CCDS55568.1; -. [O15350-6]
DR   CCDS; CCDS55569.1; -. [O15350-11]
DR   CCDS; CCDS59965.1; -. [O15350-4]
DR   RefSeq; NP_001119712.1; NM_001126240.2. [O15350-8]
DR   RefSeq; NP_001119713.1; NM_001126241.2. [O15350-9]
DR   RefSeq; NP_001119714.1; NM_001126242.2.
DR   RefSeq; NP_001191113.1; NM_001204184.1. [O15350-2]
DR   RefSeq; NP_001191114.1; NM_001204185.1.
DR   RefSeq; NP_001191115.1; NM_001204186.1. [O15350-4]
DR   RefSeq; NP_001191116.1; NM_001204187.1. [O15350-13]
DR   RefSeq; NP_001191117.1; NM_001204188.1. [O15350-6]
DR   RefSeq; NP_001191118.1; NM_001204189.1.
DR   RefSeq; NP_001191119.1; NM_001204190.1.
DR   RefSeq; NP_001191120.1; NM_001204191.1.
DR   RefSeq; NP_001191121.1; NM_001204192.1. [O15350-11]
DR   RefSeq; NP_005418.1; NM_005427.3. [O15350-1]
DR   UniGene; Hs.192132; -.
DR   PDB; 1COK; NMR; -; A=487-554.
DR   PDB; 1DXS; X-ray; 2.54 A; A=487-564.
DR   PDB; 2KBY; NMR; -; A/B/C/D=351-398.
DR   PDB; 2MPS; NMR; -; B=10-25.
DR   PDB; 2WQI; X-ray; 1.70 A; A/B/C/D=351-399.
DR   PDB; 2WQJ; X-ray; 2.00 A; 1/2/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z=351-383.
DR   PDB; 2WTT; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=351-399.
DR   PDB; 2XWC; X-ray; 1.82 A; A=112-311.
DR   PDB; 3VD0; X-ray; 2.95 A; A/B/C/D/I/J/K/L=115-312.
DR   PDB; 3VD1; X-ray; 2.95 A; A/B/C/D/I/J/K/L=115-312.
DR   PDB; 3VD2; X-ray; 4.00 A; A/B/C/D/I/J=115-312.
DR   PDB; 4A63; X-ray; 2.27 A; A/C/E/G/I/K=112-311.
DR   PDB; 4G82; X-ray; 3.10 A; A/B=115-312.
DR   PDB; 4G83; X-ray; 4.00 A; A/B=115-312.
DR   PDB; 4GUO; X-ray; 3.19 A; A/B/C/D/I/J/K/L=115-312.
DR   PDB; 4GUQ; X-ray; 3.70 A; A/B=115-312.
DR   PDB; 5HOB; X-ray; 1.22 A; A/B/C/D/E/F/G/H=351-398.
DR   PDB; 5HOC; X-ray; 1.36 A; A/B=351-398.
DR   PDB; 5KBD; X-ray; 2.80 A; A/B=115-312.
DR   PDBsum; 1COK; -.
DR   PDBsum; 1DXS; -.
DR   PDBsum; 2KBY; -.
DR   PDBsum; 2MPS; -.
DR   PDBsum; 2WQI; -.
DR   PDBsum; 2WQJ; -.
DR   PDBsum; 2WTT; -.
DR   PDBsum; 2XWC; -.
DR   PDBsum; 3VD0; -.
DR   PDBsum; 3VD1; -.
DR   PDBsum; 3VD2; -.
DR   PDBsum; 4A63; -.
DR   PDBsum; 4G82; -.
DR   PDBsum; 4G83; -.
DR   PDBsum; 4GUO; -.
DR   PDBsum; 4GUQ; -.
DR   PDBsum; 5HOB; -.
DR   PDBsum; 5HOC; -.
DR   PDBsum; 5KBD; -.
DR   DisProt; DP00319; -.
DR   ProteinModelPortal; O15350; -.
DR   SMR; O15350; -.
DR   BioGrid; 113014; 117.
DR   DIP; DIP-24202N; -.
DR   IntAct; O15350; 21.
DR   MINT; MINT-97729; -.
DR   STRING; 9606.ENSP00000367545; -.
DR   iPTMnet; O15350; -.
DR   PhosphoSitePlus; O15350; -.
DR   BioMuta; TP73; -.
DR   MaxQB; O15350; -.
DR   PaxDb; O15350; -.
DR   PeptideAtlas; O15350; -.
DR   PRIDE; O15350; -.
DR   DNASU; 7161; -.
DR   Ensembl; ENST00000346387; ENSP00000340740; ENSG00000078900. [O15350-6]
DR   Ensembl; ENST00000354437; ENSP00000346423; ENSG00000078900. [O15350-2]
DR   Ensembl; ENST00000357733; ENSP00000350366; ENSG00000078900. [O15350-13]
DR   Ensembl; ENST00000378285; ENSP00000367534; ENSG00000078900. [O15350-9]
DR   Ensembl; ENST00000378288; ENSP00000367537; ENSG00000078900. [O15350-8]
DR   Ensembl; ENST00000378290; ENSP00000367539; ENSG00000078900. [O15350-11]
DR   Ensembl; ENST00000378295; ENSP00000367545; ENSG00000078900. [O15350-1]
DR   Ensembl; ENST00000603362; ENSP00000474626; ENSG00000078900. [O15350-13]
DR   Ensembl; ENST00000604074; ENSP00000475143; ENSG00000078900. [O15350-4]
DR   Ensembl; ENST00000604479; ENSP00000474322; ENSG00000078900. [O15350-6]
DR   GeneID; 7161; -.
DR   KEGG; hsa:7161; -.
DR   UCSC; uc001akp.4; human. [O15350-1]
DR   CTD; 7161; -.
DR   DisGeNET; 7161; -.
DR   GeneCards; TP73; -.
DR   HGNC; HGNC:12003; TP73.
DR   HPA; CAB002514; -.
DR   HPA; CAB003022; -.
DR   HPA; HPA027314; -.
DR   HPA; HPA044516; -.
DR   MalaCards; TP73; -.
DR   MIM; 601990; gene.
DR   neXtProt; NX_O15350; -.
DR   OpenTargets; ENSG00000078900; -.
DR   PharmGKB; PA36684; -.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039956; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; O15350; -.
DR   KO; K10148; -.
DR   OMA; NEGQSAP; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   PhylomeDB; O15350; -.
DR   TreeFam; TF106101; -.
DR   BioCyc; ZFISH:ENSG00000078900-MONOMER; -.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   SignaLink; O15350; -.
DR   SIGNOR; O15350; -.
DR   ChiTaRS; TP73; human.
DR   EvolutionaryTrace; O15350; -.
DR   GeneWiki; P73; -.
DR   GenomeRNAi; 7161; -.
DR   PMAP-CutDB; O15350; -.
DR   PRO; PR:O15350; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000078900; -.
DR   ExpressionAtlas; O15350; baseline and differential.
DR   Genevisible; O15350; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:AgBase.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0008134; F:transcription factor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:NTNU_SB.
DR   GO; GO:0000187; P:activation of MAPK activity; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:InterPro.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; TAS:ProtInc.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0006298; P:mismatch repair; TAS:ProtInc.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IMP:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:AgBase.
DR   GO; GO:0043508; P:negative regulation of JUN kinase activity; IBA:GO_Central.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:MGI.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR032646; Tp73.
DR   PANTHER; PTHR11447; PTHR11447; 2.
DR   PANTHER; PTHR11447:SF21; PTHR11447:SF21; 2.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Cell cycle; Complete proteome;
KW   Cytoplasm; DNA-binding; Host-virus interaction; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Tumor suppressor;
KW   Ubl conjugation; Zinc.
FT   CHAIN         1    636       Tumor protein p73.
FT                                /FTId=PRO_0000185728.
FT   DOMAIN      485    551       SAM.
FT   REGION        1     46       Transactivation. {ECO:0000250}.
FT   REGION      131    310       DNA-binding. {ECO:0000255}.
FT   REGION      345    386       Oligomerization. {ECO:0000255}.
FT   REGION      345    380       Interaction with HIPK2.
FT                                {ECO:0000269|PubMed:11925430}.
FT   MOTIF       483    487       WW-binding.
FT   COMPBIAS      1     55       Asp/Glu-rich (acidic).
FT   COMPBIAS    168    171       Poly-Pro.
FT   COMPBIAS    391    394       Poly-Gln.
FT   COMPBIAS    483    486       Poly-Pro.
FT   METAL       194    194       Zinc. {ECO:0000250}.
FT   METAL       197    197       Zinc. {ECO:0000250}.
FT   METAL       258    258       Zinc. {ECO:0000250}.
FT   METAL       262    262       Zinc. {ECO:0000250}.
FT   MOD_RES      27     27       Phosphothreonine; by PLK1.
FT                                {ECO:0000269|PubMed:18174154,
FT                                ECO:0000269|PubMed:18418051}.
FT   MOD_RES      28     28       Phosphotyrosine; by SRC and HCK.
FT                                {ECO:0000269|PubMed:17535448}.
FT   MOD_RES      99     99       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:10391251}.
FT   CROSSLNK    627    627       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO); in
FT                                isoform Alpha.
FT                                {ECO:0000269|PubMed:10961991}.
FT   VAR_SEQ       1     71       Missing (in isoform 10).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045082.
FT   VAR_SEQ       1     62       MAQSTATSPDGGTTFEHLWSSLEPDSTYFDLPQSSRGNNEV
FT                                VGGTDSSMDVFHLEGMTTSVM -> MLYVGDPARHLAT
FT                                (in isoform dN-Alpha, isoform dN-Beta,
FT                                isoform dN-Gamma and isoform 11).
FT                                {ECO:0000303|PubMed:11753569,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_014368.
FT   VAR_SEQ     400    636       Missing (in isoform 11).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_053809.
FT   VAR_SEQ     400    526       SHLQPPSYGPVLSPMNKVHGGMNKLPSVNQLVGQPPPHSSA
FT                                ATPNLGPVGPGMLNNHGHAVPANGEMSSSHSAQSMVSGSHC
FT                                TPPPPYHADPSLVSFLTGLGCPNCIEYFTSQGLQSIYHLQN
FT                                LTIE -> PRDAQQPWPRSASQRRDEQQPQRPVHGLGVPLH
FT                                SATPLPRRPQPRQ (in isoform 12).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_053810.
FT   VAR_SEQ     400    495       Missing (in isoform Zeta).
FT                                {ECO:0000303|PubMed:10381648}.
FT                                /FTId=VSP_006546.
FT   VAR_SEQ     400    476       SHLQPPSYGPVLSPMNKVHGGMNKLPSVNQLVGQPPPHSSA
FT                                ATPNLGPVGPGMLNNHGHAVPANGEMSSSHSAQSMV -> P
FT                                RDAQQPWPRSASQQRRDEQQPQRPVHGLGVPLHSATPLPRR
FT                                PQPRQFFNRIGVSKLHRVFHLPRVTEHLPPAEPDH (in
FT                                isoform Gamma and isoform dN-Gamma).
FT                                {ECO:0000303|PubMed:11753569,
FT                                ECO:0000303|PubMed:9802988}.
FT                                /FTId=VSP_006540.
FT   VAR_SEQ     400    445       SHLQPPSYGPVLSPMNKVHGGMNKLPSVNQLVGQPPPHSSA
FT                                ATPNL -> PRDAQQPWPRSASQQRRDEQQPQRPVHGLGVP
FT                                LHSATPLPRRPQPR (in isoform Epsilon).
FT                                {ECO:0000303|PubMed:10381648}.
FT                                /FTId=VSP_006544.
FT   VAR_SEQ     400    403       SHLQ -> TWGP (in isoform Delta).
FT                                {ECO:0000303|PubMed:9802988}.
FT                                /FTId=VSP_006542.
FT   VAR_SEQ     404    636       Missing (in isoform Delta).
FT                                {ECO:0000303|PubMed:9802988}.
FT                                /FTId=VSP_006543.
FT   VAR_SEQ     446    526       Missing (in isoform Epsilon).
FT                                {ECO:0000303|PubMed:10381648}.
FT                                /FTId=VSP_006545.
FT   VAR_SEQ     477    636       Missing (in isoform Gamma and isoform dN-
FT                                Gamma). {ECO:0000303|PubMed:11753569,
FT                                ECO:0000303|PubMed:9802988}.
FT                                /FTId=VSP_006541.
FT   VAR_SEQ     495    636       SFLTGLGCPNCIEYFTSQGLQSIYHLQNLTIEDLGALKIPE
FT                                QYRMTIWRGLQDLKQGHDYSTAQQLLRSSNAATISIGGSGE
FT                                LQRQRVMEAVHFRVRHTITIPNRGGPGGGPDEWADFGFDLP
FT                                DCKARKQPIKEEFTEAEIH -> RTWGP (in isoform
FT                                Beta and isoform dN-Beta).
FT                                {ECO:0000303|PubMed:11753569,
FT                                ECO:0000303|PubMed:9288759,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_006539.
FT   MUTAGEN      27     27       T->A: Impaired phosphorylation.
FT                                {ECO:0000269|PubMed:18174154}.
FT   MUTAGEN      99     99       Y->F: Impaired phosphorylation of isoform
FT                                beta by ABL1.
FT                                {ECO:0000269|PubMed:10391251}.
FT   MUTAGEN     487    487       Y->A: Loss of interaction with WWOX.
FT                                {ECO:0000269|PubMed:15070730}.
FT   MUTAGEN     627    627       K->R: Strongly diminishes sumoylation but
FT                                does not affect transcriptional activity.
FT                                {ECO:0000269|PubMed:10961991}.
FT   HELIX        15     20       {ECO:0000244|PDB:2MPS}.
FT   TURN        123    126       {ECO:0000244|PDB:2XWC}.
FT   STRAND      128    130       {ECO:0000244|PDB:2XWC}.
FT   STRAND      136    138       {ECO:0000244|PDB:4G82}.
FT   STRAND      141    145       {ECO:0000244|PDB:2XWC}.
FT   TURN        146    149       {ECO:0000244|PDB:2XWC}.
FT   STRAND      150    153       {ECO:0000244|PDB:2XWC}.
FT   STRAND      157    164       {ECO:0000244|PDB:2XWC}.
FT   STRAND      174    181       {ECO:0000244|PDB:2XWC}.
FT   TURN        184    188       {ECO:0000244|PDB:2XWC}.
FT   HELIX       195    199       {ECO:0000244|PDB:2XWC}.
FT   TURN        202    206       {ECO:0000244|PDB:2XWC}.
FT   STRAND      214    219       {ECO:0000244|PDB:2XWC}.
FT   STRAND      224    227       {ECO:0000244|PDB:2XWC}.
FT   TURN        229    231       {ECO:0000244|PDB:2XWC}.
FT   STRAND      234    239       {ECO:0000244|PDB:2XWC}.
FT   STRAND      250    256       {ECO:0000244|PDB:2XWC}.
FT   HELIX       260    262       {ECO:0000244|PDB:2XWC}.
FT   TURN        263    268       {ECO:0000244|PDB:4A63}.
FT   STRAND      271    278       {ECO:0000244|PDB:2XWC}.
FT   STRAND      280    282       {ECO:0000244|PDB:3VD1}.
FT   STRAND      284    294       {ECO:0000244|PDB:2XWC}.
FT   HELIX       298    311       {ECO:0000244|PDB:2XWC}.
FT   STRAND      354    361       {ECO:0000244|PDB:5HOB}.
FT   HELIX       362    377       {ECO:0000244|PDB:5HOB}.
FT   HELIX       378    380       {ECO:0000244|PDB:5HOB}.
FT   HELIX       383    394       {ECO:0000244|PDB:5HOB}.
FT   HELIX       493    499       {ECO:0000244|PDB:1DXS}.
FT   TURN        503    505       {ECO:0000244|PDB:1COK}.
FT   HELIX       506    510       {ECO:0000244|PDB:1DXS}.
FT   TURN        511    513       {ECO:0000244|PDB:1DXS}.
FT   HELIX       517    521       {ECO:0000244|PDB:1DXS}.
FT   HELIX       525    530       {ECO:0000244|PDB:1DXS}.
FT   TURN        535    537       {ECO:0000244|PDB:1DXS}.
FT   HELIX       538    547       {ECO:0000244|PDB:1DXS}.
SQ   SEQUENCE   636 AA;  69623 MW;  A467493C5D93EEE0 CRC64;
     MAQSTATSPD GGTTFEHLWS SLEPDSTYFD LPQSSRGNNE VVGGTDSSMD VFHLEGMTTS
     VMAQFNLLSS TMDQMSSRAA SASPYTPEHA ASVPTHSPYA QPSSTFDTMS PAPVIPSNTD
     YPGPHHFEVT FQQSSTAKSA TWTYSPLLKK LYCQIAKTCP IQIKVSTPPP PGTAIRAMPV
     YKKAEHVTDV VKRCPNHELG RDFNEGQSAP ASHLIRVEGN NLSQYVDDPV TGRQSVVVPY
     EPPQVGTEFT TILYNFMCNS SCVGGMNRRP ILIIITLEMR DGQVLGRRSF EGRICACPGR
     DRKADEDHYR EQQALNESSA KNGAASKRAF KQSPPAVPAL GAGVKKRRHG DEDTYYLQVR
     GRENFEILMK LKESLELMEL VPQPLVDSYR QQQQLLQRPS HLQPPSYGPV LSPMNKVHGG
     MNKLPSVNQL VGQPPPHSSA ATPNLGPVGP GMLNNHGHAV PANGEMSSSH SAQSMVSGSH
     CTPPPPYHAD PSLVSFLTGL GCPNCIEYFT SQGLQSIYHL QNLTIEDLGA LKIPEQYRMT
     IWRGLQDLKQ GHDYSTAQQL LRSSNAATIS IGGSGELQRQ RVMEAVHFRV RHTITIPNRG
     GPGGGPDEWA DFGFDLPDCK ARKQPIKEEF TEAEIH
//
ID   MDM2_MOUSE              Reviewed;         489 AA.
AC   P23804; Q61040; Q64330; Q91XK7;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   18-JAN-2017, entry version 177.
DE   RecName: Full=E3 ubiquitin-protein ligase Mdm2;
DE            EC=2.3.2.27;
DE   AltName: Full=Double minute 2 protein;
DE   AltName: Full=Oncoprotein Mdm2;
DE   AltName: Full=RING-type E3 ubiquitin transferase Mdm2 {ECO:0000305};
DE   AltName: Full=p53-binding protein Mdm2;
GN   Name=Mdm2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MDM2-P90).
RX   PubMed=2026149;
RA   Fakharzadeh S.S., Trusko S.P., George D.L.;
RT   "Tumorigenic potential associated with enhanced expression of a gene
RT   that is amplified in a mouse tumor cell line.";
RL   EMBO J. 10:1565-1569(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM MDM2-P90).
RC   STRAIN=129/Sv;
RX   PubMed=8917101; DOI=10.1016/0378-1119(96)00151-5;
RA   Jones S.N., Ansari-Lari M.A., Hancock A.R., Jones W.J., Gibbs R.A.,
RA   Donehower L.A., Bradley A.;
RT   "Genomic organization of the mouse double minute 2 gene.";
RL   Gene 175:209-213(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM MDM2-P90).
RC   STRAIN=129/Sv;
RX   PubMed=8660994; DOI=10.1006/geno.1996.0210;
RA   de Oca Luna R.M., Tabor A.D., Eberspaecher H., Hulboy D.L.,
RA   Worth L.L., Colman M.S., Finlay C.A., Lozano G.;
RT   "The organization and expression of the mdm2 gene.";
RL   Genomics 33:352-357(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ISOFORMS MDM2-P90 AND MDM2-P76), TISSUE
RP   SPECIFICITY, AND INDUCTION.
RX   PubMed=10075719; DOI=10.1074/jbc.274.12.8161;
RA   Saucedo L.J., Myers C.D., Perry M.E.;
RT   "Multiple murine double minute gene 2 (MDM2) proteins are induced by
RT   ultraviolet light.";
RL   J. Biol. Chem. 274:8161-8168(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Lung, and Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOLAR LOCALIZATION SIGNAL.
RX   PubMed=10713175; DOI=10.1128/MCB.20.7.2517-2528.2000;
RA   Weber J.D., Kuo M.-L., Bothner B., DiGiammarino E.L., Kriwacki R.W.,
RA   Roussel M.F., Sherr C.J.;
RT   "Cooperative signals governing ARF-mdm2 interaction and nucleolar
RT   localization of the complex.";
RL   Mol. Cell. Biol. 20:2517-2528(2000).
RN   [8]
RP   PHOSPHORYLATION BY ATM.
RX   PubMed=10611322; DOI=10.1073/pnas.96.26.14973;
RA   Khosravi R., Maya R., Gottlieb T., Oren M., Shiloh Y., Shkedy D.;
RT   "Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation
RT   in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:14973-14977(1999).
RN   [9]
RP   INTERACTION WITH MTBP.
RX   PubMed=10906133; DOI=10.1074/jbc.M004252200;
RA   Boyd M.T., Vlatkovic N., Haines D.S.;
RT   "A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest
RT   that is suppressed by MDM2.";
RL   J. Biol. Chem. 275:31883-31890(2000).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH AARB2.
RX   PubMed=11588219; DOI=10.1126/science.1063866;
RA   Shenoy S.K., McDonald P.H., Kohout T.A., Lefkowitz R.J.;
RT   "Regulation of receptor fate by ubiquitination of activated beta 2-
RT   adrenergic receptor and beta-arrestin.";
RL   Science 294:1307-1313(2001).
RN   [11]
RP   FUNCTION, INTERACTION WITH PML AND RPL11, AND SUBCELLULAR LOCATION.
RX   PubMed=15195100; DOI=10.1038/ncb1147;
RA   Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H.,
RA   Pandolfi P.P.;
RT   "PML regulates p53 stability by sequestering Mdm2 to the nucleolus.";
RL   Nat. Cell Biol. 6:665-672(2004).
RN   [12]
RP   INTERACTION WITH TBRG1.
RX   PubMed=17110379; DOI=10.1074/jbc.M609612200;
RA   Tompkins V.S., Hagen J., Frazier A.A., Lushnikova T., Fitzgerald M.P.,
RA   di Tommaso A.D., Ladeveze V., Domann F.E., Eischen C.M., Quelle D.E.;
RT   "A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains
RT   chromosomal stability.";
RL   J. Biol. Chem. 282:1322-1333(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Kidney, Lung, Pancreas, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [14]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=25088421; DOI=10.1016/j.celrep.2014.06.056;
RA   Yoshihara S., Takahashi H., Nishimura N., Kinoshita M., Asahina R.,
RA   Kitsuki M., Tatsumi K., Furukawa-Hibi Y., Hirai H., Nagai T.,
RA   Yamada K., Tsuboi A.;
RT   "Npas4 regulates Mdm2 and thus Dcx in experience-dependent dendritic
RT   spine development of newborn olfactory bulb interneurons.";
RL   Cell Rep. 8:843-857(2014).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination
CC       of p53/TP53, leading to its degradation by the proteasome
CC       (PubMed:15195100). Inhibits p53/TP53- and p73/TP73-mediated cell
CC       cycle arrest and apoptosis by binding its transcriptional
CC       activation domain (By similarity). Also acts as a ubiquitin ligase
CC       E3 toward itself, ARRB1 and ARBB2 (PubMed:11588219). Permits the
CC       nuclear export of p53/TP53 (By similarity). Promotes proteasome-
CC       dependent ubiquitin-independent degradation of retinoblastoma RB1
CC       protein (By similarity). Inhibits DAXX-mediated apoptosis by
CC       inducing its ubiquitination and degradation (By similarity).
CC       Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in
CC       stabilizing p53/TP53 (By similarity). Also component of the
CC       TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA
CC       damage response pathways (By similarity). Mediates ubiquitination
CC       and subsequent proteasome degradation of DYRK2 in nucleus (By
CC       similarity). Ubiquitinates IGF1R and SNAI1 and promotes them to
CC       proteasomal degradation (By similarity). Ubiquitinates DCX,
CC       leading to DCX degradation and reduction of the dendritic spine
CC       density of olfactory bulb granule cells (PubMed:25088421).
CC       {ECO:0000250|UniProtKB:Q00987, ECO:0000269|PubMed:11588219,
CC       ECO:0000269|PubMed:15195100, ECO:0000269|PubMed:25088421}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- SUBUNIT: Interacts with p53/TP53, TP73/p73, RBL5 and RP11. Binds
CC       specifically to RNA. Can interact with RB1, E1A-associated protein
CC       EP300 and the E2F1 transcription factor. Forms a ternary complex
CC       with p53/TP53 and WWOX. Interacts with CDKN2AIP, RFWD3, USP7,
CC       PYHIN1, UBXN6, and RBBP6. Interacts with ARRB1 and ARRB2.
CC       Interacts with PSMA3. Found in a trimeric complex with MDM2, MDM4
CC       and USP2. Interacts with USP2 (via N-terminus and C-terminus).
CC       Interacts with MDM4. Part of a complex with MDM2, DAXX, RASSF1 and
CC       USP7. Part of a complex with DAXX, MDM2 and USP7. Interacts
CC       directly with DAXX and USP7. Interacts (via C-terminus) with
CC       RASSF1 isoform A (via N-terminus); the interaction is independent
CC       of TP53. Interacts with APEX1; leading to its ubiquitination and
CC       degradation. Interacts with RYBP; this inhibits ubiquitination of
CC       TP53. Identified in a complex with RYBP and p53/TP53. Also
CC       component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in
CC       regulating p53/TP53 stabilization and activity. Binds directly
CC       both p53/TP53 and TRIM28. Component of the TRIM28/KAP1-ERBB4-MDM2
CC       complex involved in connecting growth factor responses with DNA
CC       damage. Interacts directly with both TRIM28 and ERBB4 in the
CC       complex. Interacts with DYRK2. Interacts with IGF1R. Interacts
CC       with TRIM13; the interaction ubiquitinates MDM2 leading to its
CC       proteasomal degradation. Interacts with SNAI1; this interaction
CC       promotes SNAI1 ubiquitination. Interacts with NOTCH1 (via
CC       intracellular domain). Interacts with FHIT. Interacts with RFFL
CC       and RNF34; the interaction stabilizes MDM2. Interacts with
CC       CDK5RAP3 and CDKN2A/ARF; form a ternary complex involved in
CC       regulation of p53/TP53. Interacts with MTA1 (By similarity).
CC       Interacts with AARB2 (PubMed:11588219). Interacts with MTBP
CC       (PubMed:10906133). Interacts with PML (PubMed:15195100). Interacts
CC       with RPL11 (PubMed:15195100). Interacts with TBRG1
CC       (PubMed:17110379). {ECO:0000250|UniProtKB:Q00987,
CC       ECO:0000269|PubMed:10906133, ECO:0000269|PubMed:11588219,
CC       ECO:0000269|PubMed:15195100, ECO:0000269|PubMed:17110379}.
CC   -!- INTERACTION:
CC       Q8BWG8:Arrb1; NbExp=4; IntAct=EBI-641788, EBI-641778;
CC       Q62108:Dlg4; NbExp=3; IntAct=EBI-641788, EBI-300895;
CC       O88904:Hipk1; NbExp=3; IntAct=EBI-641788, EBI-692945;
CC       O35618:Mdm4; NbExp=2; IntAct=EBI-3386480, EBI-2603376;
CC       P53350:PLK1 (xeno); NbExp=2; IntAct=EBI-641788, EBI-476768;
CC       Q5EBH1:Rassf5; NbExp=3; IntAct=EBI-641788, EBI-960530;
CC       Q9CXW4:Rpl11; NbExp=4; IntAct=EBI-641788, EBI-1548890;
CC       P62830:Rpl23; NbExp=2; IntAct=EBI-641788, EBI-2365752;
CC       P47962:Rpl5; NbExp=3; IntAct=EBI-641788, EBI-773940;
CC       Q8BSK8:Rps6kb1; NbExp=2; IntAct=EBI-641788, EBI-646423;
CC       P02340:Tp53; NbExp=5; IntAct=EBI-641788, EBI-474016;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:15195100}. Cytoplasm
CC       {ECO:0000269|PubMed:15195100}. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:15195100}. Note=Colocalizes with RASSF1
CC       isoform A in the nucleus (By similarity). Expressed predominantly
CC       in the nucleoplasm. Interaction with ARF(P14) results in the
CC       localization of both proteins to the nucleolus. The nucleolar
CC       localization signals in both ARF(P14) and MDM2 may be necessary to
CC       allow efficient nucleolar localization of both proteins.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=2;
CC       Name=Mdm2-p90;
CC         IsoId=P23804-1; Sequence=Displayed;
CC       Name=Mdm2-p76;
CC         IsoId=P23804-2; Sequence=VSP_003215;
CC         Note=Does not bind to p53. Can be produced by alternative
CC         initiation at Met-50 of isoform Mdm2-p90, but is produced more
CC         efficiently by alternative splicing.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed at low-level throughout
CC       embryo development and in adult tissues. MDM2-p90 is much more
CC       abundant than MDM2-p76 in testis, brain, heart, and kidney, but in
CC       the thymus, spleen, and intestine, the levels of the MDM2 proteins
CC       are roughly equivalent. {ECO:0000269|PubMed:10075719}.
CC   -!- INDUCTION: By UV light (PubMed:10075719). Down-regulated by NPAS4
CC       (PubMed:25088421). {ECO:0000269|PubMed:10075719,
CC       ECO:0000269|PubMed:25088421}.
CC   -!- DOMAIN: Region I is sufficient for binding p53 and inhibiting its
CC       G1 arrest and apoptosis functions. It also binds p73 and E2F1.
CC       Region II contains most of a central acidic region required for
CC       interaction with ribosomal protein L5 and a putative C4-type zinc
CC       finger. The RING finger domain which coordinates two molecules of
CC       zinc interacts specifically with RNA whether or not zinc is
CC       present and mediates the heterooligomerization with MDM4. It is
CC       also essential for its ubiquitin ligase E3 activity toward p53 and
CC       itself.
CC   -!- PTM: Phosphorylation on Ser-163 by SGK1 activates ubiquitination
CC       of p53/TP53. Phosphorylated at multiple sites near the RING domain
CC       by ATM upon DNA damage; this prevents oligomerization and E3
CC       ligase processivity and impedes constitutive p53/TP53 degradation
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Autoubiquitination leads to proteasomal degradation;
CC       resulting in p53/TP53 activation it may be regulated by SFN. Also
CC       ubiquitinated by TRIM13. Deubiquitinated by USP2 leads to its
CC       accumulation and increases deubiquitination and degradation of
CC       p53/TP53. Deubiquitinated by USP7 leading to its stabilization (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=The gene for this protein is amplified in a mouse
CC       tumor cell line.
CC   -!- SIMILARITY: Belongs to the MDM2/MDM4 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 RanBP2-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00322}.
CC   -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00175}.
CC   -!- SIMILARITY: Contains 1 SWIB domain. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X58876; CAA41684.1; -; mRNA.
DR   EMBL; U40145; AAA91167.1; -; Genomic_DNA.
DR   EMBL; U47944; AAB09030.1; -; Genomic_DNA.
DR   EMBL; U47935; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47936; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47937; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47938; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47939; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47940; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47941; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47942; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47943; AAB09030.1; JOINED; Genomic_DNA.
DR   EMBL; U47934; AAB09031.1; -; mRNA.
DR   EMBL; AK004719; BAB23502.1; -; mRNA.
DR   EMBL; AK088638; BAC40470.1; -; mRNA.
DR   EMBL; BC050902; AAH50902.1; -; mRNA.
DR   CCDS; CCDS24194.1; -. [P23804-1]
DR   CCDS; CCDS70110.1; -. [P23804-2]
DR   PIR; S15349; S15349.
DR   RefSeq; NP_001275515.1; NM_001288586.2. [P23804-2]
DR   RefSeq; NP_034916.1; NM_010786.4. [P23804-1]
DR   UniGene; Mm.22670; -.
DR   UniGene; Mm.447669; -.
DR   ProteinModelPortal; P23804; -.
DR   SMR; P23804; -.
DR   BioGrid; 201372; 85.
DR   DIP; DIP-24174N; -.
DR   DIP; DIP-24196N; -.
DR   IntAct; P23804; 19.
DR   MINT; MINT-139756; -.
DR   STRING; 10090.ENSMUSP00000020408; -.
DR   ChEMBL; CHEMBL3600279; -.
DR   iPTMnet; P23804; -.
DR   PhosphoSitePlus; P23804; -.
DR   PaxDb; P23804; -.
DR   PeptideAtlas; P23804; -.
DR   PRIDE; P23804; -.
DR   Ensembl; ENSMUST00000020408; ENSMUSP00000020408; ENSMUSG00000020184. [P23804-1]
DR   Ensembl; ENSMUST00000105263; ENSMUSP00000100898; ENSMUSG00000020184. [P23804-2]
DR   GeneID; 17246; -.
DR   KEGG; mmu:17246; -.
DR   UCSC; uc007hdl.2; mouse. [P23804-1]
DR   CTD; 4193; -.
DR   MGI; MGI:96952; Mdm2.
DR   eggNOG; ENOG410IGXG; Eukaryota.
DR   eggNOG; ENOG41125MP; LUCA.
DR   GeneTree; ENSGT00530000063539; -.
DR   HOGENOM; HOG000293341; -.
DR   HOVERGEN; HBG013472; -.
DR   InParanoid; P23804; -.
DR   KO; K06643; -.
DR   OMA; GELPCKL; -.
DR   OrthoDB; EOG091G0FYK; -.
DR   TreeFam; TF105306; -.
DR   BRENDA; 6.3.2.19; 3474.
DR   Reactome; R-MMU-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-MMU-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-MMU-2559585; Oncogene Induced Senescence.
DR   Reactome; R-MMU-399719; Trafficking of AMPA receptors.
DR   Reactome; R-MMU-5689880; Ub-specific processing proteases.
DR   Reactome; R-MMU-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-MMU-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-MMU-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-MMU-69541; Stabilization of p53.
DR   ChiTaRS; Mdm2; mouse.
DR   PMAP-CutDB; Q91XK7; -.
DR   PRO; PR:P23804; -.
DR   Proteomes; UP000000589; Chromosome 10.
DR   Bgee; ENSMUSG00000020184; -.
DR   CleanEx; MM_MDM2; -.
DR   ExpressionAtlas; P23804; baseline and differential.
DR   Genevisible; P23804; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0043234; C:protein complex; ISO:MGI.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0016874; F:ligase activity; ISO:MGI.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0019789; F:SUMO transferase activity; ISO:MGI.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:MGI.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:MGI.
DR   GO; GO:0008270; F:zinc ion binding; ISO:MGI.
DR   GO; GO:0003283; P:atrial septum development; IGI:MGI.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; IGI:MGI.
DR   GO; GO:0001568; P:blood vessel development; IMP:MGI.
DR   GO; GO:0001974; P:blood vessel remodeling; IMP:MGI.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IGI:MGI.
DR   GO; GO:0071312; P:cellular response to alkaloid; IEA:Ensembl.
DR   GO; GO:0071236; P:cellular response to antibiotic; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl.
DR   GO; GO:0071301; P:cellular response to vitamin B1; IEA:Ensembl.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; ISO:MGI.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; IMP:MGI.
DR   GO; GO:0045184; P:establishment of protein localization; ISO:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0003170; P:heart valve development; IGI:MGI.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; ISO:MGI.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; ISO:MGI.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0010955; P:negative regulation of protein processing; IEA:Ensembl.
DR   GO; GO:1901797; P:negative regulation of signal transduction by p53 class mediator; ISO:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISO:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0018205; P:peptidyl-lysine modification; ISO:MGI.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISO:MGI.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISO:MGI.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0006461; P:protein complex assembly; ISO:MGI.
DR   GO; GO:0031648; P:protein destabilization; ISO:MGI.
DR   GO; GO:0034504; P:protein localization to nucleus; ISO:MGI.
DR   GO; GO:0016567; P:protein ubiquitination; ISS:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:0002027; P:regulation of heart rate; IGI:MGI.
DR   GO; GO:0042176; P:regulation of protein catabolic process; ISO:MGI.
DR   GO; GO:0009743; P:response to carbohydrate; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045472; P:response to ether; IEA:Ensembl.
DR   GO; GO:0010039; P:response to iron ion; IEA:Ensembl.
DR   GO; GO:0032026; P:response to magnesium ion; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:1990785; P:response to water-immersion restraint stress; IEA:Ensembl.
DR   GO; GO:0007089; P:traversing start control point of mitotic cell cycle; IDA:MGI.
DR   GO; GO:0003281; P:ventricular septum development; IGI:MGI.
DR   Gene3D; 1.10.245.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR028340; Mdm2.
DR   InterPro; IPR015459; MDM2_E3_ligase.
DR   InterPro; IPR016495; p53_neg-reg_MDM_2/4.
DR   InterPro; IPR003121; SWIB_MDM2_domain.
DR   InterPro; IPR001876; Znf_RanBP2.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR13844:SF15; PTHR13844:SF15; 1.
DR   Pfam; PF02201; SWIB; 1.
DR   Pfam; PF00641; zf-RanBP; 1.
DR   PIRSF; PIRSF500700; MDM2; 1.
DR   PIRSF; PIRSF006748; p53_MDM_2/4; 1.
DR   SUPFAM; SSF47592; SSF47592; 2.
DR   SUPFAM; SSF90209; SSF90209; 1.
DR   PROSITE; PS01358; ZF_RANBP2_1; 1.
DR   PROSITE; PS50199; ZF_RANBP2_2; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative initiation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Metal-binding; Nucleus; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    489       E3 ubiquitin-protein ligase Mdm2.
FT                                /FTId=PRO_0000018650.
FT   DOMAIN       27    107       SWIB.
FT   ZN_FING     297    326       RanBP2-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00322}.
FT   ZN_FING     436    477       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        1    110       Necessary for interaction with USP2.
FT                                {ECO:0000250}.
FT   REGION      147    228       Interaction with PYHIN1 and necessary for
FT                                interaction with RFFL and RNF34.
FT                                {ECO:0000250|UniProtKB:Q00987}.
FT   REGION      167    304       Interaction with MTBP.
FT                                {ECO:0000269|PubMed:10906133}.
FT   REGION      208    302       ARF-binding.
FT   REGION      221    230       Interaction with USP7. {ECO:0000250}.
FT   REGION      240    329       Region II.
FT   REGION      274    489       Necessary for interaction with USP2.
FT                                {ECO:0000250}.
FT   MOTIF       176    182       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOTIF       183    195       Nuclear export signal.
FT   MOTIF       464    471       Nucleolar localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    203    213       Poly-Ser.
FT   COMPBIAS    221    299       Asp/Glu-rich (acidic).
FT   MOD_RES     163    163       Phosphoserine; by SGK1. {ECO:0000250}.
FT   MOD_RES     183    183       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES     238    238       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00987}.
FT   MOD_RES     240    240       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00987}.
FT   MOD_RES     244    244       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00987}.
FT   MOD_RES     258    258       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00987}.
FT   MOD_RES     260    260       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q00987}.
FT   MOD_RES     394    394       Phosphoserine; by ATM. {ECO:0000250}.
FT   MOD_RES     406    406       Phosphoserine; by ATM. {ECO:0000250}.
FT   MOD_RES     417    417       Phosphothreonine; by ATM. {ECO:0000250}.
FT   MOD_RES     423    423       Phosphoserine; by ATM. {ECO:0000250}.
FT   MOD_RES     427    427       Phosphoserine; by ATM. {ECO:0000250}.
FT   VAR_SEQ       1     49       Missing (in isoform Mdm2-p76).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_003215.
FT   CONFLICT    203    203       S -> T (in Ref. 1; CAA41684).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       D -> H (in Ref. 1; CAA41684).
FT                                {ECO:0000305}.
FT   CONFLICT    486    486       T -> S (in Ref. 1; CAA41684 and 2;
FT                                AAA91167). {ECO:0000305}.
SQ   SEQUENCE   489 AA;  54558 MW;  4ABF489A82038DF4 CRC64;
     MCNTNMSVST EGAASTSQIP ASEQETLVRP KPLLLKLLKS VGAQNDTYTM KEIIFYIGQY
     IMTKRLYDEK QQHIVYCSND LLGDVFGVPS FSVKEHRKIY AMIYRNLVAV SQQDSGTSLS
     ESRRQPEGGS DLKDPLQAPP EEKPSSSDLI SRLSTSSRRR SISETEENTD ELPGERHRKR
     RRSLSFDPSL GLCELREMCS GGSSSSSSSS SESTETPSHQ DLDDGVSEHS GDCLDQDSVS
     DQFSVEFEVE SLDSEDYSLS DEGHELSDED DEVYRVTVYQ TGESDTDSFE GDPEISLADY
     WKCTSCNEMN PPLPSHCKRC WTLRENWLPD DKGKDKVEIS EKAKLENSAQ AEEGLDVPDG
     KKLTENDAKE PCAEEDSEEK AEQTPLSQES DDYSQPSTSS SIVYSSQESV KELKEETQDK
     DESVESSFSL NAIEPCVICQ GRPKNGCIVH GKTGHLMSCF TCAKKLKKRN KPCPVCRQPI
     QMIVLTYFN
//
ID   TOPRS_HUMAN             Reviewed;        1045 AA.
AC   Q9NS56; O43273; Q6P987; Q9NS55; Q9UNR9;
DT   18-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-NOV-2016, entry version 137.
DE   RecName: Full=E3 ubiquitin-protein ligase Topors;
DE            EC=6.3.2.-;
DE   AltName: Full=SUMO1-protein E3 ligase Topors;
DE   AltName: Full=Topoisomerase I-binding RING finger protein;
DE   AltName: Full=Topoisomerase I-binding arginine/serine-rich protein;
DE   AltName: Full=Tumor suppressor p53-binding protein 3;
DE            Short=p53-binding protein 3;
DE            Short=p53BP3;
GN   Name=TOPORS; Synonyms=LUN, TP53BPL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH TOP1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=10352183; DOI=10.1093/nar/27.12.2538;
RA   Haluska P. Jr., Saleem A., Rasheed Z., Ahmed F., Su E.W., Liu L.F.,
RA   Rubin E.H.;
RT   "Interaction between human topoisomerase I and a novel RING
RT   finger/arginine-serine protein.";
RL   Nucleic Acids Res. 27:2538-2544(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PUTATIVE DNA-BINDING,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Lung;
RX   PubMed=11278651; DOI=10.1074/jbc.M010262200;
RA   Chu D., Kakazu N., Gorrin-Rivas M.J., Lu H.P., Kawata M., Abe T.,
RA   Ueda K., Adachi Y.;
RT   "Cloning and characterization of LUN, a novel RING-finger protein that
RT   is highly expressed in lung and specifically binds to a palindromic
RT   sequence.";
RL   J. Biol. Chem. 276:14004-14013(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   THR-154; LYS-517 AND ASP-749.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 51-1045 (ISOFORM 1), INTERACTION WITH
RP   TP53, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10415337; DOI=10.1016/S0378-1119(99)00203-6;
RA   Zhou R., Wen H., Ao S.-Z.;
RT   "Identification of a novel gene encoding a p53-associated protein.";
RL   Gene 235:93-101(1999).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12083797; DOI=10.1006/excr.2002.5550;
RA   Rasheed Z.A., Saleem A., Ravee Y., Pandolfi P.P., Rubin E.H.;
RT   "The topoisomerase I-binding RING protein, topors, is associated with
RT   promyelocytic leukemia nuclear bodies.";
RL   Exp. Cell Res. 277:152-160(2002).
RN   [7]
RP   INTERACTION WITH SUMO1 AND UBE2I, SUBCELLULAR LOCATION, SUMOYLATION,
RP   AND MUTAGENESIS OF LYS-76; LYS-301; LYS-485; LYS-560 AND LYS-921.
RX   PubMed=14516784; DOI=10.1016/S0014-4827(03)00292-1;
RA   Weger S., Hammer E., Engstler M.;
RT   "The DNA topoisomerase I binding protein topors as a novel cellular
RT   target for SUMO-1 modification: characterization of domains necessary
RT   for subcellular localization and sumolation.";
RL   Exp. Cell Res. 290:13-27(2003).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF TRP-131.
RX   PubMed=15247280; DOI=10.1074/jbc.C400300200;
RA   Rajendra R., Malegaonkar D., Pungaliya P., Marshall H., Rasheed Z.,
RA   Brownell J., Liu L.F., Lutzker S., Saleem A., Rubin E.H.;
RT   "Topors functions as an E3 ubiquitin ligase with specific E2 enzymes
RT   and ubiquitinates p53.";
RL   J. Biol. Chem. 279:36440-36444(2004).
RN   [9]
RP   REDUCED EXPRESSION IN LUNG CANCERS.
RX   PubMed=15364129; DOI=10.1016/j.lungcan.2004.03.009;
RA   Oyanagi H., Takenaka K., Ishikawa S., Kawano Y., Adachi Y., Ueda K.,
RA   Wada H., Tanaka F.;
RT   "Expression of LUN gene that encodes a novel RING finger protein is
RT   correlated with development and progression of non-small cell lung
RT   cancer.";
RL   Lung Cancer 46:21-28(2004).
RN   [10]
RP   TISSUE SPECIFICITY, AND REDUCED EXPRESSION IN COLON CANCERS.
RX   PubMed=15107820; DOI=10.1038/sj.onc.1207700;
RA   Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z.,
RA   Rajendra R., Marshall H., Luo M., Li H., Rubin E.H.;
RT   "The topoisomerase I- and p53-binding protein topors is differentially
RT   expressed in normal and malignant human tissues and may function as a
RT   tumor suppressor.";
RL   Oncogene 23:5293-5300(2004).
RN   [11]
RP   FUNCTION, AND SUMOYLATION.
RX   PubMed=16122737; DOI=10.1016/j.febslet.2005.07.088;
RA   Weger S., Hammer E., Heilbronn R.;
RT   "Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo.";
RL   FEBS Lett. 579:5007-5012(2005).
RN   [12]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=15735665; DOI=10.1038/sj.onc.1208554;
RA   Lin L., Ozaki T., Takada Y., Kageyama H., Nakamura Y., Hata A.,
RA   Zhang J.H., Simonds W.F., Nakagawara A., Koseki H.;
RT   "Topors, a p53 and topoisomerase I-binding RING finger protein, is a
RT   coactivator of p53 in growth suppression induced by DNA damage.";
RL   Oncogene 24:3385-3396(2005).
RN   [13]
RP   INVOLVEMENT IN RP31.
RX   PubMed=17924349; DOI=10.1086/521953;
RA   Chakarova C.F., Papaioannou M.G., Khanna H., Lopez I., Waseem N.,
RA   Shah A., Theis T., Friedman J., Maubaret C., Bujakowska K.,
RA   Veraitch B., El-Aziz M.M.A., Prescott de Q., Parapuram S.K.,
RA   Bickmore W.A., Munro P.M.G., Gal A., Hamel C.P., Marigo V.,
RA   Ponting C.P., Wissinger B., Zrenner E., Matter K., Swaroop A.,
RA   Koenekoop R.K., Bhattacharya S.S.;
RT   "Mutations in TOPORS cause autosomal dominant retinitis pigmentosa
RT   with perivascular retinal pigment epithelium atrophy.";
RL   Am. J. Hum. Genet. 81:1098-1103(2007).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH SIN3A.
RX   PubMed=17803295; DOI=10.1021/pr0703674;
RA   Pungaliya P., Kulkarni D., Park H.J., Marshall H., Zheng H.,
RA   Lackland H., Saleem A., Rubin E.H.;
RT   "TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying
RT   proteins.";
RL   J. Proteome Res. 6:3918-3923(2007).
RN   [15]
RP   PHOSPHORYLATION AT SER-98; SER-499; SER-585 AND SER-866, MUTAGENESIS
RP   OF SER-98, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19053840; DOI=10.1021/bi801904q;
RA   Park H.J., Zheng H., Kulkarni D., Kerrigan J., Pungaliya P.,
RA   Saleem A., Rubin E.H.;
RT   "Identification of phosphorylation sites of TOPORS and a role for
RT   serine 98 in the regulation of ubiquitin but not SUMO E3 ligase
RT   activity.";
RL   Biochemistry 47:13887-13896(2008).
RN   [16]
RP   FUNCTION, INTERACTION WITH NKX3-1, AND SUBCELLULAR LOCATION.
RX   PubMed=18077445; DOI=10.1074/jbc.M708630200;
RA   Guan B., Pungaliya P., Li X., Uquillas C., Mutton L.N., Rubin E.H.,
RA   Bieberich C.J.;
RT   "Ubiquitination by TOPORS regulates the prostate tumor suppressor
RT   NKX3.1.";
RL   J. Biol. Chem. 283:4834-4840(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   FUNCTION, INTERACTION WITH PLK1, PHOSPHORYLATION AT SER-718 BY PLK1,
RP   MUTAGENESIS OF SER-718, AND SUBCELLULAR LOCATION.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   FUNCTION, INTERACTION WITH IKBKE, AND SUBCELLULAR LOCATION.
RX   PubMed=20188669; DOI=10.1016/j.molcel.2010.01.018;
RA   Renner F., Moreno R., Schmitz M.L.;
RT   "SUMOylation-dependent localization of IKKepsilon in PML nuclear
RT   bodies is essential for protection against DNA-damage-triggered cell
RT   death.";
RL   Mol. Cell 37:503-515(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-194; SER-585 AND
RP   SER-734, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76; LYS-83; LYS-249 AND
RP   LYS-701, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [28]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
CC   -!- FUNCTION: Functions as an E3 ubiquitin-protein ligase and as an E3
CC       SUMO1-protein ligase. Probable tumor suppressor involved in cell
CC       growth, cell proliferation and apoptosis that regulates p53/TP53
CC       stability through ubiquitin-dependent degradation. May regulate
CC       chromatin modification through sumoylation of several chromatin
CC       modification-associated proteins. May be involved in DNA damage-
CC       induced cell death through IKBKE sumoylation.
CC       {ECO:0000269|PubMed:15247280, ECO:0000269|PubMed:15735665,
CC       ECO:0000269|PubMed:16122737, ECO:0000269|PubMed:17803295,
CC       ECO:0000269|PubMed:18077445, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:20188669}.
CC   -!- SUBUNIT: Interacts with PARK7/DJ-1 (By similarity). Interacts with
CC       TOP1. Interacts with p53/TP53; can both ubiquitinate and sumoylate
CC       p53/TP53. Interacts with the SUMO1 conjugating enzyme UBE2I.
CC       Interacts with SUMO1. Interacts with NKX3-1; polyubiquitinates
CC       NKX3-1 and induces its proteasomal degradation. Interacts with
CC       SIN3A; sumoylates SIN3A. Interacts with IKBKE; induced by DNA
CC       damage. {ECO:0000250, ECO:0000269|PubMed:10352183,
CC       ECO:0000269|PubMed:10415337, ECO:0000269|PubMed:14516784,
CC       ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:18077445,
CC       ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:20188669}.
CC   -!- INTERACTION:
CC       P03132:Rep68 (xeno); NbExp=3; IntAct=EBI-1996473, EBI-7387242;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, PML body. Note=Localizes
CC       to discrete nuclear foci which partly overlap with PML nuclear
CC       bodies. Targeted to PML nuclear bodies upon DNA damage.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=LUN-1;
CC         IsoId=Q9NS56-1; Sequence=Displayed;
CC       Name=2; Synonyms=LUN-2;
CC         IsoId=Q9NS56-2; Sequence=VSP_017916, VSP_017917;
CC   -!- TISSUE SPECIFICITY: Expressed at highest levels in testis and at
CC       lower levels in adrenal gland, bone marrow, brain, colon, heart,
CC       kidney, liver, muscle, ovary, pancreas, placenta, prostate,
CC       skeletal muscle, skin, small intestine, spleen, stomach, testis,
CC       thymus, thyroid and uterus. Expressed in the alveolar epithelium
CC       of the lung. Expression is commonly decreased in colon
CC       adenocarcinomas and lung cancers. {ECO:0000269|PubMed:10415337,
CC       ECO:0000269|PubMed:11278651, ECO:0000269|PubMed:15107820}.
CC   -!- INDUCTION: By genotoxic agents such as cisplatin and camptothecin.
CC       {ECO:0000269|PubMed:15735665}.
CC   -!- PTM: Phosphorylation at Ser-98 regulates the E3 ubiquitin-protein
CC       ligase activity but not the SUMO1-protein ligase activity.
CC       Phosphorylation at Ser-718 increases the E3 ubiquitin-protein
CC       ligase activity versus the SUMO1-protein ligase activity resulting
CC       in increased p53/TP53 ubiquitination and degradation.
CC       {ECO:0000269|PubMed:19053840, ECO:0000269|PubMed:19473992}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:14516784,
CC       ECO:0000269|PubMed:16122737}.
CC   -!- DISEASE: Retinitis pigmentosa 31 (RP31) [MIM:609923]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies.
CC       Retinitis pigmentosa is characterized by retinal pigment deposits
CC       visible on fundus examination and primary loss of rod
CC       photoreceptor cells followed by secondary loss of cone
CC       photoreceptors. Patients typically have night vision blindness and
CC       loss of midperipheral visual field. As their condition progresses,
CC       they lose their far peripheral visual field and eventually central
CC       vision as well. {ECO:0000269|PubMed:17924349}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00175}.
CC   -!- CAUTION: Was originally thought to bind to the palindromic
CC       consensus sequence 5'-TCCCAGCACTTTGGGA-3' and to regulate the
CC       transcription of numerous genes in the lung.
CC       {ECO:0000305|PubMed:11278651}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC98530.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TOPORSID42663ch9p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF098300; AAD23379.1; -; mRNA.
DR   EMBL; AB045732; BAB03714.1; -; mRNA.
DR   EMBL; AB045733; BAB03715.1; -; mRNA.
DR   EMBL; AL353671; CAH71253.1; -; Genomic_DNA.
DR   EMBL; AL353671; CAH71254.1; -; Genomic_DNA.
DR   EMBL; BC060884; AAH60884.1; -; mRNA.
DR   EMBL; U82939; AAC98530.1; ALT_INIT; mRNA.
DR   CCDS; CCDS56566.1; -. [Q9NS56-2]
DR   CCDS; CCDS6527.1; -. [Q9NS56-1]
DR   RefSeq; NP_001182551.1; NM_001195622.1. [Q9NS56-2]
DR   RefSeq; NP_005793.2; NM_005802.4. [Q9NS56-1]
DR   UniGene; Hs.589962; -.
DR   ProteinModelPortal; Q9NS56; -.
DR   SMR; Q9NS56; -.
DR   BioGrid; 115505; 64.
DR   IntAct; Q9NS56; 19.
DR   MINT; MINT-94004; -.
DR   STRING; 9606.ENSP00000353735; -.
DR   iPTMnet; Q9NS56; -.
DR   PhosphoSitePlus; Q9NS56; -.
DR   BioMuta; TOPORS; -.
DR   DMDM; 74752935; -.
DR   EPD; Q9NS56; -.
DR   MaxQB; Q9NS56; -.
DR   PaxDb; Q9NS56; -.
DR   PeptideAtlas; Q9NS56; -.
DR   PRIDE; Q9NS56; -.
DR   Ensembl; ENST00000360538; ENSP00000353735; ENSG00000197579. [Q9NS56-1]
DR   Ensembl; ENST00000379858; ENSP00000369187; ENSG00000197579. [Q9NS56-2]
DR   GeneID; 10210; -.
DR   KEGG; hsa:10210; -.
DR   UCSC; uc003zrb.4; human. [Q9NS56-1]
DR   CTD; 10210; -.
DR   DisGeNET; 10210; -.
DR   GeneCards; TOPORS; -.
DR   GeneReviews; TOPORS; -.
DR   HGNC; HGNC:21653; TOPORS.
DR   HPA; HPA065661; -.
DR   MalaCards; TOPORS; -.
DR   MIM; 609507; gene.
DR   MIM; 609923; phenotype.
DR   neXtProt; NX_Q9NS56; -.
DR   OpenTargets; ENSG00000197579; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA134979531; -.
DR   eggNOG; KOG4430; Eukaryota.
DR   eggNOG; ENOG410XQZR; LUCA.
DR   GeneTree; ENSGT00530000064170; -.
DR   HOGENOM; HOG000231723; -.
DR   HOVERGEN; HBG080410; -.
DR   InParanoid; Q9NS56; -.
DR   KO; K10631; -.
DR   OMA; DIINFRR; -.
DR   OrthoDB; EOG091G089U; -.
DR   PhylomeDB; Q9NS56; -.
DR   TreeFam; TF339497; -.
DR   SIGNOR; Q9NS56; -.
DR   ChiTaRS; TOPORS; human.
DR   GeneWiki; TOPORS; -.
DR   GenomeRNAi; 10210; -.
DR   PRO; PR:Q9NS56; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000197579; -.
DR   CleanEx; HS_TOPORS; -.
DR   Genevisible; Q9NS56; HS.
DR   GO; GO:0005814; C:centriole; IDA:BHF-UCL.
DR   GO; GO:0036064; C:ciliary basal body; IDA:BHF-UCL.
DR   GO; GO:0000930; C:gamma-tubulin complex; IDA:BHF-UCL.
DR   GO; GO:0030496; C:midbody; TAS:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032391; C:photoreceptor connecting cilium; IDA:BHF-UCL.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IDA:BHF-UCL.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IDA:BHF-UCL.
DR   GO; GO:0003823; F:antigen binding; IPI:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0044547; F:DNA topoisomerase binding; IPI:UniProtKB.
DR   GO; GO:0016874; F:ligase activity; IEA:UniProtKB-KW.
DR   GO; GO:0019789; F:SUMO transferase activity; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0051457; P:maintenance of protein location in nucleus; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0035845; P:photoreceptor cell outer segment organization; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; IDA:BHF-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB.
DR   GO; GO:0006513; P:protein monoubiquitination; IDA:BHF-UCL.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:BHF-UCL.
DR   GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010842; P:retina layer formation; ISS:BHF-UCL.
DR   GO; GO:0046549; P:retinal cone cell development; ISS:BHF-UCL.
DR   GO; GO:0046548; P:retinal rod cell development; ISS:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; DNA damage; Isopeptide bond;
KW   Ligase; Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Retinitis pigmentosa; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1   1045       E3 ubiquitin-protein ligase Topors.
FT                                /FTId=PRO_0000232626.
FT   ZN_FING     103    142       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        1    195       E3 ubiquitin-protein ligase activity.
FT   REGION       51    374       Required for DNA-binding.
FT   REGION      437    654       Interaction with SUMO1.
FT                                {ECO:0000269|PubMed:14516784}.
FT   REGION      437    574       Required for sumoylation and localization
FT                                to discrete nuclear foci.
FT   REGION      456    882       Interaction with TOP1.
FT                                {ECO:0000269|PubMed:10352183}.
FT   REGION      456    731       Interaction with p53/TP53.
FT                                {ECO:0000269|PubMed:10415337}.
FT   REGION      854    917       Interaction with UBE2I.
FT                                {ECO:0000269|PubMed:14516784}.
FT   COMPBIAS    579    788       Arg-rich.
FT   COMPBIAS    854    895       Lys-rich.
FT   MOD_RES      98     98       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:19053840}.
FT   MOD_RES     194    194       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     499    499       Phosphoserine.
FT                                {ECO:0000269|PubMed:19053840}.
FT   MOD_RES     585    585       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:19053840}.
FT   MOD_RES     718    718       Phosphoserine; by PLK1.
FT                                {ECO:0000269|PubMed:19473992}.
FT   MOD_RES     734    734       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     864    864       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     866    866       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:19053840}.
FT   MOD_RES     912    912       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80Z37}.
FT   MOD_RES     914    914       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80Z37}.
FT   MOD_RES    1028   1028       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80Z37}.
FT   CROSSLNK     76     76       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK     83     83       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    249    249       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    560    560       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    701    701       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ       1     65       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11278651}.
FT                                /FTId=VSP_017916.
FT   VAR_SEQ      66     66       E -> M (in isoform 2).
FT                                {ECO:0000303|PubMed:11278651}.
FT                                /FTId=VSP_017917.
FT   VARIANT     154    154       A -> T (in dbSNP:rs17855104).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037629.
FT   VARIANT     517    517       E -> K (in dbSNP:rs17855103).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037630.
FT   VARIANT     749    749       N -> D (in dbSNP:rs17857515).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037631.
FT   VARIANT     812    812       P -> R (in dbSNP:rs36034138).
FT                                /FTId=VAR_037632.
FT   MUTAGEN      76     76       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN      98     98       S->A: Loss of phosphorylation but no
FT                                effect on E3 ubiquitin-protein ligase
FT                                activity. {ECO:0000269|PubMed:19053840}.
FT   MUTAGEN      98     98       S->D: Increase in E3 ubiquitin-protein
FT                                ligase activity and increased binding to
FT                                UBE2D1. No effect on SUMO1-protein ligase
FT                                activity. {ECO:0000269|PubMed:19053840}.
FT   MUTAGEN     131    131       W->A: Abrogates E3 ubiquitin-protein
FT                                ligase activity.
FT                                {ECO:0000269|PubMed:15247280}.
FT   MUTAGEN     301    301       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN     485    485       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN     560    560       K->R: Strongly reduces sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   MUTAGEN     718    718       S->A: Loss of phosphorylation by PLK1 and
FT                                increases in p53/TP53 stability.
FT                                {ECO:0000269|PubMed:19473992}.
FT   MUTAGEN     921    921       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:14516784}.
FT   CONFLICT    124    125       CF -> K (in Ref. 5; AAC98530).
FT                                {ECO:0000305}.
FT   CONFLICT    257    257       N -> S (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
FT   CONFLICT    308    308       F -> S (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
FT   CONFLICT    922    922       E -> G (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
FT   CONFLICT   1040   1040       R -> K (in Ref. 1; AAD23379).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1045 AA;  119198 MW;  3DA635FDB5C83B77 CRC64;
     MGSQPPLGSP LSREEGEAPP PAPASEGRRR SRRVRLRGSC RHRPSFLGCR ELAASAPARP
     APASSEIMAS AAKEFKMDNF SPKAGTSKLQ QTVPADASPD SKCPICLDRF DNVSYLDRCL
     HKFCFRCVQE WSKNKAECPL CKQPFDSIFH SVRAEDDFKE YVLRPSYNGS FVTPDRRFRY
     RTTLTRERNA SVYSPSGPVN RRTTTPPDSG VLFEGLGIST RPRDVEIPQF MRQIAVRRPT
     TADERSLRKI QEQDIINFRR TLYRAGARVR NIEDGGRYRD ISAEFFRRNP ACLHRLVPWL
     KRELTVLFGA HGSLVNIVQH IIMSNVTRYD LESQAFVSDL RPFLLNRTEH FIHEFISFAR
     SPFNMAAFDQ HANYDCPAPS YEEGSHSDSS VITISPDEAE TQELDINVAT VSQAPWDDET
     PGPSYSSSEQ VHVTMSSLLN TSDSSDEELV TGGATSQIQG VQTNDDLNND SDDSSDNCVI
     VGFVKPLAER TPELVELSSD SEDLGSYEKM ETVKTQEQEQ SYSSGDSDVS RCSSPHSVLG
     KDEQINKGHC DSSTRIKSKK EEKRSTSLSS PRNLNSSVRG DRVYSPYNHR HRKRGRSRSS
     DSRSQSRSGH DQKNHRKHHG KKRMKSKRSR SRESSRPRGR RDKKRSRTRD SSWSRRSQTL
     SLSSESTSRS RSRSSDHGKR RSRSRNRDRY YLRNNYGSRY KWEYTYYSRN KDRDGYESSY
     RRRTLSRAHY SRQSSSPEFR VQSFSERTNA RKKNNHSERK YYYYERHRSR SLSSNRSRTA
     STGTDRVRNE KPGGKRKYKT RHLEGTNEVA QPSREFASKA KDSHYQKSSS KLDGNYKNES
     DTFSDSRSSD RETKHKRRKR KTRSLSVEIV YEGKATDTTK HHKKKKKKHK KKHKKHHGDN
     ASRSPVVITI DSDSDKDSEV KEDTECDNSG PQDPLQNEFL APSLEPFETK DVVTIEAEFG
     VLDKECDIAT LSNNLNNANK TVDNIPPLAA SVEQTLDVRE ESTFVSDLEN QPSNIVSLQT
     EPSRQLPSPR TSLMSVCLGR DCDMS
//
ID   ASPP2_HUMAN             Reviewed;        1128 AA.
AC   Q13625; B4DG66; Q12892; Q86X75; Q96KQ3;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-AUG-2003, sequence version 2.
DT   18-JAN-2017, entry version 179.
DE   RecName: Full=Apoptosis-stimulating of p53 protein 2;
DE   AltName: Full=Bcl2-binding protein;
DE            Short=Bbp;
DE   AltName: Full=Renal carcinoma antigen NY-REN-51;
DE   AltName: Full=Tumor suppressor p53-binding protein 2;
DE            Short=53BP2;
DE            Short=p53-binding protein 2;
DE            Short=p53BP2;
GN   Name=TP53BP2; Synonyms=ASPP2, BBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND INTERACTION WITH BCL2.
RX   PubMed=8668206; DOI=10.1128/MCB.16.7.3884;
RA   Naumovski L., Cleary M.L.;
RT   "The p53-binding protein 53BP2 also interacts with Bcl2 and impedes
RT   cell cycle progression at G2/M.";
RL   Mol. Cell. Biol. 16:3884-3892(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND INTERACTION WITH TP53.
RX   PubMed=11684014; DOI=10.1016/S1097-2765(01)00367-7;
RA   Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G.,
RA   Hsieh J.-K., Zhong S., Campargue I., Naumovski L., Crook T., Lu X.;
RT   "ASPP proteins specifically stimulate the apoptotic function of p53.";
RL   Mol. Cell 8:781-794(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 600-1128, AND INTERACTION WITH TP53.
RX   PubMed=8016121; DOI=10.1073/pnas.91.13.6098;
RA   Iwabuchi K., Bartel P.L., Li B., Marraccino R., Fields S.;
RT   "Two cellular proteins that bind to wild-type but not mutant p53.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6098-6102(1994).
RN   [7]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [8]
RP   TISSUE SPECIFICITY, AND INTERACTION WITH RELA.
RX   PubMed=10498867; DOI=10.1038/sj.onc.1202904;
RA   Yang J.-P., Hori M., Takahashi N., Kawabe T., Kato H., Okamoto T.;
RT   "NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced
RT   by 53BP2.";
RL   Oncogene 18:5177-5186(1999).
RN   [9]
RP   INTERACTION WITH APC2, MUTAGENESIS OF TRP-1098, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10646860;
RA   Nakagawa H., Koyama K., Murata Y., Morito M., Akiyama T., Nakamura Y.;
RT   "APCL, a central nervous system-specific homologue of adenomatous
RT   polyposis coli tumor suppressor, binds to p53-binding protein 2 and
RT   translocates it to the perinucleus.";
RL   Cancer Res. 60:101-105(2000).
RN   [10]
RP   INDUCTION.
RX   PubMed=11027272; DOI=10.1128/MCB.20.21.8018-8025.2000;
RA   Lopez C.D., Ao Y., Rohde L.H., Perez T.D., O'Connor D.J., Lu X.,
RA   Ford J.M., Naumovski L.;
RT   "Proapoptotic p53-interacting protein 53BP2 is induced by UV
RT   irradiation but suppressed by p53.";
RL   Mol. Cell. Biol. 20:8018-8025(2000).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=10631318; DOI=10.1016/S0014-5793(99)01726-3;
RA   Mori T., Okamoto H., Takahashi N., Ueda R., Okamoto T.;
RT   "Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines.";
RL   FEBS Lett. 465:124-128(2000).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH APPBP1.
RX   PubMed=12694406;
RA   Chen Y., Liu W., Naumovski L., Neve R.L.;
RT   "ASPP2 inhibits APP-BP1-mediated NEDD8 conjugation to cullin-1 and
RT   decreases APP-BP1-induced cell proliferation and neuronal apoptosis.";
RL   J. Neurochem. 85:801-809(2003).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480 AND SER-556, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   FUNCTION, INTERACTION WITH DDX42, AND SUBCELLULAR LOCATION.
RX   PubMed=19377511; DOI=10.1038/onc.2009.75;
RA   Uhlmann-Schiffler H., Kiermayer S., Stahl H.;
RT   "The DEAD box protein Ddx42p modulates the function of ASPP2, a
RT   stimulator of apoptosis.";
RL   Oncogene 28:2065-2073(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480; SER-556 AND
RP   SER-572, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480; SER-556; SER-569;
RP   SER-576; SER-714 AND SER-737, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   ANKYRIN REPEATS.
RX   PubMed=25547411; DOI=10.1186/s12859-014-0440-9;
RA   Chakrabarty B., Parekh N.;
RT   "Identifying tandem Ankyrin repeats in protein structures.";
RL   BMC Bioinformatics 15:6599-6599(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 892-1128.
RX   PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
RT   domains of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [24]
RP   STRUCTURE BY NMR OF 1-83.
RX   PubMed=17594908; DOI=10.1016/j.jmb.2007.05.024;
RA   Tidow H., Andreeva A., Rutherford T.J., Fersht A.R.;
RT   "Solution structure of ASPP2 N-terminal domain (N-ASPP2) reveals a
RT   ubiquitin-like fold.";
RL   J. Mol. Biol. 371:948-958(2007).
CC   -!- FUNCTION: Regulator that plays a central role in regulation of
CC       apoptosis and cell growth via its interactions. Regulates TP53 by
CC       enhancing the DNA binding and transactivation function of TP53 on
CC       the promoters of proapoptotic genes in vivo. Inhibits the ability
CC       of APPBP1 to conjugate NEDD8 to CUL1, and thereby decreases APPBP1
CC       ability to induce apoptosis. Impedes cell cycle progression at
CC       G2/M. Its apoptosis-stimulating activity is inhibited by its
CC       interaction with DDX42. {ECO:0000269|PubMed:11684014,
CC       ECO:0000269|PubMed:12694406, ECO:0000269|PubMed:19377511}.
CC   -!- SUBUNIT: Binds to the central domain of TP53 as well as to BCL2.
CC       Interacts with protein phosphatase 1. Interacts with RELA NF-
CC       kappa-B subunit. This interaction probably prevents the activation
CC       of apoptosis, possibly by preventing its interaction with TP53.
CC       Interacts with APC2 and APPBP1. Interacts with DDX42 (via the C-
CC       terminus); the interaction is not inhibited by TP53BP2
CC       ubiquitination and is independent of p53/TP53.
CC       {ECO:0000269|PubMed:10498867, ECO:0000269|PubMed:10646860,
CC       ECO:0000269|PubMed:11684014, ECO:0000269|PubMed:12694406,
CC       ECO:0000269|PubMed:19377511, ECO:0000269|PubMed:8016121,
CC       ECO:0000269|PubMed:8668206}.
CC   -!- INTERACTION:
CC       Self; NbExp=7; IntAct=EBI-77642, EBI-77642;
CC       A8KAD6:-; NbExp=3; IntAct=EBI-10175039, EBI-10174974;
CC       P27958:- (xeno); NbExp=5; IntAct=EBI-77642, EBI-6377335;
CC       O95996:APC2; NbExp=4; IntAct=EBI-77642, EBI-1053045;
CC       P05067:APP; NbExp=3; IntAct=EBI-77642, EBI-77613;
CC       Q8N5M1:ATPAF2; NbExp=3; IntAct=EBI-10175039, EBI-1166928;
CC       Q9UQB8:BAIAP2; NbExp=3; IntAct=EBI-10175039, EBI-525456;
CC       P10415:BCL2; NbExp=13; IntAct=EBI-77642, EBI-77694;
CC       Q07817-1:BCL2L1; NbExp=4; IntAct=EBI-77642, EBI-287195;
CC       Q92843:BCL2L2; NbExp=2; IntAct=EBI-77642, EBI-707714;
CC       Q53HC0:CCDC92; NbExp=3; IntAct=EBI-10175039, EBI-719994;
CC       Q96GG9:DCUN1D1; NbExp=3; IntAct=EBI-10175039, EBI-740086;
CC       Q09472:EP300; NbExp=2; IntAct=EBI-77642, EBI-447295;
CC       P62993:GRB2; NbExp=3; IntAct=EBI-10175039, EBI-401755;
CC       P62807:HIST1H2BI; NbExp=3; IntAct=EBI-10175039, EBI-354552;
CC       Q9BUJ2:HNRNPUL1; NbExp=3; IntAct=EBI-10175039, EBI-1018153;
CC       P35569:Irs1 (xeno); NbExp=2; IntAct=EBI-287091, EBI-400825;
CC       P35570:Irs1 (xeno); NbExp=4; IntAct=EBI-287091, EBI-520230;
CC       Q96J02:ITCH; NbExp=2; IntAct=EBI-77642, EBI-1564678;
CC       P61968:LMO4; NbExp=3; IntAct=EBI-10175039, EBI-2798728;
CC       Q8NCE2:MTMR14; NbExp=3; IntAct=EBI-10175039, EBI-5658424;
CC       O14777:NDC80; NbExp=3; IntAct=EBI-10175039, EBI-715849;
CC       Q86Y26:NUTM1; NbExp=3; IntAct=EBI-10175039, EBI-10178410;
CC       Q9UBU9:NXF1; NbExp=3; IntAct=EBI-10175039, EBI-398874;
CC       Q96DC9:OTUB2; NbExp=3; IntAct=EBI-10175039, EBI-746259;
CC       Q494U1:PLEKHN1; NbExp=3; IntAct=EBI-10175039, EBI-10241513;
CC       P62875:POLR2L; NbExp=3; IntAct=EBI-10175039, EBI-359527;
CC       P62136:PPP1CA; NbExp=7; IntAct=EBI-77642, EBI-357253;
CC       P62140:PPP1CB; NbExp=3; IntAct=EBI-10175039, EBI-352350;
CC       P36873:PPP1CC; NbExp=6; IntAct=EBI-77642, EBI-356283;
CC       F1T0A5:PRPF31; NbExp=3; IntAct=EBI-10175039, EBI-10177194;
CC       P62826:RAN; NbExp=5; IntAct=EBI-77642, EBI-286642;
CC       Q04206:RELA; NbExp=6; IntAct=EBI-287091, EBI-73886;
CC       Q8IUQ4:SIAH1; NbExp=3; IntAct=EBI-10175039, EBI-747107;
CC       Q9Y2D8:SSX2IP; NbExp=3; IntAct=EBI-10175039, EBI-2212028;
CC       Q92844:TANK; NbExp=3; IntAct=EBI-10175039, EBI-356349;
CC       Q9NU19:TBC1D22B; NbExp=3; IntAct=EBI-10175039, EBI-8787464;
CC       P56279:TCL1A; NbExp=3; IntAct=EBI-10175039, EBI-749995;
CC       P04637:TP53; NbExp=5; IntAct=EBI-77642, EBI-366083;
CC       Q9BUZ4:TRAF4; NbExp=3; IntAct=EBI-10175039, EBI-3650647;
CC       P40222:TXLNA; NbExp=3; IntAct=EBI-10175039, EBI-359793;
CC       P57075:UBASH3A; NbExp=3; IntAct=EBI-10175039, EBI-2105393;
CC       P46936:YAP1 (xeno); NbExp=6; IntAct=EBI-287091, EBI-7804091;
CC       P46937:YAP1; NbExp=9; IntAct=EBI-287091, EBI-1044059;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-77642, EBI-347088;
CC       Q8N5A5:ZGPAT; NbExp=3; IntAct=EBI-10175039, EBI-3439227;
CC       Q8N5A5-2:ZGPAT; NbExp=3; IntAct=EBI-10175039, EBI-10183064;
CC       P17031:ZNF26; NbExp=5; IntAct=EBI-10175039, EBI-2841331;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Nucleus.
CC       Note=Predominantly found in the perinuclear region. Some small
CC       fraction is nuclear. Sequester in the cytoplasm on overexpression
CC       of DDX42.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q13625-1; Sequence=Displayed;
CC       Name=2; Synonyms=Bbp;
CC         IsoId=Q13625-2; Sequence=VSP_008010;
CC         Note=Due to Alu sequence insertion that creates a shorter but
CC         existing form that may have an alternative function.;
CC       Name=3;
CC         IsoId=Q13625-3; Sequence=VSP_043509;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed in spleen, thymus,
CC       prostate, testis, ovary, small intestine, colon and peripheral
CC       blood leukocyte. Reduced expression in breast carcinomas
CC       expressing a wild-type TP53 protein. Overexpressed in lung cancer
CC       cell lines. {ECO:0000269|PubMed:10498867,
CC       ECO:0000269|PubMed:10631318, ECO:0000269|PubMed:11684014}.
CC   -!- INDUCTION: Following DNA damage induced by UV irradiation. Down-
CC       regulated by wild-type, but not mutant, p53/TP53.
CC       {ECO:0000269|PubMed:11027272}.
CC   -!- DOMAIN: The ankyrin repeats and the SH3 domain are required for a
CC       specific interactions with TP53.
CC   -!- SIMILARITY: Belongs to the ASPP family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 ANK repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00023, ECO:0000305|PubMed:25547411}.
CC   -!- SIMILARITY: Contains 1 SH3 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00192}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH46150.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAH46150.2; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH58918.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TP53BP2ID42667ch1q42.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U58334; AAC50557.1; -; mRNA.
DR   EMBL; AJ318888; CAC83012.1; -; mRNA.
DR   EMBL; AK294432; BAG57677.1; -; mRNA.
DR   EMBL; AC096542; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC046150; AAH46150.2; ALT_SEQ; mRNA.
DR   EMBL; BC058918; AAH58918.2; ALT_INIT; mRNA.
DR   EMBL; U09582; AAA21597.1; -; mRNA.
DR   CCDS; CCDS1538.1; -. [Q13625-2]
DR   CCDS; CCDS44319.1; -. [Q13625-3]
DR   PIR; I38607; I38607.
DR   RefSeq; NP_001026855.2; NM_001031685.2. [Q13625-3]
DR   RefSeq; NP_005417.1; NM_005426.2. [Q13625-2]
DR   RefSeq; XP_011542571.1; XM_011544269.2. [Q13625-2]
DR   UniGene; Hs.523968; -.
DR   PDB; 1YCS; X-ray; 2.20 A; B=892-1126.
DR   PDB; 2UWQ; NMR; -; A=1-83.
DR   PDB; 4A63; X-ray; 2.27 A; B/D/F/H/J/L=892-1128.
DR   PDB; 4IRV; X-ray; 2.04 A; E/F/G/H=726-782.
DR   PDBsum; 1YCS; -.
DR   PDBsum; 2UWQ; -.
DR   PDBsum; 4A63; -.
DR   PDBsum; 4IRV; -.
DR   ProteinModelPortal; Q13625; -.
DR   SMR; Q13625; -.
DR   BioGrid; 113012; 109.
DR   DIP; DIP-426N; -.
DR   IntAct; Q13625; 113.
DR   MINT; MINT-106406; -.
DR   STRING; 9606.ENSP00000341957; -.
DR   iPTMnet; Q13625; -.
DR   PhosphoSitePlus; Q13625; -.
DR   BioMuta; TP53BP2; -.
DR   DMDM; 33860140; -.
DR   EPD; Q13625; -.
DR   MaxQB; Q13625; -.
DR   PaxDb; Q13625; -.
DR   PeptideAtlas; Q13625; -.
DR   PRIDE; Q13625; -.
DR   Ensembl; ENST00000343537; ENSP00000341957; ENSG00000143514. [Q13625-3]
DR   Ensembl; ENST00000391878; ENSP00000375750; ENSG00000143514. [Q13625-2]
DR   GeneID; 7159; -.
DR   KEGG; hsa:7159; -.
DR   UCSC; uc001hod.4; human. [Q13625-1]
DR   CTD; 7159; -.
DR   DisGeNET; 7159; -.
DR   GeneCards; TP53BP2; -.
DR   HGNC; HGNC:12000; TP53BP2.
DR   HPA; HPA021603; -.
DR   HPA; HPA050429; -.
DR   MIM; 602143; gene.
DR   neXtProt; NX_Q13625; -.
DR   OpenTargets; ENSG00000143514; -.
DR   PharmGKB; PA36681; -.
DR   eggNOG; KOG0515; Eukaryota.
DR   eggNOG; ENOG410Y17W; LUCA.
DR   GeneTree; ENSGT00760000119141; -.
DR   HOGENOM; HOG000034106; -.
DR   HOVERGEN; HBG050596; -.
DR   InParanoid; Q13625; -.
DR   KO; K16823; -.
DR   OMA; LYQRTTL; -.
DR   OrthoDB; EOG091G0R1R; -.
DR   PhylomeDB; Q13625; -.
DR   TreeFam; TF105545; -.
DR   BioCyc; ZFISH:ENSG00000143514-MONOMER; -.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   SIGNOR; Q13625; -.
DR   ChiTaRS; TP53BP2; human.
DR   EvolutionaryTrace; Q13625; -.
DR   GeneWiki; TP53BP2; -.
DR   GenomeRNAi; 7159; -.
DR   PRO; PR:Q13625; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143514; -.
DR   CleanEx; HS_TP53BP2; -.
DR   ExpressionAtlas; Q13625; baseline and differential.
DR   Genevisible; Q13625; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:AgBase.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051059; F:NF-kappaB binding; IPI:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:AgBase.
DR   GO; GO:0005070; F:SH3/SH2 adaptor activity; TAS:ProtInc.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase.
DR   GO; GO:1901216; P:positive regulation of neuron death; IEA:Ensembl.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR013315; Spectrin_alpha_SH3.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR01887; SPECTRNALPHA.
DR   SMART; SM00248; ANK; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ANK repeat; Apoptosis; Cell cycle;
KW   Complete proteome; Cytoplasm; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; SH3 domain; SH3-binding.
FT   CHAIN         1   1128       Apoptosis-stimulating of p53 protein 2.
FT                                /FTId=PRO_0000066964.
FT   REPEAT      926    957       ANK 1.
FT   REPEAT      958    990       ANK 2.
FT   REPEAT      991   1024       ANK 3.
FT   REPEAT     1025   1067       ANK 4.
FT   DOMAIN     1057   1119       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   REGION      332    348       Interaction with APPBP1.
FT                                {ECO:0000269|PubMed:12694406}.
FT   REGION      876   1128       Mediates interaction with APC2.
FT                                {ECO:0000269|PubMed:10646860}.
FT   MOTIF       866    875       SH3-binding. {ECO:0000255}.
FT   COMPBIAS    132    173       Gln-rich.
FT   COMPBIAS    824    902       Pro-rich.
FT   MOD_RES     480    480       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     556    556       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     569    569       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     572    572       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     576    576       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     698    698       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8CG79}.
FT   MOD_RES     714    714       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     737    737       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    123       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8668206}.
FT                                /FTId=VSP_008010.
FT   VAR_SEQ       1      1       M -> MRFGSKM (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043509.
FT   MUTAGEN    1098   1098       W->K: Loss of interaction with APC2.
FT                                {ECO:0000269|PubMed:10646860}.
FT   STRAND        2      9       {ECO:0000244|PDB:2UWQ}.
FT   STRAND       17     22       {ECO:0000244|PDB:2UWQ}.
FT   HELIX        29     34       {ECO:0000244|PDB:2UWQ}.
FT   STRAND       40     42       {ECO:0000244|PDB:2UWQ}.
FT   STRAND       44     49       {ECO:0000244|PDB:2UWQ}.
FT   STRAND       52     56       {ECO:0000244|PDB:2UWQ}.
FT   HELIX        62     69       {ECO:0000244|PDB:2UWQ}.
FT   HELIX        73     75       {ECO:0000244|PDB:2UWQ}.
FT   STRAND       77     81       {ECO:0000244|PDB:2UWQ}.
FT   HELIX       747    760       {ECO:0000244|PDB:4IRV}.
FT   TURN        761    764       {ECO:0000244|PDB:4IRV}.
FT   HELIX       927    936       {ECO:0000244|PDB:1YCS}.
FT   HELIX       939    945       {ECO:0000244|PDB:1YCS}.
FT   HELIX       946    948       {ECO:0000244|PDB:4A63}.
FT   HELIX       962    969       {ECO:0000244|PDB:1YCS}.
FT   HELIX       972    981       {ECO:0000244|PDB:1YCS}.
FT   HELIX       995   1001       {ECO:0000244|PDB:1YCS}.
FT   HELIX      1005   1013       {ECO:0000244|PDB:1YCS}.
FT   STRAND     1023   1025       {ECO:0000244|PDB:1YCS}.
FT   HELIX      1029   1032       {ECO:0000244|PDB:1YCS}.
FT   STRAND     1035   1037       {ECO:0000244|PDB:1YCS}.
FT   HELIX      1043   1053       {ECO:0000244|PDB:1YCS}.
FT   TURN       1054   1057       {ECO:0000244|PDB:1YCS}.
FT   HELIX      1058   1060       {ECO:0000244|PDB:1YCS}.
FT   STRAND     1061   1066       {ECO:0000244|PDB:1YCS}.
FT   STRAND     1083   1086       {ECO:0000244|PDB:1YCS}.
FT   STRAND     1091   1093       {ECO:0000244|PDB:4A63}.
FT   STRAND     1095   1102       {ECO:0000244|PDB:1YCS}.
FT   STRAND     1105   1110       {ECO:0000244|PDB:1YCS}.
FT   HELIX      1111   1113       {ECO:0000244|PDB:1YCS}.
FT   STRAND     1114   1117       {ECO:0000244|PDB:4A63}.
SQ   SEQUENCE   1128 AA;  125616 MW;  C75D056FBC1DAD75 CRC64;
     MMPMFLTVYL SNNEQHFTEV PVTPETICRD VVDLCKEPGE SDCHLAEVWC GSERPVADNE
     RMFDVLQRFG SQRNEVRFFL RHERPPGRDI VSGPRSQDPS LKRNGVKVPG EYRRKENGVN
     SPRMDLTLAE LQEMASRQQQ QIEAQQQLLA TKEQRLKFLK QQDQRQQQQV AEQEKLKRLK
     EIAENQEAKL KKVRALKGHV EQKRLSNGKL VEEIEQMNNL FQQKQRELVL AVSKVEELTR
     QLEMLKNGRI DSHHDNQSAV AELDRLYKEL QLRNKLNQEQ NAKLQQQREC LNKRNSEVAV
     MDKRVNELRD RLWKKKAALQ QKENLPVSSD GNLPQQAASA PSRVAAVGPY IQSSTMPRMP
     SRPELLVKPA LPDGSLVIQA SEGPMKIQTL PNMRSGAASQ TKGSKIHPVG PDWSPSNADL
     FPSQGSASVP QSTGNALDQV DDGEVPLREK EKKVRPFSMF DAVDQSNAPP SFGTLRKNQS
     SEDILRDAQV ANKNVAKVPP PVPTKPKQIN LPYFGQTNQP PSDIKPDGSS QQLSTVVPSM
     GTKPKPAGQQ PRVLLSPSIP SVGQDQTLSP GSKQESPPAA AVRPFTPQPS KDTLLPPFRK
     PQTVAASSIY SMYTQQQAPG KNFQQAVQSA LTKTHTRGPH FSSVYGKPVI AAAQNQQQHP
     ENIYSNSQGK PGSPEPETEP VSSVQENHEN ERIPRPLSPT KLLPFLSNPY RNQSDADLEA
     LRKKLSNAPR PLKKRSSITE PEGPNGPNIQ KLLYQRTTIA AMETISVPSY PSKSASVTAS
     SESPVEIQNP YLHVEPEKEV VSLVPESLSP EDVGNASTEN SDMPAPSPGL DYEPEGVPDN
     SPNLQNNPEE PNPEAPHVLD VYLEEYPPYP PPPYPSGEPE GPGEDSVSMR PPEITGQVSL
     PPGKRTNLRK TGSERIAHGM RVKFNPLALL LDSSLEGEFD LVQRIIYEVD DPSLPNDEGI
     TALHNAVCAG HTEIVKFLVQ FGVNVNAADS DGWTPLHCAA SCNNVQVCKF LVESGAAVFA
     MTYSDMQTAA DKCEEMEEGY TQCSQFLYGV QEKMGIMNKG VIYALWDYEP QNDDELPMKE
     GDCMTIIHRE DEDEIEWWWA RLNDKEGYVP RNLLGLYPRI KPRQRSLA
//
ID   P53_RAT                 Reviewed;         391 AA.
AC   P10361; O09168; Q4KMA9; Q66HM0;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   30-NOV-2016, entry version 192.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=Tp53; Synonyms=P53;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3060862; DOI=10.1093/nar/16.23.11384;
RA   Soussi T.;
RT   "Nucleotide sequence of a cDNA encoding the rat p53 nuclear
RT   oncoprotein.";
RL   Nucleic Acids Res. 16:11384-11384(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8441680; DOI=10.1093/nar/21.3.713;
RA   Hulla J.E., Schneider R.P.;
RT   "Structure of the rat p53 tumor suppressor gene.";
RL   Nucleic Acids Res. 21:713-717(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RX   PubMed=9278438; DOI=10.1074/jbc.272.36.22776;
RA   Mathupala S.P., Heese C., Pedersen P.L.;
RT   "Glucose catabolism in cancer cells. The type II hexokinase promoter
RT   contains functionally active response elements for the tumor
RT   suppressor p53.";
RL   J. Biol. Chem. 272:22776-22780(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart, and Thymus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH HSP90AB1.
RC   TISSUE=Embryo;
RX   PubMed=8663025; DOI=10.1074/jbc.271.25.15084;
RA   Sepehrnia B., Paz I.B., Dasgupta G., Momand J.;
RT   "Heat shock protein 84 forms a complex with mutant p53 protein
RT   predominantly within a cytoplasmic compartment of the cell.";
RL   J. Biol. Chem. 271:15084-15090(1996).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S.,
RA   Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       BANP. Interacts with ARMD10, E4F1, CDKN2AIP, NUAK1, UHRF2 and
CC       STK11/LKB1. Interacts with CHD8, leading to recruit histone H1 and
CC       prevent transactivation activity. Interacts with YWHAZ; the
CC       interaction enhances TP53 transcriptional activity.
CC       Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction.
CC       Interacts with HSP90AB1. Directly interacts with FBXO42; leading
CC       to ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-380)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts with ZNF385A; the interaction is
CC       direct and enhances p53/TP53 transactivation functions on cell-
CC       cycle arrest target genes, resulting in growth arrest. Interacts
CC       with ANKRD2. Interacts with RFFL and RNF34; involved in p53/TP53
CC       ubiquitination. Interacts with MTA1 and RFWD2. Interacts with
CC       CCAR2 (via N-terminus). Interacts with MORC3.
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000269|PubMed:22726440}. Note=Interaction with BANP
CC       promotes nuclear localization. Translocates to mitochondria upon
CC       oxidative stress (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-
CC       18 by VRK1, which may prevent the interaction with MDM2.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Probably phosphorylated on by CDK7 in a CAK
CC       complex in response to DNA damage. Phosphorylated by HIPK1.
CC       Phosphorylated on Ser-390 following UV but not gamma irradiation.
CC       Phosphorylated on Ser-15 upon ultraviolet irradiation; which is
CC       enhanced by interaction with BANP. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, leading to accumulation of p53/TP53, particularly in the
CC       nucleus, thus inducing the transactivation of p53/TP53 target
CC       genes. Phosphorylated at Ser-313 and Ser-390 by CDK2 in response
CC       to DNA-damage (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-289 and Lys-290, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-370 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       368 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-370
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-368. Dimethylated at Lys-371 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-380 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-368 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-384 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13058; CAA31457.1; -; mRNA.
DR   EMBL; L07910; AAA41788.1; -; Genomic_DNA.
DR   EMBL; L07904; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07905; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07906; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07907; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07908; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07909; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; U90328; AAB80959.1; -; mRNA.
DR   EMBL; BC081788; AAH81788.2; -; mRNA.
DR   EMBL; BC098663; AAH98663.1; -; mRNA.
DR   PIR; S02192; S02192.
DR   RefSeq; NP_112251.2; NM_030989.3.
DR   RefSeq; XP_006246656.1; XM_006246594.3.
DR   RefSeq; XP_006246657.1; XM_006246595.3.
DR   UniGene; Rn.54443; -.
DR   ProteinModelPortal; P10361; -.
DR   SMR; P10361; -.
DR   BioGrid; 246960; 9.
DR   DIP; DIP-46016N; -.
DR   IntAct; P10361; 4.
DR   MINT; MINT-4651801; -.
DR   STRING; 10116.ENSRNOP00000047840; -.
DR   iPTMnet; P10361; -.
DR   PhosphoSitePlus; P10361; -.
DR   PaxDb; P10361; -.
DR   PRIDE; P10361; -.
DR   Ensembl; ENSRNOT00000046490; ENSRNOP00000047840; ENSRNOG00000010756.
DR   Ensembl; ENSRNOT00000085115; ENSRNOP00000074031; ENSRNOG00000010756.
DR   GeneID; 24842; -.
DR   KEGG; rno:24842; -.
DR   UCSC; RGD:3889; rat.
DR   CTD; 7157; -.
DR   RGD; 3889; Tp53.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P10361; -.
DR   KO; K04451; -.
DR   OMA; VVSTRIC; -.
DR   PhylomeDB; P10361; -.
DR   TreeFam; TF106101; -.
DR   PRO; PR:P10361; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000010756; -.
DR   ExpressionAtlas; P10361; baseline and differential.
DR   Genevisible; P10361; RN.
DR   GO; GO:0000785; C:chromatin; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IPI:RGD.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:RGD.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0001221; F:transcription cofactor binding; IPI:RGD.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:RGD.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IEP:RGD.
DR   GO; GO:0071417; P:cellular response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:RGD.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:GO_Central.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:RGD.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:RGD.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IMP:RGD.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:1903205; P:regulation of hydrogen peroxide-induced cell death; IMP:UniProtKB.
DR   GO; GO:0051453; P:regulation of intracellular pH; IMP:RGD.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:RGD.
DR   GO; GO:0043200; P:response to amino acid; IEP:RGD.
DR   GO; GO:0031000; P:response to caffeine; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0055093; P:response to hyperoxia; IEP:RGD.
DR   GO; GO:0010035; P:response to inorganic substance; IEP:RGD.
DR   GO; GO:0010038; P:response to metal ion; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IEP:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0009411; P:response to UV; IEP:RGD.
DR   GO; GO:0010224; P:response to UV-B; IEP:RGD.
DR   GO; GO:0033552; P:response to vitamin B3; IEP:RGD.
DR   GO; GO:0010165; P:response to X-ray; IEP:RGD.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; IEP:RGD.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; DNA-binding; Endoplasmic reticulum;
KW   Isopeptide bond; Metal-binding; Methylation; Mitochondrion; Necrosis;
KW   Nucleus; Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    391       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185712.
FT   DNA_BIND    100    290       {ECO:0000250}.
FT   REGION        1    318       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     47       Transcription activation (acidic).
FT   REGION       64    108       Interaction with WWOX. {ECO:0000250}.
FT   REGION       98    368       Interaction with HIPK1. {ECO:0000250}.
FT   REGION       98    298       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      111    234       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      114    290       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      254    292       Interaction with E4F1. {ECO:0000250}.
FT   REGION      271    278       Interaction with DNA. {ECO:0000250}.
FT   REGION      317    358       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      323    354       Oligomerization.
FT   REGION      357    361       Interaction with USP7. {ECO:0000250}.
FT   REGION      366    385       Basic (repression of DNA-binding).
FT   MOTIF       303    319       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       337    348       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       368    370       [KR]-[STA]-K motif.
FT   METAL       174    174       Zinc. {ECO:0000250}.
FT   METAL       177    177       Zinc. {ECO:0000250}.
FT   METAL       236    236       Zinc. {ECO:0000250}.
FT   METAL       240    240       Zinc. {ECO:0000250}.
FT   SITE        118    118       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      39     39       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES     118    118       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     181    181       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     267    267       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     282    282       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     303    303       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     313    313       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     319    319       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     368    368       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     368    368       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     370    370       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     371    371       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     371    371       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     379    379       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     380    380       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     380    380       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     380    380       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     390    390       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    289    289       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    290    290       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    384    384       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VARIANT     103    103       G -> S.
FT   VARIANT     256    256       E -> G.
FT   CONFLICT    174    174       C -> W (in Ref. 2; AAA41788).
FT                                {ECO:0000305}.
SQ   SEQUENCE   391 AA;  43451 MW;  E62522313A5C872F CRC64;
     MEDSQSDMSI ELPLSQETFS CLWKLLPPDD ILPTTATGSP NSMEDLFLPQ DVAELLEGPE
     EALQVSAPAA QEPGTEAPAP VAPASATPWP LSSSVPSQKT YQGNYGFHLG FLQSGTAKSV
     MCTYSISLNK LFCQLAKTCP VQLWVTSTPP PGTRVRAMAI YKKSQHMTEV VRRCPHHERC
     SDGDGLAPPQ HLIRVEGNPY AEYLDDRQTF RHSVVVPYEP PEVGSDYTTI HYKYMCNSSC
     MGGMNRRPIL TIITLEDSSG NLLGRDSFEV RVCACPGRDR RTEEENFRKK EEHCPELPPG
     SAKRALPTST SSSPQQKKKP LDGEYFTLKI RGRERFEMFR ELNEALELKD ARAAEESGDS
     RAHSSYPKTK KGQSTSRHKK PMIKKVGPDS D
//
ID   P53_DANRE               Reviewed;         373 AA.
AC   P79734; Q7ZW62; Q90440;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   18-JAN-2017, entry version 137.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=tp53; Synonyms=drp53;
OS   Danio rerio (Zebrafish) (Brachydanio rerio).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC   Cyprinidae; Danio.
OX   NCBI_TaxID=7955;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9200835;
RA   Cheng R., Ford B.L., O'Neal P.E., Mathews C.Z., Bradford C.S.,
RA   Thongtan T., Barnes D.W., Hendricks J.D., Bailey G.S.;
RT   "Zebrafish (Danio rerio) p53 tumor suppressor gene: cDNA sequence and
RT   expression during embryogenesis.";
RL   Mol. Mar. Biol. Biotechnol. 6:88-97(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Bauer M.P., Goetz F.W.;
RT   "Isolation of p53 in the zebrafish.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 140-212.
RA   Winge P.;
RL   Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION.
RX   PubMed=12477391; DOI=10.1016/S0960-9822(02)01319-2;
RA   Langheinrich U., Hennen E., Stott G., Vacun G.;
RT   "Zebrafish as a model organism for the identification and
RT   characterization of drugs and genes affecting p53 signaling.";
RL   Curr. Biol. 12:2023-2028(2002).
RN   [5]
RP   FUNCTION, AND MUTAGENESIS OF SER-26; ASN-168 AND MET-214.
RX   PubMed=15630097; DOI=10.1073/pnas.0406252102;
RA   Berghmans S., Murphey R.D., Wienholds E., Neuberg D., Kutok J.L.,
RA   Fletcher C.D.M., Morris J.P., Liu T.X., Schulte-Merker S., Kanki J.P.,
RA   Plasterk R., Zon L.I., Look A.T.;
RT   "tp53 mutant zebrafish develop malignant peripheral nerve sheath
RT   tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:407-412(2005).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       bax and fas antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000269|PubMed:12477391,
CC       ECO:0000269|PubMed:15630097}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U60804; AAB40617.1; -; mRNA.
DR   EMBL; AF365873; AAO85406.1; -; mRNA.
DR   EMBL; U46693; AAA97408.1; -; mRNA.
DR   RefSeq; NP_571402.1; NM_131327.2.
DR   UniGene; Dr.75100; -.
DR   PDB; 4CZ6; X-ray; 1.53 A; A/B/C/D=301-330.
DR   PDBsum; 4CZ6; -.
DR   ProteinModelPortal; P79734; -.
DR   SMR; P79734; -.
DR   BioGrid; 78756; 1.
DR   STRING; 7955.ENSDARP00000051548; -.
DR   PaxDb; P79734; -.
DR   PRIDE; P79734; -.
DR   GeneID; 30590; -.
DR   KEGG; dre:30590; -.
DR   CTD; 7157; -.
DR   ZFIN; ZDB-GENE-990415-270; tp53.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P79734; -.
DR   KO; K04451; -.
DR   PRO; PR:P79734; -.
DR   Proteomes; UP000000437; Unplaced.
DR   Bgee; ENSDARG00000035559; -.
DR   GO; GO:0000785; C:chromatin; IDA:ZFIN.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:ZFIN.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:ZFIN.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IMP:ZFIN.
DR   GO; GO:0006914; P:autophagy; IGI:ZFIN.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:ZFIN.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0090398; P:cellular senescence; IGI:ZFIN.
DR   GO; GO:0060216; P:definitive hemopoiesis; IGI:ZFIN.
DR   GO; GO:0000077; P:DNA damage checkpoint; IMP:ZFIN.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IMP:ZFIN.
DR   GO; GO:0048730; P:epidermis morphogenesis; IMP:ZFIN.
DR   GO; GO:0048821; P:erythrocyte development; IGI:ZFIN.
DR   GO; GO:0043249; P:erythrocyte maturation; IGI:ZFIN.
DR   GO; GO:0061484; P:hematopoietic stem cell homeostasis; IGI:ZFIN.
DR   GO; GO:0060729; P:intestinal epithelial structure maintenance; IGI:ZFIN.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IMP:ZFIN.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:BHF-UCL.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IGI:ZFIN.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:ZFIN.
DR   GO; GO:0051782; P:negative regulation of cell division; IMP:ZFIN.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0010526; P:negative regulation of transposition, RNA-mediated; IMP:ZFIN.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:ZFIN.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:ZFIN.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:ZFIN.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IGI:ZFIN.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:ZFIN.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:ZFIN.
DR   GO; GO:2000779; P:regulation of double-strand break repair; IMP:ZFIN.
DR   GO; GO:0031647; P:regulation of protein stability; IGI:ZFIN.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0051597; P:response to methylmercury; IDA:ZFIN.
DR   GO; GO:0009411; P:response to UV; IMP:ZFIN.
DR   GO; GO:0010165; P:response to X-ray; IMP:ZFIN.
DR   GO; GO:0007283; P:spermatogenesis; IGI:ZFIN.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Apoptosis; Cell cycle; Complete proteome;
KW   Cytoplasm; DNA-binding; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Tumor suppressor; Zinc.
FT   CHAIN         1    373       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185718.
FT   DNA_BIND     70    260       {ECO:0000250}.
FT   REGION        1     31       Transcription activation (acidic).
FT   REGION      241    248       Interaction with DNA. {ECO:0000250}.
FT   REGION      301    332       Oligomerization.
FT   REGION      345    366       Basic (repression of DNA-binding).
FT   MOTIF       274    296       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       315    326       Nuclear export signal. {ECO:0000250}.
FT   METAL       144    144       Zinc. {ECO:0000250}.
FT   METAL       147    147       Zinc. {ECO:0000250}.
FT   METAL       206    206       Zinc. {ECO:0000250}.
FT   METAL       210    210       Zinc. {ECO:0000250}.
FT   SITE         88     88       Interaction with DNA. {ECO:0000250}.
FT   MUTAGEN      26     26       S->F: No effect on transactivation
FT                                activity. {ECO:0000269|PubMed:15630097}.
FT   MUTAGEN     168    168       N->K: Loss of transactivation activity.
FT                                Temperature-sensitive suppression of
FT                                irradiation-induced apoptosis. No effect
FT                                on embryonic development.
FT                                {ECO:0000269|PubMed:15630097}.
FT   MUTAGEN     214    214       M->K: Loss of transactivation activity.
FT                                Suppression of irradiation-induced
FT                                apoptosis. Defective G1-phase but not G2-
FT                                phase checkpoint response. Development of
FT                                malignant peripheral nerve sheath tumors.
FT                                No effect on embryonic development.
FT                                {ECO:0000269|PubMed:15630097}.
FT   CONFLICT    276    280       SLVKE -> K (in Ref. 2; AAO85406).
FT                                {ECO:0000305}.
FT   CONFLICT    286    286       L -> S (in Ref. 2; AAO85406).
FT                                {ECO:0000305}.
FT   STRAND      303    310       {ECO:0000244|PDB:4CZ6}.
FT   HELIX       311    327       {ECO:0000244|PDB:4CZ6}.
SQ   SEQUENCE   373 AA;  41899 MW;  AC7AB724FA6B61FF CRC64;
     MAQNDSQEFA ELWEKNLIIQ PPGGGSCWDI INDEEYLPGS FDPNFFENVL EEQPQPSTLP
     PTSTVPETSD YPGDHGFRLR FPQSGTAKSV TCTYSPDLNK LFCQLAKTCP VQMVVDVAPP
     QGSVVRATAI YKKSEHVAEV VRRCPHHERT PDGDNLAPAG HLIRVEGNQR ANYREDNITL
     RHSVFVPYEA PQLGAEWTTV LLNYMCNSSC MGGMNRRPIL TIITLETQEG QLLGRRSFEV
     RVCACPGRDR KTEESNFKKD QETKTMAKTT TGTKRSLVKE SSSATLRPEG SKKAKGSSSD
     EEIFTLQVRG RERYEILKKL NDSLELSDVV PASDAEKYRQ KFMTKNKKEN RESSEPKQGK
     KLMVKDEGRS DSD
//
ID   P53_PIG                 Reviewed;         386 AA.
AC   Q9TUB2;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   30-NOV-2016, entry version 165.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10490836; DOI=10.1038/sj.onc.1202870;
RA   Burr P.D., Argyle D.J., Reid S.W.J., Nasir L.;
RT   "Nucleotide sequence of the porcine p53 cDNA, and the detection of
RT   recombinant porcine p53 expressed in vitro with a variety of anti-p53
RT   antibodies.";
RL   Oncogene 18:5005-5009(1999).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-375)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       Interacts with MORC3. {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated on Thr-18 by VRK1, which may prevent
CC       the interaction with MDM2. Phosphorylated on Ser-20 by CHEK2 in
CC       response to DNA damage, which prevents ubiquitination by MDM2.
CC       Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen
CC       species (ROS), promoting p53/TP53-mediated apoptosis.
CC       Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to
CC       DNA damage. Phosphorylated by HIPK1. Phosphorylated on Ser-385
CC       following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction
CC       with BANP. Stabilized by CDK5-mediated phosphorylation in response
CC       to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-47,
CC       leading to accumulation of p53/TP53, particularly in the nucleus,
CC       thus inducing the transactivation of p53/TP53 target genes.
CC       Phosphorylated by DYRK2 at Ser-47 in response to genotoxic stress.
CC       Phosphorylated at Ser-308 and Ser-385 by CDK2 in response to DNA-
CC       damage (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-284 and Lys-285, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-365 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       363 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-365
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-363. Dimethylated at Lys-366 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-375 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-363 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-379 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF098067; AAF04620.1; -; mRNA.
DR   RefSeq; NP_998989.3; NM_213824.3.
DR   UniGene; Ssc.15917; -.
DR   ProteinModelPortal; Q9TUB2; -.
DR   SMR; Q9TUB2; -.
DR   STRING; 9823.ENSSSCP00000019016; -.
DR   PaxDb; Q9TUB2; -.
DR   PRIDE; Q9TUB2; -.
DR   Ensembl; ENSSSCT00000019534; ENSSSCP00000019016; ENSSSCG00000017950.
DR   GeneID; 397276; -.
DR   KEGG; ssc:397276; -.
DR   CTD; 7157; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; Q9TUB2; -.
DR   KO; K04451; -.
DR   OMA; SFMCNSS; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   TreeFam; TF106101; -.
DR   Reactome; R-SSC-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-SSC-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF).
DR   Reactome; R-SSC-2559585; Oncogene Induced Senescence.
DR   Reactome; R-SSC-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-SSC-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-SSC-5689880; Ub-specific processing proteases.
DR   Reactome; R-SSC-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-SSC-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-SSC-6804754; Regulation of TP53 Expression.
DR   Reactome; R-SSC-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-SSC-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-SSC-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-SSC-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-SSC-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-SSC-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-SSC-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-SSC-69481; G2/M Checkpoints.
DR   Reactome; R-SSC-69541; Stabilization of p53.
DR   Reactome; R-SSC-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-SSC-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Proteomes; UP000008227; Chromosome 12.
DR   Bgee; ENSSSCG00000017950; -.
DR   Genevisible; Q9TUB2; SS.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IEA:Ensembl.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:Ensembl.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0031497; P:chromatin assembly; IEA:Ensembl.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:GO_Central.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:2000871; P:negative regulation of progesterone secretion; IMP:AgBase.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IEA:Ensembl.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IEA:Ensembl.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0008104; P:protein localization; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEA:Ensembl.
DR   GO; GO:0090276; P:regulation of peptide hormone secretion; IMP:AgBase.
DR   GO; GO:0032306; P:regulation of prostaglandin secretion; IMP:AgBase.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; DNA-binding; Endoplasmic reticulum;
KW   Isopeptide bond; Metal-binding; Methylation; Mitochondrion; Necrosis;
KW   Nucleus; Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    386       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185710.
FT   DNA_BIND     94    285       {ECO:0000250}.
FT   REGION        1    313       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     45       Transcription activation (acidic).
FT   REGION       63    102       Interaction with WWOX. {ECO:0000250}.
FT   REGION       92    363       Interaction with HIPK1. {ECO:0000250}.
FT   REGION       92    293       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      105    229       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      108    285       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      249    287       Interaction with E4F1. {ECO:0000250}.
FT   REGION      266    273       Interaction with DNA. {ECO:0000250}.
FT   REGION      312    353       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      318    349       Oligomerization.
FT   REGION      352    356       Interaction with USP7. {ECO:0000250}.
FT   REGION      361    380       Basic (repression of DNA-binding).
FT   MOTIF       298    314       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       332    343       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       363    365       [KR]-[STA]-K motif.
FT   METAL       168    168       Zinc. {ECO:0000250}.
FT   METAL       171    171       Zinc. {ECO:0000250}.
FT   METAL       231    231       Zinc. {ECO:0000250}.
FT   METAL       235    235       Zinc. {ECO:0000250}.
FT   SITE        112    112       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES      47     47       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES     112    112       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     175    175       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     262    262       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     277    277       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     298    298       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     308    308       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     314    314       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     363    363       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     363    363       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     365    365       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     366    366       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     366    366       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     374    374       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     375    375       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     375    375       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     375    375       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     385    385       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    284    284       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    285    285       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    379    379       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
SQ   SEQUENCE   386 AA;  42862 MW;  A4C3D88E8DF55162 CRC64;
     MEESQSELGV EPPLSQETFS DLWKLLPENN LLSSELSLAA VNDLLLSPVT NWLDENPDDA
     SRVPAPPAAT APAPAAPAPA TSWPLSSFVP SQKTYPGSYD FRLGFLHSGT AKSVTCTYSP
     ALNKLFCQLA KTCPVQLWVS SPPPPGTRVR AMAIYKKSEY MTEVVRRCPH HERSSDYSDG
     LAPPQHLIRV EGNLRAEYLD DRNTFRHSVV VPYEPPEVGS DCTTIHYNFM CNSSCMGGMN
     RRPILTIITL EDASGNLLGR NSFEVRVCAC PGRDRRTEEE NFLKKGQSCP EPPPGSTKRA
     LPTSTSSSPV QKKKPLDGEY FTLQIRGRER FEMFRELNDA LELKDAQTAR ESGENRAHSS
     HLKSKKGQSP SRHKKPMFKR EGPDSD
//
ID   Q8IMZ4_DROME            Unreviewed;       495 AA.
AC   Q8IMZ4;
DT   01-MAR-2003, integrated into UniProtKB/TrEMBL.
DT   05-JUL-2004, sequence version 2.
DT   18-JAN-2017, entry version 132.
DE   SubName: Full=p53 protein long form variant 1 {ECO:0000313|EMBL:ABB80263.1};
DE   SubName: Full=p53, isoform B {ECO:0000313|EMBL:AAN13925.2};
GN   Name=p53 {ECO:0000313|EMBL:AAN13925.2,
GN   ECO:0000313|FlyBase:FBgn0039044};
GN   ORFNames=CG33336 {ECO:0000313|FlyBase:FBgn0039044},
GN   Dmel_CG33336 {ECO:0000313|EMBL:AAN13925.2};
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227 {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803};
RN   [1] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA   Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., WoodageT, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA   Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA   Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [2] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537568;
RA   Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,
RA   Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA   George R.A., Hoskins R.A., Laverty T., Muzny D.M., Nelson C.R.,
RA   Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA   Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA   Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT   "Finishing a whole-genome shotgun: release 3 of the Drosophila
RT   melanogaster euchromatic genome sequence.";
RL   Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN   [3] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfied E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [4] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537573;
RA   Kaminker J.S., Bergman C.M., Kronmiller B., Carlson J., Svirskas R.,
RA   Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA   Ashburner M., Celniker S.E.;
RT   "The transposable elements of the Drosophila melanogaster euchromatin:
RT   a genomics perspective.";
RL   Genome Biol. 3:RESEARCH0084.1-RESEARCH0084.20(2002).
RN   [5] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537574;
RA   Hoskins R.A., Smith C.D., Carlson J.W., Carvalho A.B., Halpern A.,
RA   Kaminker J.S., Kennedy C., Mungall C.J., Sullivan B.A., Sutton G.G.,
RA   Yasuhara J.C., Wakimoto B.T., Myers E.W., Celniker S.E., Rubin G.M.,
RA   Karpen G.H.;
RT   "Heterochromatic sequences in a Drosophila whole-genome shotgun
RT   assembly.";
RL   Genome Biol. 3:RESEARCH0085-RESEARCH0085(2002).
RN   [6] {ECO:0000313|EMBL:ABB80263.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
RN   [7] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=16110336; DOI=10.1371/journal.pcbi.0010022;
RA   Quesneville H., Bergman C.M., Andrieu O., Autard D., Nouaud D.,
RA   Ashburner M., Anxolabehere D.;
RT   "Combined evidence annotation of transposable elements in genome
RT   sequences.";
RL   PLoS Comput. Biol. 1:166-175(2005).
RN   [8] {ECO:0000313|EMBL:AAN13925.2}
RP   NUCLEOTIDE SEQUENCE.
RG   Berkeley Drosophila Genome Project;
RA   Celniker S., Carlson J., Wan K., Pfeiffer B., Frise E., George R.,
RA   Hoskins R., Stapleton M., Pacleb J., Park S., Svirskas R., Smith E.,
RA   Yu C., Rubin G.;
RT   "Drosophila melanogaster release 4 sequence.";
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [9] {ECO:0000313|EMBL:AAN13925.2}
RP   NUCLEOTIDE SEQUENCE.
RA   Celniker S., Carlson J., Wan K., Frise E., Hoskins R., Park S.,
RA   Svirskas R., Rubin G.;
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [10] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=17569856; DOI=10.1126/science.1139815;
RA   Smith C.D., Shu S., Mungall C.J., Karpen G.H.;
RT   "The Release 5.1 annotation of Drosophila melanogaster
RT   heterochromatin.";
RL   Science 316:1586-1591(2007).
RN   [11] {ECO:0000313|EMBL:AAN13925.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=17569867; DOI=10.1126/science.1139816;
RA   Hoskins R.A., Carlson J.W., Kennedy C., Acevedo D., Evans-Holm M.,
RA   Frise E., Wan K.H., Park S., Mendez-Lago M., Rossi F., Villasante A.,
RA   Dimitri P., Karpen G.H., Celniker S.E.;
RT   "Sequence finishing and mapping of Drosophila melanogaster
RT   heterochromatin.";
RL   Science 316:1625-1628(2007).
RN   [12] {ECO:0000313|EMBL:AAN13925.2}
RP   NUCLEOTIDE SEQUENCE.
RG   FlyBase;
RL   Submitted (OCT-2015) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AE014297; AAN13925.2; -; Genomic_DNA.
DR   EMBL; DQ191318; ABB80263.1; -; mRNA.
DR   RefSeq; NP_996267.1; NM_206544.2.
DR   UniGene; Dm.3257; -.
DR   ProteinModelPortal; Q8IMZ4; -.
DR   SMR; Q8IMZ4; -.
DR   IntAct; Q8IMZ4; 2.
DR   MINT; MINT-4053220; -.
DR   STRING; 7227.FBpp0083753; -.
DR   EnsemblMetazoa; FBtr0084360; FBpp0083753; FBgn0039044.
DR   GeneID; 2768677; -.
DR   UCSC; CG33336-RB; d. melanogaster.
DR   CTD; 2768677; -.
DR   FlyBase; FBgn0039044; p53.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   OMA; CTCPKRD; -.
DR   OrthoDB; EOG091G06IB; -.
DR   PhylomeDB; Q8IMZ4; -.
DR   GenomeRNAi; 2768677; -.
DR   Proteomes; UP000000803; Chromosome 3R.
DR   Bgee; FBgn0039044; -.
DR   ExpressionAtlas; Q8IMZ4; differential.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:FlyBase.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0001047; F:core promoter binding; IDA:FlyBase.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001097; F:TFIIH-class transcription factor binding; IPI:FlyBase.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0008134; F:transcription factor binding; IPI:FlyBase.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:FlyBase.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:FlyBase.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:FlyBase.
DR   GO; GO:0006915; P:apoptotic process; IMP:FlyBase.
DR   GO; GO:0008219; P:cell death; IMP:FlyBase.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:FlyBase.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IMP:BHF-UCL.
DR   GO; GO:0009267; P:cellular response to starvation; IMP:FlyBase.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:FlyBase.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:FlyBase.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IMP:FlyBase.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:BHF-UCL.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:BHF-UCL.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IGI:FlyBase.
DR   GO; GO:0090278; P:negative regulation of peptide hormone secretion; IMP:FlyBase.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IMP:FlyBase.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0014016; P:neuroblast differentiation; IMP:FlyBase.
DR   GO; GO:0007405; P:neuroblast proliferation; IMP:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IGI:FlyBase.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:FlyBase.
DR   GO; GO:2000685; P:positive regulation of cellular response to X-ray; IMP:FlyBase.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:FlyBase.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:FlyBase.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; IMP:FlyBase.
DR   GO; GO:0060785; P:regulation of apoptosis involved in tissue homeostasis; IMP:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0006282; P:regulation of DNA repair; IMP:FlyBase.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0046620; P:regulation of organ growth; IMP:FlyBase.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:FlyBase.
DR   GO; GO:1990248; P:regulation of transcription from RNA polymerase II promoter in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0010212; P:response to ionizing radiation; IMP:FlyBase.
DR   GO; GO:0009314; P:response to radiation; IMP:FlyBase.
DR   GO; GO:0042594; P:response to starvation; IMP:FlyBase.
DR   GO; GO:0009411; P:response to UV; IMP:FlyBase.
DR   GO; GO:0042246; P:tissue regeneration; IMP:FlyBase.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR024631; p53_C_Drosophila.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF11619; P53_C; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
PE   2: Evidence at transcript level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000000803};
KW   Reference proteome {ECO:0000313|Proteomes:UP000000803}.
FT   DOMAIN      214    383       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      429    495       P53_C. {ECO:0000259|Pfam:PF11619}.
SQ   SEQUENCE   495 AA;  55565 MW;  7BEDD6D749DAA28D CRC64;
     MSLHKSASFS LTFNQNTSIV SRSNSRTIFE AFKEFLDFWD IGNEVSAESA VRVSSNGAFN
     LPQSFGNESN EYAHLATPVD PAYGGNNTNN MMQFTNNLEI LANNNSDGNN KINACNKFVC
     HKGTDSEDDS TEVDIKEDIP KTVEVSGSEL TTEPMAFLQG LNSGNLMQFS QQSVLREMML
     QDIQIQANTL PKLENHNIGG YCFSMVLDEP PKSLWMYSIP LNKLYIRMNK AFNVDVQFKS
     KMPIQPLNLR VFLCFSNDVS APVVRCQNHL SVEPLTANNA KMRESLLRSE NPNSVYCGNA
     QGKGISERFS VVVPLNMSRS VTRSGLTRQT LAFKFVCQNS CIGRKETSLV FCLEKACGDI
     VGQHVIHVKI CTCPKRDRIQ DERQLNSKKR KSVPEAAEED EPSKVRRCIA IKTEDTESND
     SRDCDDSAAE WNVSRTPDGD YRLAITCPNK EWLLQSIEGM IKEAAAEVLR NPNQENLRRH
     ANKLLSLKKR AYELP
//
ID   Q9N6D8_DROME            Unreviewed;       385 AA.
AC   Q9N6D8; Q9VCR8;
DT   01-OCT-2000, integrated into UniProtKB/TrEMBL.
DT   01-OCT-2000, sequence version 1.
DT   18-JAN-2017, entry version 155.
DE   SubName: Full=GH11591p {ECO:0000313|EMBL:AAL39241.1};
DE   SubName: Full=Transcription factor {ECO:0000313|EMBL:AAF74277.1};
DE   SubName: Full=Transcription factor p53 {ECO:0000313|EMBL:AAF75270.1};
DE   SubName: Full=p53 tumor suppressor-like protein {ECO:0000313|EMBL:AAF61572.1};
DE   SubName: Full=p53, isoform A {ECO:0000313|EMBL:AAF56087.2};
DE   SubName: Full=p53, isoform C {ECO:0000313|EMBL:ACZ94989.1};
DE   SubName: Full=p53-like regulator of apoptosis and cell cycle {ECO:0000313|EMBL:AAL56639.1};
GN   Name=p53 {ECO:0000313|EMBL:AAF75270.1,
GN   ECO:0000313|FlyBase:FBgn0039044};
GN   Synonyms=prac {ECO:0000313|EMBL:AAL56639.1};
GN   ORFNames=CG33336 {ECO:0000313|FlyBase:FBgn0039044},
GN   Dmel_CG33336 {ECO:0000313|EMBL:AAF56087.2};
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227 {ECO:0000313|EMBL:AAF75270.1};
RN   [1] {ECO:0000313|EMBL:AAL56639.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Inohara N., Nunez G.;
RT   "PRAC, p53-like regulator of apoptosis and cell cycle.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:AAF75270.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=10778859; DOI=10.1016/S0092-8674(00)80626-1;
RA   Ollmann M., Young L.M., Di Como C.J., Karim F., Belvin M.,
RA   Robertson S., Whittaker K., Demsky M., Fisher W.W., Buchman A.,
RA   Duyk G., Friedman L., Prives C., Kopczynski C.;
RT   "Drosophila p53 is a structural and functional homolog of the tumor
RT   suppressor p53.";
RL   Cell 101:91-101(2000).
RN   [3] {ECO:0000313|EMBL:AAF40427.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=10778860; DOI=10.1016/S0092-8674(00)80627-3;
RA   Brodsky M.H., Nordstrom W., Tsang G., Kwan E., Rubin G.M.,
RA   Abrams J.M.;
RT   "Drosophila p53 binds a damage response element at the reaper locus.";
RL   Cell 101:103-113(2000).
RN   [4] {ECO:0000313|EMBL:AAF74277.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=10860994; DOI=10.1073/pnas.97.13.7301;
RA   Jin S., Martinek S., Joo W.S., Wortman J.R., Mirkovic N., Sali A.,
RA   Yandell M.D., Pavletich N.P., Young M.W., Levine A.J.;
RT   "Identification and characterization of a p53 homologue in Drosophila
RT   melanogaster.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:7301-7306(2000).
RN   [5] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA   Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., WoodageT, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA   Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA   Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [6] {ECO:0000313|EMBL:AAF61572.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Potter C.J., Xu T.;
RT   "The identification and characterization of Drosophila melanogaster
RT   p53.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7] {ECO:0000313|EMBL:AAL39241.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Berkeley {ECO:0000313|EMBL:AAL39241.1};
RA   Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA   Champe M., Chavez C., Dorsett V., Farfan D., Frise E., George R.,
RA   Gonzalez M., Guarin H., Li P., Liao G., Miranda A., Mungall C.J.,
RA   Nunoo J., Pacleb J., Paragas V., Park S., Phouanenavong S., Wan K.,
RA   Yu C., Lewis S.E., Rubin G.M., Celniker S.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537568;
RA   Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,
RA   Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA   George R.A., Hoskins R.A., Laverty T., Muzny D.M., Nelson C.R.,
RA   Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA   Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA   Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT   "Finishing a whole-genome shotgun: release 3 of the Drosophila
RT   melanogaster euchromatic genome sequence.";
RL   Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN   [9] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfied E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [10] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537573;
RA   Kaminker J.S., Bergman C.M., Kronmiller B., Carlson J., Svirskas R.,
RA   Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA   Ashburner M., Celniker S.E.;
RT   "The transposable elements of the Drosophila melanogaster euchromatin:
RT   a genomics perspective.";
RL   Genome Biol. 3:RESEARCH0084.1-RESEARCH0084.20(2002).
RN   [11] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537574;
RA   Hoskins R.A., Smith C.D., Carlson J.W., Carvalho A.B., Halpern A.,
RA   Kaminker J.S., Kennedy C., Mungall C.J., Sullivan B.A., Sutton G.G.,
RA   Yasuhara J.C., Wakimoto B.T., Myers E.W., Celniker S.E., Rubin G.M.,
RA   Karpen G.H.;
RT   "Heterochromatic sequences in a Drosophila whole-genome shotgun
RT   assembly.";
RL   Genome Biol. 3:RESEARCH0085-RESEARCH0085(2002).
RN   [12] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=16110336; DOI=10.1371/journal.pcbi.0010022;
RA   Quesneville H., Bergman C.M., Andrieu O., Autard D., Nouaud D.,
RA   Ashburner M., Anxolabehere D.;
RT   "Combined evidence annotation of transposable elements in genome
RT   sequences.";
RL   PLoS Comput. Biol. 1:166-175(2005).
RN   [13] {ECO:0000313|EMBL:AAF56087.2}
RP   NUCLEOTIDE SEQUENCE.
RG   Berkeley Drosophila Genome Project;
RA   Celniker S., Carlson J., Wan K., Pfeiffer B., Frise E., George R.,
RA   Hoskins R., Stapleton M., Pacleb J., Park S., Svirskas R., Smith E.,
RA   Yu C., Rubin G.;
RT   "Drosophila melanogaster release 4 sequence.";
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [14] {ECO:0000313|EMBL:AAF56087.2}
RP   NUCLEOTIDE SEQUENCE.
RA   Celniker S., Carlson J., Wan K., Frise E., Hoskins R., Park S.,
RA   Svirskas R., Rubin G.;
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [15] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=17569856; DOI=10.1126/science.1139815;
RA   Smith C.D., Shu S., Mungall C.J., Karpen G.H.;
RT   "The Release 5.1 annotation of Drosophila melanogaster
RT   heterochromatin.";
RL   Science 316:1586-1591(2007).
RN   [16] {ECO:0000313|EMBL:AAF56087.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=17569867; DOI=10.1126/science.1139816;
RA   Hoskins R.A., Carlson J.W., Kennedy C., Acevedo D., Evans-Holm M.,
RA   Frise E., Wan K.H., Park S., Mendez-Lago M., Rossi F., Villasante A.,
RA   Dimitri P., Karpen G.H., Celniker S.E.;
RT   "Sequence finishing and mapping of Drosophila melanogaster
RT   heterochromatin.";
RL   Science 316:1625-1628(2007).
RN   [17] {ECO:0000313|EMBL:AAF56087.2}
RP   NUCLEOTIDE SEQUENCE.
RG   FlyBase;
RL   Submitted (OCT-2015) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF224713; AAF40427.1; -; mRNA.
DR   EMBL; AF224714; AAF40428.1; -; mRNA.
DR   EMBL; AE014297; AAF56087.2; -; Genomic_DNA.
DR   EMBL; AF244918; AAF61572.1; -; mRNA.
DR   EMBL; AF250918; AAF74277.1; -; mRNA.
DR   EMBL; AF263722; AAF75270.1; -; mRNA.
DR   EMBL; AY069096; AAL39241.1; -; mRNA.
DR   EMBL; AF192555; AAL56639.1; -; mRNA.
DR   EMBL; AE014297; ACZ94989.1; -; Genomic_DNA.
DR   RefSeq; NP_001163694.1; NM_001170223.1.
DR   RefSeq; NP_996268.1; NM_206545.2.
DR   UniGene; Dm.3257; -.
DR   ProteinModelPortal; Q9N6D8; -.
DR   SMR; Q9N6D8; -.
DR   IntAct; Q9N6D8; 22.
DR   MINT; MINT-1014674; -.
DR   STRING; 7227.FBpp0083753; -.
DR   EnsemblMetazoa; FBtr0084359; FBpp0083752; FBgn0039044.
DR   EnsemblMetazoa; FBtr0301765; FBpp0290979; FBgn0039044.
DR   GeneID; 2768677; -.
DR   KEGG; dme:Dmel_CG33336; -.
DR   UCSC; CG33336-RA; d. melanogaster.
DR   CTD; 2768677; -.
DR   FlyBase; FBgn0039044; p53.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   KO; K10149; -.
DR   OrthoDB; EOG091G06IB; -.
DR   GenomeRNAi; 2768677; -.
DR   Proteomes; UP000000803; Chromosome 3R.
DR   Bgee; FBgn0039044; -.
DR   ExpressionAtlas; Q9N6D8; differential.
DR   GO; GO:0005634; C:nucleus; IDA:FlyBase.
DR   GO; GO:0001047; F:core promoter binding; IDA:FlyBase.
DR   GO; GO:0001097; F:TFIIH-class transcription factor binding; IPI:FlyBase.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0008134; F:transcription factor binding; IPI:FlyBase.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:FlyBase.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:FlyBase.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:FlyBase.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:FlyBase.
DR   GO; GO:0006915; P:apoptotic process; IMP:FlyBase.
DR   GO; GO:0008219; P:cell death; IMP:FlyBase.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:FlyBase.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IMP:FlyBase.
DR   GO; GO:0009267; P:cellular response to starvation; IMP:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:BHF-UCL.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:FlyBase.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IMP:FlyBase.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:FlyBase.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IGI:FlyBase.
DR   GO; GO:0090278; P:negative regulation of peptide hormone secretion; IMP:FlyBase.
DR   GO; GO:0043553; P:negative regulation of phosphatidylinositol 3-kinase activity; IMP:BHF-UCL.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IMP:FlyBase.
DR   GO; GO:0042992; P:negative regulation of transcription factor import into nucleus; IMP:BHF-UCL.
DR   GO; GO:0014016; P:neuroblast differentiation; IMP:FlyBase.
DR   GO; GO:0007405; P:neuroblast proliferation; IMP:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IGI:FlyBase.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:FlyBase.
DR   GO; GO:2000685; P:positive regulation of cellular response to X-ray; IMP:FlyBase.
DR   GO; GO:0040010; P:positive regulation of growth rate; IMP:BHF-UCL.
DR   GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:FlyBase.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:FlyBase.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; IMP:FlyBase.
DR   GO; GO:0060785; P:regulation of apoptosis involved in tissue homeostasis; IMP:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0006282; P:regulation of DNA repair; IMP:FlyBase.
DR   GO; GO:0046620; P:regulation of organ growth; IMP:FlyBase.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:FlyBase.
DR   GO; GO:1990248; P:regulation of transcription from RNA polymerase II promoter in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0010212; P:response to ionizing radiation; IMP:FlyBase.
DR   GO; GO:0009314; P:response to radiation; IMP:FlyBase.
DR   GO; GO:0042594; P:response to starvation; IMP:FlyBase.
DR   GO; GO:0009411; P:response to UV; IMP:FlyBase.
DR   GO; GO:0042246; P:tissue regeneration; IMP:FlyBase.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR024631; p53_C_Drosophila.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF11619; P53_C; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
PE   2: Evidence at transcript level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000000803};
KW   Reference proteome {ECO:0000313|Proteomes:UP000000803}.
FT   DOMAIN      104    273       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      319    385       P53_C. {ECO:0000259|Pfam:PF11619}.
SQ   SEQUENCE   385 AA;  43654 MW;  8389C8FE9B8E6369 CRC64;
     MYISQPMSWH KESTDSEDDS TEVDIKEDIP KTVEVSGSEL TTEPMAFLQG LNSGNLMQFS
     QQSVLREMML QDIQIQANTL PKLENHNIGG YCFSMVLDEP PKSLWMYSIP LNKLYIRMNK
     AFNVDVQFKS KMPIQPLNLR VFLCFSNDVS APVVRCQNHL SVEPLTANNA KMRESLLRSE
     NPNSVYCGNA QGKGISERFS VVVPLNMSRS VTRSGLTRQT LAFKFVCQNS CIGRKETSLV
     FCLEKACGDI VGQHVIHVKI CTCPKRDRIQ DERQLNSKKR KSVPEAAEED EPSKVRRCIA
     IKTEDTESND SRDCDDSAAE WNVSRTPDGD YRLAITCPNK EWLLQSIEGM IKEAAAEVLR
     NPNQENLRRH ANKLLSLKKR AYELP
//
ID   P53_MACMU               Reviewed;         393 AA.
AC   P56424;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 1.
DT   18-JAN-2017, entry version 165.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Macaca mulatta (Rhesus macaque).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Cercopithecidae; Cercopithecinae; Macaca.
OX   NCBI_TaxID=9544;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=8125305; DOI=10.1016/0378-1119(94)90812-5;
RA   Kay H.D., Mountjoy C.P., Wu G., Cornish K.G., Smith L.J.;
RT   "Sequence of a cDNA encoding the p53 protein in rhesus monkey (Macaca
RT   mulatta).";
RL   Gene 138:223-226(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Khan M.A., Hansen C., Welsh J.A., Bennett W.P.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       Interacts with MORC3. {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-
CC       18 by VRK1, which may prevent the interaction with MDM2.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Thr-55 by TAF1 which
CC       promotes MDM2-mediated TP53 degradation. Phosphorylated on Ser-33
CC       by CDK7 in a CAK complex in response to DNA damage. Phosphorylated
CC       by HIPK1. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation.
CC       Phosphorylation on Ser-46 is required for acetylation by CREBBP.
CC       Phosphorylated on Ser-392 following UV but not gamma irradiation.
CC       Phosphorylated on Ser-15 upon ultraviolet irradiation; which is
CC       enhanced by interaction with BANP. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in
CC       response to genotoxic stress. Phosphorylated at Ser-315 and Ser-
CC       392 by CDK2 in response to DNA-damage (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-370 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L20442; AAA17994.1; -; mRNA.
DR   EMBL; U48956; AAB91534.1; -; Genomic_DNA.
DR   RefSeq; NP_001040616.1; NM_001047151.2.
DR   UniGene; Mmu.3286; -.
DR   ProteinModelPortal; P56424; -.
DR   SMR; P56424; -.
DR   STRING; 9544.ENSMMUP00000035274; -.
DR   Ensembl; ENSMMUT00000067326; ENSMMUP00000053928; ENSMMUG00000008639.
DR   GeneID; 716170; -.
DR   KEGG; mcc:716170; -.
DR   CTD; 7157; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P56424; -.
DR   KO; K04451; -.
DR   OMA; SFMCNSS; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   TreeFam; TF106101; -.
DR   Proteomes; UP000006718; Chromosome 16.
DR   Bgee; ENSMMUG00000008639; -.
DR   ExpressionAtlas; P56424; baseline.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IEA:Ensembl.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:Ensembl.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0031497; P:chromatin assembly; IEA:Ensembl.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:GO_Central.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IEA:Ensembl.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IEA:Ensembl.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0008104; P:protein localization; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEA:Ensembl.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; DNA-binding; Endoplasmic reticulum;
KW   Isopeptide bond; Metal-binding; Methylation; Mitochondrion; Necrosis;
KW   Nucleus; Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185706.
FT   DNA_BIND    102    292       {ECO:0000250}.
FT   REGION        1    320       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     83       Interaction with HRMT1L2. {ECO:0000250}.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX. {ECO:0000250}.
FT   REGION      100    370       Interaction with HIPK1. {ECO:0000250}.
FT   REGION      100    300       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      113    236       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      116    292       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      256    294       Interaction with E4F1. {ECO:0000250}.
FT   REGION      273    280       Interaction with DNA. {ECO:0000250}.
FT   REGION      300    393       Interaction with CARM1. {ECO:0000250}.
FT   REGION      319    360       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7. {ECO:0000250}.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       339    350       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc. {ECO:0000250}.
FT   METAL       179    179       Zinc. {ECO:0000250}.
FT   METAL       238    238       Zinc. {ECO:0000250}.
FT   METAL       242    242       Zinc. {ECO:0000250}.
FT   SITE        120    120       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1 and GRK5.
FT                                {ECO:0000250}.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     183    183       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     269    269       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     284    284       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     381    381       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     382    382       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
SQ   SEQUENCE   393 AA;  43655 MW;  E212E5E4FE650103 CRC64;
     MEEPQSDPSI EPPLSQETFS DLWKLLPENN VLSPLPSQAV DDLMLSPDDL AQWLTEDPGP
     DEAPRMSEAA PPMAPTPAAP TPAAPAPAPS WPLSSSVPSQ KTYHGSYGFR LGFLHSGTAK
     SVTCTYSPDL NKMFCQLAKT CPVQLWVDST PPPGSRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYSDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENFR KKGEPCHQLP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPA
     GSRAHSSHLK SKKGQSTSRH KKFMFKTEGP DSD
//
ID   A0A0B4K7P1_DROME        Unreviewed;       334 AA.
AC   A0A0B4K7P1;
DT   01-APR-2015, integrated into UniProtKB/TrEMBL.
DT   01-APR-2015, sequence version 1.
DT   18-JAN-2017, entry version 18.
DE   SubName: Full=p53, isoform E {ECO:0000313|EMBL:AFH06570.2};
GN   Name=p53 {ECO:0000313|EMBL:AFH06570.2,
GN   ECO:0000313|FlyBase:FBgn0039044};
GN   ORFNames=CG33336 {ECO:0000313|FlyBase:FBgn0039044},
GN   Dmel_CG33336 {ECO:0000313|EMBL:AFH06570.2};
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227 {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803};
RN   [1] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA   Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., WoodageT, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA   Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA   Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [2] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537568;
RA   Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,
RA   Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA   George R.A., Hoskins R.A., Laverty T., Muzny D.M., Nelson C.R.,
RA   Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA   Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA   Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT   "Finishing a whole-genome shotgun: release 3 of the Drosophila
RT   melanogaster euchromatic genome sequence.";
RL   Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN   [3] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfied E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [4] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537573;
RA   Kaminker J.S., Bergman C.M., Kronmiller B., Carlson J., Svirskas R.,
RA   Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA   Ashburner M., Celniker S.E.;
RT   "The transposable elements of the Drosophila melanogaster euchromatin:
RT   a genomics perspective.";
RL   Genome Biol. 3:RESEARCH0084.1-RESEARCH0084.20(2002).
RN   [5] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=12537574;
RA   Hoskins R.A., Smith C.D., Carlson J.W., Carvalho A.B., Halpern A.,
RA   Kaminker J.S., Kennedy C., Mungall C.J., Sullivan B.A., Sutton G.G.,
RA   Yasuhara J.C., Wakimoto B.T., Myers E.W., Celniker S.E., Rubin G.M.,
RA   Karpen G.H.;
RT   "Heterochromatic sequences in a Drosophila whole-genome shotgun
RT   assembly.";
RL   Genome Biol. 3:RESEARCH0085-RESEARCH0085(2002).
RN   [6] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=16110336; DOI=10.1371/journal.pcbi.0010022;
RA   Quesneville H., Bergman C.M., Andrieu O., Autard D., Nouaud D.,
RA   Ashburner M., Anxolabehere D.;
RT   "Combined evidence annotation of transposable elements in genome
RT   sequences.";
RL   PLoS Comput. Biol. 1:166-175(2005).
RN   [7] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=17569856; DOI=10.1126/science.1139815;
RA   Smith C.D., Shu S., Mungall C.J., Karpen G.H.;
RT   "The Release 5.1 annotation of Drosophila melanogaster
RT   heterochromatin.";
RL   Science 316:1586-1591(2007).
RN   [8] {ECO:0000313|EMBL:AFH06570.2, ECO:0000313|Proteomes:UP000000803}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley {ECO:0000313|Proteomes:UP000000803};
RX   PubMed=17569867; DOI=10.1126/science.1139816;
RA   Hoskins R.A., Carlson J.W., Kennedy C., Acevedo D., Evans-Holm M.,
RA   Frise E., Wan K.H., Park S., Mendez-Lago M., Rossi F., Villasante A.,
RA   Dimitri P., Karpen G.H., Celniker S.E.;
RT   "Sequence finishing and mapping of Drosophila melanogaster
RT   heterochromatin.";
RL   Science 316:1625-1628(2007).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AE014297; AFH06570.2; -; Genomic_DNA.
DR   RefSeq; NP_001247252.2; NM_001260323.2.
DR   UniGene; Dm.3257; -.
DR   SMR; A0A0B4K7P1; -.
DR   STRING; 7227.FBpp0083753; -.
DR   PaxDb; A0A0B4K7P1; -.
DR   EnsemblMetazoa; FBtr0345262; FBpp0311439; FBgn0039044.
DR   GeneID; 2768677; -.
DR   CTD; 2768677; -.
DR   FlyBase; FBgn0039044; p53.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   OrthoDB; EOG091G06IB; -.
DR   GenomeRNAi; 2768677; -.
DR   Proteomes; UP000000803; Chromosome 3R.
DR   ExpressionAtlas; A0A0B4K7P1; differential.
DR   GO; GO:0005634; C:nucleus; IDA:FlyBase.
DR   GO; GO:0001047; F:core promoter binding; IDA:FlyBase.
DR   GO; GO:0001097; F:TFIIH-class transcription factor binding; IPI:FlyBase.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0008134; F:transcription factor binding; IPI:FlyBase.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:FlyBase.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:FlyBase.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:FlyBase.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:FlyBase.
DR   GO; GO:0006915; P:apoptotic process; IMP:FlyBase.
DR   GO; GO:0008219; P:cell death; IMP:FlyBase.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:FlyBase.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IMP:FlyBase.
DR   GO; GO:0009267; P:cellular response to starvation; IMP:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:FlyBase.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:FlyBase.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IMP:FlyBase.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:FlyBase.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IGI:FlyBase.
DR   GO; GO:0090278; P:negative regulation of peptide hormone secretion; IMP:FlyBase.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IMP:FlyBase.
DR   GO; GO:0014016; P:neuroblast differentiation; IMP:FlyBase.
DR   GO; GO:0007405; P:neuroblast proliferation; IMP:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IGI:FlyBase.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:FlyBase.
DR   GO; GO:2000685; P:positive regulation of cellular response to X-ray; IMP:FlyBase.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:FlyBase.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:FlyBase.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; IMP:FlyBase.
DR   GO; GO:0060785; P:regulation of apoptosis involved in tissue homeostasis; IMP:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0006282; P:regulation of DNA repair; IMP:FlyBase.
DR   GO; GO:0046620; P:regulation of organ growth; IMP:FlyBase.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:FlyBase.
DR   GO; GO:1990248; P:regulation of transcription from RNA polymerase II promoter in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0010212; P:response to ionizing radiation; IMP:FlyBase.
DR   GO; GO:0009314; P:response to radiation; IMP:FlyBase.
DR   GO; GO:0042594; P:response to starvation; IMP:FlyBase.
DR   GO; GO:0009411; P:response to UV; IMP:FlyBase.
DR   GO; GO:0042246; P:tissue regeneration; IMP:FlyBase.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR024631; p53_C_Drosophila.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF11619; P53_C; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
PE   4: Predicted;
KW   Complete proteome {ECO:0000313|Proteomes:UP000000803};
KW   Reference proteome {ECO:0000313|Proteomes:UP000000803}.
FT   DOMAIN       53    222       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      268    334       P53_C. {ECO:0000259|Pfam:PF11619}.
SQ   SEQUENCE   334 AA;  38185 MW;  6E72B1A476C2A5CF CRC64;
     MKLYQLYERK QSVLREMMLQ DIQIQANTLP KLENHNIGGY CFSMVLDEPP KSLWMYSIPL
     NKLYIRMNKA FNVDVQFKSK MPIQPLNLRV FLCFSNDVSA PVVRCQNHLS VEPLTANNAK
     MRESLLRSEN PNSVYCGNAQ GKGISERFSV VVPLNMSRSV TRSGLTRQTL AFKFVCQNSC
     IGRKETSLVF CLEKACGDIV GQHVIHVKIC TCPKRDRIQD ERQLNSKKRK SVPEAAEEDE
     PSKVRRCIAI KTEDTESNDS RDCDDSAAEW NVSRTPDGDY RLAITCPNKE WLLQSIEGMI
     KEAAAEVLRN PNQENLRRHA NKLLSLKKRA YELP
//
ID   Q2XVY7_DROME            Unreviewed;       495 AA.
AC   Q2XVY7;
DT   20-DEC-2005, integrated into UniProtKB/TrEMBL.
DT   20-DEC-2005, sequence version 1.
DT   18-JAN-2017, entry version 90.
DE   SubName: Full=p53 protein long form variant 2 {ECO:0000313|EMBL:ABB80264.1};
GN   Name=p53 {ECO:0000313|EMBL:ABB80264.1,
GN   ECO:0000313|FlyBase:FBgn0039044};
GN   ORFNames=CG33336 {ECO:0000313|FlyBase:FBgn0039044};
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227 {ECO:0000313|EMBL:ABB80264.1};
RN   [1] {ECO:0000313|EMBL:ABB80264.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ191319; ABB80264.1; -; mRNA.
DR   STRING; 7227.FBpp0083753; -.
DR   PaxDb; Q2XVY7; -.
DR   PRIDE; Q2XVY7; -.
DR   FlyBase; FBgn0039044; p53.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   OrthoDB; EOG091G06IB; -.
DR   Bgee; FBgn0039044; -.
DR   GO; GO:0005634; C:nucleus; IDA:FlyBase.
DR   GO; GO:0001047; F:core promoter binding; IDA:FlyBase.
DR   GO; GO:0001097; F:TFIIH-class transcription factor binding; IPI:FlyBase.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0008134; F:transcription factor binding; IPI:FlyBase.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:FlyBase.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:FlyBase.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:FlyBase.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:FlyBase.
DR   GO; GO:0006915; P:apoptotic process; IMP:FlyBase.
DR   GO; GO:0008219; P:cell death; IMP:FlyBase.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:FlyBase.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IMP:FlyBase.
DR   GO; GO:0009267; P:cellular response to starvation; IMP:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:FlyBase.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:FlyBase.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IMP:FlyBase.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:FlyBase.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IGI:FlyBase.
DR   GO; GO:0090278; P:negative regulation of peptide hormone secretion; IMP:FlyBase.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IMP:FlyBase.
DR   GO; GO:0014016; P:neuroblast differentiation; IMP:FlyBase.
DR   GO; GO:0007405; P:neuroblast proliferation; IMP:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IGI:FlyBase.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:FlyBase.
DR   GO; GO:2000685; P:positive regulation of cellular response to X-ray; IMP:FlyBase.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:FlyBase.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:FlyBase.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; IMP:FlyBase.
DR   GO; GO:0060785; P:regulation of apoptosis involved in tissue homeostasis; IMP:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0006282; P:regulation of DNA repair; IMP:FlyBase.
DR   GO; GO:0046620; P:regulation of organ growth; IMP:FlyBase.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:FlyBase.
DR   GO; GO:1990248; P:regulation of transcription from RNA polymerase II promoter in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0010212; P:response to ionizing radiation; IMP:FlyBase.
DR   GO; GO:0009314; P:response to radiation; IMP:FlyBase.
DR   GO; GO:0042594; P:response to starvation; IMP:FlyBase.
DR   GO; GO:0009411; P:response to UV; IMP:FlyBase.
DR   GO; GO:0042246; P:tissue regeneration; IMP:FlyBase.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR024631; p53_C_Drosophila.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF11619; P53_C; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN      214    383       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      429    495       P53_C. {ECO:0000259|Pfam:PF11619}.
SQ   SEQUENCE   495 AA;  55592 MW;  65CAF3046EFF7754 CRC64;
     MSLHKSASFS LTFNQNTSIV SRSNSRTIFE AFKEFLDFWD IGNEVSAESA VRVSSNGAFN
     LPQSFGNESN EYAHLATPVD PAYGGNNTNN MMQFTNNLEI LANNNSDGNN KINACNKFVC
     HKGTDSEDDS TEVDIKEDIP KTVEVSGSEL TTEPMAFLQG LNSGNLMQFS QQSVLREMML
     QDIQIQANTL PKLENHNIGG YCFSMVLDEP PKSLWMYSIP LNKLYIRMNK AFNVDVQFKS
     KMPIQPLNLR VFLCFSNDVS APVVRCQNHL SVEPLTANNA KMRESLLRNE NPNSVYCGNA
     QGKGISERFS VVVPLNMSRS VTRSGLTRQT LAFKFVCQNS CIGRKETSLV FCLEKACGDI
     VGQHVIHVKI CTCPKRDRIQ DERQLNSKKR KSVPEAAEED EPSKVRRCIA IKTEDTESND
     SRDCDDSAAE WNVSRTPDGD YRLAITCPNK EWLLQSIEGM IKEAAAEVLR NPNQENLRRH
     ANKLLSLKKR AYELP
//
ID   Q2XVY6_DROME            Unreviewed;       123 AA.
AC   Q2XVY6;
DT   20-DEC-2005, integrated into UniProtKB/TrEMBL.
DT   20-DEC-2005, sequence version 1.
DT   30-NOV-2016, entry version 68.
DE   SubName: Full=Truncated p53 splice variant isoform {ECO:0000313|EMBL:ABB80265.1};
GN   Name=p53 {ECO:0000313|FlyBase:FBgn0039044};
GN   Synonyms=p53s {ECO:0000313|EMBL:ABB80265.1};
GN   ORFNames=CG33336 {ECO:0000313|FlyBase:FBgn0039044};
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1] {ECO:0000313|EMBL:ABB80265.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ191320; ABB80265.1; -; mRNA.
DR   STRING; 7227.FBpp0083753; -.
DR   PaxDb; Q2XVY6; -.
DR   FlyBase; FBgn0039044; p53.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   OrthoDB; EOG091G06IB; -.
DR   Bgee; FBgn0039044; -.
DR   GO; GO:0005634; C:nucleus; IDA:FlyBase.
DR   GO; GO:0001047; F:core promoter binding; IDA:FlyBase.
DR   GO; GO:0001097; F:TFIIH-class transcription factor binding; IPI:FlyBase.
DR   GO; GO:0008134; F:transcription factor binding; IPI:FlyBase.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:FlyBase.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:FlyBase.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:FlyBase.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:FlyBase.
DR   GO; GO:0006915; P:apoptotic process; IMP:FlyBase.
DR   GO; GO:0008219; P:cell death; IMP:FlyBase.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:FlyBase.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IMP:FlyBase.
DR   GO; GO:0009267; P:cellular response to starvation; IMP:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:FlyBase.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:FlyBase.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IMP:FlyBase.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:FlyBase.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IGI:FlyBase.
DR   GO; GO:0090278; P:negative regulation of peptide hormone secretion; IMP:FlyBase.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IMP:FlyBase.
DR   GO; GO:0014016; P:neuroblast differentiation; IMP:FlyBase.
DR   GO; GO:0007405; P:neuroblast proliferation; IMP:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IGI:FlyBase.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:FlyBase.
DR   GO; GO:2000685; P:positive regulation of cellular response to X-ray; IMP:FlyBase.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:FlyBase.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:FlyBase.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; IMP:FlyBase.
DR   GO; GO:0060785; P:regulation of apoptosis involved in tissue homeostasis; IMP:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:0006282; P:regulation of DNA repair; IMP:FlyBase.
DR   GO; GO:0046620; P:regulation of organ growth; IMP:FlyBase.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:FlyBase.
DR   GO; GO:1990248; P:regulation of transcription from RNA polymerase II promoter in response to DNA damage; IMP:FlyBase.
DR   GO; GO:0010212; P:response to ionizing radiation; IMP:FlyBase.
DR   GO; GO:0009314; P:response to radiation; IMP:FlyBase.
DR   GO; GO:0042594; P:response to starvation; IMP:FlyBase.
DR   GO; GO:0009411; P:response to UV; IMP:FlyBase.
DR   GO; GO:0042246; P:tissue regeneration; IMP:FlyBase.
PE   2: Evidence at transcript level;
SQ   SEQUENCE   123 AA;  13535 MW;  D6F1A3620DD60B32 CRC64;
     MSLHKSASFS LTFNQNTSIV SRSNSRTIFE AFKEFLDFWD IGNEVSAESA VRVSSNGAFN
     LPQSFGNESN EYAHLATPVD PAYGGNNTNN MMQFTNNLEI LANNNSDGNN KINACNKFVC
     HKG
//
ID   P53_CANLF               Reviewed;         381 AA.
AC   Q29537; Q9TV78;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   05-OCT-2016, entry version 160.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Canis lupus familiaris (Dog) (Canis familiaris).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Carnivora; Caniformia; Canidae;
OC   Canis.
OX   NCBI_TaxID=9615;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Leukocyte;
RX   PubMed=9519881; DOI=10.1038/sj.onc.1201863;
RA   Veldhoen N., Milner J.;
RT   "Isolation of canine p53 cDNA and detailed characterization of the
RT   full length canine p53 protein.";
RL   Oncogene 16:1077-1084(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Spleen;
RA   Setoguchi A., Sakai T., Okuda M., Minehata K., Yazawa M., Ishizaka T.,
RA   Watari T., Hasagawa A., Tsujimoto H.;
RT   "Aberrations of p53 tumor suppressor gene in various spontaneous
RT   tumors in the dog.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 25-300.
RC   STRAIN=Beagle;
RX   PubMed=7600529; DOI=10.1016/0304-3835(95)03779-V;
RA   Kraegel S.A., Pazzi K.A., Madewell B.R.;
RT   "Sequence analysis of canine p53 in the region of exons 3-8.";
RL   Cancer Lett. 92:181-186(1995).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-370)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       Interacts with MORC3. {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated on Thr-18 by VRK1, which may prevent
CC       the interaction with MDM2. Phosphorylated on Ser-20 by CHEK2 in
CC       response to DNA damage, which prevents ubiquitination by MDM2.
CC       Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen
CC       species (ROS), promoting p53/TP53-mediated apoptosis.
CC       Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to
CC       DNA damage. Phosphorylated by HIPK1. Phosphorylated on Ser-15 upon
CC       ultraviolet irradiation; which is enhanced by interaction with
CC       BANP. Stabilized by CDK5-mediated phosphorylation in response to
CC       genotoxic and oxidative stresses at Ser-15 and Ser-33, leading to
CC       accumulation of p53/TP53, particularly in the nucleus, thus
CC       inducing the transactivation of p53/TP53 target genes.
CC       Phosphorylated at Ser-303 and Ser-380 by CDK2 in response to DNA-
CC       damage. Phosphorylated on Ser-380 following UV but not gamma
CC       irradiation (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-279 and Lys-280, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-360 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       358 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-360
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-358. Dimethylated at Lys-361 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-370 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-358 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-374 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF060514; AAC16909.1; -; mRNA.
DR   EMBL; AB020761; BAA78379.1; -; Genomic_DNA.
DR   EMBL; S77819; AAB42022.1; -; mRNA.
DR   RefSeq; NP_001003210.1; NM_001003210.1.
DR   UniGene; Cfa.3658; -.
DR   ProteinModelPortal; Q29537; -.
DR   STRING; 9615.ENSCAFP00000024579; -.
DR   PaxDb; Q29537; -.
DR   GeneID; 403869; -.
DR   KEGG; cfa:403869; -.
DR   CTD; 7157; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; Q29537; -.
DR   KO; K04451; -.
DR   Proteomes; UP000002254; Unplaced.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:GO_Central.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; DNA-binding; Endoplasmic reticulum;
KW   Isopeptide bond; Metal-binding; Methylation; Mitochondrion; Necrosis;
KW   Nucleus; Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    381       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185695.
FT   DNA_BIND     89    280       {ECO:0000250}.
FT   REGION        1    308       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       63     97       Interaction with WWOX. {ECO:0000250}.
FT   REGION       87    358       Interaction with HIPK1. {ECO:0000250}.
FT   REGION       87    288       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      100    224       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      103    280       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      244    282       Interaction with E4F1. {ECO:0000250}.
FT   REGION      261    268       Interaction with DNA. {ECO:0000250}.
FT   REGION      307    348       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      313    344       Oligomerization.
FT   REGION      347    351       Interaction with USP7. {ECO:0000250}.
FT   REGION      356    375       Basic (repression of DNA-binding).
FT   MOTIF       293    309       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       327    338       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       358    360       [KR]-[STA]-K motif.
FT   METAL       163    163       Zinc. {ECO:0000250}.
FT   METAL       166    166       Zinc. {ECO:0000250}.
FT   METAL       226    226       Zinc. {ECO:0000250}.
FT   METAL       230    230       Zinc. {ECO:0000250}.
FT   SITE        107    107       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES     107    107       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     170    170       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     257    257       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     272    272       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     293    293       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     303    303       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     309    309       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     358    358       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     358    358       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     360    360       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     361    361       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     361    361       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     369    369       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     370    370       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     370    370       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     380    380       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    279    279       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    280    280       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    374    374       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   CONFLICT      1      4       MEES -> MQEP (in Ref. 2). {ECO:0000305}.
FT   CONFLICT    378    378       L -> P (in Ref. 2; BAA78379).
FT                                {ECO:0000305}.
SQ   SEQUENCE   381 AA;  42486 MW;  761A718FDC93DA59 CRC64;
     MEESQSELNI DPPLSQETFS ELWNLLPENN VLSSELCPAV DELLLPESVV NWLDEDSDDA
     PRMPATSAPT APGPAPSWPL SSSVPSPKTY PGTYGFRLGF LHSGTAKSVT WTYSPLLNKL
     FCQLAKTCPV QLWVSSPPPP NTCVRAMAIY KKSEFVTEVV RRCPHHERCS DSSDGLAPPQ
     HLIRVEGNLR AKYLDDRNTF RHSVVVPYEP PEVGSDYTTI HYNYMCNSSC MGGMNRRPIL
     TIITLEDSSG NVLGRNSFEV RVCACPGRDR RTEEENFHKK GEPCPEPPPG STKRALPPST
     SSSPPQKKKP LDGEYFTLQI RGRERYEMFR NLNEALELKD AQSGKEPGGS RAHSSHLKAK
     KGQSTSRHKK LMFKREGLDS D
//
ID   Q549C9_MOUSE            Unreviewed;       390 AA.
AC   Q549C9;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   02-NOV-2016, entry version 118.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=Trp53 {ECO:0000313|EMBL:ABS81351.1,
GN   ECO:0000313|Ensembl:ENSMUSP00000104298, ECO:0000313|MGI:MGI:98834};
GN   Synonyms=p53 {ECO:0000313|EMBL:AAD44340.1};
GN   ORFNames=mCG_20908 {ECO:0000313|EMBL:EDL10507.1};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1] {ECO:0000313|EMBL:AAD44340.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Radiosensitive breast carcinoma {ECO:0000313|EMBL:AAD44340.1};
RA   Jiang G.C., Yuan L.Z., Wei K., Guo X.M.;
RT   "Sequence of tumor supressor gene p53 in radiosensitive mouse breast
RT   carcinoma cell line SX-9.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:EDL10507.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Mixed {ECO:0000313|EMBL:EDL10507.1};
RX   PubMed=12040188; DOI=10.1126/science.1069193;
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Miklos G.L., Wides R.,
RA   Halpern A., Li P.W., Sutton G.G., Nadeau J., Salzberg S.L., Holt R.A.,
RA   Kodira C.D., Lu F., Chen L., Deng Z., Evangelista C.C., Gan W.,
RA   Heiman T.J., Li J., Li Z., Merkulov G.V., Milshina N.V., Naik A.K.,
RA   Qi R., Shue B.C., Wang A., Wang J., Wang X., Yan X., Ye J.,
RA   Yooseph S., Zhao Q., Zheng L., Zhu S.C., Biddick K., Bolanos R.,
RA   Delcher A.L., Dew I.M., Fasulo D., Flanigan M.J., Huson D.H.,
RA   Kravitz S.A., Miller J.R., Mobarry C.M., Reinert K., Remington K.A.,
RA   Zhang Q., Zheng X.H., Nusskern D.R., Lai Z., Lei Y., Zhong W., Yao A.,
RA   Guan P., Ji R.R., Gu Z., Wang Z.Y., Zhong F., Xiao C., Chiang C.C.,
RA   Yandell M., Wortman J.R., Amanatides P.G., Hladun S.L., Pratts E.C.,
RA   Johnson J.E., Dodson K.L., Woodford K.J., Evans C.A., Gropman B.,
RA   Rusch D.B., Venter E., Wang M., Smith T.J., Houck J.T., Tompkins D.E.,
RA   Haynes C., Jacob D., Chin S.H., Allen D.R., Dahlke C.E., Sanders R.,
RA   Li K., Liu X., Levitsky A.A., Majoros W.H., Chen Q., Xia A.C.,
RA   Lopez J.R., Donnelly M.T., Newman M.H., Glodek A., Kraft C.L.,
RA   Nodell M., Ali F., An H.J., Baldwin-Pitts D., Beeson K.Y., Cai S.,
RA   Carnes M., Carver A., Caulk P.M., Center A., Chen Y.H., Cheng M.L.,
RA   Coyne M.D., Crowder M., Danaher S., Davenport L.B., Desilets R.,
RA   Dietz S.M., Doup L., Dullaghan P., Ferriera S., Fosler C.R.,
RA   Gire H.C., Gluecksmann A., Gocayne J.D., Gray J., Hart B., Haynes J.,
RA   Hoover J., Howland T., Ibegwam C., Jalali M., Johns D., Kline L.,
RA   Ma D.S., MacCawley S., Magoon A., Mann F., May D., McIntosh T.C.,
RA   Mehta S., Moy L., Moy M.C., Murphy B.J., Murphy S.D., Nelson K.A.,
RA   Nuri Z., Parker K.A., Prudhomme A.C., Puri V.N., Qureshi H.,
RA   Raley J.C., Reardon M.S., Regier M.A., Rogers Y.H., Romblad D.L.,
RA   Schutz J., Scott J.L., Scott R., Sitter C.D., Smallwood M.,
RA   Sprague A.C., Stewart E., Strong R.V., Suh E., Sylvester K.,
RA   Thomas R., Tint N.N., Tsonis C., Wang G., Wang G., Williams M.S.,
RA   Williams S.M., Windsor S.M., Wolfe K., Wu M.M., Zaveri J.,
RA   Chaturvedi K., Gabrielian A.E., Ke Z., Sun J., Subramanian G.,
RA   Venter J.C., Pfannkoch C.M., Barnstead M., Stephenson L.D.;
RT   "A comparison of whole-genome shotgun-derived mouse chromosome 16 and
RT   the human genome.";
RL   Science 296:1661-1671(2002).
RN   [3] {ECO:0000313|EMBL:EDL10507.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Mixed {ECO:0000313|EMBL:EDL10507.1};
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|EMBL:ABS81351.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=FVB/N {ECO:0000313|EMBL:ABS81351.1};
RA   Cullen J.M., Brown D.L., Kissling G.E., Foley J.F., Buzzard J.,
RA   Marion P.L., Parron V.I., French J.E.;
RT   "Aflatoxin B1 and/or HBV induced tumor spectrum in a genetically-
RT   engineered HBV expression and Trp53 mouse model for
RT   hepatocarcinogenesis.";
RL   Submitted (JUL-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000313|Ensembl:ENSMUSP00000104298, ECO:0000313|Proteomes:UP000000589}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J {ECO:0000313|Ensembl:ENSMUSP00000104298,
RC   ECO:0000313|Proteomes:UP000000589};
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [6] {ECO:0000313|Ensembl:ENSMUSP00000104298}
RP   IDENTIFICATION.
RC   STRAIN=C57BL/6J {ECO:0000313|Ensembl:ENSMUSP00000104298};
RG   Ensembl;
RL   Submitted (FEB-2012) to UniProtKB.
RN   [7] {ECO:0000213|PubMed:23806337}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23806337; DOI=10.1016/j.molcel.2013.06.001;
RA   Park J., Chen Y., Tishkoff D.X., Peng C., Tan M., Dai L., Xie Z.,
RA   Zhang Y., Zwaans B.M., Skinner M.E., Lombard D.B., Zhao Y.;
RT   "SIRT5-mediated lysine desuccinylation impacts diverse metabolic
RT   pathways.";
RL   Mol. Cell 50:919-930(2013).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL731687; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF161020; AAD44340.1; -; mRNA.
DR   EMBL; EU031806; ABS81351.1; -; mRNA.
DR   EMBL; CH466601; EDL10507.1; -; Genomic_DNA.
DR   RefSeq; NP_035770.2; NM_011640.3.
DR   RefSeq; XP_006533220.1; XM_006533157.3.
DR   UniGene; Mm.222; -.
DR   MINT; MINT-8072076; -.
DR   STRING; 10090.ENSMUSP00000104298; -.
DR   Ensembl; ENSMUST00000108658; ENSMUSP00000104298; ENSMUSG00000059552.
DR   GeneID; 22059; -.
DR   KEGG; mmu:22059; -.
DR   UCSC; uc007jqn.2; mouse.
DR   CTD; 22059; -.
DR   MGI; MGI:98834; Trp53.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOVERGEN; HBG005201; -.
DR   KO; K04451; -.
DR   OMA; SFMCNSS; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   TreeFam; TF106101; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   Bgee; ENSMUSG00000059552; -.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0000790; C:nuclear chromatin; IEA:Ensembl.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IEA:Ensembl.
DR   GO; GO:0016605; C:PML body; IEA:Ensembl.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0005507; F:copper ion binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:Ensembl.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0071417; P:cellular response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:0031497; P:chromatin assembly; IEA:Ensembl.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0000733; P:DNA strand renaturation; IEA:Ensembl.
DR   GO; GO:0006983; P:ER overload response; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0006289; P:nucleotide-excision repair; IEA:Ensembl.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IEA:Ensembl.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IEA:Ensembl.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IEA:Ensembl.
DR   GO; GO:0008104; P:protein localization; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEA:Ensembl.
DR   GO; GO:1903205; P:regulation of hydrogen peroxide-induced cell death; IEA:Ensembl.
DR   GO; GO:0051453; P:regulation of intracellular pH; IEA:Ensembl.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0034097; P:response to cytokine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010038; P:response to metal ion; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0010224; P:response to UV-B; IEA:Ensembl.
DR   GO; GO:0033552; P:response to vitamin B3; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Complete proteome {ECO:0000313|Proteomes:UP000000589};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Proteomics identification {ECO:0000213|MaxQB:Q549C9,
KW   ECO:0000213|PeptideAtlas:Q549C9};
KW   Reference proteome {ECO:0000313|Proteomes:UP000000589};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN        8     30       P53_TAD. {ECO:0000259|Pfam:PF08563}.
FT   DOMAIN       93    286       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      316    353       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   390 AA;  43458 MW;  ED5A607378D921D7 CRC64;
     MTAMEESQSD ISLELPLSQE TFSGLWKLLP PEDILPSPHC MDDLLLPQDV EEFFEGPSEA
     LRVSGAPAAQ DPVTETPGPV APAPATPWPL SSFVPSQKTY QGNYGFHLGF LQSGTAKSVM
     CTYSPPLNKL FCQLAKTCPV QLWVSATPPA GSRVRAMAIY KKSQHMTEVV RRCPHHERCS
     DGDGLAPPQH LIRVEGNLYP EYLEDRQTFR HSVVVPYEPP EAGSEYTTIH YKYMCNSSCM
     GGMNRRPILT IITLEDSSGN LLGRDSFEVR VCACPGRDRR TEEENFRKKE VLCPELPPGS
     AKRALPTCTS ASPPQKKKPL DGEYFTLKIR GRKRFEMFRE LNEALELKDA HATEESGDSR
     AHSSYLKTKK GQSTSRHKKT MVKKVGPDSD
//
ID   P53_HORSE               Reviewed;         280 AA.
AC   P79892; Q29481;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   05-OCT-2016, entry version 136.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
DE   Flags: Fragment;
GN   Name=TP53; Synonyms=P53;
OS   Equus caballus (Horse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Perissodactyla; Equidae; Equus.
OX   NCBI_TaxID=9796;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-263.
RC   TISSUE=Spleen;
RX   PubMed=8913276; DOI=10.1016/0304-3835(96)04359-5;
RA   Pazzi K.A., Kraegel S.A., Griffey S.M., Theon A.P., Madewell B.R.;
RT   "Analysis of the equine tumor suppressor gene p53 in the normal horse
RT   and in eight cutaneous squamous cell carcinomas.";
RL   Cancer Lett. 107:125-130(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 76-280.
RX   PubMed=8722575;
RA   Nasir L., Reid S.W.;
RT   "Nucleotide sequence of exons 5 to 9 of the p53 tumour-suppressor gene
RT   of the horse (Equus caballus).";
RL   DNA Seq. 6:185-187(1996).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated) with
CC       L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       Interacts with MORC3. {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated by VRK1, which may prevent the interaction
CC       with MDM2. Phosphorylated by CHEK2 in response to DNA damage,
CC       which prevents ubiquitination by MDM2. Phosphorylated by PLK3 in
CC       response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Probably phosphorylated on by CDK7 in a CAK
CC       complex in response to DNA damage. Phosphorylated by CK2 following
CC       UV but not gamma irradiation. Phosphorylated upon ultraviolet
CC       irradiation; which is enhanced by interaction with BANP.
CC       Stabilized by CDK5-mediated phosphorylation in response to
CC       genotoxic and oxidative stresses at Ser-9, leading to accumulation
CC       of p53/TP53, particularly in the nucleus, thus inducing the
CC       transactivation of p53/TP53 target genes. Phosphorylated by DYRK2
CC       at Ser-9 in response to genotoxic stress. Phosphorylated at Ser-
CC       266 by CDK2 in response to DNA-damage (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-242 and Lys-243, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated by SETD7, leading to stabilization and
CC       increased transcriptional activation. Monomethylated by SMYD2,
CC       leading to decreased DNA-binding activity and subsequent
CC       transcriptional regulation activity. Monomethylation by SETD7
CC       prevents interaction with SMYD2 and subsequent monomethylation by
CC       SMYD2 (By similarity). Dimethylated by EHMT1 and EHMT2.
CC       Monomethylated by KMT5A, promoting interaction with L3MBTL1 and
CC       leading to repress transcriptional activity. Demethylation by
CC       KDM1A prevents interaction with TP53BP1 and represses TP53-
CC       mediated transcriptional activation (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S83123; AAB46899.1; -; mRNA.
DR   EMBL; U37120; AAB18936.1; -; Genomic_DNA.
DR   UniGene; Eca.16089; -.
DR   UniGene; Eca.21708; -.
DR   ProteinModelPortal; P79892; -.
DR   STRING; 9796.ENSECAP00000006210; -.
DR   PaxDb; P79892; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P79892; -.
DR   Proteomes; UP000002281; Unplaced.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IBA:GO_Central.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:GO_Central.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; DNA-binding; Endoplasmic reticulum;
KW   Isopeptide bond; Metal-binding; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN        <1   >280       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185702.
FT   DNA_BIND     52    243       {ECO:0000250}.
FT   REGION       26     60       Interaction with WWOX. {ECO:0000250}.
FT   REGION       50    251       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION       63    187       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      207    245       Interaction with E4F1. {ECO:0000250}.
FT   REGION      224    231       Interaction with DNA. {ECO:0000250}.
FT   REGION      276   >280       Oligomerization.
FT   MOTIF       256    272       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   METAL       126    126       Zinc. {ECO:0000250}.
FT   METAL       129    129       Zinc. {ECO:0000250}.
FT   METAL       189    189       Zinc. {ECO:0000250}.
FT   METAL       193    193       Zinc. {ECO:0000250}.
FT   SITE         70     70       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES      70     70       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     133    133       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     220    220       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     235    235       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     256    256       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     266    266       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     272    272       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   CROSSLNK    242    242       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    243    243       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CONFLICT     79     79       T -> A (in Ref. 2; AAB18936).
FT                                {ECO:0000305}.
FT   CONFLICT     83     83       L -> M (in Ref. 2; AAB18936).
FT                                {ECO:0000305}.
FT   CONFLICT    111    111       A -> V (in Ref. 2; AAB18936).
FT                                {ECO:0000305}.
FT   CONFLICT    138    138       G -> A (in Ref. 2; AAB18936).
FT                                {ECO:0000305}.
FT   NON_TER       1      1
FT   NON_TER     280    280
SQ   SEQUENCE   280 AA;  30985 MW;  040F12030B5ACEE9 CRC64;
     PAVNNLLLSP DVVNWLDEGP DEAPRMPAAP APLAPAPATS WPLSSFVPSQ KTYPGCYGFR
     LGFLNSGTAK SVTCTYSPTL NKLFCQLAKT CPVQLLVSSP PPPGTRVRAM AIYKKSEFMT
     EVVRRCPHHE RCSDSSDGLA PPQHLIRVEG NLRAEYLDDR NTFRHSVVVP YEPPEVGSDC
     TTIHYNFMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG RDRRTEEENF
     RKKEEPCPEP PPRSTKRVLS SNTSSSPPQK KKPLDGEYFT
//
ID   P53_CRIGR               Reviewed;         393 AA.
AC   O09185; P97258; P97788; Q64397;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 1.
DT   05-OCT-2016, entry version 155.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Cricetulus griseus (Chinese hamster) (Cricetulus barabensis griseus).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Cricetidae; Cricetinae; Cricetulus.
OX   NCBI_TaxID=10029;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Chaung W., Mi L.J., Boorstein R.J.;
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=9031625; DOI=10.1016/S0378-1119(96)00592-6;
RA   Lee H., Larner J.M., Hamlin J.L.;
RT   "Cloning and characterization of Chinese hamster p53 cDNA.";
RL   Gene 184:177-183(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Embryonic fibroblast;
RA   Shimizu T., Nikaido O., Suzuki F.;
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       Interacts with MORC3. {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-
CC       18 by VRK1, which may prevent the interaction with MDM2.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Ser-33 by CDK7 in a CAK
CC       complex in response to DNA damage. Phosphorylated by HIPK1.
CC       Phosphorylated on Ser-392 following UV but not gamma irradiation.
CC       Phosphorylated on Ser-15 upon ultraviolet irradiation; which is
CC       enhanced by interaction with BANP. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, Ser-33 and Ser-47, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-47 in
CC       response to genotoxic stress. Phosphorylated at Ser-315 and Ser-
CC       392 by CDK2 in response to DNA-damage (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-370 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y08900; CAA70108.1; -; mRNA.
DR   EMBL; Y08901; CAA70109.1; -; mRNA.
DR   EMBL; U50395; AAC53040.1; -; mRNA.
DR   EMBL; D86070; BAA13004.1; -; mRNA.
DR   PIR; JC6176; JC6176.
DR   RefSeq; NP_001230905.1; NM_001243976.1.
DR   ProteinModelPortal; O09185; -.
DR   GeneID; 100682525; -.
DR   KEGG; cge:100682525; -.
DR   CTD; 7157; -.
DR   HOVERGEN; HBG005201; -.
DR   KO; K04451; -.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Methylation; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Repressor; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185698.
FT   DNA_BIND    102    292       {ECO:0000250}.
FT   REGION        1    320       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     45       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX. {ECO:0000250}.
FT   REGION      100    370       Interaction with HIPK1. {ECO:0000250}.
FT   REGION      100    300       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      113    236       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      116    292       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      256    294       Interaction with E4F1. {ECO:0000250}.
FT   REGION      273    280       Interaction with DNA. {ECO:0000250}.
FT   REGION      319    360       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7. {ECO:0000250}.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       339    350       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc. {ECO:0000250}.
FT   METAL       179    179       Zinc. {ECO:0000250}.
FT   METAL       238    238       Zinc. {ECO:0000250}.
FT   METAL       242    242       Zinc. {ECO:0000250}.
FT   SITE        120    120       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES      47     47       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     183    183       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     269    269       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     284    284       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     381    381       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     382    382       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VARIANT     133    133       L -> Q (in cell line V79-4).
FT   VARIANT     135    135       C -> W (in cell line V79-4).
FT   CONFLICT    103    103       Y -> F (in Ref. 2; AAC53040).
FT                                {ECO:0000305}.
SQ   SEQUENCE   393 AA;  43378 MW;  2A7830E788311689 CRC64;
     MEEPQSDLSI ELPLSQETFS DLWKLLPPNN VLSTLPSSDS IEELFLSENV TGWLEDSGGA
     LQGVAAAAAS TAEDPVTETP APVASAPATP WPLSSSVPSY KTYQGDYGFR LGFLHSGTAK
     SVTCTYSPSL NKLFCQLAKT CPVQLWVNST PPPGTRVRAM AIYKKLQYMT EVVRRCPHHE
     RSSEGDSLAP PQHLIRVEGN LHAEYLDDKQ TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDP SGNLLGRNSF EVRICACPGR DRRTEEKNFQ KKGEPCPELP
     PKSAKRALPT NTSSSPPPKK KTLDGEYFTL KIRGHERFKM FQELNEALEL KDAQASKGSE
     DNGAHSSYLK SKKGQSASRL KKLMIKREGP DSD
//
ID   P53_MACFU               Reviewed;         393 AA.
AC   P61260;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 1.
DT   02-NOV-2016, entry version 123.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Macaca fuscata fuscata (Japanese macaque).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Cercopithecidae; Cercopithecinae; Macaca.
OX   NCBI_TaxID=9543;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=12099687; DOI=10.1016/S0006-291X(02)00730-1;
RA   Shimizu Y., Ishida T.;
RT   "Somatic mutations in the p53 gene account for the extension of
RT   replicative life span of macaque cells.";
RL   Biochem. Biophys. Res. Commun. 295:644-650(2002).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       Interacts with MORC3. {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-
CC       18 by VRK1, which may prevent the interaction with MDM2.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Ser-392 following UV but not
CC       gamma irradiation. Phosphorylated on Thr-55 by TAF1 which promotes
CC       MDM2-mediated TP53 degradation. Phosphorylated on Ser-33 by CDK7
CC       in a CAK complex in response to DNA damage. Phosphorylated on Ser-
CC       15 upon ultraviolet irradiation; which is enhanced by interaction
CC       with BANP. Stabilized by CDK5-mediated phosphorylation in response
CC       to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46,
CC       leading to accumulation of p53/TP53, particularly in the nucleus,
CC       thus inducing the transactivation of p53/TP53 target genes.
CC       Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress.
CC       Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-
CC       damage (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-370 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF456344; AAN64028.1; -; mRNA.
DR   ProteinModelPortal; P61260; -.
DR   SMR; P61260; -.
DR   HOVERGEN; HBG005201; -.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Methylation; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Repressor; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185705.
FT   DNA_BIND    102    292       {ECO:0000250}.
FT   REGION        1    320       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     83       Interaction with HRMT1L2. {ECO:0000250}.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX. {ECO:0000250}.
FT   REGION      100    300       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      113    236       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      256    294       Interaction with E4F1. {ECO:0000250}.
FT   REGION      273    280       Interaction with DNA. {ECO:0000250}.
FT   REGION      300    393       Interaction with CARM1. {ECO:0000250}.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7. {ECO:0000250}.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       339    350       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc. {ECO:0000250}.
FT   METAL       179    179       Zinc. {ECO:0000250}.
FT   METAL       238    238       Zinc. {ECO:0000250}.
FT   METAL       242    242       Zinc. {ECO:0000250}.
FT   SITE        120    120       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1 and GRK5.
FT                                {ECO:0000250}.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     183    183       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     269    269       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     284    284       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     381    381       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     382    382       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
SQ   SEQUENCE   393 AA;  43655 MW;  E212E5E4FE650103 CRC64;
     MEEPQSDPSI EPPLSQETFS DLWKLLPENN VLSPLPSQAV DDLMLSPDDL AQWLTEDPGP
     DEAPRMSEAA PPMAPTPAAP TPAAPAPAPS WPLSSSVPSQ KTYHGSYGFR LGFLHSGTAK
     SVTCTYSPDL NKMFCQLAKT CPVQLWVDST PPPGSRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYSDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENFR KKGEPCHQLP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPA
     GSRAHSSHLK SKKGQSTSRH KKFMFKTEGP DSD
//
ID   P53_TUPBE               Reviewed;         393 AA.
AC   Q9TTA1;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   05-OCT-2016, entry version 147.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Tupaia belangeri (Common tree shrew) (Tupaia glis belangeri).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Scandentia; Tupaiidae; Tupaia.
OX   NCBI_TaxID=37347;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Chinensis; TISSUE=Liver;
RA   Park U., Lee Y.;
RT   "Wild-type p53 sequence of tree shrews.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Interacts with HSP90AB1. Directly interacts with
CC       FBXO42; leading to ubiquitination and degradation of TP53.
CC       Interacts with AURKB, SETD2, UHRF2 and NOC2L. Interacts with
CC       AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at
CC       Lys-382) with L3MBTL1. Interacts with GRK5. Binds to the CAK
CC       complex (CDK7, cyclin H and MAT1) in response to DNA damage.
CC       Interacts with CDK5 in neurons. Interacts (via N-terminus) with
CC       PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with
CC       PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with
CC       PPIF; the association implicates preferentially tetrameric TP53,
CC       is induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-
CC       18 by VRK1, which may prevent the interaction with MDM2.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Thr-55 by TAF1 which
CC       promotes MDM2-mediated TP53 degradation. Phosphorylated on Ser-33
CC       by CDK7 in a CAK complex in response to DNA damage. Phosphorylated
CC       by HIPK1 (By similarity). Phosphorylated on Ser-46 by HIPK2 upon
CC       UV irradiation. Phosphorylation on Ser-46 is required for
CC       acetylation by CREBBP. Phosphorylated on Ser-392 following UV but
CC       not gamma irradiation. Phosphorylated on Ser-15 upon ultraviolet
CC       irradiation; which is enhanced by interaction with BANP.
CC       Stabilized by CDK5-mediated phosphorylation in response to
CC       genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46,
CC       leading to accumulation of p53/TP53, particularly in the nucleus,
CC       thus inducing the transactivation of p53/TP53 target genes.
CC       Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress.
CC       Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-
CC       damage (By similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to its
CC       stabilization. Ubiquitinated by TRIM24, RFFL and RNF34, which
CC       leads to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-370 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF175893; AAF22640.1; -; mRNA.
DR   ProteinModelPortal; Q9TTA1; -.
DR   HOVERGEN; HBG005201; -.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Methylation; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Repressor; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185715.
FT   DNA_BIND    102    292       {ECO:0000250}.
FT   REGION        1    320       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     83       Interaction with HRMT1L2. {ECO:0000250}.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX. {ECO:0000250}.
FT   REGION      100    370       Interaction with HIPK1. {ECO:0000250}.
FT   REGION      100    300       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      113    236       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      116    292       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      256    294       Interaction with E4F1. {ECO:0000250}.
FT   REGION      273    280       Interaction with DNA. {ECO:0000250}.
FT   REGION      300    393       Interaction with CARM1. {ECO:0000250}.
FT   REGION      319    360       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      325    356       Oligomerization.
FT   REGION      357    383       Interaction with USP7. {ECO:0000250}.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       339    350       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc. {ECO:0000250}.
FT   METAL       179    179       Zinc. {ECO:0000250}.
FT   METAL       238    238       Zinc. {ECO:0000250}.
FT   METAL       242    242       Zinc. {ECO:0000250}.
FT   SITE        120    120       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1 and GRK5.
FT                                {ECO:0000250}.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     183    183       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     269    269       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     284    284       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     382    382       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
SQ   SEQUENCE   393 AA;  43552 MW;  FD9F36603945A1FA CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPDL NKLFCQLAKT CPVQLWVDSA PPPGTRVRAM AIYKQSQYVT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LHAEYSDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGKLLGRNSF EVRICACPGR DRRTEEENFR KKGESCPKLP
     TGSIKRALPT GSSSSPQPKK KPLDEEYFTL QIRGRERFEM LREINEALEL KDAMAGKESA
     GSRAHSSHLK SKKGQSTSRH RKLMFKTEGP DSD
//
ID   P53_MACFA               Reviewed;         393 AA.
AC   P56423;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 2.
DT   02-NOV-2016, entry version 149.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Macaca fascicularis (Crab-eating macaque) (Cynomolgus monkey).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Cercopithecidae; Cercopithecinae; Macaca.
OX   NCBI_TaxID=9541;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Khan M.A., Hansen C., Welsh J.A., Bennett W.P.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skin;
RX   PubMed=12099687; DOI=10.1016/S0006-291X(02)00730-1;
RA   Shimizu Y., Ishida T.;
RT   "Somatic mutations in the p53 gene account for the extension of
RT   replicative life span of macaque cells.";
RL   Biochem. Biophys. Res. Commun. 295:644-650(2002).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L.
CC       Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Forms a complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with
CC       ZNF385A; the interaction is direct and enhances p53/TP53
CC       transactivation functions on cell-cycle arrest target genes,
CC       resulting in growth arrest. Interacts with ANKRD2. Interacts with
CC       RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and RFWD2. Interacts with CCAR2 (via N-terminus).
CC       Interacts with MORC3. {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-
CC       18 by VRK1, which may prevent the interaction with MDM2.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Thr-55 by TAF1 which
CC       promotes MDM2-mediated TP53 degradation. Phosphorylated on Ser-33
CC       by CDK7 in a CAK complex in response to DNA damage. Phosphorylated
CC       by HIPK1. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation.
CC       Phosphorylation on Ser-46 is required for acetylation by CREBBP.
CC       Phosphorylated on Ser-392 following UV but not gamma irradiation.
CC       Phosphorylated on Ser-15 upon ultraviolet irradiation; which is
CC       enhanced by interaction with BANP. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in
CC       response to genotoxic stress. Phosphorylated at Ser-315 and Ser-
CC       392 by CDK2 in response to DNA-damage (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-370 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U48957; AAB91535.1; -; Genomic_DNA.
DR   EMBL; AF456343; AAN64027.1; -; mRNA.
DR   RefSeq; NP_001274608.1; NM_001287679.1.
DR   RefSeq; XP_005582844.1; XM_005582787.2.
DR   UniGene; Mfa.6170; -.
DR   ProteinModelPortal; P56423; -.
DR   SMR; P56423; -.
DR   GeneID; 102135998; -.
DR   KEGG; mcf:102135998; -.
DR   CTD; 7157; -.
DR   HOVERGEN; HBG005201; -.
DR   KO; K04451; -.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Methylation; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Repressor; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185704.
FT   DNA_BIND    102    292       {ECO:0000250}.
FT   REGION        1    320       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     83       Interaction with HRMT1L2. {ECO:0000250}.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX. {ECO:0000250}.
FT   REGION      100    370       Interaction with HIPK1. {ECO:0000250}.
FT   REGION      100    300       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      113    236       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      116    292       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      256    294       Interaction with E4F1. {ECO:0000250}.
FT   REGION      273    280       Interaction with DNA. {ECO:0000250}.
FT   REGION      300    393       Interaction with CARM1. {ECO:0000250}.
FT   REGION      319    360       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7. {ECO:0000250}.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       339    350       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc. {ECO:0000250}.
FT   METAL       179    179       Zinc. {ECO:0000250}.
FT   METAL       238    238       Zinc. {ECO:0000250}.
FT   METAL       242    242       Zinc. {ECO:0000250}.
FT   SITE        120    120       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1. {ECO:0000250}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1 and GRK5.
FT                                {ECO:0000250}.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     183    183       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     269    269       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     284    284       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     381    381       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     382    382       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   CONFLICT     30     30       N -> H (in Ref. 1; AAB91535).
FT                                {ECO:0000305}.
SQ   SEQUENCE   393 AA;  43655 MW;  E212E5E4FE650103 CRC64;
     MEEPQSDPSI EPPLSQETFS DLWKLLPENN VLSPLPSQAV DDLMLSPDDL AQWLTEDPGP
     DEAPRMSEAA PPMAPTPAAP TPAAPAPAPS WPLSSSVPSQ KTYHGSYGFR LGFLHSGTAK
     SVTCTYSPDL NKMFCQLAKT CPVQLWVDST PPPGSRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYSDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENFR KKGEPCHQLP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPA
     GSRAHSSHLK SKKGQSTSRH KKFMFKTEGP DSD
//
ID   P53_DELLE               Reviewed;         387 AA.
AC   Q8SPZ3;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   05-OCT-2016, entry version 120.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Delphinapterus leucas (Beluga whale).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Cetacea;
OC   Odontoceti; Monodontidae; Delphinapterus.
OX   NCBI_TaxID=9749;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Leukocyte;
RX   PubMed=12034505; DOI=10.1016/S0378-1119(02)00472-9;
RA   Xu N., Shiraki T., Yamada T., Nakajima M., Gauthier J.M.,
RA   Pfeiffer C.J., Sato S.;
RT   "Nucleotide sequence of the p53 cDNA of beluga whale (Delphinapterus
RT   leucas).";
RL   Gene 288:159-166(2002).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Regulates the circadian clock by repressing
CC       CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2.
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-376)
CC       with L3MBTL1. Binds to the CAK complex (CDK7, cyclin H and MAT1)
CC       in response to DNA damage. Interacts with CDK5 in neurons.
CC       Interacts with AURKB, SETD2, UHRF2 and NOC2L. Interacts (via N-
CC       terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2.
CC       Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2.
CC       Interacts with PRKCG. Interacts with PPIF; the association
CC       implicates preferentially tetrameric TP53, is induced by oxidative
CC       stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion. Interacts
CC       with KAT6A. Interacts with UBC9. Forms a complex with UBC9 and
CC       PRKRA. Interacts with ZNF385B; the interaction is direct.
CC       Interacts (via DNA-binding domain) with ZNF385A; the interaction
CC       is direct and enhances p53/TP53 transactivation functions on cell-
CC       cycle arrest target genes, resulting in growth arrest. Interacts
CC       with ANKRD2. Interacts with RFFL and RNF34; involved in p53/TP53
CC       ubiquitination. Interacts with MTA1 and RFWD2. Interacts with
CC       CCAR2 (via N-terminus). Interacts with MORC3.
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Mitochondrion
CC       matrix {ECO:0000250}. Note=Interaction with BANP promotes nuclear
CC       localization. Translocates to mitochondria upon oxidative stress
CC       (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase. {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated on Thr-18 by VRK1, which may prevent
CC       the interaction with MDM2. Phosphorylated on Ser-20 by CHEK2 in
CC       response to DNA damage, which prevents ubiquitination by MDM2.
CC       Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen
CC       species (ROS), promoting p53/TP53-mediated apoptosis.
CC       Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to
CC       DNA damage. Phosphorylated by HIPK1. Phosphorylated on Ser-386
CC       following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction
CC       with BANP. Stabilized by CDK5-mediated phosphorylation in response
CC       to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46,
CC       leading to accumulation of p53/TP53, particularly in the nucleus,
CC       thus inducing the transactivation of p53/TP53 target genes.
CC       Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress.
CC       Phosphorylated at Ser-309 and Ser-386 by CDK2 in response to DNA-
CC       damage (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-285 and Lys-286, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, RFFL and RNF34, which leads
CC       to proteasomal degradation. Ubiquitination by TOPORS induces
CC       degradation. Deubiquitination by USP7, leading to stabilize it.
CC       Ubiquitinated by RFWD2, which leads to proteasomal degradation.
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-366 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       364 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-366
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-364. Dimethylated at Lys-367 EHMT1 and
CC       EHMT2. Monomethylated at Lys-376 KMT5A, promoting interaction with
CC       L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-364 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-380 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF475081; AAL83290.1; -; mRNA.
DR   ProteinModelPortal; Q8SPZ3; -.
DR   HOVERGEN; HBG005201; -.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Methylation; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Repressor; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    387       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185699.
FT   DNA_BIND     95    286       {ECO:0000250}.
FT   REGION        1    314       Interaction with CCAR2.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   REGION        1     45       Transcription activation (acidic).
FT                                {ECO:0000250}.
FT   REGION       59    103       Interaction with WWOX. {ECO:0000250}.
FT   REGION       93    364       Interaction with HIPK1. {ECO:0000250}.
FT   REGION       93    294       Required for interaction with ZNF385A.
FT                                {ECO:0000250}.
FT   REGION      106    230       Required for interaction with FBXO42.
FT                                {ECO:0000250}.
FT   REGION      109    286       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      250    288       Interaction with E4F1. {ECO:0000250}.
FT   REGION      267    274       Interaction with DNA. {ECO:0000250}.
FT   REGION      313    354       Interaction with HIPK2. {ECO:0000250}.
FT   REGION      319    350       Oligomerization. {ECO:0000250}.
FT   REGION      353    357       Interaction with USP7. {ECO:0000250}.
FT   REGION      362    381       Basic (repression of DNA-binding).
FT                                {ECO:0000250}.
FT   MOTIF       299    315       Bipartite nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       333    344       Nuclear export signal. {ECO:0000250}.
FT   MOTIF       364    366       [KR]-[STA]-K motif.
FT   METAL       169    169       Zinc. {ECO:0000250}.
FT   METAL       172    172       Zinc. {ECO:0000250}.
FT   METAL       232    232       Zinc. {ECO:0000250}.
FT   METAL       236    236       Zinc. {ECO:0000250}.
FT   SITE        113    113       Interaction with DNA. {ECO:0000250}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000250}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000250}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000250}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000250}.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000250}.
FT   MOD_RES     113    113       N6-acetyllysine; by KAT6A. {ECO:0000250}.
FT   MOD_RES     176    176       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     263    263       Phosphoserine; by AURKB. {ECO:0000250}.
FT   MOD_RES     278    278       Phosphothreonine; by AURKB.
FT                                {ECO:0000250}.
FT   MOD_RES     299    299       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     309    309       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000250}.
FT   MOD_RES     315    315       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     364    364       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     364    364       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     366    366       N6-methyllysine; by SETD7. {ECO:0000250}.
FT   MOD_RES     367    367       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     367    367       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     375    375       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     376    376       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   MOD_RES     376    376       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     376    376       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     386    386       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000250}.
FT   CROSSLNK    285    285       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    286    286       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P04637}.
FT   CROSSLNK    380    380       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
SQ   SEQUENCE   387 AA;  43034 MW;  E4C8BEDBF34A540E CRC64;
     MEESQAELGV EPPLSQETFS DLWKLLPENN LLSSELSPAV DDLLLSPEDV ANWLDERPDE
     APQMPEPPAP AAPTPAAPAP ATSWPLSSFV PSQKTYPGSY GFHLGFLHSG TAKSVTCTYS
     PALNKLFCQL AKTCPVQLWV SSPPPPGTRV RAMAIYKKSE YMTEVVRRCP HHERCSDYSD
     GLAPPQHLIR VEGNLRAEYL DDRNTFRHSV VVPYEPPEVG SDCTTIHYNF MCNSSCMGGM
     NRRPILTIIT LEDSNGNLLG RNSFEVRVCA CPGRDRRTEE ENFHKKGQSC PELPTGSAKR
     ALPTGTSSSP PQKKKPLDGE YFTLQIRGRE RFEMFRELNE ALELKDAQAG KEPGESRAHS
     SHLKSKKGQS PSRHKKLMFK REGPDSD
//
